Table of Contents

As filed with the Securities and Exchange Commission on June 24, 2004
Registration Number: 333-____________
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM SB-2

REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933


NATIONAL SCIENTIFIC CORPORATION
(Name of Small Business Issuer in its Charter)

 
Texas
3674
86-0837077
(State or Other Jurisdiction of
Incorporation or Organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer Identification No.)

14455 North Hayden Road, Suite 202
Scottsdale, Arizona 85260
(480) 948-8324
(Address and Telephone Number of Principal Executive Offices)

CT Corporation System
3225 North Central Avenue, Suite 1601
Phoenix, Arizona 85012
(602) 277-4792
(Name, Address and Telephone Number of Agent for Service)

Copies to:

Michael A. Grollman, Chief Executive Officer
National Scientific Corporation
14455 North Hayden Road, Suite 202
Scottsdale, Arizona 85260
 
 

 
Table of Contents
 
Approximate date of proposed sale to the public -- from time to time after the effective date of this Registration Statement by the Selling Securityholders identified herein.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering  o _____________________________

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering  o _____________________________

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering  o ______________________________

If delivery of the prospectus is expected to be made pursuant to Rule 434, check the following box  o

CALCULATION OF REGISTRATION FEE
 
 

 

 

Proposed

 

 

 

 

 

Proposed

 

 

 

 

 

 

 

Number of  

 

 

Maximum

 

 

Maximum

 

 

 

 

 

 

 

Shares  

 

 

Offering

 

 

Aggregate

 

 

Amount of

 

 

 

 

to be  

 

 

Price Per

 

 

Offering

 

 

Registration

 

Title of Each Class of Securities Being Registered

 

 

Registered

 

 

Share

 

 

Price

 

 

Fee

 


 
 
 
 
 
Common Stock $0.01 par value
   
10,334,266
(1)
$
0.14
(2)
$
1,446,797
(1)
$
183
 
Common Stock issuable upon exercise of warrants $0.01 par value (3)
   
10,669,197
 
$
0.11
 
$
1,173,612
 
$
149
 
Total
   
21,003,463
   
 
 
$
2,723,752
 
$
332
 
______________
(1)
There is also registered hereunder an indeterminate number of shares of common stock as shall be issuable as a result of a stock split, stock dividend, combination or other change in the outstanding shares of common stock.
(2)
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457 of the Securities Act based upon a $0.14 per share average of high and low prices of the Registrants common stock on the OTC Bulletin Board on June 18, 2004.
(3)
The price per share is based upon the exercise price of the warrants pursuant to which such shares of common stock are issuable, in accordance with Rule 457(g).
 
The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective on such date as the Commission, acting pursuant to Section 8(a) of the Securities Act of 1933, as amended, may determine.
 
The information in this prospectus is incomplete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not a solicitation of an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, Dated June 24, 2004

 
 
  -2-  

 
Table of Contents
 
Prospectus

 

21,033,463 Shares of Common Stock
 
This prospectus relates to the shares of our common stock being registered for possible resale, from time to time, to allow the shareholders identified in this prospectus (“Selling Securityholders”) to sell up to 21,033,463 shares of our common stock. The Selling Securityholders currently hold 10,334,266 shares of common stock and warrants to acquire 10,699,197 shares of our common stock. See the section in this prospectus entitled “Selling Securityholders” for the names of the Selling Securityholders.

We are registering these shares by filing a registration statement with the Securities and Exchange Commission using a “Shelf” registration process. This process allows the Selling Securityholders to sell their common stock over a period of time in varying amounts as described under "Plan of Distribution" in this prospectus.

We will receive no proceeds from the sale of any of our common stock by the Selling Securityholders. We will receive the proceeds from the Selling Securityholders' exercise of warrants. However, the Selling Securityholders are under no obligation to exercise the warrants.

Our common stock is traded on the OTC Bulletin Board under the symbol “NSCT.” On June 4, 2004, the closing bid price of our common stock was $0.15 per share.

Investing In Our Common Stock Involves Risks, Which Are Described In The “Risk Factors” Section Of This Prospectus, Beginning On Page 8.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this Prospectus. Any representation to the contrary is a criminal offense.


The date of this prospectus is June 24, 2004.

 
  -3-  

 
Table of Contents

 
Page
5
8
13
13
14
14
14
15
17
21
25
43
44
48
49
52
52
53
54
F-1
 
 
II-1
II-1
II-2
II-3
II-4
II-4
II-6
II-7

Except as otherwise required by the context, all references in this prospectus to "we," "us, "our," or "National Scientific" refer to the operations of National Scientific Corporation, a Texas corporation. All trademarks listed in this document are property of their respective holders.
 
  -4-  

 
Table of Contents
 
PART I

Prospectus Summary

This summary provides a brief overview of some information about us and this offering. You should read the entire prospectus carefully including the risk factors and our financial statements and related notes before deciding to invest in our common stock.

Our Company

Our business involves the research, development and sale of devices and designs commonly used in the electronics industry. The majority of our products are electronic location-determining devices. These devices are typically very small portable radios, intended to help establish the physical location of people and objects to which these devices are attached. Some of our location technologies use Global Positioning Systems (GPS) technology to determine position. We also have other products that use non-GPS technology to establish and then report position. We refer to our location-determining devices as our location tracking products, or as location tools.

Our primary focus for these location tracking products is the safety market, related in many cases to the safety of children. Our products and services help our customers keep better track of their children. Our products are also used to keep track of adults, and as well to help keep track of physical assets, such as equipment or vehicles. Our location tracking products are often used in conjunction with software that displays maps, to show where people or things are located. These mapping functions we often sell as a service, to assist us in selling our location tracking products.

We have focused extensively on developing location tools since early 2002, and our primary business objective is to generate revenue and profit from the sale of our location tracking products and related services. The sale of these products and services resulted in small amounts of revenue late in the fiscal year ended September 30, 2002. Our revenue was $63,579 for the fiscal year ended September 30, 2003, and our revenue for the six months ended March 31, 2004 was $74,538, all derived from the sale of location tracking products and services. Our net losses were $952,564 and $1,883,489 for the years ended September 30, 2003 and 2002, respectively. Our net loss for the six month period ended March 31, 2004 was $418,190.

We also have developed products that are electronic components, some of which are used in radio equipment, and some of which have other application in the electronics field, such as in the memory systems of personal computers. All of these electronic component products have been issued U.S. patents. We focused extensively on developing these products and patenting them from 1996 through early 2002, with the objective of licensing these products to other electronic companies for their use. This strategy has not generated any revenue to date. In early 2002, our focus shifted away from further development of our electronic component products, but we continue to explore licensing opportunities for our component products from time to time, keeping in mind that our primary objective today is to sell our location tools products.

We originally incorporated as a Texas corporation in 1953. We changed our name to National Scientific Corporation in 1996 and we began the activities described in this prospectus. Our principal executive offices are located at 14455 North Hayden Road, Suite 202, Scottsdale, Arizona 85260 and our telephone number is (480) 948-8324. Our Internet site is www.national-scientific.com .

Recent Developments

On March 15, 2004, we commenced a private placement of units consisting of our common stock and warrants to purchase our common stock. On June 14, 2004, we completed this private placement. Each investor received our common stock and a five-year warrant to purchase three quarters of a share of common stock for each share purchased. We issued 10,334,266 shares of our common stock and warrants to purchase an aggregate of 7,750,700 shares of common stock. After deducting commissions and other expenses relating to the private placement, we received aggregate net proceeds of approximately $972,864. We also issued various seven-year warrants to purchase an aggregate of 2,308,497 shares of our common stock at a price of $0.10 per share to our placement agent.
 
  -5-  

 
Table of Contents
 
Risk Factors

For a discussion of some of the risks you should consider before purchasing shares of our common stock, you are urged to carefully review and consider the section entitled “Risk Factors” in this prospectus.

The Offering

The selling securityholders are identified in the section below of this prospectus entitled “Selling Securityholders” are offering on a resale basis a total of 21,033,463 shares of the following shares of our common stock:

·
10,334,266 shares of our common stock issued in connection with our March 15, 2004 private placement;
   
·
7,750,700 shares of our common stock issuable at a price of $0.11 per share upon the exercise of warrants issued to the Selling Securityholders in our March 15, 2004 private placement;
   
·
500,000 shares of our common stock issuable at a price of $0.10 per share upon the exercise of warrants issued to the placement agents as initiation warrants in connection with our March 15, 2004 private placement;
   
·
1,808,497 shares of our common stock issuable at a price of $0.10 per share upon the exercise of warrants issued to the placement agents as placement agent warrants in connection with our March 15, 2004 private placement;
   
·
640,000 shares of our common stock issuable at a price ranging from $0.13 to $0.15 per share upon the exercise of warrants issued to Strategic Working Capital Fund L.P. in connection with our January 6, 2004 financing.

 
Common Stock Offered by Selling Securityholders (includes 10,699,197 shares of common stock underlying warrants held by the Selling Securityholders)
 
21,033,463
     
Common Stock Outstanding before this Offering (includes 10,334,266 shares of the issued and outstanding common stock being offered by the Selling Securityholders) (1)
 
84,335,669
     
Common Stock Outstanding after this Offering (assumes all warrants of the Selling Securityholders to purchase 10,699,197 shares of common stock are exercised)
 
95,034,866
     
Common Stock to be Outstanding after this Offering (assumes all other currently issued and outstanding warrants and options which total 10,912,257, are exercised)
 
105,947,123
     
Use of Proceeds from Sale of Common Stock
 
We will not receive any proceeds from the sale of the shares of our Common Stock by the Selling Securityholders.
     
Use of Proceeds from Exercise of Warrants
 
We will receive the exercise price of any warrants that are exercised by the Selling Securityholders. We intend to use any proceeds from exercise of warrants for research and development, product marketing, working capital and other general corporate purposes.
     
NASD OTC Bulletin Board Symbol
 
NSCT
____________________
(1)     Outstanding shares of our common stock as of June 10, 2004. Does not include any outstanding options or warrants.
 
-6-  

 
Table of Contents
 

National Scientific Corporation
Selected Summary Financial Information
 
   
 
   
 
   
 
   
Six Months Ended  

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2004  

 

 

 

 

2001
2002
2003
(Unaudited)
 
   
 
 
 
 
Statement of Operations Data:
   
 
   
 
   
 
   
 
 

Net Revenues

   $ 882,715     $ 2,914     $ 63,579     $ 74,538   
Direct cost of revenues
   
869,750
   
1,889
   
25,848
   
55,998
 
Gross profit
   
12,965
   
1,025
   
37,731
   
18,540
 
 
   
 
   
 
   
 
   
 
 
Salaries and benefits
   
1,040,777
   
624,069
   
438,244
   
257,395
 
Research and development
   
1,589,005
   
154,548
   
84,301
   
9,398
 
Stock compensation
   
2,173,592
   
460,168
   
291,658
   
28,293
 
Consulting fees, related party
   
422,008
   
--
   
17,650
   
--
 
Other operating expenses
   
1,121,011
   
667,250
   
149,245
   
131,170
 
Total costs and expenses
   
6,346,393
   
1,906,035
   
981,098
   
426,256
 
Income (loss) from operations
   
(6,333,428
)
 
(1,905,010
)
 
(943,367
)
 
(407,716
)
Other income (expense) net
   
98,560
   
21,521
   
(9,197
)
 
(10,474
)
Net loss
 
$
(6,234,868
)
$
(1,883,489
)
$
(952,564
)
$
(418,190
)
   
 
 
 
 
 
   
 
   
 
   
 
   
 
 
Net loss per common share basic and diluted
 
$
(0.13
)
$
(0.04
)
$
(0.02
)
$
(0.01
)
 
   
 
   
 
   
 
   
 
 
 
 

      As of September 30,    

   
 

 

   
   
As of    
 
 

 

 

2001

 

 

2002

 

 

2003

 

 

March 31, 2004
 
   
 
 
 
 
  Balance Sheet Data:                          
Cash and cash equivalents
 
$
604,761
 
$
1,405
 
$
17,903
 
$
549,439
 
Total current assets
   
746,119
   
18,752
   
72,729
   
677,238
 
Total current liabilities
   
756,367
   
840,536
   
673,420
   
801,117
 
Long-term debt, net of current portion
   
--
   
--
   
43,250
   
43,250
 
Total stockholders' (deficit) equity
 
$
318,603
 
$
(771,746
)
$
(606,829
)
$
(136,480
)


This table is a summary of certain important financial results. Please see section below entitled “Financial Statements”
for a more complete and detailed presentation of our financial results.
 
-7-  

 
Table of Contents
 
Risk Factors

An investment in our common stock is very risky. You may lose the entire amount of your investment. Before you invest in shares of our common stock, you should be aware of various risks, including those described below. You should carefully consider these risk factors, together with all of the other information included in this prospectus, before you decide whether to purchase the shares of our common stock. The risks set out below are not the only risks we face.

If any of the following risks occur, our business, financial condition and results of operation could be materially and adversely affected. In such a case, the trading price of our common stock could decline, and you may lose all or part of your investment.

Keep these risk factors in mind when you read “forward-looking” statements elsewhere in this prospectus. These are statements that relate to our expectations for future events and time periods. Generally, the words, “anticipate,” “expect,” “intend” and similar expressions identify forward-looking statements. Forward-looking statements involve risks and uncertainties, and future events and circumstances could differ significantly from those anticipated in the forward-looking statements.

Risks Relating to our Business

We have experienced significant losses and we may never be profitable.

We have generated nominal revenue and significant losses and negative cash flows from our research and development endeavors since we began these activities in 1996. As of September 30, 2003, we had an accumulated deficit of $21,757,900. We had revenue for the fiscal year ended September 30, 2003 of $63,579, and a net loss for the same fiscal year of $952,564. The future profitability of our business will depend primarily on our ability to generate revenues from the sale of our products and the licensing of our technology. If our revenue grows at a slower rate than we anticipate or if our expenditures exceed our expectations or cannot be adjusted to reflect slower revenue growth, we may not achieve or sustain profitability. Our auditors have issued going concern opinions on our financial statements for the fiscal years ending September 30, 2002 and 2003.

Our future success is highly dependent on the continued availability of key employees and consultants including Michael Grollman and Graham Clark.

Our success depends substantially on the continued services of our two executive officers, Michael Grollman and Graham Clark. The loss of the services of any of our executive officers or key employees could harm our business. Mr. Grollman and Mr. Clark have entered into employment and non-compete agreements with us, but the loss of their services would have a material adverse effect on our business. In addition to Mr. Grollman and Mr. Clark, we employ or contract with other engineers and scientists who may be also critical to our success, especially Dr. El-Badawy El-Sharawy, who developed the majority of our semiconductor patented products. Although our scientists and engineers have entered into confidentiality agreements with us, most have not entered into non-compete agreements with us. The loss of one or more of our research personnel could prevent or delay the ongoing development of our products and services, which would materially and adversely affect our business.

We have a limited operating history on which to evaluate our business or prospects.

We are a development stage company with limited revenue. Our business focus changed in 2002 from semiconductor product licensing to development of location tools and we have only a limited operating history on which you can base an evaluation of our business and prospects, with only approximately $66,493 in net revenue generated from this new line of location tools business over the last two full fiscal years, and only approximately $74,538 from this line of business for the six month period ending March 31, 2004. Accordingly, our business prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development, particularly companies in new and rapidly evolving markets, such as the electronics and wireless location tools services markets.
 
-8-  

 
Table of Contents
 
We will require additional financing in order to complete the development of our products and services and otherwise develop our business operations. Such financing may not be available on acceptable terms, if at all.

We changed our business emphasis in 2002 and we do not know if our products will achieve significant levels of market acceptance. We may encounter unforeseen difficulties that may deplete our limited capital resources more rapidly than anticipated.

We will likely be required to make significant product development expenditures and spend additional money to maintain and expand our marketing efforts. Although we recently completed a private offering that should provide us with sufficient capital for the next twelve months, we may need to seek additional equity financing in the future if our products do not generate revenue or if our expenses are greater than expected. The timing and amount of any capital requirements cannot be predicted at this time. We cannot be sure that any financing will be available on acceptable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to continue, develop or expand our business, develop new products or penetrate existing markets at the rate desired and our ability to continue in business may be jeopardized. If adequate financing is not available, we may be required to terminate or significantly curtail our operations, or enter into arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, or potential markets that we would not otherwise relinquish. This could have a negative impact on the value of your shares.

We rely heavily on international third-parties to manufacture our products.

We currently lack the facilities to manufacture our products on a commercial scale . If any of our customers require our location tools in commercial quantities in the near term, we will have to rely on one or more third-party contractors, some of which are outside the United States such as Electroconnect, Ltd., to manufacture the products to satisfy the needs of such customers. Reliance on one or more international third-party manufacturers exposes us to the risk that delivery schedules cannot be met, and that we cannot fulfill orders for some of our products in a timely way at the right price in U.S. dollars. An example of a product we make outside the U.S. is our Gotcha!® child safety product, which Electroconnect, Ltd makes for us in Scotland. This risk includes the concern that:

·
Third-party manufacturers might be unable to manufacture our products in the volume and of the quality required to meet customers’ needs;
   
·
Our existing and future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our customers;
   
·
If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation.

Each of these conditions could delay the shipments to our customers, approvals required by regulatory authorities, and the commercialization of some of our customers’ products. These risks could also result in higher costs to the customer or could deprive us of potential product revenues.

We will need to significantly increase our sales and support operations.

We will need to create and substantially grow our direct and indirect sales operations, both domestically and internationally, in order to create and increase market awareness and sales of our products and services. For example, our IBUS™ products will require us to gain significant new sales skills in the education market. Our WiFi Tracker™ product will require us to gain new skills in the healthcare market. The sale of our products and services will require the engagement of sophisticated and highly knowledgeable sales personnel. Similarly, the anticipated complexity of our products and services and the difficulty of customizing them will require us to hire research and development personnel and customer service and support personnel, highly trained in hardware and software engineering. Competition between us and others to retain qualified sales personnel, engineers, and scientists is intense due to the limited number of available qualified candidates for such positions. Because of our limited resources, many of our competitors are in a financial position to offer potential employees greater compensation and benefits than those that we may be able offer them.
 
-9-  

 
Table of Contents
 
Risks Relating To Our Industry

We may be held liable for harm caused by products that our customers use.

Often times, our products are used to enhance the safety and security of individuals and organizations because they provide real time information on location. For example, our Gotcha!® is used to help keep track of children and keep them safe in public places. Should these products fail to perform as intended, or should these products directly or indirectly cause injuries or illness to people, we may be required to incur substantial costs in defending against claims and may be required to pay damages arising from these actions. Although we have liability insurance and will try to limit our liability for improper use of our products, such protections may not be sufficient to protect us from the cost of such claims. Damages awarded in a product liability action could be substantial and if damages exceed our insurance coverage, our financial condition would be negatively affected.

Since many of our prospective business partners and suppliers are small electronics and software companies, we are and will be subject to risks, uncertainties and trends that affect these small companies in these industries.

For the foreseeable future, we will derive a substantial portion of our revenue from selling our products in combination with software and hardware products developed by other companies in areas complementary to our line of business. These are sometimes other small technology companies. As a result, we will be subject to risks and uncertainties that affect the electronic and software industries and possible reduction and delays in research and development expenditures by companies in these industries. For example, our GPS products produce coordinates that are usually displayed on a map to be meaningful. As a result, we have developed partnerships with mapping software companies to help us display this data in ways useful to our customers. For special mapping services such as this, we often deal with small privately-held technology firms, such as Geotechnologies, Inc. for military and related applications, or Verify Systems for school bus tracking software and mapping applications. Although we take certain steps to locate secondary suppliers and partners in each market where we depend on such small suppliers, we are often dependant on these firms to supply us and our customers with key products in a timely way. High costs and delays in product delivery by us to our customers could be experienced as a result of supplier changeover if these suppliers do not perform as we expect them to perform. Additionally, smaller firms that issue us purchase orders for our products to include in offerings to their own customers, such as Verify Systems for our IBUS™ product, may not have the financial resources to meet the terms of their purchase orders should they be unsuccessful in generating their own sales to their own customer base in a timely way. These factors could negatively affect our delivery schedules and potentially our financial results.

The semiconductor and electronics markets experience wider demand and pricing fluctuations than most other industries.

We may experience extreme cyclical fluctuations in the demand and supply for our products, which may cause a decline in our sales or the prices of our products and a corresponding decline in our revenues and profitability. For example, our TMOS® memory products fall into a class of computer memory products that often see annual price swings of over 50% or more in particular lines of products, according to the reports issued by the Semiconductor Industry Association over the last 10 years. We believe, based on reports from the Semiconductor Industry Association and on the rate at which technologies in these markets become popular, and then rapidly obsolete, that year-to-year price swings in the semiconductor industry can be more extreme than in many other industries. Should we be successful in licensing our semiconductor patented designs at all, these kinds of extreme price swings could delay by several years the development of revenue from these patented semiconductor products.  
 
-10-  

 
 
Risks Relating to Our Technology

Some of our wireless technology is subject to substantial government regulation.

The wireless electronics industry faces significant regulation by governmental entities in the United States and other countries. The nature and the extent to which these regulations apply to our customers will vary depending on the nature of any of our customer’s products. Most of the wireless products developed by us will require regulatory approval by governmental agencies prior to sale. In particular, radios we include in our products will require testing and other approval procedures by the Federal Communications Commission (“FCC”) and by foreign regulatory authorities. Some of this work has been completed, such as FCC approval of our Gotcha!® child safety product. In some cases, we purchase pre-approved assemblies for use in our products that have existing FCC approval for their radios, such as with our IBUS™ products. Other work remains to be done for other products with the FCC before the products can be sold to consumers, such as with the next version of our WiFi Tracker™ product. The process of obtaining these approvals and the subsequent compliance with appropriate federal and foreign statutes and regulations can be costly and time consuming, and can cause significant delays in the sale of our some of our products.

We may not be able to license or maintain access to the technologies that we need to conduct our business, such as GPS.

In addition to the technologies that we develop, we will rely heavily on technologies that we license from other companies or institutions. We may not be able to license technologies that we need in the future or we may be unable to license such technologies on a commercially reasonable basis. In particular, we depend on wireless technologies such as GPS that have been developed and are owned by others. If we are unable to license the technologies we need in the future, or to license or otherwise acquire such technologies on commercially reasonable terms, we may experience increased costs (and, therefore, reduced profits) or be unable to engage in certain activities that require those technologies. In the case of GPS, we are dependant on the U.S. Department of Defense to operate a large network of GPS satellites safely and at a low cost to consumers into the future, without degrading the signal accuracy. Prior to the year 2000, the Department of Defense degraded GPS accuracy for civilian uses on a regular basis, and has reserved the right to do so again in the future, without warning. Such an action by the Department of Defense could make our GPS based products less accurate, and thus potentially less desirable to our customers, and have a negative effect on our sales.

Our success will depend on our ability to protect our proprietary technology, especially our location tools product designs.

Our rights to a substantial portion of our components products technology are as the assignee of several United States patents and patent applications. We also protect our intellectual property, especially for our location tools, through the use of confidentiality agreements and other trade secret management practices. We also hold U.S. trademarks, such as TMOS® and Gotcha!®. In the case of most of our patented electronic component products, we have a contractual obligation to pay royalties to Dr. El-Badawy El-Sharawy in the event that these products generate any royalties to us, in order to maintain these rights of assignment. Our success will depend largely on our ability to protect and exploit our intellectual property, to obtain additional patents for other technologies and products, to defend patents once obtained, and maintain trade secrets over time. Failure to do so may introduce domestic or foreign competition that could significantly reduce our ability to generate sales at acceptable margins.

Risks Related to Our Securities

A significant number of shares of our common stock may become available for sale and their sale could depress the price of our common stock.

A substantial number of shares of our common stock may be traded as a result of this offering. As of June 16, 2004, our total outstanding shares of common stock were approximately 84,360,669. As a result of this offering, 10,334,266 shares of our common stock that are currently restricted from trading will become free trading shares. An additional 10,699,197 shares could potentially also enter into the market of free trading shares if all the warrants included in this offering are exercised. We may also issue additional shares in connection with our business and may grant additional stock options to our employees, officers, directors and consultants or warrants to third parties. Sales of a substantial number of additional shares of our common stock in the public market after this offering could adversely affect the market price for our common stock and make it more difficult for you to sell our shares at times and prices that you feel are appropriate.
 
-11-  

 
Table of Contents
 
Our stock price has been volatile and we expect it to remain volatile, which could limit investors’ ability to sell stock at a profit at the time of the investor’s choosing.

We have a limited trading market for our common stock, and our common stock has experienced price volatility in that market. In fiscal 2002, our stock price ranged from a high of $0.39 to a low of $0.078 per share, and in fiscal 2003 our stock price ranged from a high of $0.225 to a low of $0.065. This price volatility may substantially increase your risk of loss.

The volatile price of our stock makes it difficult for investors to predict the value of their investment, to sell shares at a profit at any given time, or to plan purchases and sales in advance. A variety of factors may affect the market price of our common stock. These include, but are not limited to:

·
announcements of technological innovations or new commercial products by our competitors or us;
 
 
·
developments concerning proprietary rights, including patents;
 
 
·
regulatory developments in the United States and foreign countries;
 
 
·
economic or other crises and other external factors;
 
 
·
period-to-period fluctuations in our revenues and other results of operations;
 
 
·
changes in financial estimates by securities analysts; and
 
 
·
sales of our common stock.

We will not be able to control many of these factors, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.

In addition, the stock market in general, and the market for electronics companies in particular, has experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of individual companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may have a negative impact on your ability to sell shares of our stock.

Our Articles of Incorporation allow us to sell preferred stock without shareholder approval.

Our Board of Directors has the authority to issue up to 4,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any additional vote or action by our shareholders. The rights of the holders of the common stock will be subject to, and could be materially adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. For example we could issue preferred stock that has superior rights to dividends or is convertible into shares of common stock. This might adversely affect the market price of the common stock.

Trading of our common stock is limited.

Trading of our common stock is conducted on the National Association of Securities Dealers’ Over-the-Counter Bulletin Board, or “OTC Bulletin Board.” This adversely effects the liquidity of our common stock, not only in terms of the number of shares that can be bought and sold at a given price, but also through delays in the timing of transactions and reduction in security analysts’ and the media’s coverage of us. This may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between the bid and ask prices for our common stock.
 
-12-  

 
 
A Note About Forward-Looking Statements

This prospectus contains various forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our beliefs as well as assumptions made by and information currently available to us. For this purpose, any statements contained in this Prospectus that are not statements of historical fact may be deemed to be forward-looking statements. When used in this prospectus, the words “believe,” “expect,” “anticipate,” “estimate,” “plan” and similar expressions are intended to help identify forward-looking statements. These statements are subject to certain risks, uncertainties, and assumptions, including those identified under “Risk Factors” above. These statements by their nature involve substantial risks and uncertainties and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which our future customers participate; competition within our industry, including competition from much larger competitors; technological advances which could render our products less competitive or obsolete; failure by us to successfully develop new products or to anticipate current or prospective customers’ product needs; price increases or supply limitations for components purchased by us for use in its products; and delays, reductions, or cancellation of orders that may be placed with us. There can be no assurance that we will be able to develop our products or markets for our products in the future.
 
Use of Proceeds

We will not receive any proceeds from the Selling Securityholders’ sale of shares of our common stock. However, we will receive the proceeds from any sale of common stock to the Selling Securityholders upon the exercise of the Selling Securityholders’ warrants, when and if they are exercised. We may also receive proceeds from the exercise of the placement agent’s warrants, when and if they are exercised.

If the Selling Securityholder’s exercise their warrants, then we expect to use substantially all the net proceeds for research and development of our products, and expansion of sales and marketing activities, debt repayment, and other general working capital and corporate purposes. The amounts we actually expend for working capital and other purposes may vary significantly and will depend on a number of factors including, but not limited to, the actual net proceeds received, if any, the amount of our future revenues and other factors described under “Risk Factors.” Accordingly, our management will retain broad discretion in the allocation of the net proceeds of these funds. A portion of the net proceeds may also be used to acquire or invest in complementary businesses, technologies, product lines or products.
 
-13-  

 
Table of Contents
 
Market for Common Equity and Related Stockholder Matters

Our common stock is quoted and traded on a limited and sporadic basis on the OTC Bulletin Board operated by The NASDAQ Stock Market, Inc. under the trading symbol “NSCT.” The limited and sporadic trading does not constitute, nor should it be considered, an established public trading market for our common stock. We have 875 stockholders of record of our common stock as of May 31, 2004. The following table sets forth the high and low closing sale prices for our common stock for the periods indicated, as reported by the OTC Bulletin Board, NASDAQ Trading and Market Services.

Market for Common Equity
   
High
   
Low
 

 
 
 
Fiscal 2004 (Year to Date)
   
 
   
 
 
Two Months (through May 31, 2004)
 
$
0.190
 
$
0.120
 
Second Quarter (through March 31, 2004)
 
$
0.200
 
$
0.135
 
First Quarter (through December 31, 2003)
 
$
0.205
 
$
0.130
 
 
   
 
   
 
 
Fiscal 2003
   
 
   
 
 
Fourth Quarter (through September 30, 2003)
 
$
0.210
 
$
0.145
 
Third Quarter (through June 30, 2003)
 
$
0.225
 
$
0.095
 
Second Quarter (through March 31, 2003)
 
$
0.170
 
$
0.085
 
First Quarter (through December 31, 2002)
 
$
0.220
 
$
0.065
 
 
   
 
   
 
 
Fiscal 2002
   
 
   
 
 
Fourth Quarter (through September 30, 2002)
 
$
0.160
 
$
0.078
 
Third Quarter (through June 30, 2002)
 
$
0.205
 
$
0.140
 
Second Quarter (through March 31, 2002)
 
$
0.265
 
$
0.135
 
First Quarter (through December 31, 2001)
 
$
0.390
 
$
0.220
 

Dividends
 
We have never declared or paid any cash dividends on our common stock. We anticipate that any earnings will be retained for development and expansion of our business and we do not anticipate paying any cash dividends in the near future. Our board of directors has sole discretion to pay cash dividends or other dividends with respect to our common stock based on our financial condition, results of operations, capital requirements, contractual obligations and other relevant factors.

Impact of the “Penny Stock” Rules on Buying or Selling our Common Stock

Trading in our common stock is subject to the “penny stock” rules. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share. These rules require that any broker-dealer who recommends our securities to persons other than prior customers and accredited investors, must, before the sale, make a special written suitability determination for the purchaser and receive the purchaser’s written agreement to execute the transaction. In addition, unless an exception is available, the broker-dealer must deliver a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market prior to any transaction. Further, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers by such requirements may discourage them from transactions in our common stock, which could severely limit the market price and liquidity of our securities.
 
-14-  

 
Table of Contents
 
Plan of Distribution

Manner of Sale

The shares being offered by the Selling Securityholders may be sold from time to time in one or more transactions (which may involve block transactions):

·
on the OTC Bulletin Board or on such other market on which the common stock may from time to time be trading;
   
·
in privately-negotiated transactions;
   
·
short sales; or
   
·
any combination of the above.

The sale price to the public may be the market price prevailing at the time of sale, a price related to the prevailing market price, at negotiated prices or another price as the Selling Securityholders determine from time to time. The shares may also be sold pursuant to Rule 144. The Selling Securityholders have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if they deem the purchase price to be unsatisfactory at any particular time.

The Selling Securityholders may also sell the shares directly to market makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the Selling Securityholders and/or the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principal, or both, which compensation as to a particular broker-dealer might be in excess of customary commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. It is possible that a Selling Securityholder will attempt to sell shares of common stock in block transactions to market makers or other purchasers at a price per share that may be below the then market price. There can be no assurance that all or any of the shares offered by this prospectus will be sold by the Selling Securityholders. The Selling Securityholders and any brokers, dealers or agents, upon effecting the sale of any of the shares offered by this prospectus, may be deemed "underwriters" as that term is defined under the Securities Act of 1933 or the Securities Exchange Act of 1934, or the rules and regulations there under.

The Selling Securityholders and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Securities Exchange Act of 1934 and the rules and regulations there under, including, without limitation, Regulation M, which may restrict certain activities of, and limit the timing of purchases and sales of any of the shares by the Selling Securityholders or any other such person. Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period of time prior to the commencement of such distributions, subject to specified exceptions or exemptions. All of these limitations may affect the marketability of the shares.

Grant of Registration Rights

We granted registration rights to the Selling Securityholders to enable them to sell the common stock and shares underlying the warrants they purchased from us. In connection with any such registration, we will have no obligation:
 
-15-  

 
Table of Contents
 

·
to assist or cooperate with the Selling Securityholders in the offering or disposition of such shares;
   
·
to indemnify or hold harmless the holders of any such shares, other than the Selling Securityholders, or any underwriter designated by such holders;
   
·
to obtain a commitment from an underwriter relative to the sale of any such shares;
   
·
We assume no obligation or responsibility whatsoever to determine a method of disposition for such shares.

We will use our best efforts to file, during any period during which we are required to do so under our agreement with the Selling Securityholders, one or more post-effective amendments to the registration statement of which this prospectus is a part to describe any material information with respect to the plan of distribution not previously disclosed in this prospectus or any material change to such information in this prospectus. This obligation may include, to the extent required under the Securities Act of 1933, that a supplemental prospectus be filed, disclosing:

·
the name of any broker-dealers;
 
 
·
the number of common shares involved;
 
 
·
the price at which the common shares are to be sold;
 
 
·
the commissions paid or discounts or concessions allowed to broker-dealers, where applicable;
 
 
·
that broker-dealers did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, as supplemented; and
 
 
·
any other facts material to the transaction.

 
-16-  

 
Table of Contents
 
Selling Securityholders

The following table sets forth the name of each Selling Securityholder, the number of shares of common stock and the number of shares underlying the warrants owned by each Selling Securityholder. Because the Selling Securityholders may sell all, a portion or none of their shares, no estimate can be made of the aggregate number of shares that may actually be sold by any Selling Securityholder or that may be subsequently owned by any Selling Securityholder.

The shares offered by this prospectus may be sold from time to time by the Selling Securityholders listed below. This table includes shares of common stock known to us to be owned outright by the Selling Securityholders listed below, as well as shares of common stock underlying warrants owned by the Selling Securityholders.

 

 

Number of Shares Offered Under This Offeri ng  
 
 
 
 
 

 
 
 
                 

Number of   

       
 
 
 
 
 
 
 
 
 
Shares   Offered By
 
 
 
 
 
 
 
Number of Shares  
 
 
Number Of Shares
 
 
SellingSecurityholder
 
 
 
 
 
 
 
Beneficially Owned
 
 
Offered By Selling
 
 
 Upon Exercise
 
 
Percent of
 
Selling Securityholders
 
 
Before Offering (1)
 
 
Securityholder
 
 
 of Warrants (2)
 
 
Class (3)
 

 
 
 
 
 
Source One
   
300,000
   
300,000
   
225,000
   
*
 
Stephen M. Abbott & Patricia N. Abbott
   
200,000
   
200,000
   
150,000
   
*
 
Rocco J. Brescia Jr.
   
220,000
   
220,000
   
165,000
   
*
 
George R. Martin
   
100,000
   
100,000
   
75,000
   
*
 
Donald L. Massey
   
300,000
   
300,000
   
225,000
   
*
 
Garry Higdem
   
200,000
   
200,000
   
150,000
   
*
 
Steven A. Heggelke
   
125,000
   
125,000
   
93,750
   
*
 
Keith D. Camp
   
200,000
   
200,000
   
150,000
   
*
 
Paul Coplan
   
45,455
   
45,455
   
34,091
   
*
 
Greg John Dawe
   
700,000
   
700,000
   
525,000
   
1.29
%
Daniel E. Larson
   
100,000
   
100,000
   
75,000
   
*
 
Murray W. Grigg
   
500,000
   
500,000
   
375,000
   
*
 
Joseph B. Ryan Jr.
   
100,000
   
100,000
   
75,000
   
*
 
John Igoe
   
150,000
   
150,000
   
112,500
   
*
 
Joseph Kump & Joan Kump
   
46,000
   
46,000
   
34,500
   
*
 
William M. & Deborah Haskell
   
100,000
   
100,000
   
75,000
   
*
 
Richard A. Jacoby
   
250,000
   
250,000
   
187,500
   
*
 
James W. Robertson
   
100,000
   
100,000
   
75,000
   
*
 
Michael Grabert
   
60,000
   
60,000
   
45,000
   
*
 
Andrew Denka
   
800,000
   
800,000
   
600,000
   
1.47
%
Ronald Danielak
   
20,000
   
20,000
   
15,000
   
*
 
Larry D. Hunter
   
50,000
   
50,000
   
37,500
   
*
 
David R. Beck
   
100,000
   
100,000
   
75,000
   
*
 
John Younts
   
100,000
   
100,000
   
75,000
   
*
 
Marc C. McGeever
   
50,000
   
50,000
   
37,500
   
*
 
Christopher J. Whyman
   
68,182
   
68,182
   
51,136
   
*
 
Denno Family Limited Partnership
   
200,000
   
200,000
   
150,000
   
*
 
Joseph P. Kalinoski
   
100,000
   
100,000
   
75,000
   
*
 
Thomas G. Howard
   
20,000
   
20,000
   
15,000
   
*
 
Gregg Brune
   
50,000
   
50,000
   
37,500
   
*
 
Gregory W. Nelson & Judy C. Nelson
   
100,000
   
100,000
   
75,000
   
*
 
Michael Lusk
   
100,000
   
100,000
   
75,000
   
*
 
 
-17-  

 
 

 

Number of Shares Offered Under This Offeri ng  
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
Number of   
 
 
 
 
 
 
 
 
 
 
 
 
 
Shares Offered By   
 
 
 
 
 
 
 
Number of Shares  
 
 
Number of Shares
 
 
Selling Securityholder
 
 
 
 
 
 
 
Beneficially Owned  
 
 
Offered By Selling
 
 
 Upon Exercise
 
 
Percent of
 
Selling Securityholders
 
 
Before Offering (1)
 
 
Securityholder
 
 
 of Warrants (2)
 
 
Class (3)
 

 


 


 


 


 

Dorothy Cox Paris Q-Tip Trust
   
30,000
   
30,000
   
22,500
   
*
 
David E. Hallberg
   
20,000
   
20,000
   
15,000
   
*
 
Philip W. Madow & Amber D. Madow
   
65,000
   
65,000
   
48,750
   
*
 
Graham Richards & Mireya Richards
   
100,000
   
100,000
   
75,000
   
*
 
Kim D. Biggs & Kimberly S. Biggs
   
20,000
   
20,000
   
15,000
   
*
 
Govin T. Rajan
   
50,000
   
50,000
   
37,500
   
*
 
Gary Meteer
   
45,455
   
45,455
   
34,091
   
*
 
Rock II, LLC
   
500,000
   
500,000
   
375,000
   
*
 
Hargopal Singh
   
50,000
   
50,000
   
37,500
   
*
 
Patrick R. Discepola
   
12,000
   
12,000
   
9,000
   
*
 
Mark L. Merhar
   
10,000
   
10,000
   
7,500
   
*
 
Thomas Webber
   
20,000
   
20,000
   
15,000
   
*
 
Michael J. Maloney
   
100,000
   
100,000
   
75,000
   
*
 
SRG Capital, LLC
   
300,000
   
300,000
   
225,000
   
*
 
Gerard Caviston
   
250,000
   
250,000
   
187,500
   
*
 
Gordon Gregoretti
   
200,000
   
200,000
   
150,000
   
*
 
Hugh W. Richardson
   
90,909
   
90,909
   
68,182
   
*
 
Gregory C. Herr & Carol Herr
   
30,000
   
30,000
   
22,500
   
*
 
Thomas J. Banholzer
   
90,909
   
90,909
   
68,182
   
*
 
Gerald H. Negley
   
50,000
   
50,000
   
37,500
   
*
 
John R. Lower
   
90,909
   
90,909
   
68,182
   
*
 
Gerald L. Meyr
   
140,000
   
140,000
   
105,000
   
*
 
Gary L. Willoughby & Sarah Willoughby
   
200,000
   
200,000
   
150,000
   
*
 
Kevin T. Crofton
   
100,000
   
100,000
   
75,000
   
*
 
Manish Gupta & Charu Gupta
   
20,000
   
20,000
   
15,000
   
*
 
Herman David Overbeeke
   
250,000
   
250,000
   
187,500
   
*
 
Paul Mikkola & Pamela Mikkola
   
50,000
   
50,000
   
37,500
   
*
 
Raymond A. Fox
   
37,000
   
37,000
   
27,750
   
*
 
William A. Weeks
   
50,000
   
50,000
   
37,500
   
*
 
John Pirillo
   
200,000
   
200,000
   
150,000
   
*
 
M.O. Hess & Martha S. Hess
   
50,000
   
50,000
   
37,500
   
*
 
Jeffrey R. Freeman
   
50,000
   
50,000
   
37,500
   
*
 
Daniel Bettencourt
   
20,000
   
20,000
   
15,000
   
*
 
Matthew J. Rund
   
100,000
   
100,000
   
75,000
   
*
 
Hartley D. Blaha
   
100,000
   
100,000
   
75,000
   
*
 
Michael Lauria
   
181,818
   
181,818
   
136,364
   
*
 
Stuart Bunting
   
100,000
   
100,000
   
75,000
   
*
 
David D. Le Norman
   
95,000
   
95,000
   
71,250
   
*
 
William R. Seybold
   
50,000
   
50,000
   
37,500
   
*
 
Suman T. Patel & Shobhana Patel
   
50,000
   
50,000
   
37,500
   
*
 
Ron Lucas
   
91,000
   
91,000
   
68,250
   
*
 
Richard Sahagian
   
20,000
   
20,000
   
15,000
   
*
 
Nancy Elaine Mc Govern
   
136,400
   
136,400
   
102,300
   
*
 
Iqbal Dar
   
45,500
   
45,500
   
34,125
   
*
 
 
-18-  

 
 
 
Number of Shares Offered Under This Offeri ng  
 
 
 
   
     
 
   
 
   
 
   
Number of   

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Offered By   

 

 

 

 

 

 

 

Number of Shares  

 

 

Number Of Shares

 

 

Selling Securityholder

 

 

 

 

 

 

 

Beneficially Owned  

 

 

Offered By Selling

 

 

 Upon Exercise

 

 

Percent of

 

Selling Securityholders

 

 

Before Offering (1)
 

 

Securityholder

 

 

 of Warrants (2)
 

 

Class (3)
 

 
 
 
 
 
James C. Collings
   
27,275
   
27,275
   
20,456
   
*
 
Michael Bray & Mary A. Bray
   
55,000
   
55,000
   
41,250
   
*
 
Michael A. Mohr & Denise A. Mohr
   
100,000
   
100,000
   
75,000
   
*
 
Paul E. Meyr Revocable Living Trust
   
140,000
   
140,000
   
105,000
   
*
 
Robert Marino
   
50,000
   
50,000
   
37,500
   
*
 
Douglas Spangler
   
45,454
   
45,454
   
34,091
   
*
 
Gerrard A. Rutter & Gillian T. Rutter
   
100,000
   
100,000
   
75,000
   
*
 
Strategic Working Capital Fund (4)
   
 
   
 
   
640,000
   
*
 
Richard F. Sands
   
 
   
 
   
950,000
   
*
 
Wayde Walker
   
 
   
 
   
303,069
   
*
 
Kevin Wilson
   
 
   
 
   
30,000
   
*
 
Richard Brewster
   
 
   
 
   
30,000
   
*
 
Rafael Vasquez
   
 
   
 
   
30,000
   
*
 
Matthew Eitner
   
 
   
 
   
30,000
   
*
 
Matthew Richard McGovern Living Trust Dated 7/28/2000, c/o Matthew R. McGovern - Trustee
   
 
   
 
   
377,250
   
*
 
Nathaniel Clay
   
 
   
 
   
20,000
   
*
 
William Poon
   
 
   
 
   
20,000
   
*
 
Shraga Faskowitz
   
 
   
 
   
20,000
   
*
 
Richard Michalski
   
 
   
 
   
10,000
   
*
 
Brian Smith
   
 
   
 
   
10,000
   
*
 
James Ahern
   
 
   
 
   
10,000
   
*
 
Scott Kenneth Steele
   
 
   
 
   
10,000
   
*
 
Anthony Miller
   
 
   
 
   
10,000
   
*
 
Alan Feldman
   
 
   
 
   
40,000
   
*
 
Charles Savage
   
 
   
 
   
151,226
   
*
 
David Bloom
   
 
   
 
   
10,000
   
*
 
Matthew E. Donohue
   
 
   
 
   
10,000
   
*
 
David Roth
   
 
   
 
   
10,500
   
*
 
Thomas Gaito
   
 
   
 
   
3,804
   
*
 
Kent Mitchell
   
 
   
 
   
10,000
   
*
 
Ian O’Brien Rupert
   
 
   
 
   
10,000
   
*
 
Jonathan Gutman
   
 
   
 
   
15,000
   
*
 
Michael R. Hamblett
   
 
   
 
   
93,823
   
*
 
Anthony J. Spatacco Jr.
   
 
   
 
   
46,912
   
*
 
Starboard Capital Markets, LLC
   
 
   
 
   
46,913
   
*
 
     
  
   
  
   
  
   
  
 
Subtotal by Share and Warrant Category
   
10,334,266
   
10,334,266
   
10,699,197
   
 
 
               
Grand Total (All Shares & Shares Underlying Warrants )
 
       
21,033,463         
22.13
%
__________________

*
Less than 1%.
(1)
Includes 10,334,266 shares of our outstanding common stock issued in connection with our March 15, 2004 private placement of units.
 
-19-  

 
(2)
Includes the following: (i) 7,750,700 Investor warrants to purchase our common stock, dated April 8, 2004, to various purchasers in our March 15, 2004 private placement of units; (ii) 500,000 Initiation warrants, dated February 9, 2004, issued in conjunction with National Scientific's March 15, 2004 private placement, to Richard F. Sands and Wayde Walker, employees of Casimir Capital L.P., and the Matthew Richard McGovern Living Trust Dated 7/28/2000, c/o Matthew R. McGovern – Trustee (Matthew R. McGovern is an employee of Casimir Capital); (iii) 1,808,497 Placement Agent warrants to purchase our common stock, dated April 8, 2004, to employees of our employees of our Placement Agent, Casimir Capital L.P. or employees of their associated firm Starboard Capital LLC , in conjunction with our March 15, 2004 private placement of units; and (iv) 640,000 warrants to purchase common stock, dated January 6, 2004, to Strategic Working Capital Fund L.P., in conjunction with National Scientific’s financing January 2004.
(3)
Based on 95,034,866 shares outstanding, which assumes that all warrants of the Selling Securityholders to purchase 10,699,197 shares of common stock are exercised.
(4)
All securities held by persons listed in this table from this row and below are beneficially held by employees of our Placement Agent, Casimir Capital L.P., other than Michael R. Hamblett and Anthony J. Spatacco Jr., who are employees of Starboard Capital LLC., and Starboard Capital LLC, which is a limited liability company, and Strategic Working Capital Fund L.P., which is a limited partnership.


Casimir Capital L.P. (“Casimir”) has acted as placement agent in connection with the sale of our common stock and warrants to all of the Selling Securityholders, except Strategic Working Capital Fund L.P. Casimir’s duties as placement agent were undertaken on a best efforts basis only. It made no commitment to purchase shares from us and did not ensure us of the successful sale of any securities. Prior to our private placement in conjunction with Casimir, Casimir did not own any of our securities, although three principles in Casimir, Richard F. Sands, Wayde Walker, and Matthew R. McGovern, beneficially held 500,000 initiation warrants to purchase our common stock, which were issued in February 2004 in conjunction with the March 15, 2004 private offering. Casimir is a registered securities broker dealer. A separate registered securities broker, Starboard Capital LLC, assisted Casimir with a small portion of the placement agent activities associated with our March 15, 2004 private placement of units.

Neither the Selling Securityholders nor Casimir Capital have held any positions or offices or had material relationships with us or any of our affiliates within the past three years other than as a result of the ownership of warrants to purchase our common stock. Starting March 15, 2004, Casimir was granted the right to appoint one person to our advisory board, and the right to appoint one person as an observer to our board of directors for an eighteen-month period. Casimir also has a first right of refusal agreement on future financing we may do over the next eighteen months, including certain non-exclusive rights related to potential mergers and acquisitions. If, in the future, the Selling Securityholders’ or Casimir’s relationship with us changes, we will amend or supplement this prospectus to update this disclosure.
 
-20-  

 
Table of Contents
 
Management’s Discussion, Analysis and Plan of Operation

Overview

Our business focuses on the research, development and sale of location tools used to track or monitor people or objects such as vehicles or other mobile equipment. We also own devices and designs that are used in the semiconductor and electronics industries.

From 1996 to 2002, we engaged primarily in developing devices and designs that are used in the semiconductor and electronics industries. This resulted in a number of U.S. patents, but did not produce any significant amount of revenue. Additionally, during the period from 2000 to 2001 we engaged in the business of distributing electronic and other semiconductor-related products to customers in Asia and the United States in order to generate revenue. In 2001, we discontinued those activities because they did not produce the profit margins we had originally expected.

In 2002, we began to focus on applications of electronic devices in the location tools market. We also began to decrease our focus on semiconductor designs and devices, due primarily to difficult market conditions in the semiconductor industry. We plan to continue our focus on location tools for the foreseeable future.

Our first shipment and sale of our location tools began with the sale and shipment of our Followit™ product in August 2002.

In December of 2002, we entered into an agreement with Electroconnect of Scotland to produce a prototype and then manufacture our Gotcha!® product. This agreement is based on us paying for units as ordered, and does not require minimum purchase amounts.

In December 2002, we entered into an agreement with FutureCom Global, Inc. (FCG) of Arizona to assist us in the marketing and distribution of our location tools. The term of the agreement is two years and it is renewable for up to one additional year. The agreement allows FCG to market our Followit™, StarPilot™, and Gotcha!® products through media and trade shows, as well as through networks of sales representatives in a variety of consumer marketplaces, including general retail. The agreement may be expanded to include stocking of our products by FCG. FCG currently provides some stocking for our Gotcha!® line of products. The agreement does not require minimum purchase amounts.

Our sales during the fiscal year ending September 30, 2003, and for the six month period ending March 31, 2004, have consisted largely of sales of our Gotcha!® child safety product through FutureCom Global, and to a lesser extent of our GPS related products, included IBUS™ to Verify Systems and early prototype versions of the TrakJack™ product to Positus Corp. During this period, we have generally seen a gradual increase in the total sales on a quarter-to-quarter basis, although we can make no assurance that this trend will continue into any future periods.

We currently hold U.S. patents on eight devices and designs and have several domestic patent applications pending. Most of our patent work is focused on protection in the United States today, due to the high cost of acquiring and maintaining patents in other markets. We plan to continue to develop our existing patented technologies as well as develop new performance-enhancing devices and designs for use in the semiconductor, electronics and location industries. Our business plan contemplates that we will generate revenue by entering into strategic joint venture licensing agreements, manufacturing agreements, development agreements, distribution and marketing agreements and other arrangements with firms and/or entities that will either incorporate our technologies into their product offerings or sell them directly to their customers.
 
-21-  

 
Table of Contents
 
Results of Operations

Years Ended September 30, 2003 and 2002

Our revenue was $63,579 and $2,914 for the fiscal years ended September 30, 2003 and 2002, respectively. Although we reported revenues of $882,715 during the fiscal year ended September 30, 2001 the revenue was derived from our distribution activities that we no longer conduct. Sales for the year ended September 30, 2003 represent the sale and delivery of our Followit™, IBUS™, TrakJack™ and Gotcha!® lines.

Our net losses were $952,564 and $1,883,489 for the fiscal years ended September 30, 2003 and 2002, respectively.

Our research and development expenditures decreased to $84,301 for the fiscal year ended September 30, 2003, from $154,548 for the fiscal year ended September 30, 2002. The decrease in research and development costs in fiscal 2003 was primarily attributable to the shift of resources from capital-intensive semiconductor-related development projects to more labor-intensive location service technology-related projects.

Our total costs and expenses decreased significantly to $981,098 in fiscal 2003 from $1,906,035 in fiscal 2002. Salaries and benefits were reduced to $438,244 in fiscal 2003, down from $624,069 in 2002. This decrease is attributable to staff reductions, pay cuts, and the movement of some staff from full time to part time status.

Our stock compensation expenses declined to $291,658 in fiscal 2003 from $460,168 in fiscal 2002. In fiscal 2003 the majority of the stock compensation expense related to the issuance of vested options to employees and consultants at an exercise price that was below the then-current market value. These options were granted in order to conserve operating cash.

Other expenses declined in fiscal 2003 to $149,245 from $667,250 in fiscal 2002 as a result of the reduction in personnel, insurance costs, filing fees, legal expenses, and contract services.

Our accounts payable declined from $368,952 on September 30, 2002, to $185,725 on September 30, 2003. In late March of 2003, we settled a liability and reduced our accounts payable by approximately $150,000, which resulted in the majority of this decline.

Six Months ended March 31, 2004 vs. Six Months ended March 31, 2003

Our revenue was $74,538 for the six months ended March 31, 2004, up from $18,548 for the six months ended March 31, 2003. Sales for the six months ended March 31, 2004 represent the sale and delivery of our Followit™, and Gotcha!® lines.

Our net losses were $418,190, for six months ended March 31, 2004 compared to $358,670 for the six months ended March 31, 2003.

Our research and development expenditures decreased from $21,177 for the six months ended March 31, 2003 to $9,398 for the six months ended March 31, 2004. This trend is expected to reverse during the second half of fiscal year 2004, as research funding is planned to increase in the near term. We have focused an increasingly significant amount of our time, energy, and resources on development of new sources of revenue through the building of new customer relationships.

Our total costs and expenses for the six months ended March 31, 2004 increased to approximately $426,256 from $370,305 in the comparable period ended March 31, 2003. Salaries and benefits increased primarily due to the hiring of two full time engineers just before the end of the last fiscal year. Stock compensation was reduced to $28,293 during the first six months of fiscal year 2004, down from $109,980 during the first six months of fiscal year 2003. Other expenses increased to $131,170 for the first six months of fiscal 2004 compared to $44,172 in the comparable period of fiscal 2003.
 
-22-  

 
 
On March 31, 2004, our accounts payable were $266,879, down from $462,893 on March 31, 2003. During the six months ended March 31, 2004 the increase in our payables from the end of fiscal 2003 was largely driven by purchases of Gotcha!® products from our manufacturer that we held in inventory.

Liquidity and Capital Resources

We have generated only limited revenue and we have not been profitable. We have experienced a cash flow deficit from operations due to our development stage, substantial on-going investment in research, and due to extensive development efforts. Consequently, we have been dependent on equity and debt financing to fund our cash requirements.

For the six months ended March 31, 2004 and years ended September 30, 2003 and 2002, we generated a total net cash flow from the financing activities, principally the sale of equity, of approximately $1,590,000. Over the same period, we had negative cash flow from operations of approximately $ 1,913,000 .

As of September 30, 2003, our cash and cash equivalents totaled $17,903 and total current assets were $72,729. We have recently initiated product-marketing efforts after several years of research and development and have not yet reached break-even in terms of both cash flow and profitability. As of September 30, 2003, our long-term debt totaled $43,250 and total liabilities were $716,670. Total liabilities increased to $844,367 at March 31, 2004 due to the debt-based short term financing program of January 2004 of approximately $160,000, and a build up of trade payables largely driven by inventory purchases of Gotcha!® products from our manufacturer in Scotland. The $160,000 note from the January 2004 financing was repaid in full in May 2004.

The equity financing we have engaged in since 2001 has involved the private placement of our common stock and warrants to purchase our common stock pursuant to exemptions from federal and state registration.

In May 2001, we entered into a common stock purchase agreement with Coriander Enterprises Limited, a British Virgin Islands corporation, for the future issuance and sale of shares of our common stock. This stock purchase agreement established an equity line of credit. Under this arrangement we were to make up to 24 draw down requests over a two year period, pursuant to which Coriander Enterprises was obligated to purchase up to $24 million of our common stock, at prices that would vary based upon the market price of the common stock. As of August 2002, changes in the market price and/or trading volume of our common stock limited our ability to draw down funds under the equity line of credit, and we permanently ceased to use it. Through the life of this line, we drew down approximately a gross amount $430,000 and in the process sold approximately 2,122,063 of shares of our common stock to Coriander Enterprises Limited.

In November 2002, we began a private offering of common stock and common stock purchase warrants. We received $470,000 in cash and $30,000 in debt forgiveness from this effort and we issued 12,125,000 shares of common stock and granted warrants to purchase 4,800,000 shares of common stock at an exercise price of $0.30 per share and warrants to purchase 200,000 shares at a price of $0.50 per share. These warrants expire in December 2004.

In June 2003, we began a private offering of common stock and common stock purchase warrants. From June 2003 through March 2004 when this offering was closed, we received a total of approximately $310,000 in cash, we issued 3,600,000 shares of our restricted common stock, and we issued 2,550,000 warrants to purchase our common stock at exercise prices ranging from $0.50 to $0.75 per share. The term of these warrants is three years.

In January of 2004, we entered into a debt-based short term financing program with a U.S. investment fund, or bridge-financing program. The terms of this program included a six-month Note payable at maturity in July 2004 for $160,000, at an effective annual interest rate of 13%. The transaction also included three year warrants to purchase 640,000 shares of our restricted common stock, at $0.13 during the first and second year of the warrants’ lifetime, and $0.15 during the third and final year of the warrants’ lifetime. These warrants include anti-dilution provisions, as well as registration rights in the event that we file an appropriate registration statement with the SEC during the next three years. The $160,000 Note was repaid in full in May of 2004.
 
-23-  

 
On March 15, 2004, we commenced a private placement of units consisting of one share of common stock and a warrant to purchase .75 shares of common stock. The initial closing was on April 8, 2004, with aggregate gross proceeds of approximately $1.1 million. We issued 10,334,266 shares of restricted common stock and warrants to purchase 7,750,700 shares of common stock at an exercise price of $0.11 per share. The warrants have a term of five years, and include certain registration rights. As of April 8, 2004 the cash proceeds to us, net of expenses to date, totaled $972,864. We intend to use part of the proceeds of the private placement to finance the continued development and marketing of Wi-Fi® and RFID related Location Tools™ products. In addition, we plan to use part of the proceeds for expanded marketing and sales efforts, for further commercialization of our other Location Tools™ product line, and for other corporate purposes.

We have an accumulated deficit of approximately $21.7 million as of September 30, 2003, which includes approximately $10 million of non-cash transactions, in fiscal years 2000 and 2001, for restricted common stock issued as payment for research, consulting and other services. We expect operating losses in the foreseeable future as we continue our efforts to commercially exploit our portfolio of patents and develop commercial products. Accumulated cash used in operating services from our inception to September 30, 2003 totaled approximately $6.9 million.

We believe that our current working capital, together with the proceeds of our most recent private placement and projected funds generated from sales of our locator products, will be sufficient to fund our operations for the next twelve months. This belief assumes the salary and consulting fee deferral programs described elsewhere in this prospectus remain in effect and that certain of our employees continue to accept a portion of their monthly salaries in options or shares of common stock. However, we may be required to raise additional capital in equity markets. Our ability to raise additional capital in public markets will be primarily dependent upon prevailing market conditions and the demand for our products and services. No assurance can be given that we will be able to raise additional capital, when needed or at all, or that such capital, if available, will be on acceptable terms. Failure to raise capital or generate sufficient sales to meet our creditors’ demands as well as working capital for ongoing operations could result in our failure to continue as a going concern.
 
-24-  

 

Overview

National Scientific Corporation was originally formed in 1953 as American Mortgage Company, Inc., a Texas corporation. In 1993, we became a subsidiary of A.F.M.S., Inc. In 1994, U.S. Network Funding, Inc., acquired A.F.M.S., Inc., including a controlling interest in American Mortgage Company, Inc. In 1995, U.S. Network Funding, Inc., divested itself of A.F.M.S., Inc. and made a dividend distribution of its common shares of American Mortgage Company, Inc. to its shareholders. On May 16, 1996, we changed our name to National Scientific Corporation and began our current operations.

From May 1996 until February of 2002, we focused primarily on research and development of certain technology relating to semiconductor devices. This research and development resulted in several patented designs or devices. When the semiconductor industry experienced a major decline in 2001, our ability to access the necessary capital to continue our semiconductor research and development effort was severely limited. We then changed the focus of National Scientific away from basic semiconductor research and development. In February of 2002, we began to focus on applications of electronic and radio devices in the location services market. The location services market involves products that track (or locate) the indoor or outdoor whereabouts of people and property. We have a special focus on applications that relate to using this technology to keep children safe, but we develop products for other tracking applications as well.

We plan to continue our focus on developing and selling our location products for the foreseeable future. Much of our effort since February 2002 has been devoted to developing, licensing, and acquiring technologies related to location services. To date, we have designed and developed a number of products on our own, and acquired rights to specific hardware and software developed by others for use in our offering to our customers. Our development of location products and subsequent sales efforts resulted in revenue of $2,914 late in the fiscal year ended September 30, 2002. Our revenue from these products increased to $63,579 for the fiscal year ended September 30, 2003. As of the six month period ended March 31, 2004, our revenue was $74,538. We plan to continue product development in 2004, and to develop and expand new sales channels and new customers for our location services products. Our net losses were $952,564 and $1,883,489 for the years ended September 30, 2003 and 2002, respectively, and for the six-month period ending March 31, 2004, our net loss was $418,190.

Location Products

Most of our customers require tracking of an object, asset or person, and reporting this information back to a central location. Our location products use different technologies to determine position of the object and report it back to the user, usually determined by whether they are trying to track items outdoors or indoors. Our customers’ choice of the type of technology to use is primarily based on their application. Our location tools products therefore fall into two different categories depending upon the type of application the customer requires. These are Outdoor Location Products and Indoor Location Products.

Our current location technology has not been awarded any patents as of the date of this prospectus, although we have filed for provisional patent protection on one of these products, and have been awarded trademark protection on one other. We use a combination of confidentiality agreements and other trade secret management to protect our trade secrets.

Outdoor Location Products

Overview of This Technology

We have developed a group of products with the capability to determine location using a technology called Global Positioning System or GPS. These products report the location information or data back to the user through a radio network. The products also contain a small computer to provide the overall control and data processing of the device. In other words, the product can be thought of as having three distinct pieces or systems. These are the data collection system, the data control & processing system, and the data transport system. This design concept is the basis for our outdoor location products. The diagram below shows in a general way how the GPS system works with our outdoor location products:
 
-25-  

 
 
Data Collection System

This system can be thought of as the ‘eyes and ears’ of the product. It is comprised of two further systems. One system determines location of the product, while the other system records specific events that the customer may be interested in such as a door opening in a delivery truck. The location system determines the position of the product using a technology developed by the U.S. Government called the Global Positioning System, or GPS, as it is commonly known. GPS was first made available by the U.S. Government for limited commercial use in the 1980’s. The system consists of approximately 24 satellites that orbit the earth every 12 hours. It is a worldwide navigation support system that allows users of GPS receivers to determine their precise geographic locations to within a few meters. The network of satellites and their ground control and monitoring stations are maintained and operated by the United States Department of Defense, which maintains an ongoing satellite replenishment program to ensure continuous global system coverage. Access to the system for all users is currently provided free of charge by the U.S. Government.

GPS works by ranging and triangulating the product’s position from a group of satellites. Of the 24 GPS satellites in orbit, a minimum of four are needed to reliably determine the product’s three–dimensional position. A GPS receiver measures distance by calculating the amount of time it takes a navigation and time reference radio signal from the satellite to make a one-way trip to the GPS receiver.

One of the main drawbacks with GPS is that the GPS receiver requires a clear line of sight of the satellites. Therefore GPS receivers generally do not work indoors. Even when the GPS receiver is outdoors, tall buildings, hills and dense foliage such as trees may also block reception.

Prior to May 2000, for reasons of national security, the U.S. Department of Defense intentionally degraded GPS signals to civilian users allowing civilian users to only obtain accurate information regarding their geographic locations accurate as to within a radius of about 100 meters. On May 2, 2000, the U.S. Department of Defense eased restrictions on civilian use of GPS technology, allowing civilian users to now calculate their geographical positions to accuracy of 10 meters or better. This change in policy significantly improves the utility of GPS for many applications.
 
-26-  

 
GPS receivers typically are very compact; it is not necessary to have a large dish antenna to receive GPS signals. Typical information that can be obtained from these GPS signals are latitude, longitude, elevation, speed, direction, date and time.

The second part of this Data Collection System is customer specific. Many customers have additional types of data that they want to know or want collected relevant to a location. An example of this could be, every time the delivery truck door is open, report its position and time the incident happened. Another example could be, report every incident of when the car traveled faster than 70 mph. This data input system can therefore be customized to meet the exact needs of a customer.

Another kind of data collection technology we use in some of our products is called RFID, which stands for Radio Frequency Identification. RFID devices are small radios that can be used to track information about people or objects. RFID provides a very low cost solution for certain kinds of tracking activities, especially short range activities, such as those at distances of less than a few hundred feet. RFID devices often are less costly to manufacture than GPS devices, although due to their short range, they may not be as versatile as GPS, which can work at distances of many miles or more.

Data Control & Processing System

This system can be thought of as the ‘brains’ of the product. A technical term for this system is an embedded system, meaning one that lives deep inside the overall product. An embedded system is a small special-purpose computer system built into a larger device. The reason we use an embedded system in our products is to keep cost to us low, so our products stay more competitive in price. Simple embedded systems can cost us as little as a few dollars each and use very little power compared to the desktop computers that many people are familiar with, which typically cost much more. On our embedded systems there is typically no disk drive, operating system, keyboard or screen. Our embedded systems instead communicate with other computers by radio. These other computers typically have keyboard and screens, and they are used to display our information.

The programs that we run on these systems are custom designed and built by our own engineers. These programs are called firmware. The firmware controls how the data is collected, what data should be collected and what events should be monitored and reported, what should be ignored and how and when and what data should be sent back to the user. As we mentioned above, the system is relatively easy to customize, and the firmware is also easy to customize as it has been written in a modular fashion that allows changes to one section to be implemented without the need to completely re-write the program. This helps us keep costs down.

Data Transport System

This system can be thought of as the ‘mouth’ of the product. It communicates to the outside world where it is and what has happened. There are many different types of technology that can be used to transport this data back to the user, generally using some kind of wireless technology based on radios. We currently use cellular radios, satellite radios, Wi-Fi® radios, and other special purpose radios.

We use a cellular radio based on GSM cellular technology. GSM, or Global System for Mobile Communications, is a second-generation digital mobile telephone standard. GSM was initially developed as a pan-European collaboration, intended to enable mobile roaming between member countries. As of 2004, there are now one billion GSM customers in the world in 193 different countries, according to a report published in February 2004 by the GSM Association. GSM technology is experiencing rapid growth in the Americas and elsewhere, according to the 3G Americas organization. We believe the use of GSM in our products makes them more attractive to customers on an international basis.

The cellular radios typically operate in ‘real time.’ When an event occurs, the data is immediately transported back to a user at a remote location.
 
-27-  

 
While cellular coverage and reception is good in urban areas, it is less effective in rural areas and is non-existent in most wilderness areas. Sometimes our products are used in areas where there is poor or no cellular coverage. To overcome this we sometimes use a special radio that communicates with satellites in orbit around the earth. This form of communication has the advantage that our products can be used in very remote areas almost anywhere in the world. The major downside is that these radios are large and expensive and the airtime usage costs can be high. Another problem associated with this technology is that, like GPS, these satellite radios work best when there is a clear line of site to the satellites; as such they may not work well indoors, or under dense foliage or in deep valleys.

The satellite radios typically operate in ‘real time.’ When an event occurs the data is immediately transported back to the user.

Some of our customers do not want to have the expense of a real time cellular or satellite connection, nor are they interested in having the data in real time. For this we use either a special purpose radio or a Wi-Fi® radio.

The Wi-Fi® radio operates in a very similar manner to cordless phones found in many households these phones typically consist of a base station and handset. Our system is very similar; it consists of a base station unit that receives data from the mobile unit that would be on the asset or vehicle being tracked. The base station is typically attached to a personal computer that takes the raw data from the radio and re-formats it into information that can be displayed by other computers on the Internet. Wi-Fi® stands for “Wireless Fidelity” and is a technology in very common use to connect personal computers to other computer networks, including to the Internet.

The special purpose radios work in a very similar manner to the Wi-Fi® radio, except that they can sometimes transmit data over longer distances.

Wi-Fi® radios operate in an unlicensed part of the radio spectrum and as such do not have any special government licensing fees associated with them. Because they operate in a license free spectrum the Federal Communications Commission (FCC) imposes some restrictions on the use of these radios. One major restriction is that the range the radio signal can go is limited to about 300 feet.

Since most of the time our product will operate well beyond 300 feet from the base station, all the data that is collected is stored within the device for later transmission when the product comes back into that range again. When the vehicle or asset comes back into range of the base station the units automatically download their information. We call this mode of operation ‘near time.’ These ‘near time’ products do not incur any special airtime usage charges. As such they can be significantly cheaper to operate than the cellular or satellite equivalents.

Once the data is transmitted back to the user they can either display the information on our Lobo™ mapping software or on some other computer application.

Outdoor Location Tools Products

IBUS . IBUS™ is a small outdoor location product designed to track school buses, as well as logging the children riding on the school bus. We announced this product in April of 2003. The unit contains a GPS that allows it to determine its current location. The unit also contains an ID card reader. As the child enters the bus they simply swipe their ID card and a record is created of who got on the bus, and where they got on the bus. As the bus travels along its route picking up passengers, there is a complete manifest created of who is riding on the bus. At journey’s end the children simply swipe their ID cards as they disembark and another log is created. Should there be a difference in the logs, then the driver will be notified that there could be someone left on the bus.
 
-28-  

 
 
This unit is designed to interface with software made by Verify Systems, Inc., that can provide reports to schools on the whereabouts of buses and students. We have only produced small numbers of this product, and have presented informational samples to various school districts, which are evaluating and testing it. We, together with Verify Systems, have run several pilot projects using IBUS
TM with school districts in Massachusetts and Arizona. We intend to market this product directly and through other sales channels. We have made very few commercially significant sales of this product as of the date of this prospectus, with total revenues from this area at approximately $10,000 since we introduced the product. However, we believe the sales cycle into school districts can take several years, due to budget cycles, especially for new safety technology, so we are uncertain if these low sales are likely to stay low or to increase in the future. We do believe that there will be seasonal factors which can materially impact the sale of this product, primarily driven by school budget year cycles, but we are not able to assess the impact of these factors on future sales at this time, as our sales have been so limited to date.

StationMaster™. StationMaster™ is an outdoor location product based on GPS technology. It is designed to track and report the location of fleets of vehicles. We announced this product in March of 2003. The product contains a GPS and other sensor inputs as required by the customer. The product can be configured for either real time data communication or near time data communication again depending upon the customer’s requirements. By upgrading the embedded processor to a single board computer we can run applications specifically designed by our customers who require a mobile general-purpose computer that can also perform tracking and reporting functions. We have only developed prototypes of this product, and have not shipped commercial quantities as of this time, other than to a small number of potential development partners. We have presented samples to various customers, who are evaluating it for inclusion in their own products. We have made no sales of this product as of the date of this prospectus.

Tracker III™. Tracker III™ is an outdoor location product based GPS technology. It is designed to track and report the location of vehicles and assets. We announced this product in September of 2003. The unit contains a GPS to determine position, as well as and GSM cellular radio to transmit that position information back to a central location. This location information can be presented as map coordinates, or it can be shown on a map using our Lobo™ tracking software (see below). This product is in the final stages of development. Operational units are expected to be available in July 2004. We have made no sales of this product as of the date of this prospectus.

Lobo Tracking Software . Lobo™ is an internet-based mapping application that can be used to display the location on a computer screen of our locator products in the field. Lobo™ is not sold as a stand-alone product, but instead is a service we offer to purchasers of our cellular-phone based locators. We use Lobo™ to make our locator product offerings more attractive to customers. Lobo™ is in active use today by most customers using our Followit™ products. We have generated revenue through the sale of service on our Lobo™ server service for over two years; since Lobo™ is part of an overall solution that includes Followit™, it is difficult to accurately separate the revenue generated solely from Lobo™ software from the revenue generated from Followit™. We estimate that Lobo™ has independently generated less than $5,000 in revenue over the last two years.

StarPilot . StarPilot™ is an outdoor location product based on a single board computer and GPS technology. We announced this product in June of 2002. The product is approximately eight inches long by three inches wide, and is intended for mounting inside a car or truck. The unit contains a small computer with a hard disk drive that operates on the commercially available Linux operating system. The unit also contains a GPS and a small cellular telephone to transmit information back to a central location. This location information can be presented as map coordinates, or it can be shown on a map using our Lobo™ tracking software. This unit is intended for tracking vehicles and for running applications designed by our customers who require a mobile general-purpose computer that can also perform tracking and reporting functions. We have only developed prototypes of this product, and have not shipped commercial quantities as of this time, other than to a small number of potential development partners. We have presented samples to various customers, who are evaluating it for inclusion in their own products. We have made no sales of this product as of the date of this prospectus.

StarPilot™ Sentinel. StarPilot™ Sentinel is an outdoor location product designed for tracking and reporting the location of field personnel at a distance. We announced this product in April of 2003. The product consists of a vehicle-mounted satellite/RF location and communications platform with a small personal RF transmitter. The unit contains a small computer with a hard disk drive that operates on the commercially available Linux operating system. The unit also contains a GPS. This is a concept product intended primarily for military use in an area most of the communications infrastructure has been destroyed. Occasionally, troops encounter hostile action close to their vehicles but are unable to return to them to summon help. We developed this product as an aid to summon help. All the troops in the vehicle carry a small radio transmitter, similar to a key fob used in car alarms.  When they experience difficulties they simply press a button on the key fob and a signal is sent to the communications module in the vehicle. This communications module then sends of an emergency alert over a satellite link back to command along with its location. We have made no sales of this product as of the date of this prospectus.
 
-29-  

 
This location information can be presented as map coordinates, or it can be shown on a map using our Lobo™ tracking software. We have only developed prototypes of this product. This product is targeted primarily at military related uses, such as assisting soldiers or civilians in hostile area such as Iraq to summon help in areas where cellular coverage in limited.

TrakJack . TrakJack™ is an outdoor location product designed for use in the power sports industry. Examples of power sports equipment are motorcycles or snowmobiles. We announced this product in March of 2003 (then called TrakForce™) along with our development partner Positus Corporation, formerly known as Bike & Cycle Trak USA, Inc. The product is aimed primarily at the expensive motorcycle industry. It is a custom designed unit and will have a number of unique features, including a crash sensor, which allows the product to automatically summon assistance in the event it detects an accident through a call center. It will also act as a theft recovery device. The major components of this product are a crash sensor, GPS and cellular radio. We have provided Positus Corporation with a proof of concept product and are currently working with them to begin the next phase of the development cycle. Our agreement with Positus allows us to market this product directly ourselves and through Positus. We have generated approximately $10,000 in cash and $20,000 in total revenue from this product design as of the date of this prospectus. TrackJack™ is a Minnesota trademark of Positus Corporation.

Followit ™. Followit™ is a small outdoor location product designed to track vehicles. We announced availability of this product in March of 2002. The unit contains a GPS to determine position, as well as a GSM cellular radio to transmit that position information back to a central location. This location information can be presented as map coordinates, or it can be shown on a map using our Lobo™ tracking software (see above). The unit is designed and manufactured for us in Sweden by Followit, AB. We currently have no units in stock as we have sold our entire inventory of the product, and we currently have no plans to replenish stock for this unit, although we will continue to support our existing customers for this unit and have it available on a special order basis. Followit™ is a trademark of Followit AB of Sweden.

UrbanTracker IIK™. UrbanTracker IIK™ is a derivative of Followit™. We announced this product in October of 2002. The product is a Followit™ product carefully integrated into a child’s backpack. This unit is primarily used for tracking children. We have only developed prototypes of this product, and have not shipped commercial quantities as of this time, other than to a small number of potential development partners. We have presented samples to various interested parties. We have made no sales of this product as of the date of this prospectus.

Indoor Products

Overview of this Technology

Indoor location presents many challenges that are not present in outdoor location. This is largely because GPS systems work poorly if at all when used indoors. While the GPS companies are working hard to overcome this limitation, there have not been any major breakthroughs as of yet. Most indoor location technology uses proprietary infrastructure and small radios called radio frequency identification tags, or RFID tags, which are typically small radio transmitters that run from battery power.

Most of our indoor positioning technology is based on measuring the strength or loudness of a radio signal between the transmitter and the receiver. We do this because the further away a transmitter is from a receiver, the weaker or quieter the signal is that you will detect. Many types of radios can measure this “loudness” phenomenon and convert it into a useful numerical value. If you have three or four radio sources spread over an area and you can detect their value you can then triangulate your position based on that information. This is similar to the concept used by GPS, but since it does not depend on distant satellites, it can be applied indoors. However, for this approach to work economically, a large number of transmitters are required throughout the indoor area. This cost has greatly limited the deployment of indoor location technology as of the date of this prospectus.
 
-30-  

 
Today many organizations are connecting their computers using Wi-Fi® technology, rather than running expensive network cables. Wi-Fi® is a trademark of Wi-Fi Alliance. We often use WiFi without the hyphen in our product names to avoid confusion with this trademark. We have developed a means of using these new Wi-Fi® networks to provide the transmitters needed for indoor positioning. We call this ‘piggy backing’ on to the Wi-Fi® network, a network which is composed of many mounted receiving devices called Wi-Fi® access points. The diagram below shows how our Wi-Fi®-based indoor tracking technology works:

 
 
WiFi Tracker™. WiFi Tracker™ is an indoor tracking product designed for tracking people and other assets. We announced this product in May of 2003. When used in conjunction with Wi-Fi® enabled tracking software, the tags can be easily identified and located within the network. One of our software partners is a Finnish company, Ekahau, Inc. They have developed a software system that takes information determined by our tags and displays the tag’s position using Ekahau™ Positioning Engine™ tracking software. The stage three version of the prototype, or “developer kit,” of this product was completed in December of 2003. A newer version of the developer tag, version 1.2, is currently under development and is expected to be ready for distribution in June or July of 2004. We have presented samples to several customers, and have engaged in competitive field trials with prospective customers, including NASA, using early versions of this product. Additionally, we have been doing application design work with iTrack of Ireland for wireless traffic management, though we have no formal agreements with this firm. This product is targeted primarily at commercial users, and uses some RFID technology in its design. We have made no commercially significant sales of this product as of the date of this prospectus.
 
-31-  

 
 

 

 


           Gotcha!®. Gotcha!® is a small electronic product designed to alert parents or guardians when their small child wanders too far away from them. A diagram showing how this technology works is displayed above. We announced this product in November of 2002, and began shipments of it during the summer of 2003 to select distribution organizations. The product consists of two parts, one about the size of a small pager that attaches to a parent and one the size of a key fob that attaches to a child. When the pre-set distance is exceeded, the child unit makes an audible sound to tell the parent that the child has wandered too far. It is then up to the parent to locate the wayward child by following the sound of the alert. The unit is designed to work well indoors or outdoors, although working through walls will tend to limit the unit’s range. We believe most of our customers will use this product indoors, in places like shopping malls. The tracker contains a small radio set used to transmit information between the parent and child, which are a form of RFID technology. The units are fully FCC certified and approved for operation in the U.S. We plan to have these units certified for use in other countries as and when the business situation warrants. We have filed and received a successful trademark claim on Gotcha!®. We are currently marketing this product through various channels for an average price of approximately $50-$90 for a set that includes one parent unit and one child unit. This product was featured in December of 2003, and again in February 2004, on cable television’s Home Shopping Network™, and QVC in April 2004. We have manufactured this unit in quantity and have inventory available for delivery. We have made commercially significant sales of this product, in excess of $80,000 as of the date of this prospectus.

          Location Tools Products Sales and Marketing

We believe the products we are developing may be more readily marketable by licensing and/or collaborating with companies that have complementary technologies. We have undertaken a search for candidates and are in the process of conducting investigations, technology evaluations and preliminary negotiations with potential licensees/partners. In May 2003, we entered into a relationship with Ekahau to co-market Wi-Fi® positioning products. In late 2002, we entered into an agreement with FutureCom Global of Arizona to assist in the distribution of some of our location tools. We have also entered into agreements with Verify Systems regarding marketing and software support for our IBUS™ systems, as well as Positus Corporation, to help market the TrakJack™ design.

We believe that maintaining a close relationship with customers and providing customers with ongoing technical support is essential to customer satisfaction in the radio based wireless and semiconductor communications industry. Our staff interacts with customers during key stages of design and production, provides customers with current product application notes and engineering data, maintains regular contact with customer engineers and assists in the resolution of technical problems. We intend to assign a contract account manager to our largest customers, who will maintain regular contact with the customer to determine their product needs and concerns. Members of senior management are also involved with the sales process and intend to be involved in managing relationships with significant customers. As is typical of other new technologies, our location-based technologies can have a lengthy sales cycle that requires extensive application engineering support. We support potential customers’ activities and consider such support an important element of our sales and marketing efforts.
 
-32-  

 
We recently hired a brand manager for our Gotcha!® product. The brand manager is responsible for finding and integrating distribution channels for Gotcha!® into marketplaces worldwide. We are currently in discussion with a number of potential distribution partners in Europe, Canada, South Africa and Latin America. We have also recently entered non-disclosure agreements and into negotiations with new distributors for our Gotcha® products, one for schools in the United States, one for distribution services in Canada, and one for distribution services in Europe.

We are marketing our location products worldwide through our internal sales resources including our web site and other contract-based marketing resources located throughout the U.S., Europe and Asia. Additionally, senior management devotes substantial time and effort to developing customer relationships and contracts.

Location Tools and Location Services Industry

The market for Location Tools with GPS-enabled products is projected to grow during the next few years. The U.S. Department of Commerce reports that the compound annual growth rate of the GPS market has been approximately 22% over the last six years. The Department’s studies stated that worldwide GPS sales reached $4B by the end of 1998, $6.2B by 2000, and exceed $8B by 2002, the last year for which figures were available from them. We believe that the following are among the key factors underlying the projected industry growth in both business and consumer markets now and in the near future:

·
improved accuracy of GPS will lead to an increase in the functions of devices using GPS;
 
 
·
additional functions capable of being installed in devices addressing GPS applications;
 
 
·
increased efficiencies in being able to track valuable assets;
 
 
·
the ability to provide relevant information (e.g. traffic reports, weather reports, location of stores and restaurants relative to the location of the vehicle) to occupants of passenger vehicles;
 
 
·
the ongoing miniaturization of technology products; and
 
 
·
the trend toward combining navigation, communications and information technologies in a single device for use in vehicles.

              To date, many market leaders in the location services industry have concentrated primarily on vehicle or asset tracking segments of the markets associated with providing information to owners of vehicles or assets. Real time tracking information of a vehicle or asset is often delivered by linking a GPS receiver to a device that is connected to a cellular network, allowing location of the vehicle or asset to be automatically transmitted to a base station via the Internet twenty-four hours a day. The user can, if needed, immediately contact an appropriate provider of emergency services. In addition, this allows those parties who are monitoring the location of the vehicle or asset to ensure that delivery and service fleet operations are using the most effective method of getting to a location, or to dispatch roadside assistance and emergency services, such as police or ambulances. The primary users include owners of expensive vehicles. This market is a segment of the overall GPS telematics services market. The GPS telematics market includes all vehicle mounted GPS systems that report their location remotely, typically using cellular phone related devices. Market consulting firm Frost and Sullivan in October of 2002 reported that revenue from this market segment exceeded $1B in 2003, and that the segment market may surpass $2.1B by 2008. Emergency assistance mandates, such as the U.S. Federal Communications Commission’s E911 Phase II initiative that require the manufacturers of cell phones and the providers of wireless communication to ensure that the location of a cell phone user can be determined with relative accuracy in emergency situations may also expand other wireless location product opportunities.
 
-33-  

 
Location Tools Customers

Our customers for location-based products include general consumers as well as businesses that need accurate tracking of people or assets. We have sold products to this group directly through our Internet Website and through relationships with stores that specialize in tracking devices and related security technologies. We do not know the final destination of all of these retail sales, but we believe many have been to private investigators or law enforcement users in the U.S. and Canada. We have also sold products to developers who are exploring adapting our hardware to meet custom solutions for specific markets, including Positus Corporation and Verify Systems. See “Strategic Relationships Including Marketing Firms, Material Suppliers, and Distributors.” We have also sold location products to customers of the Home Shopping Network and QVC through FutureCom Global, and implemented events on other direct marketing outlets, including radio commercials and through FutureCom Global. We have provided samples and demonstration products to several dozen major U.S. retailers, as well as a few distribution firms outside the U.S., in Mexico, Canada, and Europe. Our customers are primarily organizations operating in the United States and Canada, although samples have been sent for review to customers in Mexico, Central and South America, Africa, and Europe. We have also issued proposals, but not consummated sales transactions, to a variety of other prospective customers including hospitals, airports, trucking firms, a resort and entertainment complex, and the U.S. government.

Location Tools Products – Government Regulation

Since our location-based products are based on the use, in most cases, of radio technology, we are required to comply with a variety of Federal, State, and local regulations regarding the use of radio devices. The primary set of regulations that concerns our products are those promulgated by the Federal Communication Commission, or FCC, which is tasked with managing the use of the radio spectrum in the United States. We have two strategies for compliance with these regulations. First, we have certain products, such as our Gotcha!® child safety product, which we have independently tested and certified for compliance by the FCC or their approved third party laboratories. In the case of Gotcha!®, we achieved this certification, called a Grant of Equipment Authorization, on July 26, 2003, and we were issued FCC identifier number Q79-703 as a result. This process typically takes several months and creates testing costs of between $5,000 and $10,000 per device certification. In other cases, we elect to purchase complete and certified radio systems to incorporate into our products that have already achieved this certification. This is the case with our IBUS™ product, which uses 900MHz radios manufactured by Maxstream, Inc., a supplier of ours that has already achieved this certification. Using this second approach typically accelerates time to market over the first approach outlined, but may add to the cost of manufacturing the product over the long term.

For markets outside the United States, we may be required to comply with other government regulations regarding the use of radios. For example, the “CE” certification, formally called the “European Union EMC” program, has similarities in part to the FCC certification program in the United States. While we design our products to meet this and other important international regulations, we have not formally applied for the “European Union EMC” certification on any of our products, but may choose to do so in the future, when we believe we have more time to devote to developing sales channels in those international markets. We may also be required to comply with government regulations regarding the export of certain kinds of technology. To date, we have no plans to export our technology to areas where such U.S. government restrictions might be in force, such as to Cuba.

An important additional aspect of FCC government regulation that affects our location tools products is the management of the cellular airwaves. In particular, the FCC mandate entitled E911-Phase II puts a burden on cellular network operators to provide position information of cellular phone users to within approximately 100 feet of accuracy before December 31, 2005. Some cellular network operators can provide this today. We believe that some of our products based on cellular devices and GPS can in the future be manufactured without the GPS unit, while still being able to accurately determine location. This may allow us to penetrate new markets by lowering the cost and size of some of our products.
 
-34-  

 
 
Location Tools Products – Environmental Regulation

There are few if any special environmental compliance concerns unique to us that would be different than those that apply to other design companies in the United States in general. This is principally because we use third parties to manufacture and distribute our location tools products, and in the opinion of management, the significant environmental risks associated with our electronic products relate to the manufacturing of these units, not the design function.

Location Tools Products – Research and Development

Over the last three full fiscal years, we have spent approximately $1,827,800 directly accounted for as pure research and development of our products overall, including semiconductor products and location tools products. In addition to these direct expenses, our small staff spends considerable time and indirect resources in this area, and we would estimate that in excess of 50% of the available personnel resources are involved in research and development of our location tools products over the last three years.

In the last two full fiscal years, we have spent $238,849 on research and development, which has largely been related to our location tools products These products are much less mostly to develop than our semiconductor products. We have conducted several simulations and/or developed working prototypes of most of our products. We have successfully developed and sold several location products, most prominently our Gotcha!® child safety product. We continue to conduct research in several areas, especially for new location services products. Part of that research effort includes additional testing and product refinement. Our research into new location tools products is expected to be in markets such as child safety, school bus safety, military tracking markets, healthcare asset tracking, and also into first responder safety markets.

The following table summarizes the current development status of each of our current location tools products. The categories below have the following meanings:

·
“Product Name” refers to the device we described in the section just above;
 
 
·
“Proof on Concept Prototype Built” means that we produced early samples in a laboratory or test facility to demonstrate the concept of the product’s viability in a limited fashion. These early prototypes are not useful for commercial sale without additional research and development, and will likely not be available for testing by third parties;
 
 
·
“Pre-Production Prototype Tested and Available” means a form of the product was created and tested that would be directly useful for commercial sale, should we decide to manufacture it on a large enough scale, and that interested third parties may receive samples from us that they can fully test in their own environment, should they so desire;
 
 
·
“Design Available for Licensing from Us” means that we either hold patent rights or other trade secret rights to create this product, and that we are able and willing to enter into agreements with other parties for them to license from us these rights for their use;
 
 
·
“Production Device Available for Sale” means that either we or another third party under license to use is manufacturing this product currently, and is offering it for general sale in the marketplace today.
 
 
-35-  

 
 

 

 

 

 

 

 

 

 

 

 

 

Production  

 

 

 

 

Proof of  

 

 

Pre-Production

 

 

Design Available

 

 

Device

 

 

 

 

Concept  

 

 

Prototype Tested

 

 

for

 

 

Available

 

Product Name

 

 

Prototype Built

 

 

& Available

 

 

Licensing From Us

 

 

For Sale
 

 
 
 
 
 
Gotcha!®
   
Complete

 

 

Complete

 

 

Yes

 

 

Yes

 

WiFi Tracker™

 

 

Complete

 

 

Complete

 

 

Yes

 

 

Yes

 

Followit™

 

 

Complete

 

 

Complete

 

 

No (1)
 

 

Yes

 

IBUS™

 

 

Complete

 

 

Complete

 

 

Yes

 

 

Yes

 

Lobo Tracking Software™

 

 

Complete

 

 

Complete

 

 

Yes

 

 

No (2)
 
Shuttlefinder™

 

 

Complete

 

 

Complete

 

 

Yes

 

 

No

 

StationMaster™

 

 

Complete

 

 

Complete

 

 

Yes

 

 

No

 

Tracker III™ (4)

 

 

Complete

 

 

No (3)
 

 

Yes

 

 

No

 

StarPilot™

 

 

Complete

 

 

Complete

 

 

Yes

 

 

No

 

StarPilot™ Sentinel

 

 

Complete

 

 

No

 

 

No

 

 

No

 

UrbanTracker IIK™

 

 

Complete

 

 

No

 

 

Yes

 

 

No
 
______________
 
(1)
Followit™ is sold by us under a non-exclusive sales and license agreement from Followit AB. of Sweden. See “Strategic Relationships Including Marketing Firms, Material Suppliers, and Distributors.”
(2)
Lobo™ software is part of an overall tracking solution, and we do not offer it for sale as a standalone product, only as a licensed product or as part of our tracking service solution combined with other products, such as Followit™ or Tracker III™.
(3)
We are in the final stages of integrating a GSM cellular telephone module to transmit data to a remote location into our pre-production prototype. We estimate that this integration will be completed June or July 2004.
(4)
Tracker III™ is used as the platform for the design of the TrakJack™ product for Positus Corporation. TrackJack™ is a Minnesota trademark of Positus Corporation.

Location Tools - Patents and Trademarks

In the first half of calendar year 2004 we filed one provisional patent application pending for a technology to assist in the location of first responders in indoor environments. We were granted a United States trademark on our Gotcha!® location tool for child safety applications in May of 2004.

Location Tools Products and Services Competition

The market for communications and information products related to location-based services is highly competitive and we expect competition to increase. We believe that the principal competitive factors that will differentiate the various competitors in this marketplace will be product features, quality, customer service, brand, advertising, price positioning, time-to-market, and availability. The market for GPS-based products is relatively recent as a direct result of the U.S. Government’s removal of the GPS based filters in May 2000 to allow for more accurate tracking. Many of the companies in the vehicle tracking market have expensive systems that are permanently installed into the vehicle and often involve a fee-based monthly subscription service. Most of our products are removable, and some can be used without incurring any monthly airtime charges. Many GPS device vendors have been offering products to the marine, aviation and outdoors enthusiast markets for several years. We do not generally compete in those markets. For the personal safety locating products markets, we consider our principal competitors in the consumer market to be Wherify, Digital Angel, Angel Alert, and Child Guard. For our commercial vehicle and asset tracking markets, our principal competitors include @Road, Axiom Navigation, ALK, and Thales Navigation. There are approximately 100 other smaller companies offering products and services similar that we presently offer. There is significant other competition from large competitors in the GPS/Navigation market, including General Motors-OnStar® system. We have no current plans to directly compete with major automotive suppliers for in-vehicle navigation solutions, due to the amount of resources required to successfully compete.
 
-36-  

 
Semiconductor Products

Overview

The semiconductor products market is a secondary focus for us because we believe that we have a better chance of generating revenue from the sale of our location tools. This is based on our assessment of the current state of the semiconductor market, the current level of maturity of our semiconductor products, the skills of our staff, and our current size and capital structure. However, we believe that over a long period of time we may be able to extract value from the semiconductor products we have, because none of our patents in this area will expire until at least 2017 if we continue to pay required patent maintenance fees, which we intend to do. As a result, we continue to operate in this market, although we commit very few current resources to it, relative to what we commit to the location tools market.

We intend to maintain key elements of our portfolio of semiconductor intellectual property because we believe there is potential for the products we might offer to prospective licensees in the future, as the technology required to manufacture some of these designs is developed by others. There is no assurance that the technology required to manufacture some of these designs will ever be developed, or that when it is developed, that our patents will still be enforceable.

The largest target market for our products is the electronic memory market, which is the target for our TMOS® product. Electronic memory is used widely in many computer related products, such as personal computers. Our other patents tend to fall into the “discrete device market,” which the Semiconductor Industry Association (SIA) defines as discrete components including power transistors and radio frequency solutions that are found in wireless consumer products. These kinds of products are used widely in radios. These technologies form an important part of communications systems worldwide through voice and data communications networks, cordless and cellular wireless telephony systems and emerging cable and wireless broadband communications networks.

Our sales and marketing efforts for semiconductor products are limited to our web presence on our own internet site, our presence in the United States Patent and Trademark office database and website, web-based marketing in an semiconductor intellectual property sales organization named the Virtual Component Exchange, or VCX , and very limited direct sales efforts from time to time with prospective semiconductor technology licensees at trade shows and other industry events.

Our long-term strategy is to develop significant new semiconductor products that build on our existing portfolio of patents in this area, and to tie this technology into our location tools products. We believe this may be possible because these products families have in common the fact that they both rely on radios. Our location tools products have radios built into them. Our semiconductor products are components that can be used in radios. We intend to utilize unique, patentable technologies and other proprietary technologies and provide these enhancements to the marketplace through joint venture licensing agreements with manufacturing firms. We do not intend to directly manufacture any of our own technologies. When resources are available we intend to continue research and development efforts, including simulations and creation of working prototypes, where possible. Our efforts in the location tools product area may delay this strategy’s implementation indefinitely. We also may consider selling this business to another firm outright.

We filed patent applications on a number of product designs between 1997 and 2002 relating to semiconductor products. During this time we brought eight major research and development projects to the patent or patent application stage. Our first U.S. patent was awarded June 15, 1999, by the United States Patent and Trademark Office, the USPTO. All of our products in this area are based on paper designs, with limited laboratory work having been performed on some of them. Our primary semiconductor and electronic device products and related patent filings include the following areas:
 
-37-  

 
Product Name
Use and Function of Product


Heterojunction Bipolar Transistor
Used in the manufacture of digital circuits found in devices such as cellular phones, personal computers and automotive circuitry. Transistors provide electronic control over current flow, and are a part of many electronic circuits. Heterojunction bipolar transistors are used most frequently in power amplifiers, radio frequency integrated circuits and other circuits.
Monolithic Inductor
Used in a wide range of electronic circuits for telecommunications applications. The inductor’s most common application is as a component of a radio frequency circuit used to manipulate radio waves into certain other electrical signals. The inductor does this, usually in conjunction with a capacitor, by producing an amplified current when stimulated by a specific frequency of radio signal.
Distributed Amplifier
Used in all electronic products that require some level of power increase such as telecommunications, microwave, internet communications, automotive and bio-medical products as well as automated manufacturing products.
TMOS® Memory
Used in digital computing devices such as microcomputers and workstations and battery powered devices such as personal data appliances and cellular phones that require a memory function.
Mode Dielectric Resonator
Used in many applications including microwave oscillators, narrowband microwave filters, radar detectors, speed guns, automatic door openers, cellular portable phones and global positioning satellites. The resonator’s most common application is as a component of a radio frequency circuit used to manipulate radio waves into certain other electrical signals. The resonator does this by producing a current of predictable size when stimulated by a specific frequency of radio signal.
High Frequency Wireless Transceiver
Allows the transmission and reception of radio waves and is used in a variety of wireless devices.

Semiconductor Industry, Marketplace, and Competition

The semiconductor industry makes a wide variety of electrical component products found in literally millions of different devices in common use throughout the world. This includes everything from personal computers, to automobiles, to household appliances, cell phones, children’s toys, power systems, and much more. The Semiconductor Industry Association, or SIA, publishes regular reports on the projected size of this industry. In 2004, SIA has estimated the overall size of the semiconductor products marketplace at approximately $200B per year. SIA reports also show a regular trend for average annual growth in excess of 10% per year for the overall industry over the last twenty years, although there have been periods of much slower growth or even decline for significant portions of the semiconductor marketplace, such as the years 2001 and 2002.

The electronics products industry is intensely competitive. Our wireless and memory technologies experience intense competition from numerous domestic and foreign companies in all of our semiconductor products.

Based on our research and development efforts over the last seven years, we believe our most promising semiconductor product in the near term is our TMOS® product. We consider our TMOS® memory technologies to be competitive with existing memory technologies in certain applications. The companies that make memory similar to our TMOS® product are both potential customers as well as potential competitors. This is because they can choose to license products we make, or to develop competitive technologies themselves or license competitive products from others. As competitors, the companies that make memory devices similar to ours are much larger firms and are much better funded. They include firms such as Samsung, Alliance Semiconductor Corporation, Cypress Semiconductor Corporation, Integrated Device Technology, Inc., Motorola, Inc., Hitachi, ST-Microelectronics, Toshiba, Fujitsu, and Micron Technology, Inc. and others. They have substantially greater research and development resources than us. Because these companies are also potential licensees for our technology, they could also serve as sources of research and development support for our semiconductor products. However, we have been trying for the last three years to interest these kinds of large firms in licensing our semiconductor products, and to date, we have met with little or no success.
 
-38-  

 
Semiconductor Products - Patents and Trademarks

We have applied for U.S. patents relating to these technologies, most of which have already been issued. These include the following, all of which have a 20-year life following date of filing.

 
 
 
Expected  
 
 
 
 
Patent  
 
 
 
 
Expiration  
Product Name
 
Summary of Patent Information
 
Date

 

 

Heterojunction Bipolar Transistor
 
On September 29, 1997, we filed a U.S. Patent application for a Heterojunction Bipolar Transistor (HBT). U.S. Patent 5,912,481 was issued for this device on June 15, 1999. We were also successful in our Continuation in Process application on this device, as the United States Patent and Trademark Office issued us a patent on January 9, 2001 under U.S. Patent 6,171,920, covering intellectual property required to manufacture this transistor. The assignment of this patent to us is recorded at USPTO at reel no: 0111356, frame 0934.
 
Sept. 2017
Monolithic Inductor
 
On October 31, 1997, we filed a U.S. Patent application for a Monolithic Inductor. The U.S. Patent Office issued a Notice of Allowance for this application on September 7, 1999. U.S. Patent 6,013,939 was issued for this device on January 11, 2000. We were also successful in our Continuation in Process application on this device, as the United States Patent and Trademark Office issued us a patent on August 28, 2001 under U.S. Patent 6,281,778. The assignments for these patents to us are recorded directly on the issued patent from the USPTO.
 
October 2017
Distributed Amplifier
 
On July 10, 1998, we filed a U.S. Patent application for a Distributed Amplifier. The U.S. Patent Office issued a Notice of Allowance on this application on September 29, 1999. U.S. Patent 6,008,694 was received for this device on December 28, 1999. On May 23, 2001, we a filed a U.S. Patent application for a Monolithic Balanced RF Power Amplifier, another version of this product. U.S. Patent 6,424,227 was issued for this device on July 23, 2002.The assignments for these patents to us have recorded directly on the issued patents from the USPTO.
 
July 2018
TMOS® Memory
 
On December 17, 1997, we filed a U.S. Patent application for a High Performance N-Channel Metal-Oxide-Semiconductor (NMOS) Static Random Access Memory (SRAM). U.S. Patent 6,104,631 was received for this device on August 15, 2000. We were also successful in our Continuation in Process application on this device, as the United States Patent and Trademark Office issued us a patent on October 9, 2001 under U.S. Patent 6,301,147. The assignment of these patents to us is recorded directly on the issued patents from the USPTO.
 
December 2017
Mode Dielectric Resonator
 
On June 18, 1998, we filed a U.S. Patent application for a Mode Dielectric Resonator. The U.S. Patent Office issued a Notice of Allowance for this application on August 1, 2000. The U.S. Patent and Trademark Office issued us U.S. Patent 6,169,467 for this device on January 2, 2001. The assignment of this patent to us is recorded at USPTO at reel number: 011358, frame 0462.
 
June 2018
High Frequency Wireless Transceiver
 
Patent Pending.
 
Pending

We have filed patent applications for other semiconductor-related patents since 2000, including some improvements to the above existing products as well as on related devices. The commercial importance of these inventions and the final disposition of these applications are uncertain. At this time, we are not actively pursuing patent protection outside the United States for these semiconductor products. We also hold the U.S. trademark to the word TMOS®, awarded to us July 1, 2003, U.S. Trademark registration number 2732825.
 
-39-  

 
Semiconductor Products – Government Regulation

Since our semiconductor products are used, in most cases, as parts of radios, our customers are required to comply with a variety of Federal, State, and local regulations regarding the use of radio devices. The primary set of regulations that concern our customer’s products are those promulgated by the Federal Communication Commission, or FCC, which is tasked with managing the use of the radio spectrum in the United States. However, since this is our customer’s responsibility and not ours, we do not believe we are subject to any special level of government regulation in this line of business other than that which would be faced by other U.S. Companies in general.

We may also be required to comply with government regulations regarding the export of certain kinds of technology. To date, we have no plans to export our technology to areas where such U.S. government restrictions might be in force, such as to Cuba.

Semiconductor Products – Environmental Regulation

There are numerous environmental regulations that affect the manufacturing of semiconductor products in general. However, there are few if any special environmental compliance concerns unique to us that would be different from those that apply to other companies in the United States in general. This is principally because we use third parties to manufacture and distribute our semiconductor products, as our business model is based on licensing our designs to others, who then bear the main costs of complying with the environmental rules that directly relate to manufacturing these final goods. Should any single manufacturer be subject to special enforcement action in this area, we would retain the right to switch to another manufacturer, as we currently have no exclusive manufacturing relationships in this area.

Semiconductor Products – Research and Development

We have conducted little research and development of our semiconductor products since 2002. Since fiscal year 2002, we have spent $7,800 on research and development of these products, and this includes legal services required to protect patents for our products.

The following table summarizes the current development status of each of our current semiconductor products.

 
 
 
 
Production
 
Proof of
Pre-Production
Design Available
Device
 
Concept
Prototype Tested
for Licensing
Available
Product Name
Prototype Built
& Available
from Us
For Sale





TMOS® Memory
Complete
No
Yes
No
Mode Dielectric Resonator
Complete
Complete
Yes
No
High Frequency Wireless Transceiver
Complete
No
Yes
No
Distributed Amplifier
Complete
No
Yes
No
Monolithic Inductor
Complete
No
Yes
No
Heterojunction Bipolar Transistor
No
No
Yes
No

Strategic Relationships Including Marketing Firms, Material Suppliers, and Distributors

This section covers relationships that may involve both location tools products and semiconductor products, as some of these suppliers and distributors may be active in both areas. However, since most of our business activity since 2002 relates to the location tools products, you can assume unless otherwise stated below that the primary purpose of these relationships has to do with the location tools product line.
 
-40-  

 
 
In May of 2003, we commenced an informal strategic co-development and co-marketing program with Ekahau, Inc. of Finland (“Ekahau”). The purpose of the program is to develop and co-market tracking products based on Wi-Fi® technology, where we would make tracking hardware that would work cooperatively with tracking software made by Ekahau. Ekahau has developed a software application called the Ekahau Positioning Engine™ that can be used to determine location of Wi-Fi® devices in a standard Wi-Fi® network. We are developing a hardware product to interface with Ekahau’s software that can be attached to people or objects that are moving within Wi-Fi® networks, to establish the real time location of those people or objects. In December of 2003, we completed our first prototype of this Wi-Fi® product, and displayed it with Ekahau at the Wi-Fi® Planet Conference and Exposition in San Jose, California. Additional development of this product occurred during the spring of 2004, resulting in a new generation of products being introduced in June 2004 before planned full commercialization of the product in late summer 2004. Ekahau and National Scientific have not established a contractual relationship, other than a non-disclosure agreement. Ekahau is a small privately held technology development company with a limited customer base.

In May 2003, we entered into a six-month agreement with New York-based Stanton, Walker & Company for business advisory and consulting services. Stanton, Walker agreed to assist us in expanding our existing strategies for business growth as well as developing new strategies, such as merger and acquisition planning. We paid for the services of Stanton, Walker using our common stock, valued at approximately $100,000 at the time of issue. We have not yet determined what additional services, if any, we may procure from Stanton, Walker & Company in calendar year 2004 and beyond.

In March of 2003, we received a blanket purchase order for $250,000 of IBUS™ technology from Verify Systems of Connecticut, originally planned for delivery before June of 2004. Shipments began against this order in May of 2003, for pilot testing in during the summer of 2003. Testing was continued through two pilot programs. A third pilot program was conducted in Arizona in November and December of 2003. The product is still being demonstrated and developed. We do not expect the purchase order to be completed in calendar year 2004. Verify Systems is a small privately held technology development company with a limited customer base, very small operations, and limited assets. In May 2004, partially in response to Verify System’s failure to timely market our products, we agreed to license the marketing materials and software tools of Verify Systems and assume the primary sales effort for these products ourselves. The material terms of this agreement require that Verify Systems give us an unlimited and indefinite license to use their software products, in exchange for a cash payment of $6,000 and a royalty of 5% of sales of their software products over the next two years.

In March of 2003, we entered into a non-binding Memorandum of Understanding with Positus Corporation (“Positus”) doing business as, Bike & Cycle Trak USA, Inc., of Minneapolis, MN, to develop and co-market tracking products for the power sports industry. We were later issued a $75,000 purchase order by Positus to develop the prototype version of this product. We began work in the spring of 2003 to develop this product. A first proof of concept product was shipped in June of 2003, when the first payment of $10,000 was received on this order. A second prototype board was developed in the fall of 2003, and it currently continues in testing stage. Positus is a small privately held technology development company in its startup phase. The material terms of the agreement provide for us to deliver additional prototypes as payment is received.

In January 2002, we signed an agreement with the Virtual Component Exchange (“VCX”) in which we made the majority of our semiconductor products available for licensure through their marketing service. VCX is an Internet based organization focused on producing Internet tools for trading intellectual property. We have not seen substantial results from this effort with VCX, and may choose to discontinue marketing our semiconductor products through this channel in the future. Our agreement required that we pay a fee of approximately $10,000 to have our semiconductor intellectual property posted on their website through December of 2003, plus a future royalty of 5% or less should any licensing transaction result from such a posting. This vendor has dealt exclusively with our semiconductor products, and not our location tools products. VCX has continued to list our semiconductor intellectual property on their Website, although they have received no additional payments from us since our first approximately $10,000 payment in 2002.

In December of 2002, we entered into a manufacturing relationship with Electroconnect Ltd. of Scotland (“Electroconnect”) to manufacture our Gotcha!® child safety product for us. The oral understanding is based on our issuing purchase orders and specifications on an order by order basis to Electroconnect, and Electroconnect fulfilling those orders by shipping Gotcha!® units to us in Scottsdale, typically offering net 30 day terms for payment. Electroconnect is a small to mid-sized privately held manufacturing company with a broad customer base. As of the date of this prospectus, Electroconnect has manufactured approximately 6,000 units of Gotcha!® for us.
 
-41-  

 
In December of 2002 we entered into a distribution agreement with FutureCom Global, Inc. (“FCG”), a firm headquartered in Scottsdale, AZ. The two-year agreement covers the non-exclusive distribution of products from us such as Gotcha!®, Followit™, and StarPilot™. The agreement automatically renews for the third year unless terminated by one of the parties. FutureCom Global is a small privately held technology development and distribution company. The material terms of the agreement provide for payment for products delivered on net 30 days terms, although the parties have the right to enter into specific purchase orders where the payment terms may vary. On August 20, 2003, FCG issued a purchase order for 5,000 units of our Gotcha!® product valued at approximately $150,000. We have delivered approximately half of the ordered units to them as of the date of this prospectus, which they have advertised and sold on Home Shopping Network, QVC, and through other retail channels. We are not certain when or if they will accept the delivery of the remaining units on this purchase order. This has caused us to seek out new distributors for our Gotcha!® product, although we continue to work with FCG to sell Gotcha!® and other products as well.

In December 2002, we entered into a development and co-marketing agreement with Geotechnolgies, Inc., a privately held small firm headquartered in Castle Rock, CO. Geotechnologies is a software development firm that specializes in making mapping software that we believe complements our location tools products. To date our activities with Geotechnolgies have been jointly developing and presenting solutions that involve our location tools products and their mapping products to various private sector and government prospective clients. No sales have resulted from these efforts to date.

In June of 2002, we entered into an agreement with Followit AB, a Swedish technology firm, for international distribution of GPS products. The international distribution agreement, dated June 1, 2002, grants us non-exclusive distribution rights for the Followit™ locator product in the United States, Canada and Mexico. The Followit™ locator product uses the Global Positioning System (GPS) and cellular technology, with a sophisticated mapping interface to provide tracking capabilities for a wide variety of assets or individuals. Distributor prices were defined in the agreement and payment terms are letter of credit and net thirty (30) days from the receipt by us of a correct invoice. The contract automatically renews after one year unless either party provides written notice to end the agreement thirty (30) days prior to the automatic renewal period. At the current time, we do not anticipate that we will continue using their products other than on a rare special order basis, as we have developed our own products such as our Tracker III™ product.

Other key suppliers over the last three years also include Digikey Corporation of Minnesota for electronic components, and Avante Circuits of Tempe, Arizona for circuit boards. We purchase most of our GPS chipsets and GPS modules from Trimble Corporation of California. We have spent less than $25,000 with each of these suppliers over the last three years. We are not dependant on these particular suppliers, as there are alternative sources in the market for the kinds of component materials we use in our products. However, in the event we needed to change over suppliers, we may experience some small delays in time to market for certain products, or small increases in supply costs. due to small design changes that may be required in our products because of such a change.

Personnel

As of the date of this report, we have six full time employees, two part time employees, as well as a number of part time relationships with contractors for certain services. Eight employees work in the Scottsdale, Arizona corporate office. Management believes employee relations are good. None of our personnel are covered by collective bargaining agreements.
 
-42-  

 

We are currently a plaintiff in three lawsuits.

In January 2002, we initiated legal proceedings in Maricopa County Superior Court against Phoenix Semiconductor, Inc. (PSI) for breach of contract. We engaged PSI, and advanced approximately $400,000 to PSI, to build thyristors (an electronic component) for us to sell. When we engaged PSI, we obtained a security interest in a portion of PSI’s equipment assets. Before we initiated legal action, both PSI and its principal shareholder Chongkook John Rhee filed for bankruptcy protection under Chapter 11 of the U.S. Bankruptcy Code. In December 2002, PSI and the NSC agreed to a settlement of the secured claim against PSI in the form of a cash payment of approximately $100,000 to NSC together with certain other unsecured claims remaining. The cash payment is subject to a contracted sale of substantially all fixed assets of PSI and formal approval of the bankruptcy court. The sale has not occurred; therefore we are unable to determine the final outcome of the lawsuit.

We filed the second case in Maricopa County Superior Court in August 2002, seeking $155,550 plus interest from E4World Corporation for breach of contract. We were awarded a judgment of $179,000 in May 2003 against E4World Corporation. We are now in the collection phase of this judgment, and, there is no assurance that we will collect any of this judgment. Since our collection of this judgment is uncertain, it is not reflected in our current financial statements. We continue to assert our claim to secure assets held by E4World in a separate legal matter.

The last lawsuit is resolved. National Scientific Corporation vs. Netmind was filed on or around August 29, 2002 in Maricopa County Superior Court, seeking damages for failure to repay a $200,000 note. We filed this lawsuit against Netmind, Inc. to recover an investment, plus damages. Mr. Lou Ross assigned his right to certain sums as partial payment for an amount we advanced to him in 1999. A final judgment of dismissal in this case was entered on March 30, 2004.

From time to time in the normal course of business operations, we are involved in other legal proceedings, none of which are expected to have a material adverse affect on business operations.
 
-43-  

 
 

The directors, executive officers, significant employees and consultants of National Scientific, their respective ages and positions with us are as follows:

Name
Age
Position



Michael A. Grollman
43
CEO, Chairman of the Board of Directors
Graham L. Clark
49
President, Director, Secretary
Gregory Szabo
50
Director (Outside)

Directors and Executive Officers

Michael A. Grollman . Michael Grollman first became Chief Operation Officer in October 2000. Mr. Grollman was named President in April 2001, Chief Executive Officer in January of 2002, Chairman of the Board in December 2002, and Acting Chief Financial Officer in June of 2003. From 1998 to September 2000, Mr. Grollman served as Regional Service Director of MicroAge, Inc., a company that provides customer-configured technology solutions to businesses. He served as General Manager, Executive Vice President and Chief Technology Officer for Advanced Information Systems from 1987 to 1998. Mr. Grollman received his Bachelor of Science degree in chemistry from the State University of New York. He received his MBA from Arizona State University.

Graham L. Clark. Graham Clark joined National Scientific in early 2001 as general manager of the sales organization. He became Vice President of Technology Applications & Sales for National Scientific in the spring of 2002, a Director in August of 2002, and became Corporate Secretary in January of 2003. Mr. Clark was named President of National Scientific in September of 2003. For the two years immediately before joining National Scientific, Mr. Clark was the General Manager of the Billet Precision Engineering Group, a privately held manufacturing company providing custom engineering and manufacturing solutions to the semiconductor industry and other related industries. Prior to his tenure with Billet, he worked as Corporate General Manager for Amtech Systems, Inc. a semiconductor equipment manufacturer. Six years prior, he was a founder and senior partner of GC Technology, a private representative organization for semiconductor capital equipment.

Gregory Szabo joined National Scientific’s board on October 1, 2003 as an outside Director. Mr. Szabo serves on the Board's Audit and Compensation Committees. Mr. Szabo served in various executive positions at Exten Corporation, including President of Exten Corp. and CEO of MultiCell Technologies, Inc. from approximately May 2000 to April 2004, where was responsible for public reporting, fund-raising for the corporation and overall accountability for its subsidiaries, including revenue generation, intellectual property protection and organizational development. Mr. Szabo was also a director at Exten, a publicly traded company (OTC:EXTI). Immediately before joining Exten, Mr. Szabo was for a number of years President & CEO of Titan Scan Corporation, a division of Titan Corporation, with subsidiaries in sterilization, defense, software and communications. Mr. Szabo has held several executive positions with Sunrise Medical Inc., a manufacturer and distributor of numerous institutional and retail products. Mr. Szabo earned a BA in Psychology from the University of Toledo and a MA in Management from the Drucker Graduate School at Claremont University.

Significant Advisors and Key Employees

El-Badawy El-Sharawy, Ph.D. Dr. El-Sharawy is a Senior Scientific Consultant to us, starting with us in 1996. Dr. El-Sharawy is currently Assistant Professor of Electrical Engineering at Arizona State University’s Telecommunications Research Center, Department of Electrical Engineering, and has been there for over ten years. His expertise includes, but is not limited to, microwave circuits, anistropic devices and applied electromagnetics. He is a senior member of IEEE and is a recipient of the 1980 Egyptian Engineering Syndicate Medal of Honor.

Paul C. Davidson. Mr. Davidson is lead embedded systems development engineer for us. He has more than 20 years of software, hardware, and embedded systems development experience. Mr. Davidson is responsible for implementing new features within our location tools products. Prior to joining us Mr. Davidson developed software, firmware, embedded systems and device drivers for several firms, including June 2000 to August 2003 as Senior R&D Software Engineer & Team leader at C. S. & E. Inc., and October 1999 through June 2000 at Hypercom Corporation as OS/R&D Team leader/Software Engineer His career experience also includes serving as V.P. of Engineering for Advanced Video Technology, and Engineering Test Manager for Cal Omega Inc.
 
-44-  

 
 
Mr. Oscar Quadros, Chartered Accountant . Mr. Quadros is our comptroller and finance manager, and works for us on a part-time basis. He joined us in late 2002. He is a Fellow of the Institute of Chartered Accountants in Ireland, and is a graduate of University College Dublin, Ireland, with a Bachelor of Commerce, major in Accounting and Economics. From August 1998 to June 2002, he was CFO/Controller at A3T Incorporated & Axxis 3T Inc. of Scottsdale, Arizona. His 40 years of experience in international accounting and finance include senior auditor roles at MacLennan Trundell & Co. Public Accountants, Atkinson & Boyd, Public Accountants, and as an audit manager at Coopers & Lybrand, Public Accountants. He has also worked as a Director of Accounting at Canadelle Inc. (Subsidiary of Sara Lee Corporation), Canada, and as Vice President Finance/Controller - Jeno Neuman & Sons of Montreal, Canada.

Susan L. Regan, Esq. Ms. Regan is part time legal counsel for us since 2002. Ms. Regan holds a Bachelor of Science degree from Heidelberg College in Ohio, a Master’s Degree in Planning and Resource Management from the University of Alaska, and a Juris Doctorate from the Thomas M. Cooley School of Law in Michigan. She is admitted to practice law in both Washington State and the State of Arizona. She was in part time private practice for the three years prior to joining us. Previously she was employed with Standard Insurance Company group legal department as an in house counsel. She is married to Mr. Grollman.

Karen A. Fuhre . Ms. Fuhre is responsible for investor relations for us, and is involved as well in product marketing. She joined us in 2001. She is responsible for investor communications, certain matter surrounding parts of SEC compliance, and strategic planning. Ms. Fuhre is also responsible for our web site, collateral materials, and media relations. Before joining us, Ms. Fuhre spent approximately five years with FINOVA, a publicly traded commercial lender, where she worked with the company’s financial and informational communications areas. Ms. Fuhre earned a Bachelor of Science Degree in Marketing from Northwest Missouri State University and a Paralegal Certificate in Civil Litigation from the University of San Diego.

Board of Directors

Our business is managed under the direction of the Board of Directors. The Board meets on a regularly scheduled basis to review significant developments affecting us and to act on matters requiring Board approval. It also holds special meetings when an important matter requires Board action between scheduled meetings. The Board met ten (10) times during fiscal 2003 and did not act by consent in lieu of any meetings. Each serving director attended 100% of the meetings held in 2003 by the Board and the committees of the Board on which such director served. The Board of Directors was made up of three members during substantially all of fiscal 2002 and 2003. Michael A. Grollman has been a director since November of 2000. Graham L. Clark has been a director since August of 2002. Former director Mr. Lou Ross retired from the board on September 30, 2003 for personal reasons, citing no conflicts with management or board policy. Mr. Szabo joined the board on October 1, 2003. Currently, our Board of Directors consists of three members, Michael A. Grollman, Chairman, Graham L. Clark, Secretary, and Gregory Szabo. These Board members were re-elected by shareholder vote in March 2004.

Audit Committee

Auditor

Our independent auditor is Hurley & Company, based in California. This firm is licensed to practice public accounting by the State of California, and is also registered with the Public Company Accounting Oversight Board. The senior audit partner Mr. Michael Hurley is also licensed to practice public accounting in Arizona. The use of this firm has been ratified by our shareholders in each of the last three fiscal years

Hurley & Company billed us approximately $17,000 for the following professional services: audit of the annual financial statements of us for the fiscal year ended September 30, 2003, and review of the interim financial statements included in quarterly reports on Form 10-QSB for the quarterly periods ended December 31, 2002, March 31, 2003 and June 30, 2003.
 
-45-  

 
 
During the last two fiscal years we have had no changes in or disagreements with our auditors on accounting or financial disclosure.

Review of Audited Financial Statements & Report of the Audit Committee

Our Board’s audit committee was established in December 2000. The audit committee met twice during calendar year 2003. Mr. Greg Szabo is chairman of our audit committee as an outside director and financial expert, and is currently its sole member. The audit committee has reviewed our financial statements for the fiscal year ended September 30, 2003, as audited by Hurley & Company, National Scientific's independent auditors. Hurley & Company has discussed these financial statements with management and the audit committee.

The audit committee has reviewed and discussed the audited financial statements with management. The audit committee has discussed with the independent auditors the matters required to be discussed by SAS 61. The audit committee has received the written disclosures and the letter from the independent accountants required by Independence Standards Board Standard No. 1 (Independence Standards Board Standard No. 1, Independence Discussions with Audit Committees) and has discussed with the independent accountant the independent accountant's independence. Based on the review and these discussions, the audit committee recommended to the board of directors that the audited financial statements be included in the company's Annual Report on Form 10-KSB for the last fiscal year for filing with the Commission.

Financial Information Systems Design and Implementation Fees and Other Services

We did not engage Hurley & Company to provide services to us regarding financial information systems design and implementation during the fiscal year ended September 30, 2003. The Board of Directors has considered whether the provision of non-audit services is compatible with maintaining Hurley & Company’s independence, and has decided not to secure such services from Hurley & Company at this time in that area.

Compensation Committee and Board Compensation

Our board’s Compensation Committee was established in March 2003. The Compensation Committee met once during calendar year 2003, and has met once so far in calendar year 2004. Mr. Greg Szabo currently heads our Compensation Committee as an outside director, and is currently its sole member. The Compensation Committee approved the executive compensation plan for the fiscal years ending September 30, 2003 and 2004, respectively.

Our board as a whole approves board member compensation. This plan was approved by the Board originally in 2000, and was amended in the summer of 2003. Currently, employees of National Scientific who also serve on the board receive no additional compensation for board service. All newly appointed non-employee directors appointed after the end of fiscal year 2002 will be provided with a one-time grant of 20,000 shares of National Scientific restricted common stock upon original appointment to the board. This stock will be subject to forfeiture back to us should the Director for any reason not serve a full term on the board at least up to the next annual meeting of shareholders.

Additionally, non-employee directors will also be paid $1,250 per board meeting, which includes telephonic board meetings as well as face-to-face board meetings. The $1,250 fee will be in the form of $250 cash and $1,000 of National Scientific restricted common stock. The restricted common stock will be at risk of forfeiture if the director does not serve his complete term. The fee will not be paid for telephone conversations involving Board members or others where no formal board meeting has been declared, or for normal committee meetings. Non-employee directors will also be paid retrospectively a quarterly retainer of 10,000 options (as defined in the 2000 NSC Stock Option Plan) to purchase free trading National Scientific common stock at the end of each fiscal quarter they have served. The options will be immediately vested at point of grant, and will be issued at an exercise price equal to the average closing price for our common stock for that quarter. Non-employee directors who serve on a board committee, such as the audit or compensation committees, will also be paid retrospectively a quarterly additional retainer of 10,000 options, as defined in the 2000 National Scientific Stock Option Plan, to purchase free trading common stock. The options will be immediately vested at point of grant, and will be issued at an exercise price equal to the average closing price for National Scientific’s common stock for that quarter. Non-employee directors who serve on multiple committees will be paid this bonus only once for general committee service, however, as it is not paid for each committee of service. All directors are paid any reasonable out of pocket expenses required to attend board meetings, such as travel, if any.
 
-46-  

 
Controls and Procedures

Our management has responsibility for establishing and maintaining adequate internal control over financial reporting for us. Our management uses a framework for establishing these internals controls. This framework includes review of accounting detailed records on at least a quarterly basis by multiple senior officers of National Scientific, at least one of whom operates outside of the corporate finance and accounting area, and one of whom operates within the area of corporate finance and accounting. This review process includes review of significant accounting records and source documents, such as general journal entry records, accounts payable records, and monthly bank statement reconciliations. Documentary records are kept of this review process.

Our Chief Executive Officer and Acting Chief Financial Officer, Michael A. Grollman, and our President, Mr. Graham Clark, after reviewing and evaluating National Scientific’s disclosure controls and procedures within 90 days prior to the filing of this prospectus have concluded that National Scientific’s disclosure controls and procedures contained no significant deficiencies or material weakness. There have been no significant changes in National Scientific's internal controls that could significantly affect these controls subsequent to the date of their evaluation, including corrective actions.

Our management believes that upon significant future growth in the number of accounting transactions we process, perhaps within the next year, additional review and enhancement of internal controls will be required. Our management is planning to assign additional staff resources to assist with support for growth in the internal controls area when the increase in transaction velocity dictates this as a prudent step in order to maintain our effective level of internal controls.
 
-47-  

 
Security Ownership of Certain Beneficial Owners and Management

The table below sets forth certain information, as of June 10, 2004, concerning the beneficial ownership by (i) all current directors, (ii) each of our named executive officers, (iii) each person known to us to be the beneficial owner of more than five percent (5%) of our outstanding common stock, and (iv) all of our directors and executive officers as a group. To our knowledge, all persons listed in the table have sole voting and investment power with respect to their shares, except to the extent that their respective spouses share authority under applicable law.

 
   
Number of  

 

 

 
 

 

 

Common Shares  

 

 

Percent of
 

 

 

Beneficially  

 

 

Outstanding
Name and Address of Beneficial Owner (1)

 

 

Owned (2)
 

 

Shares

 
 
Michael A. Grollman
   
4,066,000
  (3)
 
4.8%
Graham L. Clark
   
1,451,667
  (4)
 
1.7%
Gregory Szabo
   
97,252
  (5)
 
0.1%
 
   
 
   
 
All executive officers and directors as a group (3 persons)
   
5,614,919
   
6.6%
_____________
 
(1)
The business address for all directors and officers is c/o National Scientific Corporation, 14455 North Hayden Road, Suite 202, Scottsdale, Arizona 85260-6947.
(2)
A person is deemed to be the beneficial owner of securities that can be acquired within 60 days from the date set forth above through the exercise of any option, warrant or right. Shares of Common Stock subject to options, warrants or rights that are currently exercisable or exercisable within 60 days are deemed outstanding for computing the percentage of the person holding such options, warrants or rights, but are not deemed outstanding for computing the percentage of any other person. The amounts and percentages are based upon the approximately 84,335,669 shares of Common Stock outstanding as June 10, 2004.
(3)
Includes 1,050,000 shares underlying currently exercisable stock options and warrants, and 2,750,000 shares of restricted Common Stock subject to substantial risk of forfeiture.
(4)
Includes 326,667 shares underlying currently exercisable stock options and warrants and 1,000,000 shares of restricted Common Stock subject to substantial risk of forfeiture.
(5)
Includes 40,000 shares underlying currently exercisable stock options and warrants and 57,252 shares of restricted Common Stock subject to substantial risk of forfeiture.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers, as well as persons beneficially owning more than 10% of the our outstanding Common Stock, to file certain reports of ownership with the Commission within specified time periods. Such officers, directors and shareholders are also required by Commission’s rules to furnish the Company with copies of all Section 16(a) forms they file.

Based solely on our review of such forms, all requirements received by it, or written representations from certain reporting persons, we believe that between October 1, 2002 and May 31, 2004, all Section 16(a) filing requirements applicable to its officers, directors and 10% shareholders were met.
 
-48-  

 
Description of Securities

Common Stock

As of June 10, 2004, we are authorized to issue up to 120,000,000 shares of common stock, par value $0.01 per share. As of June 10, 2004, there were 84,335,669 shares of common stock outstanding. We had 875 holders of record of common stock as of May 31, 2004. Each holder of common stock is entitled to one vote for each share held on all matters. Our articles of incorporation and bylaws do not provide for cumulative voting in elections of directors or any other matters brought before shareholder meetings.

The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

Preferred Stock

Our board of directors is authorized by our articles of incorporation to issue up to 4,000,000 shares of one or more series of preferred stock, par value $0.10 per share. No shares of such preferred stock have been authorized for issuance by our board of directors, and we have no present plans to issue any such shares. In the event that the board of directors issues shares of serial preferred stock, it may exercise its discretion in establishing the terms of such preferred stock.

Our board of directors may determine the voting rights, if any, of the series of preferred stock being issued, including the right to:

·
vote separately or as a single class with the common stock and/or other series of preferred stock;
 
 
·
have more or less voting power per share than that possessed by the common stock or other series of preferred stock; and
 
 
·
vote on specified matters presented to the shareholders or on all of such matters or upon the occurrence of any specified event or condition.

If our company liquidates, dissolves or winds up, the holders of our preferred stock may be entitled to receive preferential cash distributions fixed by our board of directors when creating the particular preferred stock series before the holders of our common stock are entitled to receive anything. Preferred stock authorized by our board of directors could be redeemable or convertible into shares of any other class or series of our stock.

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.


Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001.
 
-49-  

 
Summary of 2000 Plan

The following is a summary of certain provisions of the 2000 Stock Option Plan:

Administration

Either our board of directors or a committee appointed by our board of directors may administer the 2000 Stock Option Plan.

Eligibility

Nonqualified Options . Nonqualified options may be granted only to our officers, directors, including our non-employee directors, employees and advisors who, in the judgment of the committee, are responsible for our management or our success and who, at the time of the granting of the nonqualified options, are our officers, directors, employees or advisors.

Incentive Options . Incentive stock options may be granted only to our employees who, in the judgment of the committee or our board of directors, are responsible for our management or our success and who, at the time of the granting of the incentive stock option, are also our employees. No incentive stock option may be granted under the 2000 Stock Option Plan to any individual who would, immediately before the grant of such incentive stock option, directly or indirectly, own more than 10% of the total combined voting power of all classes of our capital stock unless: such incentive stock option is granted at an option price not less than 110% of the fair market value of the shares on the date the incentive stock option is granted; and such incentive stock option expires on a date not later than five years from the date the incentive stock option is granted.

Option Price

The purchase price as represented by our common stock offered under the 2000 Stock Option Plan must be at least 100% of the fair market value of our common stock (if the option is an incentive stock option), or at least 25% of the fair market value of our common stock at the time the option is granted (if the option is a nonqualified option), or such higher purchase price as may be determined by the committee or our board of directors at the time of grant. If, however, we grant an incentive stock option to an individual who would, immediately before the grant, directly or indirectly own more than 10% of the total combined voting power of all of our classes of stock, the purchase price of the shares of our common stock covered by such incentive stock option may not be less than 110% of the fair market value of such shares on the day the incentive stock option is granted. As the price of our common stock is currently quoted on the OTC Bulletin Board, the fair market value of our common stock underlying options granted under the 2000 Stock Option Plan will be the last closing sale price of our common stock on the day the options are granted. If there is no market price for our common stock, then our board of directors and the committee may, after taking all relevant facts into consideration, determine the fair market value of our common stock.

Exercise of Options

An option holder under the 2000 Stock Option Plan may exercise his or her option in whole or in part as provided under the terms of the grant, but in no event shall an option be exercisable after the expiration of ten years from the grant date. An option holder may not exercise any option after the option holder ceases to be one of our employees except in the case of disability or death. Our committee may, however, extend the right of exercise up to three months after the date of termination of the option holder’s employment with us. If we terminate an option holder’s employment by reason of disability, the committee or our board of directors may extend the exercise period for a specified period, generally one year, following the date of termination of the option holder’s employment. If an option holder dies while in our employ and the option holder has not fully exercised his or her options, the options may be exercised in whole or in part at any time within one year after the option holder’s death by the executors or administrators of the option holder’s estate or by any person or persons who acquired the option directly from the option holder by bequest or inheritance.
 
-50-  

 
In the event of the death of an employee or consultant while in our employ, the committee or our board of directors is authorized to accelerate the exercisability of all outstanding options under the 2000 Stock Option Plan.

Under the 2000 Stock Option Plan, we may grant one or more options to an individual, as long as the aggregate fair market value of the shares covered by incentive options exercisable for the first time during any calendar year shall not exceed $100,000.

Acceleration and Exercise upon Change of Control

All option holders’ unvested options automatically will become exercisable in the event of a change of control of our company as defined in the 2000 Stock Option Plan.

Payment for Option Shares

An option holder may exercise his or her options by delivering written notice to us at our principal office setting forth the number of shares with respect to which the option is to be exercised, together with cash or certified check payable to us for an amount equal to the option price of such shares. We may not issue any shares underlying an option grant until full payment has been made of all amounts due. We will deliver a certificate or certificates representing the number of shares purchased as soon as practicable after payment is received. Our board of directors or the committee may, in its discretion, permit the holder of an option to pay all or a portion of the exercise price by a simultaneous sale of our common stock to be issued upon exercise of an option pursuant to a brokerage or similar arrangement.

Termination of the 2000 Stock Option Plan

The 2000 Stock Option Plan will terminate on December 1, 2010, unless our board of directors terminates the 2000 Stock Option Plan prior to its expiration date. Any option outstanding under the 2000 Stock Option Plan at the time of termination shall remain in effect until the option is exercised or expires.

Amendment of the 2000 Stock Option Plan

Our board of directors may at any time modify or amend the 2000 Stock Option Plan without obtaining the approval of our shareholders as it shall deem advisable to comply with Section 422 of the Internal Revenue Code or Rule 16b-3 of the Securities and Exchange Act of 1934, as amended, or in any other respect.

Transferability of Options

An option holder may not assign any option under the 2000 Stock Option Plan other than by will or the laws of descent and distribution or if our board of directors or the committee agrees otherwise.

Issuance and Reservation of Shares

As of May 31, 2004, we have issued options to purchase an aggregate of 3,162,257 shares of our common stock. We have reserved the right to issue a total of 7,000,000 shares of our common stock for issuance under the 2000 St ock Option Plan, although our Board currently plans to limit issuances of options to 4,000,000 for the immediate future.
 
-51-  

 
Employee Stock Retainage Plan

In September 2002, by unanimous vote, our board initiated a restricted stock retainage program or plan (“Stock Retainage Program”) to retain key staff during a period of financial difficulty in calendar year 2002. The board allocated approximately $150,000 in restricted common stock from this Stock Retainage Program as a pool of shares of our restricted common stock, to be granted to key employees at the direction of the board for the year and the next, subject to National Scientific exceeding sales growth objectives and expense control objectives in 2003. Failure to meet these objectives under the plan would result in serious risk of forfeiture by staff of some or all of these stock grants by all participants. All goals set were team goals. The plan has been used as a tool to achieve salary deferral and other salary concessions from the staff during this period of fiscal hardship, in order to retain key employees during this period The plan’s sales goals were not met in calendar year 2003, although the plan was nonetheless largely successful in assisting to retain key staff, even during this period of deferred or reduced salary. In January of 2004, our board extended this program into 2004, and set new sales growth objectives for the year at a level 50% higher than the previous year’s program, giving plan participants an additional year to fully earn these previously outstanding restricted stock grants. No new shares were added to the plan, although plan participants were able to convert some long term back pay into restricted stock at that time, if desired. As of the date of this prospectus, the plan currently covers officers Michael Grollman and Graham Clark, and employees who are not officers including Oscar Quadros, Karen Fuhre, and Paul Davidson. The plan has not been submitted to our shareholder’s for approval.


 
Our articles of incorporation provide that no director shall incur liability to us or our shareholders for monetary damages resulting from an act or omission in a director’s capacity as a director occurring after August 31, 1987, except for: any breach of the director’s duty of loyalty to our shareholders and us; acts and omissions not taken in good faith or which involve intentional misconduct or a knowing violation of law; any transaction from which a director received an improper benefit; acts or omissions for which the liability of a director is expressly provided by statute; or acts related to an unlawful stock repurchase or dividend.

Texas law also provides a corporation the right to indemnify a director or officer or other person under certain conditions.

A person entitled to indemnification under these provisions may be indemnified against judgments, penalties (including excise and similar taxes), fines, settlements and reasonable expenses he or she actually incurs in connection with the proceeding. If the person is found liable to the corporation or is found liable on the basis that personal benefit was improperly received by the person, the indemnification is limited to reasonable expenses actually incurred by the person in connection with the proceeding, and shall not be made in respect of any proceeding in which the person is found liable for willful or intentional misconduct in the performance of his or her duty to the corporation.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to contracts, statutes, or otherwise, the SEC has advised us that in its opinion, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. If a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by our director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether our indemnification is against public policy as expressed in the Securities Act, and we will be governed by the final adjudication of such issue.



We lease 2,945 square feet of office space at 14455 North Hayden Road, Suite 202, Scottsdale, Arizona 85260. The lease for the Scottsdale facility expires October 31, 2004 and is at a rental rate of approximately $5,400 per month including taxes. We do not own any real estate.

Currently, we do not have a policy regarding investments in real estate, interests in real estate, real estate mortgages or securities of or interests in persons primarily engaged in real estate activities.
 
-52-  

 
Certain Relationships and Related Transactions

In October 2002, Mr. Lou Ross, the former Chairman of the Board, and a Director until September 30, 2003, was paid for his services as an active member of the board in shares of restricted common stock, in lieu of cash. The former Chairman received 66,806 restricted common shares at an average price on the date of grant of $0.11 per share.

In June 2003, we entered into an agreement to restructure and repay an outstanding debt to Mr. Lou Ross, a Director of National Scientific. Together with Mr. Ross, we aggregated the value of all sums we currently owed to Mr. Ross. This included notes executed of approximately $75,000, all salary deferred by Mr. Ross in 2002 of approximately $8,300, and all cash board fees deferred in 2002 by Mr. Ross of approximately $3,000, for a total amount payable to Mr. Ross as of June 11, 2003 of approximately $86,500. Mr. Ross agreed to accept one-half of this sum, or $43,250, in restricted common stock issued at the then-current market price of $0.15 cents per share, for a total share grant to Mr. Ross of 288,334 shares. Mr. Ross also agreed to convert the remaining one-half of the total debt outstanding from us to him, or $43,250, into a three-year interest free note, with no payments required by us until the end of the three-year period, and which could be paid by us at any time before the three-year period elapses with either cash or its restricted common stock or a combination of cash and stock. With this agreement, we no longer have any outstanding delinquent notes to Mr. Ross, and our liabilities have been reduced by $43,250.

Mr. Ross also agreed to take a reduction in his Director's fees for the period from February 2003 to the end of the fiscal year ending in September 2003, and to accept 50,000 shares of our restricted common stock in lieu of cash for these board services, which was paid to him in stock on June 11, 2003. On September 30, 2003, at the point of his resignation from the Board, Mr. Ross surrendered all stock options he had received from us.

On September 30, 2002 we started a restricted Stock Retainage Program to retain key staff during a period of financial difficulty with significant periods of cash wage deferrals. We allocated approximately 3,350,000 shares with a current market value of $150,000 from this Stock Retainage Program pool of shares in fiscal 2002, to be granted to key personnel. Grants from this pool of shares have been made to Michael Grollman, Graham Clark, Karen Fuhre, Oscar Quadros, and Paul Davidson. As of the date of this prospectus, none of these grants have been fully earned, and they remain subject to substantial risk of forfeiture.
 
-53-  

 
Executive Compensation

The following table sets forth certain information regarding annual and long-term compensation for services rendered to us during the fiscal years ended September 30, 2003, 2002, and 2001 to the Chief Executive Officer of National Scientific, and other named executive officers who served us in fiscal year 2003 and whose total salary and non-cash compensation exceeded $100,000 for the applicable fiscal periods. The table below includes salary earned and paid in the fiscal year ended September 30, 2003.
 
Summary Compensation Table
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
 
   
 
   
 
   
 
   
 

 

Long-Term Compensation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
Annual Compensation  
Awards
 
Payouts
 
 
 
 
 
 
 
 
 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restricted  
 
 
Securities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Annual  
 
 
Stock
 
 
Underlying
 
 
 
 
 
All other
 
 
 
 
 
 
 
Salary  
 
 
Bonus
 
 
Compensation
 
 
Award(s)
 
 
Options/ SARs
 
 
LTIP
 
 
Compensation
 
Name and Principal Position
 
 
Year
 
 
($) (1)
 
 
($)
 
 
($)
 
 
($) (2)
 
 
(#)
 
 
Payout ($)
 
 
($) (3)
 

 
 
 
 
 
 
 
 
 
Michael A. Grollman
   
2003
   
64,640
   
---
   
---
   
---
   
---
   
---
   
70,360
 
CEO, Chairman (4)
   
2002
   
138,000
   
---
   
---
   
78,750
   
---
   
---
   
42,000
 
 
   
2001
   
172,500
   
---
   
---
   
165,000
   
---
   
---
   
---
 
                                                   
Graham L. Clark
   
2003
   
69,639
   
---
   
---
   
---
   
---
   
---
   
50,360
 
President, Director (5)
   
2002
   
104,400
   
---
   
---
   
63,000
   
---
   
---
   
15,600
 
 
   
2001
   
120,000
   
---
   
---
   
---
   
---
   
---
   
---
 
                                                   
Lou L. Ross
   
2003
   
---
   
---
   
---
   
17,650
   
---
   
---
   
---
 
Former CEO & Chairman
   
2002
   
86,000
   
---
   
12,700
   
4,500
   
---
   
---
   
---
 
(retired) (6)
   
2001
   
120,465
   
---
   
---
   
---
   
---
   
---
   
---
 
                                                   
Sam H Carr
   
2003
   
---
   
---
   
32,362
   
32,362
   
---
   
---
   
---
 
Former CFO (7)
   
2002
   
160,275
   
---
   
34,166
   
194,441
   
---
   
---
   
---
 
 
   
2001
   
158,075
   
---
   
138,000
   
296,075
   
---
   
---
   
---
 

___________________
 
(1)
Unpaid wages in this table are subject to Agreements with listed persons that allow for interest of approximately prime rate plus 2% to accrue on those unpaid wages until paid. These accruals for interest are shown as approximate through fiscal year-end September 2003.
(2)
Stock grants included in this column are for common stock valued at 90% of the closing sales price for such shares on the date of grant. Closing sales price at fiscal year end September 2002 was approximately $0.07 per share, and closing sales price at fiscal year end September 2003 was approximately $0.15 per share.
(3)
Includes unpaid salary forgone at the election of executive officers Grollman and Clark pursuant to a registrant program under which stock, stock-based or other forms of non-cash compensation may be received by a named executive in lieu of a portion of annual compensation earned in a covered fiscal year.
(4)
For 2003 salary of $70,360 was not paid in cash, but deferred to a future period. Estimated interest of $2,932 on this unpaid amount is not included above. For 2002 salary of $42,000 was not paid in cash, but deferred to a future period. Estimated interest of $1,500 on this unpaid amount is not included above. Subsequent to year end of September 2002, Mr. Grollman exchanged $10,000 of this deferred salary for a B Unit in our November 2002 Private Placement Offering for 125,000 shares of restricted stock and 100,000 common stock purchase warrants exercisable at a price of $0.50 per share, thus reducing 2002 unpaid wages for that year to $33,500. Other Compensation for 2002 also includes $78,750 for common stock grants subject to risk of forfeiture if calendar 2004 sales do not meet or exceed key targets, and in exchange for salary reduction in calendar year 2003 of $60,000 (See Note 2 above and Employment Agreements below). Also subsequent to fiscal 2003 year-end, Mr. Grollman deferred substantially all his October and November salary of $10,000 each month to a future period, and this amount of $19,900 remains unpaid. From September 2002 Mr. Grollman’s share of contributions to the Company’s health insurance program of approximately $6,600 were deducted from the balance of wages owing, leaving as of the end of December 2003,unpaid wages of approximately $117,000, accrued vacation pay of approximately $60,000 and accrued interest of approximately $7,000 for a combined total of approximately $184,000.
 
-54-  

 
(5)
For 2003 salary of $50,360 was not paid in cash, but deferred to a future period. $1,929 estimated interest on this unpaid amount. For 2002 salary of $15,600 was not paid in cash, but deferred to a future period. Estimated interest of $1,929 on this unpaid amount is not included above. Subsequent to year end September 2002, Mr. Clark exchanged $10,000 of deferred salary for a B Unit in our November 2002 Private Placement Offering for 125,000 shares of restricted stock and 100,000 common stock purchase warrants exercisable at a price of $0.50 per share. Other compensation for 2002 also includes $63,000 for restricted common stock grants subject to risk of forfeiture if 2004 sales do not meet or exceed key targets (See Note 2 above and Employment Agreements below). Also subsequent to September 30, 2003 year end, Mr. Clark deferred substantially all his October and November salary of $10,000 each month to a future period, and this amount of $19,900 remains unpaid. From September 2002 Mr. Clark’s share of contributions to our health insurance program of approximately $7,900 were deducted from the balance of wages owing, leaving as of the end of December 2003, unpaid wages of approximately $68,000, accrued vacation pay of approximately $19,000 and accrued interest of approximately $3,000 for a combined total of approximately $90,000.
(6)
Other Compensation for 2003 and 2002 includes common stock grants paid as board service fees. Mr. Ross resigned as an employee in January of 2002 and as a director in September 2003.
(7)
Other Compensation for 2003 includes $32,362 of contractor fees for services rendered in the six months prior to March 2003, of which approximately $17,083 remains unpaid. For 2002 salary of $30,173 was not paid in cash, but deferred to a future period, and remains unpaid, including all accrued vacation through July 2002, plus an estimated $1,500 in interest through September 30, 2002. Other Compensation for 2002 includes $34,166 of contractor fees for services rendered in August and September of 2002, of which $21,337 remains unpaid. Subsequent to year ending September 2002, $10,000 of other deferred contractor fees was exchanged by Mr. Carr for an A Unit in our November 2002 Private Placement Offering for 250,000 shares of common stock and warrants to purchase 100,000 shares of common stock at a price of $0.30 per share. Other Compensation in 2001 for Mr. Carr includes the value of options granted at an exercise price below the market value of the stock on the date of grant, as well as options granted to Mr. Carr during his tenure as a contactor of us rather than an employee. Such options contracts have been valued using the Black-Scholes model for the purposes of this table. Mr. Carr resigned in July 2002 as an employee and a director.

Long Term Incentive Plans – Awards in the Last Fiscal Year

The table below describes all Long Term Incentive Plans under which awards were given to the named executive officers during the last fiscal year. These awards fall under our employee stock retainage program.

 
Long-Term Incentive Plans - Awards in Last Fiscal Year  

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

Estimated Future Payouts Under Non-  
 

 

 

 

 

 

 

 

Stock Priced-Based Plans  

 

 

 

 

 

 

 

 


 

 

 

Number of  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares  

 

 

Performance or Other Period

 

 

Threshold

 

 

Target

 

 

Maximum

 

Name

 

 

(#) (1)
 

 

Until Maturation or Payout

 

 

($ or #)
 

 

($ or #)
 

 

($ or #)
 

 
 
 
 
 
 
Michael A. Grollman (2)
   
1,250,000
   
Dec 2004
   
 
   
 
   
 
 
Graham L. Clark (3)
   
1,000,000
   
Dec 2004
   
 
   
 
   
 
 

____________________

(1)
All grants in this table are based on our fiscal year 2002 stock retainage program. This program was implemented by our board in September 2002, and shares were granted at that time. Actual issuance of shares for the named executive participants took place in January of 2003. Our board allocated approximately $150,000 in common stock from this Stock Retainage Program pool of shares, to be granted to key employees during the year, subject to National Scientific exceeding sales growth objectives and expense reduction objectives, and subject to the employees remaining with us through the next 15 months, or longer, if the awards were not earned after 15 months. Failure to meet these objectives under the plan can result in the forfeiture by staff of some or all of the stock grants by all participants. These goals were the same for all plan participants, which included other non-executives, as well the named executives. These goals were not met in calendar year 2003. In January of 2004, our board extended this program into 2004, and set new sales growth objectives for the year at a level 50% higher than the previous year’s program, giving plan participants an additional year to fully earn this stock grant.
(2)
Mr. Grollman was granted 750,000 shares of stock from this Stock Retainage Program pool of shares, subject to National Scientific achieving in excess of $400,000 in sales in calendar year 2004. Mr. Grollman was granted an additional 500,000 shares of stock under this program, subject to sales exceeding $1,500,000 for calendar year 2004.
(3)
Mr. Clark was granted 500,000 shares of stock from our Stock Retainage Program pool of shares discussed above, subject to National Scientific achieving in excess of $400,000 in sales in calendar year 2004. Mr. Clark was granted an additional 500,000 shares of stock under this program, subject to sales exceeding $1,500,000 for calendar year 2004.

 
-55-  

 
Table of Contents
 
Option/SAR Grants and Exercises of Options/SAR Grants during Last Fiscal Year

No individual grants of stock options (whether or not in tandem with SARs), or freestanding SARs (including options and SARs that subsequently have been transferred) were made during the fiscal year ending Septembers 30, 2003, to any of the named executive officers, nor did any of the named executive officers exercise any options or SAR grants during that period.

Employment Agreements

Mr. Grollman was engaged by us as an independent contractor from October 7, 2000 until November 30, 2000. He was paid $15,000 monthly for his services as an independent contractor. Effective December 1, 2000, Mr. Grollman became an employee of National Scientific under a one-year contract to serve as our Chief Operating Officer. Mr. Grollman was named President in April 2001. The contract automatically renews for additional one-year terms unless either party chooses to terminate, and it remains in force through at least calendar year 2004. Mr. Grollman’s contract calls for an annual gross salary of $180,000, payable semi-monthly. Also in accordance with the contract, on December 1, 2000, we granted Mr. Grollman 100,000 shares of common stock, subject to risk of forfeiture should Mr. Grollman not fulfill his employment agreement. Also on December 1, 2000, we granted Mr. Grollman 500,000 vested options to purchase common stock at the closing sales price of the common stock on December 1, 2000. Additional option grants are included in Mr. Grollman’s employment contract for each whole dollar amount increase in the market value of our Common Stock. The whole dollar amount increase is measured over a moving two-week average. For each whole dollar amount attained between $1 and $15 inclusive, Mr. Grollman will receive 75,000 options at the whole dollar amount option price. Mr. Grollman is also entitled to additional options at various but declining levels for increases in stock value up to $50 per Common Share. In the event of a change in control or sale of substantially all the assets of National Scientific, the employment agreement between Mr. Grollman and us automatically terminates, and Mr. Grollman is to receive one hundred fifty percent (150%) of the then current year’s annual salary.

In January of 2002 Mr. Grollman agreed to defer 20% of his salary until such a time as cash was more available, reducing his immediately payable cash salary to $12,000 per month. For September, October, and November of 2002, Mr. Grollman deferred 100% of his payable salary, reducing his immediately payable cash salary to $0 per month. Mr. Grollman agreed from January 2003 through December 2003 to reduce his total payable salary for the 2003 year to $120,000 per year. In addition to this reduction, during the year ended September 30, 2003 Mr. Grollman deferred $70,360 of his salary and was paid $64,640 in cash. For the three months ending December 31, 2003, Mr. Grollman deferred $19,900 in salary and was paid $10,100 in cash. For calendar year 2004, Mr. Grollman agreed to defer up to $30,000 of his contracted pay as needed.

In September 2002, our board initiated a restricted stock retainage program (“Stock Retainage Program”) to retain key staff during a period of financial difficulty in calendar year 2002. The board allocated approximately $150,000 in common stock from this Stock Retainage Program pool of shares, to be granted to key employees during the year, subject to National Scientific exceeding sales growth objectives and expense reduction objectives in 2003. Failure to meet these objectives under the plan would result in the forfeiture by staff of this entire stock grant by all participants. These goals were not met in calendar year 2003. In January of 2004, our Board extended this program into 2004, and set new sales growth objectives for the year at a level 50% higher than the previous year’s program, giving plan participants an additional year to fully earn this stock grant. On August 19, 2003, a participant of the plan left us and his grant of 800,000 shares were forfeited at the average market price per share of $0.15. On September 30, 2003 the 800,000 shares of common stock resulting from the forfeiture was allocated to the plan. We issued this stock under the terms of the plan to several employees in 2004 who are not officers or directors of National Scientific.

Mr. Grollman was granted 750,000 shares of stock from this Stock Retainage Program pool of shares, subject to National Scientific achieving in excess of $400,000 in sales in calendar year 2004. Mr. Grollman was granted an additional 500,000 shares of stock under this program, subject to sales exceeding $1,500,000 for calendar year 2004.
 
-56-  

 
In December 2003 Mr. Grollman agreed to convert approximately $150,000 of his back pay and accrued vacation pay to our restricted common stock, at a rate equal to the then currently available private placement share price of $0.10 per share. Mr. Grollman received this stock in January of 2004.

Our board of directors is also considering granting approximately 500,000 additional options to Mr. Grollman in calendar year 2004 based on the achievement of calendar year 2004 business objectives, including such areas as product development and customer base development. The plan has been approved by the board of directors, subject to availability of sufficient options in the plan. These options have not been issued.

Mr. Clark was hired in December 2000 as manager of the sales organization. His salary was $120,000 per year base salary, plus commission on sales. He became Vice President of Technology Applications & Sales for us in September 2001, and a director and a corporate officer in August of 2002. In January of 2003, Mr. Clark entered into a one-year employment agreement with National Scientific to serve as Vice President of Technology Applications & Sales. In June of 2003 Mr. Clark was named President of National Scientific. The contract automatically renews for additional one-year terms unless either party chooses to terminate. Mr. Clark’s contract provides for an annual gross salary of $150,000, payable monthly. In the event of a change in control or sale of substantially all our assets, the employment agreement between Mr. Clark and National Scientific automatically terminates, and Mr. Clark is to receive fifty percent (50%) of the then current year’s annual salary.

For September, October, and November of 2002, Mr. Clark deferred 100% of his payable salary, reducing his immediately payable cash salary to $0 per month. During the year ended September 30, 2003 Mr. Clark deferred $50,360 of his salary and was paid $69,640 in cash. For the three months ending December 31, 2003, Mr. Clark deferred $19,900 in salary and was paid $10,100 in cash.

Mr. Clark was granted 500,000 shares of stock from our Stock Retainage Program pool of shares discussed above, subject to National Scientific achieving in excess of $400,000 in sales in calendar year 2004. Mr. Clark was granted an additional 500,000 shares of stock under this program, subject to sales exceeding $1,500,000 for calendar year 2004.

Our board of directors is also considering granting approximately 500,000 additional options to Mr. Clark in calendar year 2004 based on the achievement of calendar year 2004 business objectives, including such areas as product development and customer base development. The plan has been approved by the board of directors, subject to availability of sufficient options in the plan. These options have not been issued.

Throughout fiscal 2000, Mr. Ross was engaged as an independent contractor for National Scientific. As such, Mr. Ross was paid a monthly fee of $9,500, subject to cash availability. Effective December 1, 2001, Mr. Ross became an employee of National Scientific. Throughout fiscal 2001 and continuing into 2003, Mr. Ross served without a written contract and was paid $9,500 monthly. In addition, in connection with an equity transaction involving Mr. Ross and his spouse in September 1999, the Board of Directors granted Mr. Ross the right to receive 4% of our gross revenues. In partial consideration for the forgiveness of this right to 4% of our future revenues, National Scientific agreed to issue 500,000 restricted shares of our common stock to Mr. Ross. The 500,000 shares are subject to the terms of a Restricted Stock Award Agreement, which required that the shares issued be released only when the market price of the stock exceeds $2.50 per share.

Subsequent to fiscal year end 2001, National Scientific granted Mr. Ross options to purchase an aggregate of 750,000 shares of common stock. The options consist of ten separate groups of 75,000 shares each, whose exercise prices range from $1 to $10 per share, which vest when the previous five day average market price exceeds even dollar levels beginning with $1 per share through $10 per share. On September 30, 2003, these options were forfeited and returned to us.

In February of 2002, Mr. Ross resigned as an employee of National Scientific, and became a part-time contractor, paid at a rate of $10,000 per month, of which 20% would be deferred until a future date. The term of the agreement was two years and it required that Mr. Ross provide approximately 80 hours per month management-c onsulting services to us and serve as a director. In July 2002 National Scientific and Mr. Ross amended the contract to eliminate mandatory monthly minimum cash payments and minimum hours per month for on-going consulting duties other than his responsibilities as a director. Under this revised contract, Mr. Ross was paid a director’s fee of $2,500 per month in our restricted common stock. In February 2003 this contract was again revised, and from February 2003 to September 30, 2003 Mr. Ross agreed to take a reduction in his director’s fees and accept 50,000 shares of common stock in lieu of cash for board services for the entire six-month period. Mr. Ross retired from the board on September 30, 2003. His major contract duties as a consultant with us ended in February 2004, although some confidentiality provisions of this agreement continue into 2005.
 
-57-  

 
Mr. Carr served us as an independent contractor from October 15, 2000 until November 30, 2000. He was paid $13,750 monthly for his services. Effective December 1, 2000, Mr. Carr became employed under a one year contract to serve as our Chief Financial Officer. The contract automatically renewed for additional one-year terms unless either party elected to terminate. Mr. Carr’s contract provided for an annual gross salary of $180,000, payable semi-monthly. Also in accordance with the contract, on December 1, 2000, we granted Mr. Carr 100,000 vested options to purchase common stock at a price equal to 25% of the closing price per share on December 1, 2000. Also on December 1, 2000, we granted Mr. Carr 500,000 vested options to purchase common stock at the closing sales price of the shares on December 1, 2000. Additional option grants were included in Mr. Carr’s employment contract for each whole dollar amount increase in the market value of our Common Shares. The whole dollar amount increase is measured over a moving two-week average. For each whole dollar amount attained between $1 and $15 inclusive, Mr. Carr would receive 75,000 options at the whole dollar amount option price. Mr. Carr was also entitled to additional options at various but declining levels for increases in stock value up to $50 per common share.

From January of 2002 through July of 2002, Mr. Carr deferred 20% of his salary, subject to future cash availability, reducing his monthly salary cash payments to $12,000 per month.

In July of 2002, Mr. Carr resigned as CFO and also as an employee and a company director, and became a full-time non-employee contractor for us. He signed a one-year contract, the terms of which were similar to his previous company employment contracts, although all employee-related benefits were eliminated, and his hourly rate of pay was changed to approximately $97 per hour, or approximately $17,000 per month. In November 2002, National Scientific and Mr. Carr amended this contract to eliminate mandatory monthly payments. Mr. Carr was retained on this basis during the month of December 2002 to assist with preparation of our annual report and other matters, for which he was paid approximately $12,000 in cash. In January 2003 Mr. Carr and National Scientific agreed to secure his services as a financial consultant for a minimum retainer of ten hours per month at a rate of $120 per hour. This retainer agreement ended on April 1, 2003.

In January 2003, we, under our Restricted Stock Retainage Plan initiated in September 2002, issued 2,550,000 shares of common stock at an average price of $0.06 or 90% of the price on the grant date of September 30, 2002. These grants were provided originally to Michael Grollman, Graham Clark, David Mandala, and Karen Fuhre. Mr. Mandala left the firm in mid-2003, and his shares under the plan were reallocated to other Oscar Quadros and Paul Davidson. These stock grants were contingent upon National Scientific achieving sales targets for calendar year 2003. Should these targets not be met, these shares would be forfeited, or we and the employees involved in the program would elect to establish new goals for calendar year 2004, in order to motivate the staff to perform and simultaneously conserve cash resources during the next calendar year, using the same stock grants, as yet unearned, as long term incentive.

During the fiscal years ending September 30, 2003 and 2002, we issued 946,270 and 100,000 shares, respectively, of our common stock to our consultants in lieu of cash compensation. During fiscal 2003, we granted 428,081 options to our consultants to purchase shares of our common stock. The options granted had exercise prices ranging from $0.03 per share to $0.11 per share. The exercise prices were generally below market on the date of grant, and vested. We granted these options as a means of compensation to consultants to conserve operating cash. During fiscal 2003, substantially all option grants were issued to employees.
 
-58-  

 
Where You Can Find More Information

We file reports and other information with the U.S. Securities and Exchange Commission. You may read and copy any document that we file at the SEC’s public reference facilities at 450 Fifth Street N.W., Room 1024, Washington, D.C. 20549. Please call the SEC at 1-800-732-0330 for more information about its public reference facilities. Our SEC filings are also available to you free of charge at the SEC’s web site at www.sec.gov .

Copies of publicly available documents that we have filed with the SEC can also be inspected and copied at the offices of the National Association of Securities Dealers, Inc., 1735 K. Street, N.W., Washington, D.C. 20006.

You should only rely upon the information included in or incorporated by reference into this prospectus, the exhibits to the prospectus or in any prospectus supplement that is delivered to you. We have not authorized anyone to provide you with additional or different information. You should not assume that the information included in or incorporated by reference into this prospectus or any prospectus supplement is accurate as of any date later than the date on the front of the prospectus or prospectus supplement.

We have not authorized any person to provide you with information different from that contained or incorporated by reference in this prospectus. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock.
 
-59-  

 
FINANCIAL STATEMENTS
 
INDEX
 

 
Page
For Fiscal Years Ending September 30, 2002 and 2003 (audited)
 
F-2
F-3
F-4
F-5
F-11
F-13
 
 
For the Six Month Period Ending March 31, 2004 (unaudited)
 
F-25
F-26
F-27
F-28
F-29


 
 
   F-1  

 

Board of Directors, National Scientific Corporation

We have audited the accompanying balance sheets of National Scientific Corporation (a development stage Company) as of September 30, 2003 and 2002, and the related statements of operations, shareholders’ equity (deficit) and cash flows for each of the two years in the period ended September 30, 2003 and for the period from September 30, 1997 (inception of development stage) to September 30, 2003. These financial statements are the responsibility of National Scientific Corporation’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of National Scientific Corporation as of September 30, 2003 and 2002, and the results of its operations and its cash flows for each of the two years in the period ended September 30, 2003 and from September 30, 1997 (inception of development stage) to September 30, 2003 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that National Scientific Corporation will continue as a going concern. As discussed in Note 2 to the financial statements, National Scientific Corporation is in the development stage, has not yet generated significant revenues, and is dependent upon raising capital from investors. Additionally, National Scientific Corporation has incurred aggregate losses during the past two years of over $2,800,000 and has a total shareholders’ deficit of over $600,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Hurley & Company

Granada Hills, CA
December 4, 2003, except
for Note 13 which is
January 9, 2004
 
 
 
   F-2  

 
(A Development Stage Company)
 
BALANCE SHEETS
September 30, 2003 and 2002


 
   
2003
   
2002
 
   
 
 
ASSETS
   
 
   
 
 
 
   
 
   
 
 
Current Assets:
   
 
   
 
 
Cash and cash equivalents
 
$
17,903
 
$
1,405
 
Trade receivables, net of reserve of $8,169 at September 30, 2003
   
28,200
   
1,631
 
Inventory
   
9,700
   
14,916
 
Other assets
   
16,926
   
800
 
   
 
 
Total current assets
   
72,729
   
18,752
 
 
   
 
   
 
 
Property and equipment, net
   
32,081
   
45,007
 
Deposits
   
5,031
   
5,031
 
   
 
 
 
 
$
109,841
 
$
68,790
 
   
 
 
 
   
 
   
 
 
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
   
 
   
 
 
 
   
 
   
 
 
Current Liabilities:
   
 
   
 
 
Accounts payable
 
$
185,725
 
$
368,952
 
Accrued expenses
   
457,695
   
396,505
 
Deposits
   
20,000
   
 
Notes payable
   
10,000
   
75,079
 
   
 
 
Total current liabilities
   
673,420
   
840,536
 
 
   
 
   
 
 
Notes payable, net of current portion
   
43,250
   
 
   
 
 
Total liabilities
   
716,670
   
840,536
 
 
   
 
   
 
 
Commitments and contingencies
   
   
 
   
 
 
Shareholders’ equity (deficit):
   
 
   
 
 
Preferred stock, par value $0.10; 4,000,000 shares authorized, and no shares issued or outstanding
   
   
 
Common stock, par value $0.01; 120,000,000 shares authorized, and shares issued 70,633,819 and 51,587,062 outstanding at September 30, 2003 and 2002, respectively
   
706,338
   
515,871
 
Additional paid-in capital
   
20,444,733
   
19,517,719
 
Accumulated deficit
   
(21,757,900
)
 
(20,805,336
)
   
 
 
Total shareholders' equity (deficit)
   
(606,829
)
 
(771,746
)
   
 
 
 
 
$
109,841
 
$
68,790
 
   
 
 

See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
   F-3  

 
(A Development Stage Company)
 
STATEMENTS OF OPERATIONS
For the Years Ended September 30, 2003, 2002, and Development Stage

 
   
 
   
 
   

Development

 
 
   
2003
   
2002
   
Stage
 
   
 
 
 
 
   
 
   
 
   
 
 
Revenues
 
$
63,579
 
$
2,914
 
$
949,208
 
 
   
 
   
 
   
 
 
Cost of Sales
   
25,848
   
1,889
   
897,487
 
   
 
 
 
Gross profit
   
37,731
   
1,025
   
51,721
 
 
   
 
   
 
   
 
 
Costs and expenses
   
 
   
 
   
 
 
Salaries and benefits
   
438,244
   
624,069
   
2,176,796
 
Research and development
   
84,301
   
154,548
   
3,713,135
 
Stock compensation
   
291,658
   
460,168
   
3,080,694
 
Consulting fees, related party
   
17,650
   
   
8,175,973
 
Other
   
149,245
   
667,250
   
2,407,303
 
   
 
 
 
Total costs and expenses
   
981,098
   
1,906,035
   
19,553,901
 
   
 
 
 
 
   
 
   
 
   
 
 
Loss from operations
   
(943,367
)
 
(1,905,010
)
 
(19,502,180
)
 
   
 
   
 
   
 
 
Other income (expense)
   
 
   
 
   
 
 
Interest and other income
   
   
584
   
178,972
 
Gain on settlement
   
   
89,403
   
89,403
 
Interest expense
   
(9,197
)
 
(1,874
)
 
(34,268
)
Loss on disposal of assets
   
   
(2,405
)
 
(30,960
)
Loss on impairment of equipment
   
   
(64,187
)
 
(64,187
)
   
 
 
 
 
   
(9,197
)
 
21,521
   
138,960
 
   
 
 
 
Loss before income taxes
   
(952,564
)
 
(1,883,489
)
 
(19,363,220
)
Income tax expense
   
   
   
 
   
 
 
 
 
   
 
   
 
   
 
 
Net loss
 
$
(952,564
)
$
(1,883,489
)
$
(19,363,220
)
   
 
 
 
Net loss per common share, basic and diluted
 
$
(0.02
)
$
(0.04
)
 
 
 
   
 
       
Weighted average number of shares outstanding
   
62,758,349
   
49,626,954
   
 
 
   
 
       

See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
   F-4  

 
(A Development Stage Company)
 
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
For the Years Ended September 30, 2003, 2002 and Development Stage
 
   

  Common Stock  

 

  Preferred Stock  

                   
   
 
 
 
                   
 
   
Number  
   
 
   
Number
   
 
   
Additional
   
 
   
 
 
 
   
of  
   
Par
   
of
   
Par
   
Paid-In
   
Accumulated
   
 
 
 
   
Shares  
   
Value
   
Shares
   
Value
   
Capital
   
Deficit
   
Total
 
   
 
 
 
 
 
 
 
Balance, September 30, 2002
   
51,587,062
 
$
515,871
   
 
$
 
$
19,517,719
 
$
(20,805,336
)
$
771,746
 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services @$0.17
   
946,270
   
9,462
   
   
   
152,913
   
   
162,375
 
Exercise of options
   
637,153
   
6,372
   
   
   
22,686
   
   
29,058
 
Stock options granted
   
   
   
   
   
60,733
   
   
60,733
 
Debt equity swap
   
788,334
   
7,883
   
   
   
66,232
   
   
74,115
 
Private placement @ $0.04 to $0.08
   
14,125,000
   
141,250
   
   
   
528,750
   
   
670,000
 
Stock retainage program
   
2,550,000
   
25,500
   
   
   
95,700
   
   
121,200
 
Net loss
   
   
   
   
   
   
(952,564
)
 
(952,564
)
   
 
 
 
 
 
 
 
Balance, September 30, 2003
   
70,633,819
 
$
706,338
   
 
$
 
$
20,444,733
 
$
(21,757,900
)
$
(606,829
)
   
 
 
 
 
 
 
 
 
 
See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
   F-5  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)
 
(Continued)
For the Years Ended September 30, 2002, 2001 and Development Stage

   

  Common Stock

 

  Preferred Stock

                   
   
 
                   
 
   
Number  
   
 
   
Number
   
 
   
Additional
   
 
   
 
 
   
of  
   
Par
   
of
   
Par
   
Paid-In
   
Accumulated
   
 
 
 
   
Shares  
   
Value
   
Shares
   
Value
   
Capital
   
Deficit
   
Total
 
   
 
 
 
 
 
 
 
Balance, September 30, 2001
   
47,367,498
 
$
473,675
   
 
$
 
$
18,766,775
 
$
(18,921,847
)
$
318,603
 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services @ $0.306
   
100,000
   
1,000
   
   
   
29,600
   
   
30,600
 
Issuance of stock under equity line of credit @ $0.12 to $0.27
   
2,122,064
   
21,221
   
   
   
393,603
   
   
414,824
 
Exercise of warrants
   
770,500
   
7,705
   
   
   
84,755
   
   
92,460
 
Exercise of options
   
1,477,000
   
14,770
   
   
   
154,762
   
   
169,532
 
Loan repayment by officer
   
(250,000
)
 
(2,500
)
 
   
   
(97,500
)
 
   
(100,000
)
Grants of options and warrants, net
   
   
   
   
   
185,724
   
   
185,724
 
Net loss
   
   
   
   
   
   
(1,883,489
)
 
(1,883,489
)
   
 
 
 
 
 
 
 
Balance, September 30, 2002
   
51,587,062
 
$
515,871
   
 
$
 
$
19,517,719
 
$
(20,805,336
)
$
(771,746
)
   
 
 
 
 
 
 
 

See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
   F-6  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

(Continued)
For the Years Ended September 30, 2001, 2000 and Development Stage

   

    Common Stock

 

  Preferred Stock

                   
   
 
                   
 
   
Number  
   
 
   
Number
   
 
   
Additional
   
 
   
 
 
 
   
of  
   
Par
   
of
   
Par
   
Paid-In
   
Accumulated
   
 
 
 
   
Shares  
   
Value
   
Shares
   
Value
   
Capital
   
Deficit
   
Total
 
   
 
 
 
 
 
 
 
Balance, September 30, 2000
   
47,195,768
 
$
471,958
   
 
$
 
$
15,086,920
 
$
(12,686,979
)
$
2,871,899
 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services @ $1.66
   
100,000
   
1,000
   
   
   
164,600
   
   
165,600
 
Stock issued for services  @ $1.55
   
15,000
   
150
   
   
   
23,070
   
   
23,220
 
Stock issued for services @ $4.32
   
5,000
   
50
   
   
   
21,550
   
   
21,600
 
Stock issued for services @ $1.32
   
75,000
   
750
   
   
   
98,475
   
   
99,225
 
Stock issued for services @ $0.51
   
10,000
   
100
   
   
   
5,030
   
   
5,130
 
Exercise of warrants and options
   
1,291,730
   
12,917
   
   
   
1,278,813
   
   
1,291,730
 
Amortization of stock compensation
   
   
   
   
   
3,712,500
   
   
3,712,500
 
Exchange for stock options
   
(1,325,000
)
 
(13,250
)
 
   
   
(2,424,750
)
 
   
(2,438,000
)
Common stock options exercisable
   
   
   
   
   
800,567
   
   
800,567
 
Net loss
   
   
   
   
   
   
(6,234,868
)
 
(6,234,868
)
   
 
 
 
 
 
 
 
Balance, September 30, 2001
   
47,367,498
 
$
473,675
   
 
$
 
$
18,766,775
 
$
(18,921,847
)
$
318,603
 
   
 
 
 
 
 
 
 

See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
   F-7  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

(Continued)
For the Years Ended September 30, 2000, 1999 and Development Stage


   

  Common Stock

 

  Preferred Stock

                   
   
 
                   
 
   
Number  
   
 

 

 

Number

 

 

 

 

 

Additional
   
 
   
 
 
   
of  
   
Par

 

 

of

 

 

Par

 

 

Paid-In

 

 

Accumulated
   
 
 
 
   
Shares  
   
Value

 

 

Shares

 

 

Value

 

 

Capital

 

 

Deficit

 

 

Total
 
   
 
 
 
 
 
 
 
Balance, September 30, 1999
   
36,544,289
 
$
365,443
   
 
$
 
$
3,678,315
 
$
(4,111,680
)
$
(67,922
)
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Price per share ranged
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
$0.18 to $0.85
   
775,000
   
7,750
   
   
   
397,620
   
   
405,370
 
$1.74 to $2.70
   
606,797
   
6,067
   
   
   
1,071,028
   
   
1,077,095
 
$3.26 to $4.50
   
139,000
   
1,390
   
   
   
457,884
   
   
459,274
 
$5.12 to $6.92
   
236,832
   
2,369
   
   
   
1,411,591
   
   
1,413,960
 
$7.43 to $8.80
   
1,060,000
   
10,600
   
   
   
7,929,921
   
   
7,940,521
 
Exercise of warrants and options
   
3,440,250
   
34,403
   
   
   
3,151,997
   
   
3,186,400
 
Private placement of common stock
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Shares issued for:
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
$0.11
   
2,430,000
   
24,300
   
   
   
245,700
   
   
270,000
 
$0.25
   
360,000
   
3,600
   
   
   
86,400
   
   
90,000
 
$0.40
   
975,000
   
9,750
   
   
   
380,250
   
   
390,000
 
Stock converted by director’s family member
   
1,128,600
   
11,286
   
   
   
(11,286
)
 
   
 
Common stock to collateralize loan - retired
   
(500,000
)
 
(5,000
)
 
   
   
   
   
(5,000
)
Deferred stock compensation
   
   
   
   
   
(3,712,500
)
 
   
(3,712,500
)
Net loss
   
   
   
   
   
   
(8,575,299
)
 
(8,575,299
)
   
 
 
 
 
 
 
 
Balance, September 30, 2000
   
47,195,768
 
$
471,958
   
 
$
 
$
15,086,920
 
$
(12,686,979
)
$
2,871,899
 
   
 
 
 
 
 
 
 

See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
   F-8  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

(Continued)
For the Years Ended September 30, 1999, 1998 and Development Stage

   

  Common Stock

 

  Preferred Stock

                   
   
 
                   
 
   
Number  

 

 

 

 

 

Number

 

 

 

 

 

Additional

 

 

 

 

 

 

 

 

 

 

of  

 

 

Par

 

 

of

 

 

Par

 

 

Paid-In

 

 

Accumulated

 

 

 

 

 

 

 

Shares  

 

 

Value

 

 

Shares

 

 

Value

 

 

Capital

 

 

Deficit

 

 

Total

 

   
 
 
 
 
 
 
 
Balance, September 30, 1998
   
25,331,849
 
$
253,318
   
15,000
 
$
1,500
 
$
2,823,491
 
$
(3,167,225
)
$
(88,916
)
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Price per share ranged
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
$0.09 to $0.18
   
3,020,000
   
30,200
   
   
   
528,239
   
   
558,439
 
$0.20 to $0.29
   
145,000
   
1,450
   
   
   
33,110
   
   
34,560
 
Preferred stock offering
   
   
   
47,000
   
4,700
   
230,300
   
   
235,000
 
Exercise of warrants and options
   
496,000
   
4,960
   
   
   
27,490
   
   
32,450
 
Private placement of common stock
   
400,000
   
4,000
   
   
   
96,000
   
   
100,000
 
Conversion of preferred to common stock
   
6,200,000
   
62,000
   
(62,000
)
 
(6,200
)
 
(55,800
)
 
   
 
Common stock issued to c ollateralize loan
   
500,000
   
5,000
   
   
   
   
   
5,000
 
Stock converted by director’s family member
   
451,440
   
4,515
   
   
   
(4,515
)
 
   
 
Net loss
   
   
   
   
   
   
(944,455
)
 
(944,455
)
   
 
 
 
 
 
 
 
Balance, September 30, 1999
   
36,544,289
 
$
365,443
   
 
$
 
$
3,678,315
 
$
(4,111,680
)
$
(67,922
)
   
 
 
 
 
 
 
 

See accompanying independent auditor’s report and notes to
financial statements, which are an integral part of the financial statements
 
   F-9  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
(Continued)
For the Years Ended September 30, 1998, 1997 and Development Stage

   

  Common Stock

 

  Preferred Stock

                         
   
 
                         
 
   
Number  

 

 

 

 

 

Number

 

 

 

 

 

Additional

 

 

 

 

 

Development

 

 

 

 

 

 

 

of  

 

 

Par

 

 

of

 

 

Par

 

 

Paid-In

 

 

Accumulated

 

 

Stage

 

 

 

 

 

 

 

Shares  

 

 

Value

 

 

Shares

 

 

Value

 

 

Capital

 

 

Deficit

 

 

Deficit

 

 

Total

 

   
 
 
 
 
 
 
 
 
Balance, October 1, 1997
   
17,847,292
 
$
178,473
   
 
$
 
$
2,160,780
 
$
(2,394,680
)
$
 
$
(55,427
)
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Stock issued for services
   
3,487,557
   
34,875
   
   
   
335,473
   
   
   
370,348
 
Private placement of preferred stock
   
   
   
49,500
   
4,950
   
242,550
   
   
   
247,500
 
Exercise of warrants and options
   
547,000
   
5,470
   
   
   
100,888
   
   
   
106,358
 
Conversion of preferred to common stock
   
3,450,000
   
34,500
   
(34,500
)
 
(3,450
)
 
(31,050
)  
   
   
 
Contributed capital
   
   
   
   
   
14,850
   
   
   
14,850
 
Net loss
   
   
   
   
   
   
   
(772,545
)
 
(772,545
)
   
 
 
 
 
 
 
 
 
Balance, September 30, 1998
   
25,331,849
 
$
253,318
   
15,000
 
$
1,500
 
$
2,823,491
 
$
(2,394,680
)
$
(772,545
)
$
(88,916
)
   
 
 
 
 
 
 
 
 

financial statements, which are and integral part of the financial statements
 
   F-10  

 
(A Development Stage Company)
 
STATEMENTS OF CASH FLOWS
For the Years Ended September 30, 2003, 2002 and Development Stage

 
   
 
   
 
   

Development  

 
 
   
2003
   
2002
   
Stage
 
   
 
 
 
Cash flows from operating activities:
   
 
   
 
   
 
 
Net loss
 
$
(952,564
)
$
(1,883,489
)
$
(19,363,220
)
Adjustments to reconcile net loss to net cash used in operating activities:
   
 
   
 
   
 
 
Non cash transactions
   
 
   
 
   
 
 
Depreciation
   
12,926
   
22,847
   
65,196
 
Loss on disposal of assets
   
   
2,405
   
30,960
 
Impairment loss on equipment
   
   
64,187
   
64,187
 
Stock and options issued for services, net
   
344,308
   
301,495
   
11,582,712
 
Decrease (increase) in inventory
   
5,216
   
5,084
   
(9,700
)
(Increase) decrease in deferred offering costs
   
   
107,844
   
(85,171
)
Decrease (increase) in receivables
   
(26,569
)
 
   
103,431
 
Decrease (increase) in other assets
   
(16,126
)
 
13,896
   
(13,017
)
Increase (decrease) in accounts payable and accrued expenses
   
(69,751
)
 
439,090
   
673,126
 
   
 
 
 
Net cash (used in) operating activities
   
(702,560
)
 
(926,641
)
 
(6,951,496
)
   
 
 
 
Cash flows from investing activities:
   
 
   
 
   
 
 
Acquisition of property and equipment
   
   
   
(153,692
)
Repayment of loans
   
   
   
200,000
 
Proceeds from the sale of furniture and equipment
   
   
1,390
   
6,050
 
Loans issued
   
   
   
(400,000
)
   
 
 
 
Net cash (used in) provided by investing activities
   
   
1,390
   
(347,642
)
   
 
 
 
Cash flows from financing activities:
   
 
   
 
   
 
 
Draws on the line of credit
   
   
   
430,000
 
Loan from (to) officer
   
   
75,079
   
65,079
 
Repayment of notes payable
   
   
   
(110,000
)
Repayment of line of credit
   
   
(430,000
)
 
(430,000
)
Repayment of capital lease obligations
   
   
   
(1,819
)
Proceeds from the exercise of options
   
29,058
   
169,532
   
198,590
 
Proceeds from the exercise of warrants
   
   
92,460
   
92,460
 
Proceeds from equity line of credit
   
   
414,824
   
414,824
 
Proceeds from the issuance of preferred stock
   
   
   
482,500
 
Deposits from private placement
   
20,000
   
   
20,000
 
Proceeds from issuance of common stock
   
670,000
   
   
6,151,789
 
   
 
 
 
Net cash provided by financing activities
   
719,058
   
321,895
   
7,313,423
 
   
 
 
 
Net (decrease) increase in cash and cash equivalents
   
16,498
   
(603,356
)
 
14,285
 
Cash and cash equivalents, beginning of period
   
1,405
   
604,761
   
3,618
 
   
 
 
 
Cash and cash equivalents, end of period
 
$
17,903
 
$
1,405
 
$
17,903
 
   
 
 
 
Supplementary Disclosure of Cash Flow Information
   
 
   
 
   
 
 
Cash paid for interest
 
$
3,000
 
$
1,874
 
$
25,474
 
   
 
 
 
Cash paid for income taxes
 
$
 
$
 
$
50
 
   
 
 
 

See accompanying independent auditors’ report and notes to
financial statements, which are an integral part of the financial statements
 
  F-11   

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

STATEMENTS OF CASH FLOWS (Continued)
For the Years Ended September 30, 2003, 2002 and the period October 1, 1997
(Inception of Development Stage) through September 30, 2003

 
Summary of Non-Cash Investing and Financing Activities

During 1999, the Company issued 451,440 shares of restricted common stock to a Director's family member in consideration of the family members' transfer of 320,000 shares of unrestricted common stock to investors in connection with the Company's private placement that year.

During fiscal year 2002, the Company’s Board Chairman repaid a $100,000 loan by returning 250,000 shares of the Company’s common stock valued at $0.40 per share.

During fiscal year 2003, the Company issued Mr. Lou Ross, 288,334 shares of restricted common stock as part of its program to lower debt without expending cash resources, in exchange for the forgiveness of $43,250 of debt, or one-half of the total debt of $86,500 owed by the company to Mr. Ross. The debt forgiven included various disclosed notes, salary deferred in 2002 and board fees deferred in 2002. The shares were issued at an average market price per share of $0.15. The Company also issued Mr. Ross 50,000 shares of restricted common stock for reduced Director’s fees for February 2003 through the end of this fiscal year in September 2003. These shares were issued at an average market price per share of $0.15.

See accompanying independent auditors' report and notes to
financial statements, which are an integral part of the financial statements
 
  F-12   

 
(A Development Stage Company)
 
NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002

 
1.     Summary of Significant Accounting Policies

The following is a summary of the significant accounting policies followed by National Scientific Corporation (the “Company” or “us”). The policies conform with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

a.     Operations

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly-owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on September 30, 1997. As such, management now considers to be in the development stage. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue is derived from sales of electronic devices, recognized as the product is delivered.

b.     Cash Equivalents

Cash equivalents include money market accounts and other short-term investments with an original maturity of three months or less.

c.     Inventory

Inventories are stated at the lower of cost or market values. Cost is primarily determined on a FIFO (first-in, first-out) basis.

d.     Property and Equipment

Property and equipment are recorded at cost and are being depreciated over estimated useful lives of three to five years using the straight-line method.

e.     Advertising and Promotion Costs

Advertising and promotion costs, which totaled $8,105 in 2003 and $8,832 in 2002 are expensed as incurred.

f.     Stock Options

The Company has elected to follow Accounting Principles Board Opinion No. 25, “ Accounting for Stock Issued to Employees ” and related interpretations in accounting for its employee stock options. Under APB 25, no compensation expense is recorded when the exercise price of the option equals the market price of the underlying
 
   F-13  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002

 
stock on the date of the grant. The Company has adopted the disclosure only provisions of Statement of Financial Accounting Standards No. 148, “Accounting for Stock Based Compensation.”

g.     Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases, including operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect in deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

h.     Research and Development / Patents

Both research and development and the costs associated with obtaining patents and product development have been expensed as incurred. Patent costs are expensed, since the Company has not yet developed products, which have gained market acceptance.

i.     Net Loss Per Share

Net loss per share is computed by dividing the loss attributable to common shareholders by the weighted average number of shares outstanding during the period, which was 62,758,349 and 49,626,954 for the years ended September 30, 2003 and 2002, respectively. Stock options outstanding of 3,329,757 and warrants outstanding of 7,412,201 are considered anti-dilutive and were not considered in the calculation.

j.     Recently Issued Accounting Pronouncements

In April 2002, the Financial Accounting Standards Board (the “FASB”) issued SFAS No. 145, “ Rescission of SFAS No. 4, 44, and 64, Amendment of the FASB Statement N. 13, and Technical Corrections ,” effective for financial statements issued after May 25, 2002, which effectively amends SFAS No. 13, “ Accounting for Leases ,” to eliminate an inconsistency involving sale-leaseback transactions and also gives clarity to other existing authoritative pronouncements. The adoption of SFAS 145 did not have a material impact on the Company’s financial statements.

In June 2002, the FASB issued SFAS No. 146, “ Accounting for Costs Associated with Exit or Disposal Activities ,” effective for exit or disposal activities after December 15, 2002, which addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force (EITF) Issues No. 94-3, “ Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit and Activity (Including Certain Costs Incurred in a Restructuring .)” The adoption of the provisions of this SFAS did not have a material impact on the Company’s financial statements.

In October 2002, the FASB issued SFAS No. 147, “ Acquisition of Certain Financial Institutions – an amendment of FASB Statements No. 72 and 144 and FASB Interpretation No. 9, ” application for acquisitions on or after October 1, 2002, which generally removes acquisitions of financial institutions from the scope of both
 
  F-14   

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002

 
Statement 72 and Interpretation 9 and requires that those transactions to be accounted for in accordance with FASB Statement No. 141, “Business Combinations,” and No. 142, “ Goodwill and Other Intangible Assets ,” and amends FASB Statement No. 144, “ Accounting for Impairment or Disposal of Long Lived Assets ,” to include in its scope certain long term customer-relationship intangible assets of financial institutions. The adoption of SFAS 147 did not have a material impact on the Company’s financial statements.

In December 2002, the FASB issued SFAS No. 148, “ Accounting for Stock-Based Compensation – Transition and Disclosure – an Amendment of FASB Statement No. 123 ,” effective for fiscal years ending after December 15, 2002, which provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-base employee compensation. The adoption of SFAS No. 148 did not have a material effect on the Company’s financial statements, as the adoption of this standard did not require the Company to change, and the Company did not change, to the fair value based method of accounting for stock-based compensation.

In January 2003, the FASB issued FASB Interpretation (“FIN”) No. 46, “ Consolidation of Variable Interest Entities .” FIN No. 46 clarifies the application of Accounting Research Bulletin No. 51, “ Consolidated Financial Statements ,” and applies immediately to any variable interest entities created after January 31, 2003 and to variable interest entities in which an interest is obtained after January 31, 2003. The Company holds no interest in variable interest entities.

In April 2003, the FASB issued SFAS No. 149, “Amendment of Statement 133 on Derivative Instruments and Hedging Activities .” SFAS 149 clarifies the accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts and for hedging activities under SFAS No. 133, “ Accounting for Derivative Instruments and Hedging Activities .” In particular, SFAS No. 149 clarifies under what circumstances a contract with an initial net investment meets the characteristic of a derivative as described in SFAS No. 133. SFAS No. 149 also clarifies when a derivative contains a financing component. SFAS No. 149 is generally effective for derivative instruments entered into or modified after June 30, 2003, and for hedging relationships designated after June 30, 2003. The company holds no derivative instruments and does not engage in hedging activities.

In May 2003, the FASB issued SFAS No. 150, “ Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity .” SFAS No. 150 requires certain financial instruments that have both equity and liability characteristics to be classified as a liability on the balance sheet. SFAS No. 150 is effective for the first interim period beginning after June 15, 2003. The adoption of SFAS 150 did not have a material impact on the Company’s financial statements.

2.     Development Stage Operations

Although the Company has been in operation since 1996, management considers us to be in the development stage. From September 30, 1997 through the year ended September 30, 2001, we have aimed our efforts on the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning calendar year 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Since initiation of operations in 1996, we have not realized significant revenue, except for approximately $882,000 generated through the export of electronic equipment, which occurred in fiscal 2001.
 
   F-15  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002

 
The Company experienced significant operating losses during 2003 and 2002, of $952,564 and $1,883,489, respectively, which raise substantial doubt about the Company’s ability to continue as a going concern. Of the total net operating losses, approximately $292,000 and $460,000 related to stock issued for services and compensation in 2003 and 2002, respectively. Management believes that its current cash position including cash funds arising from the exercise of outstanding options, equity private placements, product sales, and continued aggressive expense management to be sufficient to continue operations for the next twelve months. We also believe that we may be able to reduce outstanding liabilities through negotiations with our creditors, or possibly negotiate to extend the payment schedule for these debts. In the event these approaches do not provide us with adequate working capital, we may be required to further curtail or reduce our development activities, seek alternative funding sources, or seek protection under reorganization laws.

The accompanying financial statements do not include any adjustments relating to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

3.     Property and Equipment

Property and equipment consists of the following at September 30, 2003 and 2002:

 
   
2003
   
2002
 
   
 
 
 
   
 
   
 
 
Computer equipment
 
$
58,806
 
$
58,806
 
Office furniture
   
12,507
   
12,507
 
   
 
 
 
   
71,313
   
71,313
 
Less: accumulated depreciation
   
39,232
   
26,306
 
   
 
 
 
 
$
32,081
 
$
45,007
 
   
 
 

During fiscal 2002, the Company determined that the value of certain computer and other equipment previously utilized in their San Jose office for research and development was impaired. The Company recognized an impairment loss of approximately $64,000.

4.     Earnings Per Share

The following table reconciles weighted average shares outstanding to amounts used to calculate basic and diluted earnings per share for fiscal years 2003 and 2002.
 
   F-16  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002
 
 
 
   
2003
   
2002
 
   
 
 
Net (loss)
 
$
(952,564
)
$
(1,883,489
)
Weighted average shares:
   
 
   
 
 
Average shares outstanding
   
62,758,349
   
49,626,954
 
Effect of diluted shares
   
   
 
   
 
 
Average Shares outstanding, adjusted for dilutive effect
   
62,758,349
   
49,626,954
 
   
 
 
(Loss) per share - basic
 
$
(0.02
)
$
(0.04
)
(Loss) per share - diluted
 
$
(0.02
)
$
(0.04
)

Incremental common shares (not included in denominator of diluted earnings per share because of their anti-dilutive nature):

 
 
2003
2002
   
 
 
Employee options
   
3,329,757
   
3,582,839
 
Warrants
   
7,412,201
   
412,201
 
Potential common equivalents
   
10,741,958
   
3,995,040
 

If all currently outstanding potential common equivalents are exercised, the Company would receive proceeds of approximately $6,100,000.
 
5.      Lease Commitments

On September 11, 2001 the Company signed a thirty-seven month non-cancelable operating lease agreement for an office in Scottsdale, Arizona, which expires on October 31, 2004. The lease requires monthly payments of $4,785 to $5,031 plus sales tax and contains no renewal or purchase options.
 
           Future minimum lease obligations at September 30, 2003 are as follows:

Year ending September 30,
   
Amount
 

 
 
2004
 
$
60,250
 
2005
   
5,031
 
   
 
 
 
$
65,281
 
   
 

Rent expense for the years ended September 30, 2003 and 2002 was approximately $64,000 and $106,000, respectively.
 
   F-17  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002


6.     Income Taxes

Deferred income taxes consist of the following at September 30, 2003 and 2002:

 
   
2003

 

 

2002
 
   
 
 
Tax Benefit of net operating loss carry-forwards and start up costs
 
$
5,779,000
 
$
5,515,000
 
Valuation allowance
   
(5,779,000
)
 
(5,515,000
)
   
 
 
 
   $    
$
 
   
 
 

A reconciliation of expected to actual taxes follows:

 
   
2003

 

 

2002
 
   
 
 
Expected federal and state tax recovery at 40%
 
$
(381,000
)
$
(755,000
)
Non-deductible stock compensation    
   
117,000
   
20,000
 
   
 
 
 
   
(264,000
)
 
(735,000
)
Tax benefits not realized - valuation allowance
   
264,000
   
735,000
 
   
 
 
Realized tax benefit    
 
$
 
$
 
   
 
 

 
 The Company has recorded valuation allowances to offset the value of deferred tax assets, since it has recorded losses from operations since 1996 and the utilization of those assets is uncertain. During fiscal 2003 and 2002, the valuation allowance increased by $264,000 and $735,000, respectively.

The Company has net operating loss carry-forwards of approximately $14,600,000 at September 30, 2003, which may be used to offset future federal taxable income through 2022 and state taxable income through 2008.

7.     Related Party Transactions

In October 2002, Mr. Lou Ross, the former Chairman of the Board, and a Director until September 30, 2003, was paid for his services as an active member of the board in shares of restricted common stock, in lieu of cash. The former Chairman received 66,806 restricted common shares at an average price on the date of grant of $0.11 per share.

As described in the Company's 10-KSB filing for the year ending September 30, 2002, and also in the Company's Proxy Statement for 2003 filed January 30, 2003, the Company’s Board initiated on September 30, 2003 a restricted stock retainage program (“Stock Retainage Program”) to retain key staff during a period of financial difficulty. The Company allocated approximately $150,000 in restricted Common Stock from this Stock Retainage Program pool of shares in fiscal 2002, to be granted to key
 
   F-18  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002

 
employees during the year, subject to the Company exceeding sales growth objectives and expense reduction objectives in 2003. Failure to meet these objectives under the plan would result in the forfeiture by staff of this entire stock grant by all participants, unless new objectives are approved by the board for calendar year 2004, in which case the stock grant would remain with the participants but be subject to forfeiture by participants until new objectives have been achieved in 2004. All stock grants under this program were granted in September 2002 but shares were not finally issued until January of 2003. All of the stock under this program is restricted under SEC Section 144, and cannot be traded by the Stock Retainage Program participants for at least one year from date of issue.

The Company CEO, Michael Grollman was granted 750,000 shares of stock from this Stock Retainage Program pool of shares, subject to the Company achieving in excess of $200,000 in sales in calendar year 2003, and subject to him accepting a $60,000 per year pay reduction for the calendar year 2003, reducing his annual payable salary to $120,000 per year for 2003. Mr. Grollman was granted an additional 500,000 shares of stock under this program, subject to sales exceeding $1,000,000 for calendar year 2003. The Company’s President and Director Graham Clark was granted 500,000 shares of stock from the Company’s Stock Retainage Program pool of shares discussed above, subject to the Company achieving in excess of $200,000 in sales in calendar year 2003. Mr. Clark was granted an additional 500,000 shares of stock under this program, subject to sales exceeding $1,000,000 for calendar year 2003. The majority of the remaining restricted stock allocated under this program was granted to other Company staff, and is subject to substantially the same risk of forfeiture as the stock granted to Grollman and Clark under the Program.

In January 2003, Mr. Lou Ross, was paid for his services as an active member of the board in shares of restricted common stock, in lieu of cash. The former Chairman received 54,464 restricted common shares at an average market price on the date of grant of $0.14 per share.  In June 2003, the Company issued Mr. Lou Ross, 288,334 shares of restricted common stock as part of its program to lower debt without expending cash resources, in exchange for the forgiveness of $43,250 of debt, or one-half of the total debt of $86,500 owed by the Company to Mr. Ross. The debt forgiven included various disclosed notes, salary deferred in 2002 and board fees deferred in 2002. The shares were issued at an average market price per share of $0.15. The Company also issued Mr. Ross 50,000 shares of restricted common stock for reduced Director’s fees for February 2003 through the end of this fiscal year in September 2003. These shares were issued at an average market price per share of $0.15.

The CEO and the President have employment contracts that include termination clauses that fully vest their ownership of shares.

8.     Disclosures About Fair Value of Financial Instruments

Fair value estimates are made at a specific point in time and are based on relevant market information and information about the financial instrument; they are subjective in nature and involve uncertainties, matters of judgment and, therefore, cannot be determined with precision.

These estimates do not reflect any premium or discount that could result from offering for sale at one time the Company’s entire holdings of a particular instrument. Changes in assumptions could significantly affect the estimates.
 
   F-19  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002
 
 
Since the fair value is estimated as of September 30, 2003, the amounts that will actually be realized or paid at settlement of the instruments could be significantly different.

The carrying amount of cash and cash equivalents is assumed to be their fair value because of the liquidity of these instruments. Accounts payable and accrued expenses approximate fair value because of the short maturity of these instruments.

9.     Stock Options and Warrants
 
Stock Options

As of September 30, 2003, the Company has a stock-based compensation plan wherein officers and employees were granted stock options. The Company applies APB 25 and related interpretations in accounting for the plan. Accordingly, compensation expense is equal to the difference between the exercise price of the options granted and the fair value of the common stock at the date of the grant. Compensation expense of approximately $50,000 and $190,000 was recorded for the fiscal years ending September 30, 2003 and 2002, respectively.

Under the above-mentioned 2000 Stock Option Plan, the purchase price must be at least 100% of the fair market value of our common stock (if the option is an incentive stock option), or at least 25% of the fair market value of our common stock at the time the option is granted (if the option is a nonqualified grant), or such higher price as may be determined by the Board of Directors at the time of grant. If however, an incentive stock option is granted to an individual who would, immediately before the grant, directly or indirectly own more than 10% of the total combined voting power of all our classes of stock, the purchase price of the shares of common stock covered by such incentive stock option may not be less than 110% of the fair market value of such shares on the day the incentive stock option is granted. As the price of the Company’s common stock is currently quoted on the OTC Bulletin Board, the fair market value of the common stock underlying options granted under the 2000 Stock Option Plan shall be the last closing sale price of the common stock on the day the options are granted. If there is no market price for the common stock, then our Board of Directors may, after taking all relevant facts into consideration, determine the fair market value of the Company’s common stock.

As required by SFAS 148, the fair value of each grant is estimated on the date of grant using the Black-Scholes option pricing method for pro forma footnote disclosure with the following assumptions for all periods; dividend yield of 0%, risk free interest rate of 5%, and expected option life of 10 years. Expected volatility was assumed to be 50% as of the date of issue.
 
   F-20  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002
 
 
 
   

 

 

 

Weighted

 

 

Weighted

 

 

 

 

Number 

 

 

Average

 

 

Average

 

 

 

 

of 

 

 

Exercise

 

 

Fair

 

 

 

 

Shares  

 

 

Price

 

 

Value
 
   
 
 
 
Options Outstanding, September 30, 2001
   
1,534,501
 
$
1.81
 
$
0.15
 
Granted    
   
3,654,162
   
0.24
   
0.24
 
Exercised
   
(1,477,000
)
 
0.11
   
0.11
 
Canceled
   
(128,824
)
 
0.71
   
0.02
 
   
             
Options Outstanding, September 30, 2002
   
3,582,839
 
$
1.97
 
$
0.01
 
   
             
Options Outstanding September 30, 2002
   
3,582,839
 
$
1.97
 
$
0.01
 
Granted    
   
1,144,081
   
0.10
   
0.10
 
Exercised
   
(637,153
)
 
0.05
   
0.10
 
Expired    
   
(760,010
)
 
5.45
   
0.01
 
   
             
Options Outstanding, September 30, 2003
   
3,329,757
 
$
0.90
 
$
0.06
 
   
             

Had the Company fully adopted Statement of Financial Accounting Standards (“SFAS”) No. 148, the net loss for the years ended September 30, 2003 and 2002 would have been $(1,002,924) and $(2,091,901) and the basic and diluted earnings per share would have been $(0.02) and $(0.04), respectively.

Warrants

The warrants outstanding as of September 30, 2003 are as follows:

 
   
Number of  

 

 

Exercise

 

 

 

 

 

 

 

Shares  

 

 

Price

 

 

Expires
 
   
 
 
 
Outstanding at September 30, 2001
   
1,500,000
   $
0.12

 

 

Jan-04
 
Exercised
   
(770,500
)
 
 
   
 
 
Expired
   
(729,500
)
 
 
   
 
 
New issues
   
412,201
   
1.67

 

 

Nov-04

 

   
             
Outstanding at September 30, 2002
   
412,201
   
 
   
 
 
 
   
 
   
 
   
 
 
New issues
   
4,800,000
   
0.30

 

 

Dec-04

 

 
   
200,000
   
0.50

 

 

Dec-04
 
 
   
1,000,000
   
0.35

 

 

Jun-04
 
 
   
1,000,000
   
0.50

 

 

Jun-04

 

   
             
Outstanding at September 30, 2003
   
7,412,201
   
 
   
 
 
   
             
 
 
  F-21   

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002
 
 
10.     Commitments and Contingencies

The Company was a defendant in a landlord-tenant lawsuit with a landlord of leased property vacated by the Company in 2001 as part of its corporate consolidation. The Company and the landlord negotiated a settlement in this matter without admitting any wrongdoing. In order to fulfill the terms of this settlement, we must pay a remaining $10,000 in four installments by September 2004. The amount due is included in notes payable.

Mr. Lou Ross assigned his rights to certain amounts that may be recoverable from NetMind as partial payment for loan proceeds advanced to him in 1999 (see Note 7 above). The Company has filed a suit against NetMind to recover the investment, plus damages. In April of 2003 significant portions of this suit were settled by the parties, while other portions remain unsettled. Management is unable to determine the outcome of the suit.

In January 2002, the Company initiated legal proceedings against Phoenix Semiconductor, Inc. (PSI) for breach of contract. The Company has taken steps to settle this claim.

The Company was awarded a judgment of approximately $179,000 in May 2003 against E4World Corporation. However, there is no assurance that any of this amount will be collected by us. Since collection of this judgment by us is uncertain, this judgment is not reflected in our current financial statements. The Company continues to press its claim to secure assets held by E4World in a separate legal matter, although there is no assurance that we will collect this claim, and thus this claim is not shown in our financial statements.

The Company is from time to time subject to claims and suits arising in the ordinary course of operations. In the opinion of management, the ultimate resolution of such pending legal proceedings will not have a material adverse effect on the Company's financial position, results of operation or liquidity.

11.     Equity Line of Credit

In March 2001, the Company began negotiating an equity line of credit agreement with a third party investor. Under the equity line, the Company had the option to issue, during a two-year term, shares of common stock to an investor at prices that were discounted from the fair market value on the date of issuance. The shares under this equity line of credit were registered with the Securities and Exchange Commission on October 11, 2001 on Form SB-2. Subsequent to the equity line of credit’s effective date, the Company issued 2,122,064 shares of common stock to the investor, and received net proceeds of $414,824. Our ability to draw down amounts under this line of credit has been materially adversely affected, substantially due to the decline in market price for the Company’s stock. This line was not used during fiscal 2003, and the Company does not believe this line will be used again.
 
   F-22  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
For the Years Ended September 30, 2003 and 2002
 
12.     Notes Payable

As of September 30, 2003, the notes payable consisted of the following:

Note payable to shareholder, unsecured, non-interest bearing, matures in 2006
 
$
43,250
 
         
Note payable, unsecured, non-interest bearing, payable in quarterly installments of $2,500, matures in 2004
   
10,000
 
   
 
Total notes
   
53,250
 
         
Current portion
   
10,000
 
   
 
 
 
$
43,250
 
   
 

The notes mature as follows:

Year ending September 30,
   
 
 

       
2004
 
$
10,000
 
2005
   
 
2006
   
43,250
 
   
 
 
 
$
53,250
 
   
 

13.     Subsequent Events

In January of 2004, the Company entered into a financing program with a U.S. investment fund, Strategic Working Capital Fund, L.P. The terms of this program include a six-month Note payable at maturity in July 2004 for $160,000, at an effective annual interest rate of 13%. The transaction also included 640,000 warrants good for three years to purchase the Company's restricted stock, at $0.13 during the first and second year of the warrants, and $0.15 during the third and final year of the warrants. These warrants include anti-dilution provisions, as well as registration rights in the event that the Company was to file an appropriate registration statement with the SEC during the next three years. The principal of the Note is optionally convertible to the Company’s restricted stock at any time during the first six months of the Note at 90% of the then-current market value of the Company's common stock. In the event of failure to repay the Note in July 2004, the Note would be extended another six months, and the effective interest rate would be increased to 15%, and a second group of approximately 640,000 warrants priced at 50% of the average trading price of the Company's stock would be made effective, and the Company would be required to file a registration statement for the securities underlying these warrants within 90 days. An officer of the Company provided personal collateral to support this Note, which would be forfeited in the event of non-payment of the Note.
 
  F-23   

 

UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX MONTH PERIOD ENDING MARCH 31, 2004
 
 
   F-24  

 
(A Development Stage Company)
 
UNAUDITED CONDENSED BALANCE SHEETS
March 31, 2004 and September 30, 2003

 
   
March 31,  

 

 

September 30,

 

 

 

 

2004

 

 

2003
 
   
 
 
ASSETS
   
 
   
 
 
 
   
 
   
 
 
Current Assets:
   
 
   
 
 
Cash and cash equivalents
 
$
14,748
 
$
17,903
 
Cash in escrow account
   
534,691
   
 
Trade receivables, net of reserve of $18,169 at March 31, 2004 and $8,169 at September 30, 2003
   
30,000
   
28,200
 
Inventory
   
60,374
   
9,700
 
Other assets
   
37,425
   
16,926
 
   
 
 
Total current assets
   
677,238
   
72,729
 
 
   
 
   
 
 
Property and equipment, net
   
25,618
   
32,081
 
Deposits
   
5,031
   
5,031
 
   
 
 
 
 
$
707,887
 
$
109,841
 
   
 
 
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
   
 
   
 
 
 
   
 
   
 
 
Current Liabilities:
   
 
   
 
 
Accounts payable
 
$
266,879
 
$
185,725
 
Accrued expenses
   
333,238
   
457,695
 
Deposits
   
   
20,000
 
Notes payable
   
201,000
   
10,000
 
   
 
 
Total current liabilities
   
801,117
   
673,420
 
               
Notes payable, net of current portion
   
43,250
   
43,250
 
   
 
 
Total Liabilities
   
844,367
   
716,670
 
   
 
 
Commitments and contingencies
   
   
 
   
 
 
Shareholders’ equity (deficit):
   
 
   
 
 
Preferred stock, par value $0.10; 4,000,000 shares authorized, and no shares issued or outstanding
   
   
 
Common stock, par value $0.01; 120,000,000 shares authorized, and shares issued 79,700,783 and 70,633,819 outstanding at March 31, 2004 and September 30, 2003, respectively
   
797,007
   
706,338
 
Additional paid-in capital
   
21,242,603
   
20,444,733
 
Accumulated deficit
   
(22,176,090
)
 
(21,757,900
)
   
 
 
Total shareholders’ equity (deficit)
   
(136,480
)
 
(606,829
)
   
 
 
 
 
$
707,887
 
$
109,841
 
   
 
 

The accompanying notes are an integral part of these financial statements
 
   F-25  

 
(A Development Stage Company)
 
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
For the Three and Six Months Ended March 31, 2004, 2003 and Development Stage

 
   
Three Months  

 

 

Three Months

 

 

Six Months

 

 

Six Months

 

 

 

 

 

 

 

Ended  

 

 

Ended

 

 

Ended

 

 

Ended

 

 

Development

 

 

 

 

March 31, 2004  

 

 

March 31, 2003

 

 

March 31, 2004

 

 

March 31, 2003

 

 

Stage
 
   
 
 
 
 
 
Revenues
 
$
36,308
 
$
13,093
 
$
74,538
 
$
18,548
 
$
1,023,746
 
Cost of Sales
   
24,856
   
1,477
   
55,998
   
4,790
   
953,485
 
   
 
 
 
 
 
Gross profit
   
11,452
   
11,616
   
18,540
   
13,758
   
70,261
 
 
   
 
   
 
   
 
   
 
   
 
 
Costs and expenses
   
 
   
 
   
 
   
 
   
 
 
Salaries and benefits
   
112,346
   
113,243
   
257,395
   
179,376
   
2,434,191
 
Research and development
   
4,440
   
12,087
   
9,398
   
21,777
   
3,722,533
 
Stock compensation
   
22,290
   
97,080
   
28,293
   
109,980
   
3,108,987
 
Consulting fees, related party
   
   
7,500
   
   
15,000
   
8,175,973
 
Other
   
72,446
   
(51,500
)
 
131,170
   
44,172
   
2,538,473
 
   
 
 
 
 
 
Total costs and expenses
   
211,522
   
178,410
   
426,256
   
370,305
   
19,980,157
 
 
   
 
   
 
   
 
   
 
   
 
 
Loss from operations
   
(200,070
)
 
(166,794
)
 
(407,716
)
 
(356,547
)
 
(19,909,896
)
   
 
 
 
 
 
Other income (expense)
   
 
   
 
   
 
   
 
   
 
 
Interest and other income
   
   
   
   
   
178,972
 
Interest expense
   
(7,342
)
 
(979
)
 
(10,474
)
 
(2,123
)
 
(50,486
)
Loss on disposal of assets
   
   
   
   
   
 
   
 
 
 
 
 
 
   
(7,342
)
 
(979
)
 
(10,474
)
 
(2,123
)
 
128,486
 
 
   
 
   
 
   
 
   
 
   
 
 
Loss before income taxes
   
(207,412
)
 
(167,773
)
 
(418,190
)
 
(358,670
)
 
(19,781,410
)
Income tax expense
   
   
   
   
   
 
   
 
 
 
 
 
Net loss
 
$
(207,412
)
$
(167,773
)
$
(418,190
)
$
(358,670
)
  $
(19,781,410
)
   
 
 
 
 
 
Net loss per common share, basic and diluted
 
$
(0.00
)
$
(0.00
)
$
(0.01
)
$
(0.01
)
 
 
 
   
 
 
 
       

The accompanying notes are an integral part of these financial statements
 
  F-26   

 
(A Development Stage Company)
 
UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS
For the Six Months Ended March 31, 2004, 2003 and Development Stage

 
   
 
   
 
   

Development 

 
 
   
2004

 

 

2003

 

 

Stage
 
   
 
 
 
Cash flows from operating activities:
   
 
   
 
   
 
 
Net loss
 
$
(418,190
)
$
(358,670
)
$
(19,781,410
)
Adjustments to reconcile net loss to net cash used in operating activities:
   
 
   
 
   
 
 
Non cash transactions
   
 
   
 
   
 
 
Depreciation
   
6,463
   
6,462
   
71,659
 
Loss on disposal of assets
   
   
   
30,960
 
Impairment loss on equipment
   
   
   
64,187
 
Stock and options issued for services, net
   
28,293
   
142,750
   
11,611,005
 
Decrease (increase) in inventory
   
(50,674
)
 
6,094
   
(60,374
)
Deferred offering costs
   
   
   
(85,171
)
Decrease (increase) in receivables
   
(1,800
)
 
   
101,631
 
Decrease (increase) in other assets
   
(20,499
)
 
(10,394
)
 
(33,516
)
Increase in accounts payable and accrued expenses
   
172,252
   
(122,564
)
 
845,378
 
   
 
 
 
Net cash (used in) operating activities
   
(284,155
)
 
(336,322
)
 
(7,235,651
)
   
 
 
 
 
   
 
   
 
   
 
 
Cash flows from investing activities:
   
 
   
 
   
 
 
Acquisition of property and equipment
   
   
   
(153,692
)
Repayment of loans
   
   
   
200,000
 
Proceeds from the sale of furniture and equipment
   
   
   
6,050
 
Loans issued
   
   
   
(400,000
)
   
 
 
 
Net cash (used in) investing activities
   
   
   
(347,642
)
   
 
 
 
Cash flows from financing activities:
   
 
   
 
   
 
 
Increase in notes payable
   
196,000
   
15,000
   
196,000
 
Draws on the line of credit
   
   
   
430,000
 
Loan from (to) officer
   
   
   
65,079
 
Repayment of notes payable
   
(5,000
)
 
   
(115,000
)
Repayment of line of credit
   
   
   
(430,000
)
Repayment of capital lease obligations
   
   
   
(1,819
)
Proceeds from the exercise of options
   
   
29,058
   
198,590
 
Proceeds from the exercise of warrants
   
   
   
92,460
 
Proceeds from equity line of credit
   
   
   
414,824
 
Proceeds from the issuance of preferred stock
   
   
   
482,500
 
Deposits for private placement
   
(20,000
)
 
10,000
   
 
Proceeds from issuance of common stock
   
644,691
   
300,000
   
6,796,480
 
   
 
 
 
Net cash provided by financing activities
   
815,691
   
354,058
   
8,129,114
 
   
 
 
 
Net (decrease) increase in cash and cash equivalents
   
531,536
   
17,736
   
545,821
 
Cash and cash equivalents, beginning of period
   
17,903
   
1,405
   
3,618
 
   
 
 
 
Cash and cash equivalents, end of period
 
$
549,439
 
$
19,141
 
$
549,439
 
   
 
 
 
Supplementary Disclosure of Cash Flow Information:
   
 
   
 
   
 
 
Cash paid for interest
 
$
5,211
 
$
 
$
30,685
 
   
 
 
 
Cash paid for income taxes
 
$
 
$
 
$
50
 
   
 
 
 

The accompanying notes are an integral part of these financial statements
 
   F-27  

 
(A Development Stage Company)
 
UNAUDITED CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)
For the Six Months Ended March 31, 2004
 
   

  Common Stock   

 

  Preferred Stock  

                   
   
 
                   
 
   
Number  
   
 

 

 

Number

 

 

 

 

 

Additional

 

 

 

 

 

 

 

 

 

 

of  

 

 

Par

 

 

of

 

 

Par

 

 

Paid-In

 

 

Accumulated

 

 

 

 

 

 

 

Shares  

 

 

Value

 

 

Shares

 

 

Value

 

 

Capital

 

 

Deficit
   
Total
 
   
 
 
 
 
 
 
 
Balance, September 30, 2003
   
70,633,819
 
$
706,338
   
 
$
 
$
20,444,733
 
$
(21,757,900
)
$
(606,829
)
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Exercise of options
   
   
   
   
   
   
   
 
Stock issued for services
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Price per share ranged
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
$0.14
   
47,646
   
476
   
   
   
5,527
   
   
6,003
 
$0.155
   
33,000
   
330
   
   
   
4,274
   
   
4,604
 
Common stock options granted
   
   
   
   
   
13,491
   
   
13,491
 
Debt equity swap
   
1,500,000
   
15,000
   
   
   
135,000
   
   
150,000
 
Private placement of common stock
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
Shares issued for:
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
$0.10
   
1,100,000
   
11,000
   
   
   
99,000
   
   
110,000
 
$0.11
   
5,886,318
   
58,863
   
   
   
475,828
   
   
534,691
 
Stock retainage program
   
500,000
   
5,000
   
   
   
64,750
   
   
69,750
 
Net loss
   
   
   
   
   
   
(418,190
)
 
(418,190
)
   
 
 
 
 
 
 
 
Balance, March 31, 2004
   
79,700,783
 
$
797,007
   
 
$
 
$
21,242,603
 
$
(22,176,090
)
$
(136,480
)
   
 
 
 
 
 
 
 

The accompanying notes are an integral part of these financial statements
 
  F-28   

 
(A Development Stage Company)
 
NOTES TO FINANCIAL STATEMENTS
(unaudited)

1.     Basis of Presentation

The accompanying financial statements have been prepared by National Scientific Corporation (“we” or the “Company” or “us”), without audit, and reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods. The statements have been prepared in accordance with generally accepted accounting principles for interim financial reporting and Securities and Exchange Commission regulations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the financial statements reflect all adjustments (of a normal and recurring nature) that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The results of operations for the six months ended March 31, 2004 are not necessarily indicative of the results to be expected for the entire fiscal year.

These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-KSB for the fiscal year ended September 30, 2003, and the Company’s quarterly report on Form 10-QSB for the fiscal period ended December 31, 2003.

These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

2.      Issuance of Common Stock

During the three months ended March 31, 2004, the Company continued the private offering of restricted common stock, commenced in June 2003. During the six months ended March 31, 2004, the Company raised approximately $110,000 in cash and issued 1,100,000 shares of restricted common stock and granted 550,000 warrants to purchase common stock at an exercise price of between $0.50 and $0.75 per share. No underwriters were involved in connection with this private placement. The sales and issuances of the securities issued pursuant to the foregoing private placement are exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, and Rule 506 of Regulation D.

During the three months ended March 31, 2004, 33,000 shares of common stock were issued for board services at an average market price per share price of $0.155.

In January 2004, the Company, under the restricted stock retainage program initiated in September 2002, and more fully described in the Company's 10-KSB filing for the fiscal year ended September 30, 2002, and September 30, 2003 and also in the Company's Proxy Statement for 2003 and 2004, issued 500,000 shares of common stock at an average price of $0.155. The shares were issued as compensation to retain key staff that had to forego some salary payments for significant portions of this period as well as previous periods. These share grants are subject to risk of forfeiture should the Company not achieve certain objectives during calendar year 2004.
 
  F-29   

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
(unaudited)


On March 15, 2004, the Company commenced a private offering of restricted common stock units through a placement agent. During the quarter ended March 31, 2004, the Company raised approximately $534,691 net of costs, in cash and issued 5,886,318 shares of restricted common stock at a price of $0.11 per share, and granted 4,414,739 warrants to purchase common stock at an exercise price of $0.11 per share (for additional detail of the total proceeds raised in this offering as of the date of this report, see Subsequent Events below). No underwriters were involved in connection with this private placement. The sales and issuances of the securities issued pursuant to the foregoing private placement are exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, and Rule 506 of Regulation D. The cash in escrow as of March 31, 2004 represents investor funds collected from this private placement as of the end of this quarter. These funds were transferred from escrow to the Company main cash account upon the first closing of this private placement on April 8, 2004 (see Subsequent Events below).

3.     Stock Options and Warrants

The Company from time to time issues stock options for the purchase of common stock to directors, officers, employees and consultants. The Company adopted a qualified stock option plan for its executives, consultants, and employees in December 2000.

During the three months ended March 31, 2004, 170,000 non-qualified stock options were granted under the 2000 Stock Option Plan at $0.15, 250,000 non-qualified stock options were cancelled at $0.15 and no stock options were exercised.

The Company adopted Financial Accounting Standards Board APB Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations in accounting for the plan. Accordingly, compensation expense is equal to the difference between the exercise price of the options granted and the fair value of the common stock at the date of grant. As no options were granted, there was no compensation recognized for the fiscal quarter ended March 31, 2004. Under the terms of the Company's stock options granted to certain directors, officers, employees and consultants, the Board of Directors, at its sole discretion, will determine when certain options granted shall be fully vested and exercisable. On March 31, 2004, 3,244,757 outstanding stock options were vested, and fully exercisable, and 5,000 were not vested.

In accordance with The Statement of Financial Accounting Standards (SFAS) 148, Accounting for Stock-Based Compensation , the fair value of option grants is estimated on the date of grant using the Black-Scholes option-pricing model for pro forma footnote purposes with the following assumptions used for grants in all years; dividend yield of 0%, risk-free interest rate of 5%, and expected option life of 10 years. Expected volatility was assumed to be 100% as of the date of issue.

 
   
Number of  
   
Weighted Average

 

 

 

 

Shares  

 

 

Exercise Price
 
   
 
 
Options Outstanding, September 30, 2003
   
3,329,757
 
$
0.90
 
Add: Granted
   
170,000
   
0.15
 
Deduct: Forfeited
   
(250,000
)
 
(0.15
)
   
 
 
Options Outstanding, March 31, 2004
   
3,249,757
 
$
0.92
 
   
 
 

 
  F-30   

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
(unaudited)


Had the Company fully adopted SFAS 148, the Company’s net income and earnings per share would approximate the following pro forma amounts:

 
   
Three Months  
   
Three Months

 

 

 

 

Ended  

 

 

Ended

 

 

 

 

March 31, 2004  

 

 

March 31, 2003
 
   
 
 
Net (loss) income:
   
 
   
 
 
As reported
 
$
(207,412
)
$
(167,773
)
Pro forma
   
(207,412
)
 
(175,009
)
 
   
 
   
 
 
Basic (loss) earnings per share:
   
 
   
 
 
As reported
 
$
(0.00
)
$
(0.00
)
Pro forma
   
(0.00
)
 
(0.00
)

 
   F-31  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
(unaudited)


The warrants outstanding as of June 8, 2004 are as follows:

 
   
Number  

 

 

 

 

 

 

 

 

 

 

of  

 

 

Exercise

 

 

 

 

 

 

 

Shares  

 

 

Price

 

 

Expires
 
   
 
 
 
Outstanding at September 30, 2001
   
1,500,000
 
$
0.12
   
1/02
 
Exercised
   
770,500
   
 
   
 
 
Expired
   
729,500
   
 
   
 
 
New Issues
   
412,201
 
$
1.67
   
5/04
 
   
             
Outstanding at September 30, 2002
   
412,201
   
 
   
 
 
New Issues
   
4,800,000
 
$
0.30
   
12/04
 
 
   
200,000
 
$
0.50
   
12/04
 
 
   
1,000,000
 
$
0.35
   
6/06
 
 
   
1,000,000
 
$
0.50
   
6/06
 
   
             
Outstanding at September 30, 2003
   
7,412,201
   
 
   
 
 
New Issues
   
275,000
 
$
0.50
   
6/06
 
 
   
275,000
 
$
0.75
   
6/06
 
 
   
640,000
 
$
0.13
   
1/07
 
 
   
500,000
 
$
0.10
   
3/11
 
 
   
4,414,739
 
$
0.11
   
4/09
 
   
             
Outstanding at March 31, 2004
   
13,516,940
   
 
   
 
 
Expired
   
412,201
   
 
   
 
 
New Issues
   
3,335,961
 
$
0.11
   
4/09
 
 
   
1,808,497
 
$
0.10
   
4/11
 
   
             
Outstanding at June 8, 2004
   
18,249,197
   
 
   
 
 
   
             
 
 
  F-32   

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
(unaudited)

During the three months ended March 31, 2004, the Company issued warrants in conjunction with its June 2003 private placement offering (see Issuance of Common Stock, above), its January 2004 debt offering (see Borrowing, below) and its March 15, 2004 private placement offering (see Issuance of Common Stock above). The table above summarizes all outstanding warrant obligations of the Company as of March 31, 2004.

4.     Net Loss Per Share

Net loss per common share is based upon the weighted average shares outstanding. Outstanding stock options and warrants are treated as common stock equivalents, but are anti-dilutive, for purposes of computing diluted net loss per common share. The following is a summary of the computation of net loss per common share (amounts in dollars except shares):

 
 
Six months ended  
 
 
March 31,  
   
 
 
   
2004

 

 

2003
 
   
 
 
Basic net income (loss) per common share:
   
 
   
 
 
Net income (loss)
 
$
(418,190
)
$
(358,670
)
   
 
 
Basic and diluted per share amount
 
$
(0.01
)
$
(0.01
)
   
 
 

5.     Borrowings

On June 11, 2003, the Company issued a three-year interest free convertible note to its then-Director, Mr. Lou Ross, of $43,250, with no payments required of the Company until the end of the three-year period, for past services rendered (See 10-KSB report for the year ended September 30, 2003). The Company can pay this note at any time before the three-year period elapses with either cash or its restricted common stock or a combination of cash and stock, at its sole discretion. Currently this note represents the only long-term debt of the Company. Mr. Ross retired from the Company’s board on September 30, 2003.
 
   F-33  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
(unaudited)

In January of 2004, the Company entered into a financing program with U.S. investment fund, Strategic Working Capital Fund L.P.  The terms of this program include a six-month Note payable at maturity in July 2004 for $160,000, at an effective annual interest rate of 13%. The transaction also included 640,000 warrants good for three years to purchase the Company’s restricted common stock, at $0.13 during the first and second year of the warrants' lifetime, and $0.15 during the third and final year of the warrants' lifetime. These warrants include anti-dilution provisions, as well as registration rights in the event that the Company was to file an appropriate registration statement with the SEC during the next three years. The principal of the Note is optionally convertible to the Company’s restricted stock at any time during the first six months of the Note at 90% of the then-current market value of the Company's common stock. In the event of failure to repay the Note in July 2004, the Note would be extended another six months, and the effective interest rate would be increased to 15%, and a second group of approximately 640,000 warrants priced at 50% of the average trading price of the Company's common stock would be made effective, and the Company would be required to file a registration statement for the securities underlying these warrants within 90 days. An officer of the Company provided personal collateral to support this Note, which would be forfeited in the event of non-payment of the Note. This $160,000 Note was paid in full in May of 2004 (See Subsequent Events, below).

During March 2004, an officer of the Company raised approximately $36,000 using his personal credit from a group of shareholders in consideration of short-term personal promissory notes to assist the Company with very short-term cash requirements. The notes carried effective annual interest rates of less than 10%, plus minor processing fees. These notes were subsequently repaid in full in April 2004 (See Subsequent Events, below).

6.     Subsequent Events

On April 8, 2004, the Company executed an initial closing of a private placement equity offering (“Offering”) of units that commenced on March 15, 2004, with aggregate gross proceeds of approximately $1.1 million. As of April 8, 2004, this offering raised a gross amount of approximately $1,136,769 in cash in consideration for the issuance of 10,334,265 shares of restricted common stock and 7,750,700 warrants to purchase common stock at an exercise price of $0.11 per share. Each Unit in the Offering consists of one share of the Company’s common stock and a warrant to purchase 0.75 shares of the Company’s common stock. These warrants have an exercise price of $0.11 per share, and a term of five years, and include certain registration rights. As of April 8, 2004 the cash proceeds to the Company, net of expenses to date, totaled $972,864.  A placement agent sold the units on a best-efforts basis. The Company intends to use part of the proceeds of the private placement to finance the continued development and marketing of its WiFi™ and RFID related Location Tools™ products. In addition, the Company plans to use part of the proceeds for expanded marketing and sales efforts, for further commercialization of the Company’s other Location Tools™ product line, and for other corporate purposes. The Units were sold to accredited investors pursuant to an exemption from the registration requirements of the Securities Act of 1933 (the “Act”) and applicable state exemptions from registration. The securities offered have not been registered under the Act and they may not be offered or sold in the United States or any state in the absence of an effective registration statement or an applicable exemption from registration requirements.
 
   F-34  

 
NATIONAL SCIENTIFIC CORPORATION
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
(unaudited)

On April 13, 2004, the Company paid $36,000 to retire promissory notes plus interest associated with short-term bridge financing from an officer of the Company and several shareholders, originally issued in March of 2004. (See Liquidity and Capital Resources, below).

In May 2004, the Company paid off the six-month note for $160,000 entered into in January 2004.

 
  F-35   

 


No dealer, salesman or other person has been authorized to give any information or to make representations other than those contained in this prospectus, and if given or made, such information or representations must not be relied upon as having been authorized by us or the Selling Securityholders. Neither the delivery of this prospectus nor any sale hereunder will, under any circumstances, create an implication that the information herein is correct as of any time subsequent to its date. This prospectus does not constitute an offer to or solicitation of offers by anyone in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such an offer is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.



21,033,463 SHARES


 

NATIONAL SCIENTIFIC CORPORATION

 


COMMON STOCK

 
_____________________________________________

 
PROSPECTUS

_____________________________________________


June 24, 2004
 
 

 

 
 

 
 
Item 24. Indemnification of Directors and Officers

Articles of Incorporation

Our articles of incorporation provide that no director shall incur liability to our company or our shareholders for monetary damages resulting from an act or omission in a director’s capacity as a director occurring after August 31, 1987, except for:

·
Any breach of the director’s duty of loyalty to our shareholders and us.
 
 
·
Acts and omissions not taken in good faith or which involve intentional misconduct or a knowing violation of law.
 
 
·
Any transaction from which a director received an improper benefit.
 
 
·
Acts or omissions for which the liability of a director is expressly provided by statute.
 
 
·
Acts related to an unlawful stock repurchase or dividend.

Texas General Corporation Law

Under Texas law, a corporation may indemnify a director or officer or other person who was, is, or is threatened to be made a named defendant or respondent in a proceeding because the person is or was a director, officer, employee or agent of the corporation, if it is determined that the person:

·
conducted himself or herself in good faith;
 
 
·
reasonably believed, in the case of conduct in his or her official capacity as a director or officer of the corporation, that his or her conduct was in the corporation’s best interests, and, in all other cases, that his or her conduct was at least not opposed to the corporation’s best interests; and
 
 
·
in the case of any criminal proceeding had no reasonable cause to believe that his or her conduct was unlawful.

A person entitled to indemnification under these provisions may be indemnified against judgments, penalties (including excise and similar taxes), fines, settlements and reasonable expenses he or she actually incurs in connection with the proceeding. If the person is found liable to the corporation or is found liable on the basis that personal benefit was improperly received by the person, the indemnification is limited to reasonable expenses actually incurred by the person in connection with the proceeding, and shall not be made in respect of any proceeding in which the person is found liable for willful or intentional misconduct in the performance of his or her duty to the corporation.

Commission Policy on Indemnification

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to contracts, statutes, or otherwise, the SEC has advised us that in its opinion, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. If a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by our director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether our indemnification is against public policy as expressed in the Securities Act, and we will be governed by the final adjudication of such issue.
 
II-1  

 
Indemnification Agreements

We have entered into indemnification agreements with our officers and directors providing for our indemnification of our officers and directors to the fullest extent allowed under Texas law.

We have agreed to provide customary indemnification to the Selling Securityholders for any losses or liabilities suffered by it based upon material misstatements or omissions from the registration statement and prospectus, except as they relate to information supplied by the Selling Securityholders to us for inclusion in the registration statement and prospectus.

·
We also have agreed to indemnify Casimir Capital and its representatives, affiliates and controlling persons from and against all liabilities, damages, and expenses arising out of the following:
 
 
·
Any of our actions or failure to act and/or any action or failure to act of our affiliates, employees or agents in connection with this prospectus or final prospectus.
 
 
·
Any untrue statement or alleged untrue statement of material fact contained in any of the financial or other information contained in this prospectus or final prospectus.
 
 
·
The omission or alleged omission of a material fact required to be stated in this prospectus or prospectus in or necessary to make the statements in this prospectus or prospectus not misleading.

We do not have an obligation to indemnify the Casimir Capital for any liabilities, damages or expenses if it is finally and judicially determined that the Casimir Capital incurred such liabilities, damages or expenses from Casimir Capital’s gross negligence or bad faith.



The following table sets for the expenses, other than any underwriting discount and commissions, in connection with the issuance and distribution of securities being offered. All amounts indicated are estimates:


Item
   
Estimate
 

 
 
Registration Fee
 
$
350
 
Accounting fees and expenses
   
5,000
 
Printing and engraving
   
7,500
 
Blue sky and legal investment fees and expenses
   
10,000
 
Legal fees and expenses
   
30,000
 
Placement agent fees and commissions
   
155,000
 
Miscellaneous fees and expenses
   
10,000
 
 
 
Total
 
$
217,850
 
 
II-2  

 

During the fiscal years ended September 30, 2001, 2002 and 2003, and for the period ending June 14, 2004 we sold unregistered securities in the transactions described below.

In November 2002, we commenced a private offering of restricted common stock and common stock purchase warrants and raised approximately $470,000 in cash and $30,000 in debt forgiveness from this effort. We issued 11,625,000 shares of restricted common stock for the cash collected and 500,000 shares of restricted common stock for the forgiven debt, and granted 4,800,000 tow year warrants to purchase common stock at a strike price of $0.30 and 200,000 two year warrants at a strike price of $0.50 per share. No underwriters were involved in connection with this private placement. The sales and issuances of the securities issued pursuant to the foregoing private placement are exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, and Rule 506 of Regulation D.

In June 2003, we commenced a private offering of restricted common stock and common stock purchase warrants. We raised from this offering in the fiscal year ending September 30, 2003, approximately $200,000 in cash, and issued 2,500,000 shares of restricted common stock and granted 2,000,000 warrants to purchase common stock at exercise prices ranging from $0.35 and $0.50 per share. We continued to raise funds under this private offering after September 30, 2003. From June 2003 through December 31, 2003, we had raised a total of approximately $280,000 in cash from this effort, and issued a total of 3,300,000 shares of restricted common stock and granted a total of 2,400,000 warrants to purchase common stock at exercise prices ranging from $0.35 to $0.75 per share. No underwriters were involved in connection with this private placement. The sales and issuances of the securities issued pursuant to the foregoing private placement are exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, and Rule 506 of Regulation D.

In January of 2004, the Company entered into a financing program with a U.S. investment fund Strategic Working Capital Fund L.P. The terms of this program include a six-month Note payable at maturity in July 2004 for $160,000, at an effective annual interest rate of 13%. The transaction also included 640,000 warrants good for three years to purchase the Company’s restricted stock, at $0.13 during the first and second year of the warrant’s lifetime, and $0.15 during the third and final year of the warrant’s lifetime. These warrants include anti-dilution provisions, as well as registration rights in the event that the Company was to file an appropriate registration statement with the SEC during the next three years. The principal of the Note is optionally convertible to the Company’s restricted stock at any time during the first six months of the Note at 90% of the then-current market value of the Company's common stock. In the event of failure to repay the Note in July 2004, the Note would be extended another six months, and the effective interest rate would be increased to 15%, and a second group of approximately 620,000 warrants priced at 50% of the average trading price of the Company's stock would be made effective, and the Company would be required to file a registration statement for the securities underlying these warrants within 90 days. An officer of the Company provided personal collateral to secure this Note, which would be forfeited in the event of non-payment of the Note. This $160,000 Note was repaid in full in May of 2004.

On March 15, 2004, we commenced a private placement of units consisting of our common stock and warrants to purchase our common stock. On June 14, 2004, we completed this private placement. Each investor received our common stock and a five-year warrant to purchase three quarters of a share of common stock for each share purchased. In connection with the private placement, we issued 10,334,266 shares of our common stock and warrants to purchase an aggregate of 7,750,700 shares of common stock. After deducting commissions and other expenses relating to the private placement, we received aggregate net proceeds of approximately $972,864. We also issued seven-year warrants to purchase an aggregate of 2,308,497 shares of our common stock at a price of $0.10 per share to the placement agent. The sales and issuances of the securities issued pursuant to the foregoing private placement, sold solely to accredited investors, are exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, and Rule 506 of Regulation D.

From time to time, we have granted stock options to employees. We did not register the shares underlying these options granted to employees on the basis that these options were offered and sold either pursuant to a written compensatory benefit plan or pursuant to written contracts relating to consideration, as provided by Rule 701 of the Securities Act of 1933, as amended. The following table sets forth information regarding the grants to employees during the indicated time periods:
 
II-3  

 
 
   
 
 
 
Weighted  
 
 
Weighted
 
 
 
 
Number  
 
 
Average
 
 
Average
 
 
 
of  
 
 
Exercise
 
 
Fair
 
 
 
 
Shares  
 
 
Price
 
 
Value
 
   
 
 
 
Options Outstanding, September 30, 2001
   
1,534,501
 
$
1.81
 
$
0.15
 
Granted    
   
3,654,162
   
0.24
   
0.24
 
Exercised
   
(1,477,000
)
 
0.11
   
0.11
 
Canceled
   
(128,824
)
 
0.71
   
0.02
 
   
             
Options Outstanding, September 30, 2002
   
3,582,839
 
$
1.97
 
$
0.01
 
   
             
Options Outstanding September 30, 2002
   
3,582,839
 
$
1.97
 
$
0.01
 
Granted    
   
1,144,081
   
0.10
   
0.10
 
Exercised
   
(637,153
)
 
0.05
   
0.10
 
Expired    
   
(760,010
)
 
5.45
   
0.01
 
   
             
Options Outstanding, September 30, 2003
   
3,329,757
 
$
0.90
 
$
0.06
 
   
             
Options Outstanding, September 30, 2003
   
3,329,757
 
$
0.90
 
$
0.06
 
Granted
   
190,000
   
0.151
   
0.10
 
Exercised
   
107,500
)
 
0.09
   
0.10
 
Canceled
   
250,000
   
0.15
   
0.01
 
   
             
Options Outstanding, May 31, 2004
   
3,162,257
 
$
0.94
 
$
0.06
 
   
             
Non Vested
   
5,000
   
 
   
 
 
Vested
   
3,157,257
   
 
   
 
 



See the Exhibit Index located immediately following the signature page of this registration statement.



  1.     The undersigned Registrant hereby undertakes to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
 
                (a)     To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933.
 
                     (b)     To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; provided, however, that paragraphs (a) and (b) shall not apply if such information is contained in periodic reports filed by the Registrant under Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that is incorporated by reference into this Registration Statement.
 
                     (c)     To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

           2.     The undersigned Registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

           3.     The undersigned Registrant hereby undertakes to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
 

II-4

 

 
           4.     The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report under Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference into this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

           5.     The undersigned Registrant hereby undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the prospectus is sent or given, the latest annual report to Securityholders that is incorporated by reference in the prospectus and furnished under and meeting the requirements of Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of 1934; and, where interim financial information required to be presented by Article 3 of Regulation S-X are not set forth in the prospectus, to deliver, or cause to be delivered to each person to whom the prospectus is sent or given, the latest quarterly report that is specifically incorporated by reference in the prospectus to provide such interim financial information.

           6.     Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned Registrant according the foregoing provisions, or otherwise, the undersigned Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
 
II-5  

 

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form SB-2 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Scottsdale, State of Arizona, on June 23, 2004.
 
     
  NATIONAL SCIENTIFIC CORPORATION
 
 
 
 
 
 
Date:   June 23, 2004 By:   /s/  Michael A. Grollman
 
 
Title:  Director, Chief Executive Officer, Chairman, and Acting Chief Financial Officer  

 
POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael A. Grollman, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Form SB-2 Registration Statement, and to file the same, with all exhibits thereto, and documents in connection therewith with the Securities and Exchange Commission, granting said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully and to all intents and purposes as he might or could do in person hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

In accordance with the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
     
 
NATIONAL SCIENTIFIC CORPORATION
 
 
 
 
 
 
Date:   June 23, 2004 By:   /s/  Graham L. Clark
 
  Title:  Director, President, and Secretary
 
     
 
 
 
 
 
 
 
By:   /s/ Gregory Szabo
 
  Title:  Director
 
       
* /s/  Michael A. Grollman    

   
Attorney-in-Fact    


 
II-6  

 

The Exhibits and Financial Statement Schedules to the Registration Statement are listed in the Exhibit Index, which appears in this Registration Statement and is hereby incorporated herein by reference.

Exhibit
 
Number
Description


3.1
Articles of Incorporation (1)
3.2
Bylaws (2)
4.1
Form of Warrant to Purchase Common Stock, dated April 8, 2004, to various purchasers in National Scientific's March 15, 2004 private placement of units
4.2
Form of Subscription Agreement, dated March 15, 2004, with various purchasers in National Scientific's March 15, 2004 private placement of units
4.3
Form of Placement Agent Warrant to Purchase Common Stock, dated April 8, 2004, to various Casimir Capital L.P. employees and associates in National Scientific's March 15, 2004 private placement of units
4.4
Form of Placement Agent Initiation Warrant, dated February 9, 2004, with Casimir Capital L.P.’s employees in conjunction with National Scientific's March 15, 2004 private placement of units
4.5
Warrant to Purchase Common Stock, dated January 6, 2004, to Strategic Working Capital Fund L.P., in conjunction with National Scientific’s financing dated January 2004
5.1
Legal Opinion of David M. Dobbs, PC
10.1
Employment Agreement between National Scientific Corporation and Michael A. Grollman dated January 2001 (4)
10.2
Employment Agreement between National Scientific Corporation and Graham L. Clark dated January 2003
10.3
NSC Consulting Agreement dated August 2001, and Amendments dated August 2002 and July 2003, with Dr. El-Badawy El-Sharawy
10.4
Amended and Restated 2000 Stock Option Plan (3)
10.5
Form of 2004 Stock Retainage Plan Agreement
10.6
Agreement Regarding Management Consulting Services with Stanton Walker of New York dated May 2003 (5)
10.7
Agreement Regarding Distribution and Marketing of Gotcha!® Child Safety Product and other products dated December 2002 with FutureCom Global, Inc.
10.8
Purchase Order from Verify Systems, Inc, dated March 2003 for IBUS™ School Child Tracking Systems
10.9
Letter of Understanding and Agreement dated April 2004 Regarding Sales and Distribution of Verify School safety products, and an Unlimited Software License with Anthony Grosso and CIS Services, LLC
10.10
Letter of Intent from Positus, Inc. dba Bike & Cycle Trak, dated February 2003 for Design of Power Sports Tracking System
10.11
Purchase Order from Positus, Inc. dba Bike & Cycle Trak, for Design of Power Sports Tracking System dated March 2003
23.1
Consent of Hurley & Company
23.2
Consent of David M. Dobbs. (Included in Exhibit 5.1)
24
Power of Attorney (included on signature page)
___________________

*
Previously filed.
(1)
Incorporated by reference to the Registrant’s Form 10-SB filed on or about January 3, 2000.
(2)
Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended March 31, 2001 and filed on or about May 15, 2001.
(3)
Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended December 31, 2000 and filed on or about February 14, 2001.
(4)
Incorporated by reference to the Registrant’s Form 10-KSB for the year ended September 30, 2000 and filed on or about December 19, 2000
(5)
Incorporated by reference to the Registrant’s Form S-8 filed on or around June 3, 2003.

 

II-7

 

EXHIBIT 4.1

Form of Warrant to Purchase

W-_____ Shares of Common Stock

NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND NEITHER THIS WARRANT NOR SUCH SHARES MAY BE SOLD, ENCUMBERED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT, AND, IF AN EXEMPTION SHALL BE APPLICABLE, THE HOLDER SHALL HAVE DELIVERED AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

VOID AFTER 5:00 P.M. NEW YORK CITY TIME ON THE LAST DAY OF THE EXERCISE PERIOD, AS DEFINED IN THE WARRANT

COMMON STOCK PURCHASE WARRANT
OF
NATIONAL SCIENTIFIC CORPORATION

This is to certify that, FOR VALUE RECEIVED, ______, with an address at _______________ (and or its assign(s) and/or transferee(s)) (hereinafter, each a "Holder" and collectively the "Holders"), is entitled to purchase, subject to the provisions of this Warrant, from National Scientific Corporation, a Texas corporation (the "Company"), at an initial exercise price equal to $.11 per share, _____________ (______) fully paid and non-assessable shares of Common Stock, par value $.01 per share ("Common Stock"). The shares of Common Stock deliverable upon such exercise, and as adjusted from time-to-time as provided in this Warrant, are hereinafter sometimes referred to as "Warrant Stock," and the exercise price for the purchase of a share of Common Stock pursuant to this Warrant in effect at any time and as adjusted from time-to-time is hereinafter sometimes referred to as the "Exercise Price." The aggregate purchase price payable for the Warrant Stock purchasable hereunder is referred to as the "Aggregate Purchase Price." The Aggregate Purchase Price is not subject to adjustment. In the event of an adjustment to the Exercise Price, as provided in
Section 6 herein, the number of shares of Warrant Stock deliverable upon exercise of this Warrant shall be adjusted by dividing the Aggregate Purchase Price by the Exercise Price in effect immediately after such adjustment.

This warrant and additional warrants of like tenor, including warrants issued in exchange and/or substitution thereof (collectively, the "Warrants") were originally issued in connection with a private placement of securities of the Company, through Casimir Capital L.P., as Placement Agent ("Placement Agent"), pursuant to the terms of a Confidential Term Sheet dated March 15, 2004, as may be amended from time-to-time, and as set forth in the Subscription Agreements between the subscribers and the Company ("Subscription Agreements").


1. DEFINITIONS. The following terms have the meanings set forth below:

"Current Market Value" of a share of Warrant Stock as of a particular date (the "Determination Date") shall mean:

a. If the Common Stock is listed on a national securities exchange or admitted to unlisted trading privileges on such exchange or listed for trading on the NASDAQ National Market, the current market value shall be the last reported sale price of the Common Stock on such exchange or market on the last business day prior to the date of exercise of this Warrant or if no such sale is made on such day, the average closing bid and asked prices for such day on such exchange or market; or

b. If the Common Stock is not so listed or admitted to unlisted trading privileges, but is traded on the NASDAQ SmallCap Market, the current market value shall be the average of the closing bid and asked prices for such day on such market and if the Common Stock is not so traded, the current market value shall be the mean of the last reported bid-and asked prices reported by the National Quotation Bureau, Inc. on the last business day prior to the date of the exercise of this Warrant; or

c. If the Common Stock is not so listed or admitted to unlisted trading privileges and bid and asked prices are not so reported, the current market value shall be an amount, not less than book value thereof as at the end of the most recent fiscal year of the Company ending prior to the date of the exercise of the Warrant, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company.

"Convertible Securities" shall mean evidences of indebtedness, shares of stock or other securities, including but not limited to options, warrants or purchase, subscription or other rights, which are convertible into, exchangeable or exercisable for, or represent the right to receive, with or without payment of additional consideration in cash or property, shares of Common Stock (or other Convertible Securities), either immediately or upon the occurrence of a specified date or a specified event.

"Exercise Period" shall mean the period commencing on the date hereof and ending at 5 p.m., eastern time on the day preceding the fifth anniversary of the date hereof.

"Permitted Issuances" shall mean (i) Common Stock issuable or issued to employees, consultants or directors of the Company pursuant to a stock plan or other compensation arrangement approved by the Board of Directors of the Company, but in no event, more than Eight Million shares in the aggregate, and
(ii) Common Stock issued or issuable upon conversion of the Warrants or any other securities exercisable or exchangeable for, or convertible into shares of Common Stock outstanding as of March 15, 2004.

2. EXERCISE OF WARRANT. This Warrant may be exercised in whole or in part at any time or from time to time commencing on the date hereof and until April 8, 2009 (the "Exercise Period"), provided, however, that if either such day is a day on which banking institutions in the State of New York are authorized by law to close, then on the next succeeding day which shall not be such a day. This Warrant may be exercised by presentation and surrender hereof to the Company at its principal office, or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the

2

Exercise Price for the number of shares of Warrant Stock specified in such form. As soon as practicable after each such exercise of this Warrant, but not later than seven days from the date of such exercise, the Company shall issue and deliver to the Holder a certificate or certificates for the shares of Warrant Stock issuable upon such exercise, registered in the name of the Holder or its designee. If this Warrant should be exercised in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing the rights of the Holder thereof to purchase the balance of the shares of Warrant Stock purchasable thereunder. Upon receipt by the Company of this Warrant at its office, or by the stock transfer agent of the Company at its office, in proper form for exercise, the Holder shall be deemed to be the holder of record of the shares of Common Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such shares of Common Stock shall not then be physically delivered to the Holder.

3. RESERVATION OF SHARES/FRACTIONAL SHARES. The Company hereby agrees that at all times there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of Common Stock as shall be required for issuance and delivery upon exercise of this Warrant. If the Company hereafter lists its Common Stock on any national securities exchange, the Nasdaq National Market or the Nasdaq SmallCap Market, it shall use its best efforts to keep the Warrant Stock authorized for listing on such exchange upon notice of issuance. No fractional shares or script representing fractional shares shall be issued upon the exercise of this Warrant. With respect to any fraction of a share, called for upon exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the Current Market Value of a share of Warrant Stock.

4. EXCHANGE, TRANSFER, ASSIGNMENT OR LOSS OF WARRANT. This Warrant (and all rights hereunder) is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the holder or any assignee and/or transferee thereof to purchase in the aggregate the same number of shares of Common Stock purchasable hereunder. Upon surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax, the Company shall, without charge, execute and deliver a new Warrant in the name of the assignee and/or transferee named in such instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided or combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and deliver a new Warrant of like tenor. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed, or mutilated shall be at any time enforceable by anyone.

5. RIGHTS OF THE HOLDER. The Holder shall not, by virtue of this Warrant, be entitled to any rights of a stockholder in the Company, either at law or

3

equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein. In addition, no provision hereof, in the absence of affirmative action by Holder to purchase shares of Common Stock, and no enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of such Holder for the purchase price of any Common Stock or as a stockholder of Company, whether such liability is asserted by Company or by creditors of Company.

6. ANTI-DILUTION PROVISIONS. The Exercise Price in effect at any time and the number and kind of securities purchasable upon exercise of each Warrant shall be subject to adjustment as follows and the Company shall give each Holder notice of any event described below which requires an adjustment pursuant to this Section 6 at the time of such event:

(a) STOCK DIVIDENDS, SUBDIVISIONS AND COMBINATIONS. If, at any time or from time to time after the date of this Warrant, the Company shall (i) pay a dividend or make a distribution to any holder of its capital stock in shares of Common Stock, (ii) subdivide its outstanding shares of Common Stock into a greater number of shares, (iii) combine its outstanding shares of Common Stock into a smaller number of shares or (iv) issue by reclassification of its Common Stock any shares of capital stock of the Company, the Exercise Price shall be adjusted to be equal to a fraction, the numerator of which shall be the Aggregate Purchase Price and the denominator of which shall be the number of shares of Common Stock or other capital stock of the Company that the Holder would have owned immediately following such action had such Warrant been exercised immediately prior thereto. An adjustment made pursuant to this Subsection (a) shall become effective immediately after the record date in the case of a dividend or distribution, and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification, and shall result in a corresponding adjustment to the number of shares of Warrant Stock issuable upon exercise of this Warrant.

(b) CERTAIN OTHER DISTRIBUTIONS AND ADJUSTMENTS. If, at any time or from time to time after the date of this Warrant, the Company shall issue or distribute to any holder of shares of Common Stock evidence of its indebtedness, any other securities of the Company or any cash, property or other assets (excluding a subdivision, combination or reclassification, or dividend or distribution payable in shares of Common Stock, referred to in Subsection (a), and also excluding cash dividends or cash distributions paid out of net profits legally available therefor in the full amount thereof (any such non-excluded event being herein called a "Special Dividend")), the Exercise Price shall be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which shall be the then Current Market Value in effect on the record date of such issuance or distribution less the fair market value (as determined in accordance with paragraph B. of this Section 6 (g)) of the evidence of indebtedness, cash, securities or property, or other assets issued or distributed in such Special Dividend applicable to one share of Common Stock and the denominator of which shall be the then Current Market Value in effect on the record date of such issuance or distribution. An adjustment made pursuant to this Subsection (b) shall become effective immediately after the record date of any such Special Dividend and shall result in a corresponding adjustment to the number of shares of Warrant Stock issuable upon exercise of this Warrant.

4

(c) ISSUANCE OF ADDITIONAL SHARES OF COMMON STOCK AND CONVERTIBLE SECURITIES.

(i) If at any time the Company shall issue or sell any shares of Common Stock or Convertible Securities (whether directly or by assumption in a merger in which Company is the surviving corporation), in exchange for consideration in an amount per share of Common Stock ( determined by dividing (i) the total amount, if any, received or receivable by the Company in consideration of the issuance or sale of such securities plus the total consideration, if any, payable to the Company upon exercise, conversion or exchange thereof ("Total Consideration") by (ii) the number of additional shares of Common Stock issued, sold or issuable upon the exercise, conversion or exchange of such securities) that is less than the Exercise Price (excluding Permitted Issuances), then (A) the Exercise Price shall be adjusted so that it shall equal the price determined by multiplying such Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding on the date of issuance or sale (calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the number of shares of Common Stock which the aggregate offering price would purchase based upon the Exercise Price and the denominator of which shall be the number of shares of Common Stock outstanding on the date of issuance or sale (calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the maximum number of additional shares of Common Stock issued, sold or issuable in connection with such offering or transaction, and (B) the number of shares of Common Stock for which this Warrant is exercisable shall be adjusted to equal the product obtained by multiplying the Exercise Price in effect immediately prior to such issue or sale by the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such issue or sale and dividing the product thereof by the Exercise Price resulting from the adjustment made pursuant to clause (A) above.

(ii) The provisions of paragraph (i) of this Section 6(c) shall not apply to any issuance of shares of Common Stock for which an adjustment is provided under Section 6(a) or 6(b). No adjustment of the number of shares of Common Stock for which this Warrant shall be exercisable shall be made under paragraph (i) of this Section 6(c) upon the issuance of any shares of Common Stock which are issued pursuant to the exercise of any warrants or other subscription or purchase rights or pursuant to the exercise of any conversion or exchange rights in any Convertible Securities, if any such adjustment shall previously have been made upon the issuance of such warrants or other rights or upon the issuance of such Convertible Securities.

(d) No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least one cent ($0.01) in such price; provided, however, that any adjustments which by reason of this Section 6(d) are not required to be made shall be carried forward and taken into account in any subsequent adjustment; provided, further, however that adjustments shall be required and made in accordance with the provisions of this Section 6 not later than such time as may be required in order to preserve the tax-free nature of a distribution to the Holder of this Warrant or Common Stock issuable upon the exercise hereof.

5

All calculations under this Section 6(d) shall be made to the nearest cent or to the nearest one-hundredth of a share, as the case may be.

(e) The Company may retain a firm of independent public accountants of recognized standing selected by the Board (who may be the regular accountants employed by the Company) to make any computation required by this Section 6.

(f) In the event that at any time, as a result of an adjustment made pursuant to Section 6(a), (b) or (c) of this Warrant, the Holder of any Warrant thereafter shall become entitled to receive any shares of the Company, other than Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Common Stock contained in Sections 6(a) through (h), inclusive, of this Warrant.

(g) For purposes of any computation respecting consideration received pursuant to this Section 6, the following shall apply:

A. in the case of the issuance of shares of Common Stock for cash, the consideration shall be the amount of such cash, provided that in no case shall any deduction be made for any commissions, discounts or other expenses incurred by the Company for any underwriting of the issue or otherwise in connection therewith;

B. in the case of the issuance of shares of Common Stock for a consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be the fair market value thereof as determined in good faith by the Board of Directors of the Company (irrespective of the accounting treatment thereof), whose determination shall be conclusive; and

C. in the case of the issuance of securities convertible, exchangeable or exercisable for shares of Common Stock, the aggregate consideration received therefor shall be deemed to be the consideration received by the Company for the issuance of such securities plus the additional minimum consideration, if any, to be received by the Company upon the conversion or exchange thereof (the consideration in each case to be determined in the same manner as provided in clauses (A) and (B) of this Subsection).

(h) Notwithstanding the foregoing, no adjustment shall be effected due to, or as a result of, any Permitted Issuances.

7. REGISTRATION RIGHTS. The Warrant Stock shall be entitled to the registration rights described in Article V of the Subscription Agreements.

8. OFFICER'S CERTIFICATE. Whenever the Exercise Price(s) shall be adjusted as required by the provisions of Section 6 of this Warrant, the Company shall forthwith file in the custody of its Secretary or an Assistant Secretary at its principal office and with its stock transfer agent, if any, an officer's certificate showing the adjusted Exercise Price(s) and the adjusted number of shares of Common Stock issuable upon exercise of each Warrant, determined as herein provided, setting forth in reasonable detail the facts requiring such adjustment, including a statement of the number of additional shares of Common

6

Stock, if any, and such other facts as shall be necessary to show the reason for and the manner of computing such adjustment. Each such officer's certificate shall be forwarded by certified mail to Holder as provided in Section 13

9. NOTICES TO WARRANT HOLDERS. So long as this Warrant shall be outstanding, (1) if the Company shall pay any dividend or make any distribution upon Common Stock, or (2) if the Company shall offer to the holders of Common Stock for subscription or purchase by them any share of any class or any other rights, or (3) if any capital reorganization of the Company, reclassification of the capital stock of the Company, consolidation or merger of the Company with or into another entity, tender offer transaction for the Company's Common Stock, sale, lease or transfer of all or substantially all of the property and assets of the Company, or voluntary or involuntary dissolution, liquidation or winding up of the Company shall be effected, or (4) if the Company shall file a registration statement under the Securities Act of 1933, as amended (the "Act"), on any form other than on Form S-4 or S-8 or any successor form, then in any such case, the Company shall cause to be mailed by certified mail to the Holder, at least fifteen days prior to the date specified in clauses (1), (2), (3) or
(4), as the case may be, of this Section 9 a notice containing a brief description of the proposed action and stating the date on which (i) a record is to be taken for the purpose of such dividend, distribution or rights, or (ii) such reclassification, reorganization, consolidation, merger, tender offer transaction, conveyance, lease, dissolution, liquidation or winding up is to take place and the date, if any is to be fixed, as of which the holders of Common Stock or other securities shall receive cash or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation or winding up, or (iii) such registration statement is to be filed with the Securities and Exchange Commission.

10. RECLASSIFICATION, REORGANIZATION OR MERGER. In case of any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the Company, or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary in which merger the Company is the continuing or surviving corporation and which does not result in any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the class issuable upon exercise of this Warrant) or in case of any sale, lease or conveyance of all or substantially all of the assets of the Company, or in the case of any statutory exchange of securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company), the Company shall, as a condition precedent to such transaction, cause effective provisions to be made so that (i) the Holder shall have the right thereafter by exercising this Warrant, to purchase the kind and amount of shares of stock and other securities and property receivable upon such reclassification, capital reorganization and other change, consolidation, merger, sale, conveyance or statutory exchange by a holder of the number of shares of Common Stock which could have been purchased upon exercise of this Warrant immediately prior to such reclassification, change, consolidation, merger, sale, conveyance, or statutory exchange and (ii) the successor or acquiring entity shall expressly assume the due and punctual observance and performance of each covenant, agreement, obligation and condition of this Warrant to be performed and observed by Company and all obligations and liabilities hereunder (including but not limited to the provisions of Section 6 regarding the increase in the number of shares of Warrant Stock potentially issuable hereunder). Any such provision shall include provision for adjustments which shall be as nearly equivalent as possible to the adjustments provided for in this Warrant. The foregoing

7

provisions of this Section 10 shall similarly apply to successive reclassifications, capital reorganizations and changes of shares of Common Stock and to successive consolidations, mergers, sales or conveyances. In the event that in connection with any such capital reorganization or reclassification, consolidation, merger, sale, conveyance or statutory exchange, additional shares of Common Stock shall be issued in exchange, conversion, substitution or payment, in whole in part, for a security of the Company other than Common Stock, any such issue shall be treated as an issuance of Common Stock covered by the provisions of Section 6 of this Warrant. Notice of any such event shall be mailed by certified mail to the Holders of the Warrants no less than thirty (30) days prior to such event. A sale of all or substantially all of the Company's assets for a consideration consisting primarily of securities shall be deemed a consolidation or merger for the foregoing purposes.

11. TRANSFER TO COMPLY WITH THE SECURITIES ACT OF 1933. This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold or otherwise disposed of except as follows:

(i) to a person who, in the opinion of counsel for the Company, or counsel for the Holder who is reasonably acceptable to the Company, is a person to whom this Warrant or Warrant Stock may legally be transferred without registration and without the delivery of a current prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section 11 with respect to any resale or other disposition of such securities which agreement shall be satisfactory in form and substance to the Company and its counsel; or

(ii) to any person upon delivery of a prospectus then meeting the requirements of the Act relating to such securities and the offering thereof for such sale or disposition.

12. GOVERNING LAW; JURISDICTION. The corporate laws of the State of Texas shall govern all issues concerning the relative rights of the Company and its stockholders. All issues concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to the principles of conflicts of law thereof. The parties hereto agree that venue in any and all actions and proceedings related to the subject matter of this Warrant shall be in the state and federal courts in and for New York, New York, which courts shall have exclusive jurisdiction for such purpose, and the parties hereto irrevocably submit to the exclusive jurisdiction of such courts and irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or proceeding. Service of process may be made in any manner recognized by such courts. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought.

13. NOTICES. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered VIA facsimile at the facsimile telephone number specified in this Section prior to 6:30 p.m. (New York City time) on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered VIA facsimile at the facsimile telephone number specified in this Agreement later than 6:30 p.m. (New York City

8

time) on any date and earlier than 11:59 p.m. (New York City time) on such date,
(iii) the Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:

If to the Company: National Scientific Corporation Scottsdale Technology Center 14455 North Hayden Road, Suite 202 Scottsdale, AZ 85260-6497

If to the Holder: To the Address Set Forth on the cover page hereof.

14. MODIFICATION OF WARRANT. This Warrant shall not be modified, supplemented or altered in any respect, nor any provision waived, except with the consent in writing of the Holders representing not less than fifty percent (50%) of the Warrants then outstanding.

15. SOLICITATION FEE. The Company has agreed to pay a fee of 2% of the Exercise Price to the Placement Agent upon exercise of the Warrant on or before April 8, 2005.

16. PAYMENT OF TAXES. The Company will pay all documentary stamp taxes attributable to the issuance of shares of Common Stock underlying this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificate for shares of Common Stock underlying this Warrant in a name other that of the Holder. The Holder is responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving shares of Common Stock underlying this Warrant upon exercise hereof.

IN WITNESS WHEREOF, this Warrant has been duly executed as of April 8, 2004.

NATIONAL SCIENTIFIC CORPORATION

By:

Michael A. Grollman Chairman and Chief Executive Officer

ATTEST:


Secretary

[CORPORATE SEAL]

9

SUBSCRIPTION

The undersigned, ____________________________, pursuant to the provisions of the foregoing Warrant, hereby agrees to subscribe for and purchase ___________________ shares of the Common Stock, par value $_____ per share, of ______________________ covered by said Warrant, and makes payment therefor in full at the price per share provided by said Warrant.

Dated: ________________________ Signature: ___________________________

10

ASSIGNMENT

FOR VALUE RECEIVED ___________________ hereby sells, assigns and transfers unto ________________________ the foregoing Warrant and all rights evidenced thereby, and does irrevocably constitute and appoint ___________________, attorney, to transfer said Warrant on the books of _________________________.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

PARTIAL ASSIGNMENT

FOR VALUE RECEIVED ___________________ hereby sells, assigns and transfers unto ________________________ the right to purchase ____________ shares of Common Stock, par value $_____ per share of _________________________ covered by the foregoing Warrant, and a proportionate part of said Warrant and the rights evidenced thereby, and does irrevocably constitute and appoint ___________________, attorney, to transfer such part of said Warrant on the books of _________________________.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

11

EXHIBIT 4.2

FORM OF SUBSCRIPTION AGREEMENT

This Subscription Agreement (the "Agreement" or "Subscription Agreement") is made as of the date indicated on the signature page of this Agreement by and between National Scientific Corporation, a Texas corporation (the "Company"), and each party who is a signatory hereto and any other Subscribers who are made a party to this Agreement pursuant to Section 1 (individually, a "Subscriber" and collectively, the "Subscribers").

RECITALS

The Company hereby offers to persons who qualify as "accredited investors" as defined in Rule 501 of Regulation D promulgated under the under the Securities Act of 1933, as amended (the "Securities Act"), 10 million units for aggregate gross proceed of $1.1 million ("Base Offering") in a private placement ("Offering") to be conducted through Casimir Capital L.P., as Placement Agent ("Casimir" or the "Placement Agent"). The Company is offering the units pursuant to Rule 506 of Regulation D promulgated under the Securities Act. The Base Offering will be conducted on a "best efforts, all or none basis," as more thoroughly described in the Confidential Offering Memorandum, dated March 15, 2004 (hereinafter, with all Exhibits and Schedules annexed thereto, and any supplements and/or amendments, the "Offering Memorandum"). Each unit (a "Unit") shall consist of (i) one (1) share of common stock, par value $0.01 per share, of the Company (the "Common Stock"), and (ii) a 5-year warrant (the "Warrant") to purchase three quarters (3/4) of a share of Common Stock. The offering price per Unit ("Purchase Price") shall be $0.11. The initial exercise price of each Warrant shall be equal to the Purchase Price.

During the Offering Period (as hereinafter defined), the Company has the option to sell up to an additional 4,545,455 Units, for additional aggregate gross proceeds of up to $500,000, thereby possibly increasing the aggregate gross proceeds of the Offering to up to $1.6 million (hereinafter such additional gross proceeds of up to $500,000, referred to as the "Over-allotment Option"). In the event the Company exercises the Over-allotment Option, it may choose to have more than one closing in connection with the Offering.

The Common Stock, Warrants and shares of Common Stock underlying the Warrants ("Warrant Shares"), including any such securities sold in connection with the Over-allotment Option, shall collectively be referred to as the "Unit Securities." The term "Offering" shall include any Units sold in connection with the Base Offering and the Over-allotment Option.

In consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Subscribers hereby agree as follows:

ARTICLE I
PURCHASE AND SALE OF SECURITIES

1.1 PURCHASE AND SALE OF UNIT SECURITIES. Subject to the terms and conditions set forth herein, Subscriber hereby subscribes for and agrees to purchase from the Company and the Company agrees to issue and sell to each Subscriber at the Closing the number of Units set forth on the signature page hereto.

1.2 PAYMENT. Prior to the Closing, each Subscriber will deposit, by wire transfer or check of immediately available funds in accordance with the Company's wire instructions, the aggregate Purchase Price set forth beneath its

1

name on the signature page hereof in a segregated escrow account with an escrow agent reasonably acceptable to Casimir. The Company will deliver certificates representing the Common Stock and Warrants within 10 business days of the earlier to occur of the (a) Closing Date or (b) the Termination Date.

1.3 OFFERING PERIOD. Unless terminated earlier in the Company's sole discretion, the offering period (the "Offering Period") will expire May 14, 2004 (subject to extension at the Company's discretion for an additional 30 days without notice to investors) (the "Termination Date").

ARTICLE II
SUBSCRIBER'S REPRESENTATIONS AND WARRANTIES

Each Subscriber represents and warrants to the Company and Casimir, severally and solely with respect to itself and its purchase hereunder and not with respect to any other Subscriber, that:

2.1 INVESTMENT PURPOSE. The Subscriber is purchasing the Unit Securities for its own account and not with a present view toward the public sale or distribution thereof; provided, however, that by making the representation herein, the Subscriber does not agree to hold any of the Unit Securities for any minimum or other specific term and reserves the right to dispose of the Unit Securities at any time in accordance with or pursuant to a registration statement or an exemption under the Securities Act.

2.2 ACCREDITED SUBSCRIBER STATUS. The Subscriber is an "accredited investor" as defined in Rule 501(a) of Regulation D. The Subscriber has delivered to the Company a Confidential Investor Questionnaire in the form annexed to the Offering Memorandum. The Subscriber hereby represents that, either by reason of the Subscriber's business or financial experience or the business or financial experience of the Subscriber's advisors, the Subscriber has the capacity to protect the Subscriber's own interests in connection with the transaction contemplated hereby and is capable of evaluating the merits and risks of an investment in the Unit Securities.

2.3 RELIANCE ON EXEMPTIONS. The Subscriber understands that the Unit Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Subscriber's compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Subscriber set forth herein in order to determine the availability of such exemptions and the eligibility of the Subscriber to acquire the Unit Securities.

2.4 INFORMATION. (a) The Subscriber and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Company, and materials relating to the offer and sale of the Unit Securities that have been requested by the Subscriber or its advisors, if any, including, without limitation, the Offering Memorandum. The Subscriber and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other due diligence investigation conducted by Subscriber or any of its advisors or representatives modify, amend or affect the Subscriber's right to rely on the Company's representations and warranties contained in Article III below.

(b) The Subscriber acknowledges and agrees that Casimir has not supplied any information for inclusion herein other than information furnished in writing to the Company by Casimir specifically for inclusion herein relating to Casimir, that Casimir has no responsibility for the accuracy or completeness of the Offering Memorandum, and that the Subscriber has not relied upon the independent investigation or verification, if any, which may have been undertaken by Casimir.

2

2.5 ACKNOWLEDGEMENT OF RISK. The Subscriber acknowledges and understands that its investment in the Unit Securities involves a high degree of risk, including, without limitation, those risk factors set forth in the Company's Form 10-KSB for the fiscal year ended September 30, 2003, and that (i) the Company has experienced losses for the past 7 years, including net losses of $1,883,489, $952,564 and $210,778 for the years ended September 30, 2002 and 2003 and the quarter ended December 31, 2003, respectively, and its auditor's report for the years ended September 30, 2002 and 2003 raise doubt regarding the ability of the Company to continue as a going concern; (ii) the Company changed its focus in February 2002 to applications of electronic devices in the location services market and, accordingly, is considered a development stage company and as such, has limited operating history in its current business and has not generated significant revenues; (iii) the Company is dependent upon raising capital from investors and requires substantial funds in addition to the proceeds from the sale of Unit Securities; (iv) an investment in the Company is highly speculative, and only Subscribers who can afford the loss of their entire investment should consider investing in the Company and the Unit Securities; (v) the Subscriber may not be able to liquidate its investment; (vi) transferability of the Unit Securities is extremely limited; (vii) in the event of a disposition of the Unit Securities, the Subscriber could sustain the loss of its entire investment and (viii) the Company has not paid any dividends on its Common Stock since inception and does not anticipate the payment of dividends in the foreseeable future.

2.6 GOVERNMENTAL REVIEW. The Subscriber understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities or an investment therein.

2.7 TRANSFER OR RESALE. The Subscriber understands that:

(a) except as otherwise provided in Article V, the Unit Securities have not been and are not being registered under the Securities Act or any applicable state securities laws and, consequently, the Subscriber may have to bear the risk of owning the Unit Securities for an indefinite period of time because the Unit Securities may not be transferred unless (i) the resale of the Unit Securities is registered pursuant to an effective registration statement under the Securities Act; (ii) the Subscriber has delivered to the Company an opinion of counsel reasonably acceptable to the Company (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Unit Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration; or (iii) the Unit Securities are sold or transferred pursuant to Rule 144;

(b) any sale of the Unit Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and, if Rule 144 is not applicable, any resale of the Unit Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC promulgated thereunder; and

(c) except as set forth in Article V, neither the Company nor any other person is under any obligation to register the Unit Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. There can be no assurance that the Registration Statement provided for in Article V will ever be effective or remain effective, or that there will be any liquidity with respect to the sale of the Registrable Securities (as hereinafter defined), if and when registered. Subscriber understands that although the Company's Common Stock is traded on the OTCBB, there is currently a limited public market for such securities and the price of the Company's Common Stock has fluctuated widely in the past. Even if

3

the Subscriber is able to sell the Registrable Securities, there is no assurance regarding a return of or on Subscriber's investment in the Unit Securities.

2.8 LEGENDS. The Subscriber understands the certificates representing the Unit Securities will bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such securities):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.

2.9 AUTHORIZATION; ENFORCEMENT. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Subscriber and represents the valid and binding obligations of the Subscriber enforceable in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the rights of creditors generally and the application of general principles of equity.

2.10 ACKNOWLEDGEMENTS REGARDING CASIMIR. The Subscriber acknowledges that Casimir is acting as placement agent for the Unit Securities being offered hereby and will be compensated by the Company for acting in such capacity. The Subscriber further acknowledges that Casimir has acted solely as agent of the Company in connection with the offering of the Unit Securities by the Company, that the information and data provided to the Subscriber in connection with the transactions contemplated hereby have not been subjected to independent verification by Casimir, and that Casimir makes no representation or warranty with respect to the accuracy or completeness of such information, data or other related disclosure material. The Subscriber further acknowledges that in making its decision to enter into this Agreement and purchase the Unit Securities it has relied on its own examination of the Company and the terms of, and consequences, of holding the Unit Securities. The Subscriber further acknowledges that the provisions of this Section 2.10 are for the benefit of, and may be enforced by, Casimir.

2.11 NOT A REGISTERED REPRESENTATIVE. The Subscriber acknowledges that if he or she is a Registered Representative of an NASD member firm, he or she must give such firm the notice required by the NASD's Rules of Fair Practice, receipt of which must be acknowledged by such firm in the Confidential Investor Questionnaire.

2.12 INDEMNIFICATION. The Subscriber agrees to hold the Company and its directors, officers, employees, controlling persons and agents (including Casimir and its officers, directors, partners, employees, counsel, controlling persons and agents) and their respective heirs, representatives, successors and assigns harmless and to indemnify them against all liabilities, costs, and expenses incurred by them as a result of, (i) any misrepresentation made by the Subscriber contained in this Agreement (including the Confidential Investor Questionnaire, (ii) any sale or distribution by the Subscriber in violation of the Securities Act or any applicable state securities or "blue sky" laws or
(iii) any untrue statement of a material fact made by the Subscriber and contained herein.

2.13 AFFILIATE INVESTMENTS. Subscriber acknowledges and understands that certain affiliates of Casimir may purchase Unit Securities in the Offering.

4

ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company represents and warrants to the Subscribers and Casimir that:

3.1 ORGANIZATION AND QUALIFICATION. The Company is duly incorporated, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted. The Company is duly qualified to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except where the failure to be so qualified or in good standing would not have a Material Adverse Effect. The Company has no direct or indirect subsidiaries.

3.2 AUTHORIZATION; ENFORCEMENT. (a) The Company has all requisite corporate power and authority to conduct the Offering as contemplated in the Offering Memorandum and to enter into and to perform its obligations under this Agreement, the Placement Agent Agreement, Escrow Agreement, Right of First Refusal Agreement and Mergers and Acquisition Agreement (collectively, the "Transaction Documents"), to consummate the transactions contemplated hereby and thereby and to issue the Unit Securities in accordance with the terms hereof, and to issue the Placement Agent Warrants and Initiation Warrants in accordance with the Placement Agent Agreement, and to issue the shares of Common Stock underlying the Placement Agent Warrants and Initiation Warrants; (b) the execution, delivery and performance of the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation the issuance of the Securities) have been duly authorized by the Company's Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required; (c) Each of the Transaction Documents has been duly executed by the Company; and (d) Each of Transaction Documents constitutes a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws affecting the rights of creditors generally and the application of general principles of equity.

3.3 CAPITALIZATION. The authorized and issued capitalization of the Company is as set forth in the Offering Memorandum. All outstanding shares of Common Stock are, and all shares which may be issued pursuant to the Transaction Documents or otherwise will be, when issued, duly authorized, validly issued, fully paid and nonassessable and will not be subject to preemptive rights. Except as set forth on SCHEDULE 3.3, there are not issued, reserved for issuance or outstanding (a) any shares of capital stock or other voting securities of the Company, (b) any securities of the Company convertible into or exchangeable or exercisable for shares of capital stock or voting securities of the Company, (c) any warrants, calls, options or other rights to acquire from the Company, and any obligation of the Company to issue, any capital stock, voting securities or securities convertible into or exchangeable or exercisable for capital stock or voting securities of the Company.

3.4 ISSUANCE OF SECURITIES. The shares of Common Stock of the Company purchased under this Agreement, and the shares of Common Stock issuable upon exercise of the Warrants, Placement Agent Warrants and Initiation Warrants, including such indeterminate number of shares of Common Stock as may be issued as a result of the anti-dilution provisions contained therein (collectively, the "Warrant Shares"), are duly authorized and, upon issuance in accordance with the terms of this Agreement, the Placement Agent Warrants and Initiation Warrants, as the case may be, will be validly issued, fully paid and non-assessable, free from all taxes, liens, claims, encumbrances and charges with respect to the issue thereof, will not be subject to preemptive rights or other similar rights of stockholders of the Company, and will not impose personal liability on the

5

holders thereof. The Company has a sufficient number of authorized but unissued shares of Common Stock, assuming the Maximum Offering, giving effect to (i) the exercise of the Warrants, Placement Agent Warrants and Initiation Warrants and
(ii) the conversion, exercise and/or exchange of all other securities outstanding on the date hereof, which are convertible, exercisable or exchangeable for shares of Common Stock. As of the First Closing Date and for as long as the Warrants, Placement Agent Warrants and Initiation Warrants are outstanding, the Company shall have reserved a sufficient number of Warrant Shares to be issued upon exercise of the Warrants, Placement Agent Warrants and Initiation Warrants.

3.5 NO CONFLICTS; NO VIOLATION.

(a) Other than as set forth in SCHEDULE 3.5, the execution, delivery and performance of each of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby
(including, without limitation, the issuance of the Securities) will not (i) conflict with or result in a violation of any provision of its Certificate of Incorporation or Bylaws, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment (including without limitation, the triggering of any anti-dilution or right of first refusal provision), acceleration or cancellation of, any agreement, indenture, patent, patent license, or instrument to which the Company is a party ( any one or all being referred to as a "Company Obligation"), or (iii) to the best of the Company's knowledge, result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or by which any property or asset of the Company is bound or affected (except for such conflicts, breaches, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect).

(b) The Company is not in violation of its Articles of Incorporation, Bylaws or other organizational documents and is not in default (and no event has occurred which with notice or lapse of time or both could put the Company in default) under any Company Obligation to which it is a party or by which any property or assets of the Company is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect, nor is any other party in violation and/or breach of any such Company Obligation. Each such Company Obligation is the legal, valid and binding obligation of the Company enforceable in accordance with its terms.

(c) The Company is not conducting its business in violation of any law, ordinance or regulation of any governmental entity, the failure to comply with which would, individually or in the aggregate, have a Material Adverse Effect.

(d) Except as specifically contemplated by this Agreement and as required under the Securities Act and any applicable state securities laws or any listing agreement with any securities exchange or automated quotation system, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self regulatory agency in order for it to execute, deliver or perform any of its obligations under any of the Transaction Documents in accordance with the terms hereof and thereof, or to issue and sell the Unit Securities or Securities in accordance with the terms hereof and thereof. All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof.

6

3.6 SEC DOCUMENTS, FINANCIAL STATEMENTS. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC since September 30, 2000, pursuant to the reporting requirements of the Exchange Act (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred to as the "SEC Documents"). Each Subscriber has had access to, true and complete copies of the SEC Documents. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange Act or the Securities Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted stating a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with U.S. generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as set forth in the financial statements included in the SEC Documents, the Company has no liabilities, contingent or otherwise, other than liabilities incurred in the ordinary course of business subsequent to December 31, 2003 and liabilities of the type not required under generally accepted accounting principles to be reflected in such financial statements. Such liabilities incurred subsequent to December 31, 2003 are not, in the aggregate, material to the financial condition or operating results of the Company.

3.7 ABSENCE OF CERTAIN CHANGES. Except as disclosed in the SEC Documents or on SCHEDULE 3.7, Since December 31, 2003, there has been no material adverse change in the assets, liabilities, business, properties, operations, financial condition, prospects or results of operations of the Company, except that the Company has continued losses from operations.

3.8 DISCLOSURE. None of the Offering Documents contains or will contain during the Offering Period any untrue statement of a material fact or omits or will omit to state a material fact necessary in order to make the statements contained herein and therein not misleading, in light of the circumstances under which they were made.

3.9 ABSENCE OF LITIGATION. Except as disclosed in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or its officers or directors acting as such that could, individually or in the aggregate, have a Material Adverse Effect.

3.10 INTELLECTUAL PROPERTY. The Company owns or possesses adequate and enforceable rights to use all material patents, patent applications, trademarks, service marks, trade names, logos, corporate names, copyrights, trade secrets, processes, mask works, licenses, inventions, formulations, technology and

7

know-how and other intangible property used or proposed to be used in the conduct of the Company's business as currently conducted or as proposed to be conducted (the "Proprietary Rights"). The Company or the entities from whom the Company has acquired rights has taken all necessary action to protect all of the Company's Proprietary Rights. The Company has not received any notice of, and there are not any facts known to the Company which indicate the existence of (i) any infringement or misappropriation by any third party of any of the Proprietary Rights, (ii) any claim by a third party contesting the validity of any of the Proprietary Rights or (iii) any infringement, misappropriation or violation by the Company or any of its employees of any Proprietary Rights of third parties. To the best of the Company's knowledge, neither the Company nor any of its employees has infringed, misappropriated or otherwise violated any Proprietary Rights of any third parties. To the Company's knowledge, no infringement, illicit copying, misappropriation or violation of any intellectual property rights of any third party has occurred or will occur with respect to any products currently being sold by the Company or with respect to any products currently under development by the Company or with respect to the conduct of the business of the Company or as currently contemplated. The Company is not aware that any of its employees are obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with the use of the employee's best efforts to promote the interests of the Company or that would conflict with the business of the Company as currently conducted or as proposed to be conducted. To the Company's knowledge, neither the execution and delivery of this Agreement, nor the carrying on of the business of the Company by the employees of the Company, nor the conduct of the business of the Company, as currently conducted or as proposed to be conducted, will conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee is now obligated.

3.11 TAX STATUS. The Company has made or filed all federal, state and foreign income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has timely paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith, and has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. To the knowledge of the Company, there are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign, federal, state or local tax. None of the Company's tax returns is presently being audited by any taxing authority.

3.12 ENVIRONMENTAL LAWS. To the best the Company's knowledge, the Company
(i) is in compliance with all applicable foreign federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants ("Environmental Laws"), (ii) has received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct business and (iii) is in compliance with all terms and conditions of any such permit, license or approval where, in each of the three foregoing clauses, the failure to so comply would have, individually or in the aggregate, a Material Adverse Effect

3.13 NO INTEGRATED OFFERING. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to

8

buy any security under circumstances that would require registration under the Securities Act of the issuance of the Securities to the Subscribers. The issuance of the Securities to the Subscribers will not be integrated with any other issuance of the Company's securities (past, current or future) for purposes of the Securities Act or any applicable rules of Nasdaq.

3.14 NO BROKERS. Neither the Company nor any officer or director has taken any action which would give rise to any claim by any person or entity for brokerage commissions, finder's fees or similar payments relating to this Agreement or the transactions contemplated hereby, except for dealings with Casimir, whose commissions and fees will be paid by the Company. Similarly, neither the Company nor any officer or director has taken any action which would give rise to any claim or right of any person or entity to participate or act as agent in the Offering, or otherwise generate any fees.

3.15 INSURANCE. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company is engaged.

3.16 EMPLOYMENT MATTERS. The Company is in compliance with all federal, state, local and foreign laws and regulations respecting employment and employment practices, terms and conditions of employment and wages and hours except where failure to be in compliance would not have a Material Adverse Effect. The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the Company's knowledge, has sought to represent any of the employees, representatives or agents of the Company. The Company is not aware that any officer or key employee, or that any group of officers or key employees, intends to terminate their employment with the Company, nor does the Company have a present intention to terminate the employment of any of the foregoing.

3.17 INVESTMENT COMPANY STATUS. The Company is not and upon consummation of the sale of the Unit Securities will not be an "investment company," a company controlled by an "investment company" or an "affiliated person" of, or "promoter" or "principal underwriter" for, an "investment company" as such terms are defined in the Investment Company Act of 1940, as amended.

3.18 SUBSIDIARIES. Except as disclosed in the SEC Documents, the Company does not presently own or control, directly or indirectly, any interest in any other corporation, association, joint venture, partnership or other business entity and the Company is not a direct or indirect participant in any joint venture or partnership.

3.19 NO CONFLICT OF INTEREST; TRANSACTIONS WITH AFFILIATE. Except as set forth in the SEC Documents, The Company is not indebted, directly or indirectly, to any of its beneficial holders of five percent (5%) or more of the Company's outstanding Common Stock ("Principal Stockholders") or officers or directors or to their respective spouses or children, in any amount. None of the Company's officers, directors, Principal Stockholders or employees, or any members of their immediate families, are directly, or indirectly, indebted to the Company or, to the best of the Company's knowledge, have any direct or indirect ownership interest in any entity with which the Company is affiliated or with which the Company has a business relationship, or any entity which competes with the Company, except that officers, directors, employees and/or Principal Stockholders of the Company may own stock in (but not exceeding five percent (5%) of the outstanding capital stock of) any publicly traded company that may compete with the Company. To the best of the Company's knowledge, none of the Company's officers, directors, Principal Stockholders or employees or any

9

members of their immediate families are, directly or indirectly, a party to or interested in any material contract with the Company or any Subsidiary. The Company is not a guarantor or indemnitor of any indebtedness of any other person or entity.

3.20 COMPLIANCE WITH SARBANES OXLEY. To the best of its knowledge, the Company is in compliance with the Sarbanes Oxley Act of 2002.

3.21 REGISTRATION RIGHTS; SB-2 REGISTRATION STATEMENT. Except as disclosed in SCHEDULE 3.21, none of the Company's security holders have any registration rights, including any right to effect a demand or shelf-registration under the Securities Act or exercise any "piggyback" registration rights with respect to any filing under the Securities Act. The Company satisfies all requirements necessary in order to file a registration statement with the SEC on Form SB-2 under the Securities Act.

3.22 ACKNOWLEDGEMENTS REGARDING CASIMIR. The Company acknowledges that Casimir, in acting as Placement Agent for the Unit Securities offered hereby in accordance with the terms of Section 2 of the Placement Agent Agreement is relying on the representations and warranties contained in this Section 3 and that such provisions of this Section 3 are for the benefit of Casimir (in addition to the Subscribers), and may be enforced by Casimir.

ARTICLE IV
COVENANTS

4.1 COVENANTS OF THE COMPANY.

(a) FORM D; BLUE SKY LAWS. The Company will timely file a Notice of Sale of Securities on Form D with respect to the Unit Securities, as required under Regulation D. The Company will, on or before the Closing Date, take such action as it reasonably determines to be necessary to qualify the Unit Securities for sale to the Unit Subscribers under this Agreement under applicable securities (or "blue sky") laws of the states of the United States (or to obtain an exemption from such qualification).

(b) REPORTING STATUS. The Company's Common Stock is registered under
Section 12 of the Exchange Act. During the period commencing on the date of the First Closing until the expiration of the Registration Period (as defined below), the Company will timely file all reports, schedules, forms, statements and other documents required to be filed by it with the SEC under the reporting requirements of the Exchange Act, and the Company will not terminate its status as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would permit such termination.

(c) EXPENSES. The Company and each Subscriber is liable for, and will pay, its own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement and the transactions contemplated hereby, including, without limitation, attorneys' and consultants' fees and expenses.

(d) FINANCIAL INFORMATION. The financial statements of the Company will be prepared in accordance with United States generally accepted accounting principles, consistently applied, and will fairly present in all material respects the consolidated financial position of the Company and results of its operations and cash flows as of, and for the periods covered by, such financial statements (subject, in the case of unaudited statements, to normal year-end audit adjustments).

10

(e) COMPLIANCE WITH LAW. As long as any Registrable Securities (as hereinafter defined) are held by a Subscriber the Company will conduct its business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business (including, without limitation, all applicable local, state and federal environmental laws and regulations), the failure to comply with which would have a Material Adverse Effect.

(f) NO INTEGRATION. The Company will not make any offers or sales of any security (other than the Unit Securities) under circumstances that would cause the offering of the Unit Securities to be integrated with any other offering of securities by the Company (i) for the purpose of any stockholder approval provision applicable to the Company or its securities or (ii) for purposes of any registration requirement under the Securities Act.

4.2 COVENANTS OF SUBSCRIBERS.

(a) SALES BY SUBSCRIBERS. Each Subscriber covenants to sell any Unit Securities sold by it in compliance with applicable prospectus delivery requirements, if any, or otherwise in compliance with the requirements for an exemption from registration under the Securities Act and the rules and regulations promulgated thereunder. No Subscriber will make any sale, transfer or other disposition of the Unit Securities in violation of federal or state securities laws.

(b) NO VOTING AGREEMENT. Each Subscriber covenants and agrees with the Company that, so long as such Subscriber holds any of the Unit Securities, such subscriber shall refrain from entering into any voting agreement with any other Subscriber or any third-party, including without limitation Casimir.

ARTICLE V
REGISTRATION RIGHTS

5.1 DEFINITIONS. As used in this Agreement, the following terms shall have the following meanings:

(a) "AFFILIATE" shall mean, with respect to any Person (as defined below), any other Person controlling, controlled by or under direct or indirect common control with such Person (for the purposes of this definition "control," when used with respect to any specified Person, shall mean the power to direct the management and policies of such person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise; and the terms "controlling" and "controlled" shall have meanings correlative to the foregoing).

(b) "BUSINESS DAY" shall mean a day Monday through Friday on which banks are generally open for business in New York.

(c) "HOLDERS" shall mean the Subscribers, holders of the Placement Agent Warrants, holders of the Initiation Warrants and the holders of the Common Stock issued upon the exercise of the Placement Agent Warrants and Initiation Warrants, any person holding Registrable Securities, or any person to whom the rights under Article V have been transferred in accordance with Section 5.8 hereof.

(d) "PERSON" shall mean any person, individual, corporation, limited liability company, partnership, trust or other nongovernmental entity or any governmental agency, court, authority or other body (whether foreign, federal, state, local or otherwise).

(e) The terms "REGISTER," "REGISTERED" and "REGISTRATION" refer to the registration effected by preparing and filing a registration statement in

11

compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement.

(f) "REGISTRABLE SECURITIES" shall mean (i) the shares of Common Stock included in the Units; (ii) the shares of Common Stock issuable upon exercise of the Warrants included in the Units; (iii) the shares of Common Stock issuable upon exercise of the Placement Agent Warrants and the Initiation Warrants; and (iv) any shares of Common Stock issued as (or issuable upon the conversion of any warrant, right or other security which is issued as) a dividend, distribution or split, recapitalization, merger, consolidation, any reorganization of or other distribution with respect to or in replacement of the Common Stock, Warrants, Placement Warrants and/or Initiation Warrants; provided, however, that securities shall only be treated as Registrable Securities if and only for so long as they (a) have not been disposed of pursuant to a registration statement declared effective by the SEC, (b) have not been sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale or (c) are held by a Holder or a permitted transferee pursuant to Section 5.8.

(g) "REGISTRATION EXPENSES" shall mean all expenses incurred by the Company in complying with Section 5.2 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, listing fees, escrow fees, fees and expenses of counsel for the Company, blue sky fees and expenses, the expense of any special audits incident to or required by any such registration.

(h) "REGISTRATION PERIOD" shall have the meaning ascribed to such term in Section 5.4(a).

(i) "REGISTRATION STATEMENT" shall mean any registration statement filed with the SEC in accordance with Sections 5.2(a) and (b) herein.

(j) "SELLING EXPENSES" shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all fees and expenses of legal counsel for any Holder, other than as provided in paragraph (g) above.

5.2 REGISTRATION RIGHTS. (a) No later than 60 days after the Final Closing Date (the "Filing Date"), the Company shall file a Registration Statement on Form SB-2 or if unavailable another appropriate registration document, covering the Registrable Securities with the SEC and use its best efforts to effect the registration, qualifications or compliances (including, without limitation, the execution of any required undertaking to file post-effective amendments, appropriate qualifications or exemptions under applicable blue sky or other state securities laws and appropriate compliance with applicable securities laws, requirements or regulations) prior to the date which is 60 days after the Filing Date ("Effective Date").

(b) From and after the Final Closing Date if the Company shall determine to proceed with the preparation and filing of a Registration Statement in connection with the proposed offer and sale of any of its securities by it or any of its security holders (other than a registration statement on Form S-4, S-8 or other limited purpose form), the Company will give written notice of its determination to all Holders. Upon receipt of a written request from any such holder within thirty (30) days after receipt of any such notice from the Company, the Company will cause all the Registrable Securities owned by such holders to be included in such Registration Statement, all to the extent requisite to permit the sale or other disposition by the prospective seller or

12

sellers of the Registrable Securities to be so registered. If any registration pursuant to this Section 5.2(b) shall be underwritten in whole or in part, the Company may require that the Registrable Securities requested for inclusion pursuant to this Section 5.2(b) be included in the underwriting on the same terms and conditions as the securities otherwise being sold through the underwriters. The obligation of the Company under this Section 5.2(b) shall be unlimited as to the number of Registration Statements to which it applies.

5.3 REGISTRATION EXPENSES. All Registration Expenses incurred in connection with any registration, qualification, exemption or compliance pursuant to Section 5.2 shall be borne by the Company. All Selling Expenses relating to the sale of securities registered by or on behalf of Holders shall be borne by such Holders pro rata on the basis of the number of securities so registered.

5.4 COMPANY OBLIGATIONS. In the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this Agreement, the Company shall, upon reasonable request, inform each Holder as to the status of such registration, qualification, exemption and compliance. At its expense the Company shall:

(a) use its best efforts to keep any such registration under Sections 5.2(a) and (b), and any qualification, exemption compliance under state securities laws which the Company determines to obtain, continuously effective until the Holders have completed the distribution described in the registration statement relating thereto. The period of time during which the Company is required hereunder to keep any Registration Statement effective is referred to herein as "the Registration Period." Notwithstanding the foregoing, at the Company's election, the Company may cease to keep such registration, qualification, exemption or compliance effective with respect to any Registrable Securities, and the registration rights of a Holder shall expire, at such time as the earlier of (i) the date on which all the Holders have completed the distribution of the Registrable Securities, or (ii) the date all Registrable Securities may be sold under Rule 144 during any ninety (90) day period; and

(b) advise the Holders:

(i) when the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective amendment thereto has become effective;

(ii) of any request by the SEC for amendments or supplements to the Registration Statement or the prospectus included therein or for additional information;

(iii) of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for such purpose;

(iv) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

(v) of the happening of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements

13

therein (in the case of the prospectus, in the light of the circumstances under which they were made) not misleading;

(c) make every reasonable effort to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement at the earliest possible time;

(d) furnish to each Holder, without charge, at least one copy of such Registration Statement and any post-effective amendment thereto, including financial statements and schedules, and, if the Holder so requests in writing, all exhibits (including those incorporated by reference) in the form filed with the SEC;

(e) during the Registration Period, deliver to each Holder, without charge, as many copies of the prospectus included in such Registration Statement and any amendment or supplement thereto as such Holder may reasonably request; and the Company consents to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto by each of the selling Holders of Registrable Securities in connection with the offering and sale of the Registrable Securities covered by the prospectus or any amendment or supplement thereto. In addition, upon the reasonable request of the Holder and subject in all cases to confidentiality protections reasonably acceptable to the Company, the Company will meet with a Holder or a representative thereof at the Company's headquarters to discuss all information relevant for disclosure in the Registration Statement covering the Registrable Securities, and will otherwise cooperate with any Holder conducting an investigation for the purpose of reducing or eliminating such Holder's exposure to liability under the Securities Act, including the reasonable production of information at the Company's headquarters;

(f) during the Registration Period, deliver to each Holder, without charge, (i) as soon as practicable (but in the case of the annual report of the Company to its stockholders, within 120 days after the end of each fiscal year of the Company) one copy of the following documents, other than those documents available via EDGAR: (A) its annual report to its stockholders, if any (which annual report shall contain financial statements audited in accordance with generally accepted accounting principles in the United States of America by a firm of certified public accountants of recognized standing); (B) if not included in substance in its annual report to stockholders, its annual report on Form 10-KSB (or similar form); (C) each of its quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly report on Form 10-QSB (or similar form), and (D) a copy of the full Registration Statement (the foregoing, in each case, excluding exhibits); and (ii) upon reasonable request, all exhibits excluded by the parenthetical to the immediately preceding clause (E), and all other information that is generally available to the public;

(g) prior to any public offering of Registrable Securities pursuant to any Registration Statement, register or qualify or obtain an exemption for offer and sale under the securities or blue sky laws of such jurisdictions as any such Holders reasonably request in writing, provided that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction, and do any and all other acts or things reasonably necessary or advisable to enable the offer and sale in such jurisdictions of the Registrable Securities covered by such Registration Statement;

14

(h) cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold pursuant to any Registration Statement free of any restrictive legends to the extent not required at such time and in such denominations and registered in such names as Holders may request at least five (5) business days prior to sales of Registrable Securities pursuant to such Registration Statement;

(i) upon the occurrence of any event contemplated by Section 5.4(b)(v) above, the Company shall prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to subscribers of the Registrable Securities included therein, the prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading;

(j) in the event that a registration involves an underwritten offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, including, without limitation, customary indemnification and contribution obligations, with the managing underwriting underwriter or such offering;

(k) notify the security holders participating in such registration and the Placement Agent, promptly after it shall receive notice thereof, of the time when the Registration Statement has become effective or a supplement to any prospectus forming a part of the Registration Statement has been filed;

(l) at the request of holders of a majority of the Registrable Securities included in the Registration Statement, furnish to the underwriters on the date that the Registrable Securities are delivered to underwriters for sale in connection with a Registration Statement: (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters and (ii) a letter dated such date, from the independent certified accountants of the Company, in form an substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters;

(m) make available for inspection by any underwriters participating in an offering covering Registrable Securities, and the counsel, accountants or other agents retained by any such underwriter, all pertinent financial and other records, corporate documents, and properties of the Company, and cause the Company's officers, directors and employees to supply all information reasonably requested by any such underwriters in connection with such offering;

(n) if the Common Stock is then listed on a national securities exchange, cause the Registrable Securities to be listed on such exchange, or if reported on NASDAQ, to be reported on NASDAQ. If the Common Stock is not then listed on a national securities exchange or reported on NASDAQ, facilitate the reporting of the Registrable Securities on NASDAQ; and:

(o) provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the Registration Statement in which Registrable Securities are included.

5.5 INDEMNIFICATION. (a) To the extent permitted by law, the Company shall indemnify each Holder, each underwriter of the Registrable Securities and each person controlling such Holder within the meaning of Section 15 of the Act, with

15

respect to which any registration, qualification or compliance has been effected pursuant to this Agreement, against all claims, losses, damages and liabilities (or action in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to Section 5.5(c) below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus or offering circular, or any amendment or supplement thereof, incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they were made, and will reimburse each Holder, each underwriter of the Registrable Securities and each person controlling such Holder, for reasonable legal and other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action as incurred; provided that the Company will not be liable in any such case to the extent that any untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Holder and stated to be specifically for use in preparation of such registration statement, prospectus or offering circular; provided that the Company will not be liable in any such case where the claim, loss, damage or liability arises out of or is related to the failure of the Holder to comply with the covenants and agreements contained in this Agreement respecting sales of Registrable Securities, and except that the foregoing indemnity agreement is subject to the condition that, insofar as it relates to any such untrue statement or alleged untrue statement or omission or alleged omission made in the preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time the registration statement becomes effective or in the amended prospectus filed with the SEC pursuant to Rule 424(b) or in the prospectus subject to completion and term sheet under Rule 434 of the Act, which together meet the requirements of Section 10(a) of the Act (the "Final Prospectus"), such indemnity agreement shall not inure to the benefit of any such Holder, any such underwriter or any such controlling person, if a copy of the Final Prospectus furnished by the Company to the Holder for delivery was not furnished to the person or entity asserting the loss, liability, claim or damage at or prior to the time such furnishing is required by the Securities Act and the Final Prospectus would have cured the defect giving rise to such loss, liability, claim or damage.

(b) Each Holder will severally, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter of the Registrable Securities and each person who controls the Company within the meaning of Section 15 of the Act, against all claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to Section 5.5(c) below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus or offering circular, or any amendment or supplement thereof, incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they were made, and will reimburse the Company, such directors and officers, each underwriter of the Registrable Securities and each person controlling the Company for reasonable legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action as incurred, in each case to the extent, but only to the extent, that such untrue statement or omission or

16

allegation thereof is made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Holder and stated to be specifically for use in preparation of such registration statement, prospectus or offering circular; provided that the indemnity shall not apply to the extent that such claim, loss, damage or liability results from the fact that a current copy of the prospectus was not made available to the Holder and such current copy of the prospectus would have cured the defect giving rise to such loss, claim, damage or liability. Notwithstanding the foregoing, in no event shall a Holder be liable for any such claims, losses, damages or liabilities in excess of the proceeds received by such Holder in the offering, except in the event of fraud by such Holder.

(c) Each party entitled to indemnification under this Section 5.5 (the "Indemnified Party") shall give notice to the party required to provide indemnification (the "Indemnifying Party") promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such Indemnified Party's expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement, unless such failure is materially prejudicial to the Indemnifying Party in defending such claim or litigation. An Indemnifying Party shall not be liable for any settlement of an action or claim effected without its written consent (which consent will not be unreasonably withheld).

(d) If the indemnification provided for in this Section 5.5 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

5.6 HOLDER OBLIGATIONS. (a) Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event requiring the preparation of a supplement or amendment to a prospectus relating to Registrable Securities so that, as thereafter delivered to the Holders, such prospectus shall not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, each Holder will forthwith discontinue disposition of Registrable Securities pursuant to the registration statement contemplated by
Section 5.2 until its receipt of copies of the supplemented or amended prospectus from the Company and, if so directed by the Company, each Holder shall deliver to the Company all copies, other than permanent file copies then in such Holder's possession, of the prospectus covering such Registrable Securities current at the time of receipt of such notice.

17

(b) As a condition to the inclusion of its Registrable Securities, each Holder shall furnish to the Company such information regarding such Holder and the distribution proposed by such Holder as the Company may request in writing or as shall be required in connection with any registration, qualification or compliance referred to in this Article V.

(c) Each Holder agrees not to take any action with respect to any distribution deemed to be made pursuant to such Registration Statement which would constitute a violation of Regulation M under the Exchange Act or any other applicable rule, regulation or law.

5.7 COMPANY REPORTING OBLIGATIONS. With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which at any time permit the sale of the Registrable Securities to the public without registration, the Company shall use its reasonable best efforts to:

(a) make and keep public information available, as those terms are understood and defined in Rule 144 under the Act, at all times;

(b) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and

(c) so long as a Holder owns any unregistered Registrable Securities, furnish to such Holder, upon any reasonable request, a written statement by the Company as to its compliance with Rule 144 under the Securities Act, and of the Exchange Act, a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company as such Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing a Holder to sell any such securities without registration.

5.8 TRANSFER OF REGISTRATION RIGHTS. The rights to cause the Company to register Registrable Securities granted to the Holders by the Company under
Section 5.2 may be assigned in full by a Holder in connection with a transfer by such Holder of its Registrable Securities. The obligations of the Company contained in this Article V shall be binding upon any successor to the Company and continue to be in effect with respect to any securities issued by any successor to the Company in substitution or exchange for any Registrable Securities.

5.9 WAIVER OR AMENDMENT. With the written consent of the Company and the Holders holding at least a majority of the Registrable Securities that are then outstanding and/or securities convertible into or exercisable for Registrable Securities, any provision of this Article V may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely) or amended. Upon the effectuation of each such waiver or amendment, the Company shall promptly give written notice thereof to the Holders, if any, who have not previously received notice thereof or consented thereto in writing.

5.10 PENALTY UPON DELAY OF REGISTRATION FILING. Except to the extent any delay is solely and directly due to the failure of a Holder to reasonably cooperate in providing to the Company such information as shall be reasonably requested by the Company in writing for use in the Registration Statement contemplated by Section 5.2(a), if such Registration Statement is not filed with the SEC by the Filing Date or effective prior to the Effective Date, the Company shall immediately pay to each Holder of Registrable Securities issued in the Offering an amount in cash equal to one percent (1%) per month, or fraction thereof, of such Holder's aggregate investment until the Registration Statement is filed with the SEC or is declared effective by the SEC, as applicable. If the

18

Company fails to pay any liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 15% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to each Holder, accruing daily from the date such liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The liquidated damages pursuant to the terms hereof shall apply on a pro-rata basis for any portion of a month prior to the filing or effectiveness of the Registration Statement, as applicable.

5.11 CASIMIR RELIANCE. The Company acknowledges that the holders of the Placement Agent Warrants and Initiation Warrants (and the holders of the underlying shares of Common Stock) are relying on the Company's obligations in this Article V and that the provisions contained in this Article V are for the benefit of and may be enforced by such Holders.

ARTICLE VI
DEFINITIONS

6.1 "Closing" means the closing of the purchase and sale of the Unit Securities under this Agreement.

6.2 "Common Stock" means the common stock, par value $0.01 per share, of the Company.

6.3 "Company" means National Scientific Corporation.

6.4 "Exchange Act" means the Securities Exchange Act of 1934, as amended.

6.5 "Final Closing Date" means the last Closing of the Offering in the event there is more than one Closing.

6.6 "Initiation Warrants" mean Warrants to purchase an aggregate of 500,000 shares of Common Stock issued to Casimir as an initiation fee in connection with the Offering.

6.7 "Subscribers" means the Subscribers whose names are set forth on the signature pages of this Agreement, and their transferees.

6.8 "Material Adverse Effect" means a material adverse effect on (a) the business, prospects, operations, assets or financial condition of the Company, when taken as a whole, or (b) the ability of the Company to perform its obligations pursuant to the transactions contemplated by this Agreement or under any instruments to be entered into or filed in connection herewith.

6.9 "Mergers and Acquisition Agreement" means the agreement to be delivered by the Company pursuant to Section 4(f) of the Placement Agent Agreement.

6.10 "Placement Agent Agreement" means the agreement by and between the Company and the Placement Agent with respect to the Offering.

6.11 "Placement Agent Warrants" means the Warrants issued to the Placement Agent pursuant to the Placement Agent Agreement.

6.12 "Regulation D" means Regulation D as promulgated under by the SEC under the Securities Act.

19

6.13 "Right of First Refusal Agreement" means the agreement to be delivered by the Company pursuant to Section 4(e) of the Placement Agent Agreement.

6.14 "Rule 144" means Rule 144 promulgated under the Securities Act, or any successor rule.

6.15 "SEC" means the United States Securities and Exchange Commission.

6.16 "SEC Documents" has the meaning set forth in Section 3.6.

6.17 "Securities" means the Unit Securities, Placement Agent Warrants, Initiation Warrants and shares of Common Stock issuable upon exercise of the Placement Agent Warrants and Initiation Warrants.

6.18 "Securities Act" means the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute.

6.19 "Warrant Shares" means the shares of Common Stock issuable upon exercise of the Warrants, Placement Agent Warrants and Initiation Warrants.

ARTICLE VII
GOVERNING LAW; MISCELLANEOUS

7.1 GOVERNING LAW; JURISDICTION. This Agreement will be governed by and interpreted in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The parties hereto hereby submit to the exclusive jurisdiction of the United States federal and state courts located in the State of New York with respect to any dispute arising under this Agreement or the transactions contemplated hereby or thereby.

7.2 COUNTERPARTS; SIGNATURES BY FACSIMILE. This Agreement may be executed in two or more counterparts, all of which are considered one and the same agreement and will become effective when counterparts have been signed by each party and delivered to the other parties. This Agreement, once executed by a party, may be delivered to the other parties hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

7.3 HEADINGS. The headings of this Agreement are for convenience of reference only, are not part of this Agreement and do not affect its interpretation.

7.4 SEVERABILITY. If any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision will be deemed modified in order to conform with such statute or rule of law. Any provision hereof that may prove invalid or unenforceable under any law will not affect the validity or enforceability of any other provision hereof.

7.5 ENTIRE AGREEMENT; AMENDMENTS. This Agreement (including all schedules and exhibits hereto) constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein or therein. This Agreement supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter hereof. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged with enforcement.

7.6 NOTICES. Any notices required or permitted to be given under the terms of this Agreement must be sent by certified or registered mail (return receipt

20

requested) or delivered personally or by courier (including a recognized overnight delivery service) and will be effective five days after being placed in the mail, if mailed by regular U.S. mail, or upon receipt, if delivered personally, or by courier (including a recognized overnight delivery service), in each case addressed to a party. The addresses for such communications are:

If to the Company:     National Scientific Corporation
                       14455 N. Hayden Road
                       Suite 202
                       Scottsdale, AZ  85620

If to a Subscriber:    To the address set forth immediately below such
                       Subscriber's name on the signature pages hereto.

Each party will provide written notice to the other parties of any change in its address.

7.7 SUCCESSORS AND ASSIGNS. This Agreement is binding upon and inures to the benefit of the parties and their successors and assigns. The Company will not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Subscribers, and no Subscriber may assign this Agreement or any rights or obligations hereunder without the prior written consent of the Company. Notwithstanding the foregoing, a Subscriber may assign all or part of its rights and obligations hereunder to any of its "affiliates," as that term is defined under the Securities Act, without the consent of the Company so long as the affiliate is an accredited subscriber (within the meaning of Regulation D under the Securities Act) and agrees in writing to be bound by this Agreement. This provision does not limit the Subscriber's right to transfer the Securities pursuant to the terms of this Agreement or to assign the Subscriber's rights hereunder to any such transferee pursuant to the terms of this Agreement.

7.8 THIRD PARTY BENEFICIARIES. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person other than as provided in Sections 3.22 and 5.11 herein.

7.9 FURTHER ASSURANCES. Each party will do and perform, or cause to be done and performed, all such further acts and things, and will execute and deliver all other agreements, certificates, instruments and documents, as another party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

7.10 NO STRICT CONSTRUCTION. The language used in this Agreement is deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

7.11 EQUITABLE RELIEF. The Company recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to the Subscribers and other beneficiaries hereof. The Company therefore agrees that the Subscribers and other beneficiaries hereof are entitled to seek temporary and permanent injunctive relief in any such case.

21

CONFIDENTIAL INVESTOR QUESTIONNAIRE

In connection with the purchase of Units of National Scientific Corporation, pursuant to the terms of the Confidential Offering Memorandum dated March 15, 2004, as it may be supplemented from time-to-time, the Subscriber represents and warrants that he, she or it comes within one category marked below, and that for any category marked, he, she or it has truthfully set forth, where applicable, the factual basis or reason the Subscriber comes within that category. ALL INFORMATION IN RESPONSE TO THIS SECTION WILL BE KEPT STRICTLY CONFIDENTIAL. The undersigned agrees to furnish any additional information that the Company deems necessary in order to verify the answers set forth below.

A. INDIVIDUAL INVESTORS: (Please INITIAL one or more of the following five statements)

1. _____ I certify that I am an accredited investor because I have had individual income (exclusive of any income earned by my spouse) of more than $200,000 in each of the most recent two years and I reasonably expect to have an individual income in excess of $200,000 for the current year.

2. _____ I certify that I am an accredited investor because I have had joint income with my spouse in excess of $300,000 in each of the most recent two years and reasonably expect to have joint income with my spouse in excess of $300,000 for the current year.

3. _____ I certify that I am an accredited investor because I have an individual net worth, or my spouse and I have a joint net worth, in excess of $1,000,000.

4. _____ I am a director or executive officer of National Scientific Corporation.

5. _____ I have individual net worth or my spouse and I have joint net worth of over $ 5,000,000.

B. PARTNERSHIPS, CORPORATIONS, TRUSTS OR OTHER ENTITIES: (Please INITIAL one of the following seven statements). The undersigned hereby certifies that it is an accredited investor because it is:

1. _____ an employee benefit plan whose total assets exceed $5,000,000;

2. _____ an employee benefit plan whose investments decisions are made by a plan fiduciary which is either a bank, savings and loan association or an insurance company (as defined in Section 3(a) of the Securities Act) or an investment adviser registered as such under the Investment Advisers Act of 1940;

3. _____ a self-directed employee benefit plan, including an Individual Retirement Account, with investment decisions made solely by persons that are accredited investors;

4. _____ an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, not formed for the specific purpose of acquiring the Units, with total assets in excess of $5,000,000;

22

5. _____ a corporation, partnership, limited liability company, limited liability partnership, other entity or similar business trust, not formed for the specific purpose of acquiring the Units, with total assets excess of $5,000,000;

6. _____ a trust, not formed for the specific purpose of acquiring the Units, with total assets exceed $5,000,000, whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of an investment in the Units; or

7. _____ an entity (including a revocable grantor trust but other than a conventional trust) in which each of the equity owners qualifies as an accredited investor under items A(1), (2) or (3) or item B(1) above.

NASD AFFILIATION

Are you affiliated or associated with an NASD member firm (please check one):

Yes _________ No __________

If Yes, please describe:


If Subscriber is a Registered Representative with an NASD member firm, have the following acknowledgment signed by the appropriate party:

The undersigned NASD member firm acknowledges receipt of the notice required by Article 3, Sections 28(a) and (b) of the Rules of Fair Practice.


Name of NASD Member Firm

By: ______________________________
Authorized Officer

Date: ____________________________

23

SIGNATURE

THE UNDERSIGNED IS INFORMED OF THE SIGNIFICANCE TO THE COMPANY AND CASIMIR OF THE FOREGOING REPRESENTATIONS AND ANSWERS CONTAINED IN THE CONFIDENTIAL SUBSCRIBER QUESTIONNAIRE AND SUCH ANSWERS HAVE BEEN PROVIDED UNDER THE ASSUMPTION THAT THE COMPANY AND CASIMIR WILL RELY ON THEM.

IF AN INDIVIDUAL:

Sign Name:
Print Name:

Date:

IF AN ENTITY (I.E., PARTNERSHIP, CORPORATION OR TRUST):

Name of Entity:

By:(Print Name)
Title:

Signature:

Date:

24

SUBSCRIPTION AGREEMENT SIGNATURE PAGE

NUMBER OF UNITS __________ X $0.11 = $____________ (THE "PURCHASE PRICE")

------------------------------------       -------------------------------------
Signature                                  Signature (if purchasing jointly)

------------------------------------       -------------------------------------
Name Typed or Printed                      Name Typed or Printed

------------------------------------       -------------------------------------
Entity Name                                Entity Name

------------------------------------       -------------------------------------
Address                                    Address

------------------------------------       -------------------------------------
City, State and Zip Code                   City, State and Zip Code

------------------------------------       -------------------------------------
Telephone-Business                         Telephone-Business

------------------------------------       -------------------------------------
Telephone-Residence                        Telephone-Residence

------------------------------------       -------------------------------------
Facsimile-Business                         Facsimile-Business

------------------------------------       -------------------------------------
Facsimile-Residence                        Facsimile-Residence

------------------------------------       -------------------------------------
Tax ID # or Social Security #              Tax ID # or Social Security #

Name in which securities should be issued:
                                           -------------------------------------

INVESTORS: YOU MUST COMPLETE THE CONFIDENTIAL INVESTOR QUESTIONNAIRE.

Dated: _____________, 2004

This Subscription Agreement is agreed to and accepted as of ____________________, 2004.

NATIONAL SCIENTIFIC CORPORATION

By:

Name: Michael A. Grollman Title: Chief Executive Officer and Chairman

25

THIS PAGE LEFT INTENTIONALLY BLANK

26

SCHEDULES TO SUBSCRIPTION AGREEMENT

SCHEDULE 3.3: Capitalization Reservations

The Capital Structure of the Company is described in the Company's Form 10-KSB for the year ended September 30, 2003, NSC'S Annual Proxy Report on Form 14A dated January 30, 2004, and Form 10-QSB for the three months ended December 31, 2003, filed February 13, 2004, which should be read in conjunction with this Schedule.

The tables below provide unaudited summary descriptions of total shares issued and outstanding, and of the options and warrants outstanding and of any other shares reservations as OF MARCH 15, 2004.

1.)  As of March 15, 2004,  Preferred  stock,  par value  $0.10;  4,000,000
shares authorized, and no shares issued or outstanding

2.)  As of March 15, 2004,  Common  stock,  par  value  $0.01;  120,000,000

shares authorized, and 73,814,465 shares issued and outstanding.

3.) Options Outstanding at March 15, 2004 (total plan authorized shares up to 7,000,000, of which as of March 15, 2004, the board has reserved a total of 4,000,000 shares).

                                                       Weighted   Weighted
                                           Number      Average    Average
                                             of        Exercise    Fair
                                           Shares       Price      Value
                                           --------------------------------

Options Outstanding, September 30, 2003    3,329,757   $   0.90   $    0.06
Granted                                      170,000       0.15        0.10
Exercised                                         --
Canceled                                     250,000       0.015       0.11
                                           --------------------------------

Options Outstanding, March 15, 2004        3,249,757   $   0.92   $    0.08
                                           ================================

4.) Warrants Outstanding at March 15, 2004

                                           Number of   Exercise  Expiration
                                             Shares      Price      Date
                                           --------------------------------
Outstanding at September 30, 2003          7,412,201
Exercised                                         --
Expired                                           --
New issues                                   275,000   $   0.50     6/06
                                             275,000   $   0.75     6/06
                                             640,000   $   0.13     1/07
                                             500,000   $   0.10     3/11
                                           --------------------------------
    Outstanding at March 15, 2004          9,102,201
                                           ================================

S-1

5.) Other Share Reservations as of March 15, 2004

The Company has issued a Convertible Note for $160,000 in January 2004 to a Private Investment Fund, as described in the Company's Form 10-KSB report for the period ending September 30, 2003. This Note has a feature that allows the holder of the Note to covert the Note into the Company's restricted common stock at approximately a 10% discount from the then-current market price of the Company's common stock during the life of the Note. As such, the Company has reserved approximately 1,200,000 shares in the case of this Note holder executing these rights. However, since the Company plans to pay off this Note in full with the proceeds from the First Closing of this Offering, and since the Company believes it unlikely these rights will be executed prior to this Note's full pay-off at that point, the Company fully expects that the shares reserved for this Convertible Note will not longer be reserved after the First Closing of this Offering.

Additionally, the Company has reserved approximately 1,000,000 shares of its common stock to address unknown issues, including antidilution provisions and other provisions associated with the Convertible Note from this Private Investment Fund.

SCHEDULE 3.5: Conflicts, Violations and Related Matters

Other than as listed herein below, as of March 15, 2004, the Transaction Documents issued by the Company will not (i) conflict with or result in a violation of any provision of its Articles of Incorporation or Bylaws, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment (including without limitation, the triggering of any anti-dilution or right of first refusal provision), acceleration or cancellation of, any agreement, indenture, patent, patent license, or instrument to which the Company is a party ( any one or all being referred to as a "Company Obligation"), or
(iii) to the best of the Company's knowledge, result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or by which any property or asset of the Company is bound or affected (except for such conflicts, breaches, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect):

1. The issuance of common stock and warrants at less than 13 cents per share may trigger the antidilution provisions of 640,000 warrants Private Investment Fund as described in the Company's Form 10-KSB report for the period ending September 30, 2003, and as described in Schedule 3.20. The cumulative effect of the triggering of these provisions, should they be so triggered, is expected to be equal to or less than the issuance of approximately an additional 100,000 shares of Common Stock to this Private Investment Fund, should this fund choose to execute these warrants, for a total of approximately 740,000 shares of common stock.

2. The issuance of common stock and warrants under this Offering may trigger the First Right of Refusal provisions a Private Investment Fund's investment in the Company in January 2004, as described in the Company's Form 10-KSB report for the period ending September 30, 2003. The Private Investment Fund has agreed to waive these rights as relates to this Offering.

S-2

SCHEDULE 3.7: Recent Material Adverse Changes

Other than as listed herein below, of as March 15, 2004, and since February 13, 2004, date of the Company's most recent period 10-QSB filing with the SEC, there has been no material adverse change in the assets, liabilities, business, properties, operations, financial condition, prospects or results of operations of the Company, except that the Company has continued losses from operations.

Recent Material Adverse Changes: None.

SCHEDULE 3.21: Registration Rights of Current Company Security holders

Other than as listed herein below, none of the Company's security holders have any special registration rights, including any rights to effect a demand or shelf-registration under the Securities Act or exercise any "piggyback" registration rights with respect to any filing under the Securities Act.

RIGHT HOLDER: Private Investment Fund SECURITY HELD: Warrants to purchase 640,000 shares of NSC restricted common stock at prices ranging from $0.13 to $0.15. These warrants expire in January 2007.
SUMMARY OF RIGHTS HELD: Piggyback registration rights, weighted average-based antidilution provision.
SPECIAL ISSUES WITH FUTURE RIGHTS: This investor also holds a Note from the Company, due in July of 2004, for $160,000. In the event that the Company does not pay this Note on time, which the Company intends to do, this investor will be granted an additional 640,000 warrants to purchase NSC restricted Common Stock at prices ranging from $0.13 to $0.15. These new warrants expire in January 2007. Additionally, this investor will be granted some demand registration rights for all warrants held in the event that the this Note is not paid by due date.

S-3

EXHIBIT 4.3

Form of Warrant Placement Agent to Purchase

W-___ Shares of Common Stock

NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND NEITHER THIS WARRANT NOR SUCH SHARES MAY BE SOLD, ENCUMBERED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT, AND, IF AN EXEMPTION SHALL BE APPLICABLE, THE HOLDER SHALL HAVE DELIVERED AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

VOID AFTER 5:00 P.M. NEW YORK CITY TIME ON THE LAST DAY OF THE EXERCISE PERIOD, AS DEFINED IN THE WARRANT

COMMON STOCK PURCHASE WARRANT
OF
NATIONAL SCIENTIFIC CORPORATION

This is to certify that, FOR VALUE RECEIVED, ________________ with an address at ______________________________ (and or its assign(s) and/or transferee(s)) (hereinafter, each a "Holder" and collectively the "Holders"), is entitled to purchase, subject to the provisions of this Warrant, from National Scientific Corporation, a Texas corporation (the "Company"), at an initial exercise price equal to $.10 per share__________________(________) fully paid and non-assessable shares of Common Stock, par value $.01 per share ("Common Stock"). The shares of Common Stock deliverable upon such exercise, and as adjusted from time-to-time as provided in this Warrant, are hereinafter sometimes referred to as "Warrant Stock," and the exercise price for the purchase of a share of Common Stock pursuant to this Warrant in effect at any time and as adjusted from time-to-time is hereinafter sometimes referred to as the "Exercise Price." The aggregate purchase price payable for the Warrant Stock purchasable hereunder is referred to as the "Aggregate Purchase Price." The Aggregate Purchase Price is not subject to adjustment. In the event of an adjustment to the Exercise Price, as provided in Section 6 herein, the number of shares of Warrant Stock deliverable upon exercise of this Warrant shall be adjusted by dividing the Aggregate Purchase Price by the Exercise Price in effect immediately after such adjustment.

This warrant and additional warrants of like tenor, including warrants issued in exchange and/or substitution thereof (collectively, the "Warrants") were originally issued to Casimir Capital L.P. and its designees in connection with Casimir Capital L.P. ("Placement Agent" or "Casimir") acting as placement agent with respect to a private placement of securities of the Company pursuant to the terms of a Confidential Term Sheet dated March 15, 2004 and as further provided in a Placement Agent Agreement between the Company and Casimir dated March 15, 2004.


1. DEFINITIONS. The following terms have the meanings set forth below:

"Current Market Value" of a share of Warrant Stock as of a particular date (the "Determination Date") shall mean:

a. If the Common Stock is listed on a national securities exchange or admitted to unlisted trading privileges on such exchange or listed for trading on the NASDAQ National Market, the current market value shall be the last reported sale price of the Common Stock on such exchange or market on the last business day prior to the date of exercise of this Warrant or if no such sale is made on such day, the average closing bid and asked prices for such day on such exchange or market; or

b. If the Common Stock is not so listed or admitted to unlisted trading privileges, but is traded on the NASDAQ SmallCap Market, the current market value shall be the average of the closing bid and asked prices for such day on such market and if the Common Stock is not so traded, the current market value shall be the mean of the last reported bid-and asked prices reported by the National Quotation Bureau, Inc. on the last business day prior to the date of the exercise of this Warrant; or

c. If the Common Stock is not so listed or admitted to unlisted trading privileges and bid and asked prices are not so reported, the current market value shall be an amount, not less than book value thereof as at the end of the most recent fiscal year of the Company ending prior to the date of the exercise of the Warrant, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company.

"Convertible Securities" shall mean evidences of indebtedness, shares of stock or other securities, including but not limited to options, warrants or purchase, subscription or other rights, which are convertible into, exchangeable or exercisable for, or represent the right to receive, with or without payment of additional consideration in cash or property, shares of Common Stock (or other Convertible Securities), either immediately or upon the occurrence of a specified date or a specified event.

"Exercise Period" shall mean the period commencing on the date hereof and ending at 5 p.m., eastern time on the day preceding the seventh anniversary of the date hereof.

"Permitted Issuances" shall mean (i) Common Stock issuable or issued to employees, consultants or directors of the Company pursuant to a stock plan or other compensation arrangement approved by the Board of Directors of the Company, but in no event, more than Eight Million shares in the aggregate, and
(ii) Common Stock issued or issuable upon conversion of the Warrants or any other securities exercisable or exchangeable for, or convertible into shares of Common Stock outstanding as of March 15, 2004.

2. EXERCISE OF WARRANT.

(a) This Warrant may be exercised in whole or in part at any time or from time to time commencing on the date hereof and until April 8, 2011 (the "Exercise Period"), provided, however, that if either such day is a day on which banking institutions in the State of New York are authorized by law to close, then on the next succeeding day which shall not be such a day. This Warrant may be exercised by presentation and surrender hereof to the Company at its principal office, or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of shares of

2

Warrant Stock specified in such form. As soon as practicable after each such exercise of this Warrant, but not later than seven days from the date of such exercise, the Company shall issue and deliver to the Holder a certificate or certificates for the shares of Warrant Stock issuable upon such exercise, registered in the name of the Holder or its designee. If this Warrant should be exercised in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing the rights of the Holder thereof to purchase the balance of the shares of Warrant Stock purchasable thereunder. Upon receipt by the Company of this Warrant at its office, or by the stock transfer agent of the Company at its office, in proper form for exercise, the Holder shall be deemed to be the holder of record of the shares of Common Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such shares of Common Stock shall not then be physically delivered to the Holder.

(b) In lieu of the payment method set forth in Section (a) above, at any time during the Exercise Period, the Holder may, at its option, exchange this Warrant, in whole or in part (a "Warrant Exchange"), without the payment by the Holder of any additional consideration into the number of shares of Warrant Stock determined in accordance with this Section (b), by surrendering this Warrant at the principal office of the Company or at the office of its stock transfer agent, accompanied by a notice stating such Holder's intent to effect such exchange, the number of shares of Warrant Stock to be exchanged and the date on which the Holder requests that such Warrant Exchange occur (the "Notice of Exchange"). The Warrant Exchange shall take place on the date specified in the Notice of Exchange or, if later, the date the Notice of Exchange is received by the Company (the "Exchange Date"). Certificates for the shares issuable upon such Warrant Exchange and, if applicable, a new warrant of like tenor evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Exchange Date and delivered to the Holder within seven days following the Exchange Date. In connection with any Warrant Exchange, this Warrant shall represent the right to subscribe for and acquire the number of shares of Warrant Stock (rounded to the next highest integer) equal to (i) the number of shares of Warrant Stock specified by the Holder in its Notice of Exchange (the "Total Number") less (ii) the number of shares of Warrant Stock equal to the quotient obtained by dividing (A) the product of the Total Number and the existing Exercise Price by (B) the Current Market Value of a share of Common Stock. Current Market Value shall have the meaning set forth in Section (1) above, except that for purposes hereof, the date of exercise, as used in such Section (1), shall mean the Exchange Date.

3. RESERVATION OF SHARES/FRACTIONAL SHARES. The Company hereby agrees that at all times there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of Common Stock as shall be required for issuance and delivery upon exercise of this Warrant. If the Company hereafter lists its Common Stock on any national securities exchange, the Nasdaq National Market or the Nasdaq SmallCap Market, it shall use its best efforts to keep the Warrant Stock authorized for listing on such exchange upon notice of issuance. No fractional shares or script representing fractional shares shall be issued upon the exercise of this Warrant. With respect to any fraction of a share, called for upon exercise hereof, the Company shall pay to the Holder an

3

amount in cash equal to such fraction multiplied by the Current Market Value of a share of Warrant Stock.

4. EXCHANGE, TRANSFER, ASSIGNMENT OR LOSS OF WARRANT. This Warrant (and all rights hereunder) is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the holder or any assignee and/or transferee thereof to purchase in the aggregate the same number of shares of Common Stock purchasable hereunder. Upon surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax, the Company shall, without charge, execute and deliver a new Warrant in the name of the assignee and/or transferee named in such instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided or combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and deliver a new Warrant of like tenor. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed, or mutilated shall be at any time enforceable by anyone.

5. RIGHTS OF THE HOLDER. The Holder shall not, by virtue of this Warrant, be entitled to any rights of a stockholder in the Company, either at law or equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein. In addition, no provision hereof, in the absence of affirmative action by Holder to purchase shares of Common Stock, and no enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of such Holder for the purchase price of any Common Stock or as a stockholder of Company, whether such liability is asserted by Company or by creditors of Company.

6. ANTI-DILUTION PROVISIONS. The Exercise Price in effect at any time and the number and kind of securities purchasable upon exercise of each Warrant shall be subject to adjustment as follows and the Company shall give each Holder notice of any event described below which requires an adjustment pursuant to this Section 6 at the time of such event:

(a) STOCK DIVIDENDS, SUBDIVISIONS AND COMBINATIONS. If, at any time or from time to time after the date of this Warrant, the Company shall (i) pay a dividend or make a distribution to any holder of its capital stock in shares of Common Stock, (ii) subdivide its outstanding shares of Common Stock into a greater number of shares, (iii) combine its outstanding shares of Common Stock into a smaller number of shares or (iv) issue by reclassification of its Common Stock any shares of capital stock of the Company, the Exercise Price shall be adjusted to be equal to a fraction, the numerator of which shall be the Aggregate Purchase Price and the denominator of which shall be the number of shares of Common Stock or other capital stock of the Company that the Holder would have owned immediately following such action had such Warrant been exercised immediately prior

4

thereto. An adjustment made pursuant to this Subsection (a) shall become effective immediately after the record date in the case of a dividend or distribution, and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification, and shall result in a corresponding adjustment to the number of shares of Warrant Stock issuable upon exercise of this Warrant.

(b) CERTAIN OTHER DISTRIBUTIONS AND ADJUSTMENTS. If, at any time or from time to time after the date of this Warrant, the Company shall issue or distribute to any holder of shares of Common Stock evidence of its indebtedness, any other securities of the Company or any cash, property or other assets (excluding a subdivision, combination or reclassification, or dividend or distribution payable in shares of Common Stock, referred to in Subsection (a), and also excluding cash dividends or cash distributions paid out of net profits legally available therefor in the full amount thereof (any such non-excluded event being herein called a "Special Dividend")), the Exercise Price shall be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which shall be the then Current Market Value in effect on the record date of such issuance or distribution less the fair market value (as determined in accordance with paragraph B. of this Section 6 (g)) of the evidence of indebtedness, cash, securities or property, or other assets issued or distributed in such Special Dividend applicable to one share of Common Stock and the denominator of which shall be the then Current Market Value in effect on the record date of such issuance or distribution. An adjustment made pursuant to this Subsection (b) shall become effective immediately after the record date of any such Special Dividend and shall result in a corresponding adjustment to the number of shares of Warrant Stock issuable upon exercise of this Warrant.

(c) ISSUANCE OF ADDITIONAL SHARES OF COMMON STOCK AND CONVERTIBLE SECURITIES.

(i) If at any time the Company shall issue or sell any shares of Common Stock or Convertible Securities (whether directly or by assumption in a merger in which Company is the surviving corporation), in exchange for consideration in an amount per share of Common Stock ( determined by dividing (i) the total amount, if any, received or receivable by the Company in consideration of the issuance or sale of such securities plus the total consideration, if any, payable to the Company upon exercise, conversion or exchange thereof ("Total Consideration") by (ii) the number of additional shares of Common Stock issued, sold or issuable upon the exercise, conversion or exchange of such securities) that is less than the Exercise Price (excluding Permitted Issuances), then (A) the Exercise Price shall be adjusted so that it shall equal the price determined by multiplying such Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding on the date of issuance or sale (calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the number of shares of Common Stock which the aggregate offering price would purchase based upon the Exercise Price and the denominator of which shall be the number of shares of Common Stock outstanding on the date of issuance or sale

5

(calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the maximum number of additional shares of Common Stock issued, sold or issuable in connection with such offering or transaction, and (B) the number of shares of Common Stock for which this Warrant is exercisable shall be adjusted to equal the product obtained by multiplying the Exercise Price in effect immediately prior to such issue or sale by the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such issue or sale and dividing the product thereof by the Exercise Price resulting from the adjustment made pursuant to clause (A) above.

(ii) The provisions of paragraph (i) of this Section 6(c) shall not apply to any issuance of shares of Common Stock for which an adjustment is provided under Section 6(a) or 6(b). No adjustment of the number of shares of Common Stock for which this Warrant shall be exercisable shall be made under paragraph (i) of this Section 6(c) upon the issuance of any shares of Common Stock which are issued pursuant to the exercise of any warrants or other subscription or purchase rights or pursuant to the exercise of any conversion or exchange rights in any Convertible Securities, if any such adjustment shall previously have been made upon the issuance of such warrants or other rights or upon the issuance of such Convertible Securities.

(d) No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least one cent ($0.01) in such price; provided, however, that any adjustments which by reason of this Section 6(d) are not required to be made shall be carried forward and taken into account in any subsequent adjustment; provided, further, however that adjustments shall be required and made in accordance with the provisions of this Section 6 not later than such time as may be required in order to preserve the tax-free nature of a distribution to the Holder of this Warrant or Common Stock issuable upon the exercise hereof. All calculations under this Section 6(d) shall be made to the nearest cent or to the nearest one-hundredth of a share, as the case may be.

(e) The Company may retain a firm of independent public accountants of recognized standing selected by the Board (who may be the regular accountants employed by the Company) to make any computation required by this Section 6.

(f) In the event that at any time, as a result of an adjustment made pursuant to Section 6(a), (b) or (c) of this Warrant, the Holder of any Warrant thereafter shall become entitled to receive any shares of the Company, other than Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Common Stock contained in Sections 6(a) through (h), inclusive, of this Warrant.

(g) For purposes of any computation respecting consideration received pursuant to this Section 6, the following shall apply:

A. in the case of the issuance of shares of Common Stock for cash, the consideration shall be the amount of such cash, provided that in no case shall any deduction be made for any commissions, discounts or other expenses incurred by the Company for any underwriting of the issue or otherwise in connection therewith;

6

B. in the case of the issuance of shares of Common Stock for a consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be the fair market value thereof as determined in good faith by the Board of Directors of the Company (irrespective of the accounting treatment thereof), whose determination shall be conclusive; and

C. in the case of the issuance of securities convertible, exchangeable or exercisable for shares of Common Stock, the aggregate consideration received therefor shall be deemed to be the consideration received by the Company for the issuance of such securities plus the additional minimum consideration, if any, to be received by the Company upon the conversion or exchange thereof (the consideration in each case to be determined in the same manner as provided in clauses (A) and (B) of this Subsection).

(h) Notwithstanding the foregoing, no adjustment shall be effected due to, or as a result of, any Permitted Issuances.

7. REGISTRATION RIGHTS. The Warrant Stock shall be entitled to the registration rights described in Article V of the Subscription Agreements entered into between the Company and the several subscribers as further described in Section 5 of the Placement Agent Agreement.

8. OFFICER'S CERTIFICATE. Whenever the Exercise Price(s) shall be adjusted as required by the provisions of Section 6 of this Warrant, the Company shall forthwith file in the custody of its Secretary or an Assistant Secretary at its principal office and with its stock transfer agent, if any, an officer's certificate showing the adjusted Exercise Price(s) and the adjusted number of shares of Common Stock issuable upon exercise of each Warrant, determined as herein provided, setting forth in reasonable detail the facts requiring such adjustment, including a statement of the number of additional shares of Common Stock, if any, and such other facts as shall be necessary to show the reason for and the manner of computing such adjustment. Each such officer's certificate shall be forwarded by certified mail to Holder as provided in Section 13

9. NOTICES TO WARRANT HOLDERS. So long as this Warrant shall be outstanding, (1) if the Company shall pay any dividend or make any distribution upon Common Stock, or (2) if the Company shall offer to the holders of Common Stock for subscription or purchase by them any share of any class or any other rights, or (3) if any capital reorganization of the Company, reclassification of the capital stock of the Company, consolidation or merger of the Company with or into another entity, tender offer transaction for the Company's Common Stock, sale, lease or transfer of all or substantially all of the property and assets of the Company, or voluntary or involuntary dissolution, liquidation or winding up of the Company shall be effected, or (4) if the Company shall file a registration statement under the Securities Act of 1933, as amended (the "Act"), on any form other than on Form S-4 or S-8 or any successor form, then in any such case, the Company shall cause to be mailed by certified mail to the Holder, at least fifteen days prior to the date specified in clauses (1), (2), (3) or
(4), as the case may be, of this Section 9 a notice containing a brief description of the proposed action and stating the date on which (i) a record is to be taken for the purpose of such dividend, distribution or rights, or (ii) such reclassification, reorganization, consolidation, merger, tender offer transaction, conveyance, lease, dissolution, liquidation or winding up is to take place and the date, if any is to be fixed, as of which the holders of Common Stock or other securities shall receive cash or other property

7

deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation or winding up, or (iii) such registration statement is to be filed with the Securities and Exchange Commission.

10. RECLASSIFICATION, REORGANIZATION OR MERGER. In case of any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the Company, or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary in which merger the Company is the continuing or surviving corporation and which does not result in any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the class issuable upon exercise of this Warrant) or in case of any sale, lease or conveyance of all or substantially all of the assets of the Company, or in the case of any statutory exchange of securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company), the Company shall, as a condition precedent to such transaction, cause effective provisions to be made so that (i) the Holder shall have the right thereafter by exercising this Warrant, to purchase the kind and amount of shares of stock and other securities and property receivable upon such reclassification, capital reorganization and other change, consolidation, merger, sale, conveyance or statutory exchange by a holder of the number of shares of Common Stock which could have been purchased upon exercise of this Warrant immediately prior to such reclassification, change, consolidation, merger, sale, conveyance, or statutory exchange and (ii) the successor or acquiring entity shall expressly assume the due and punctual observance and performance of each covenant, agreement, obligation and condition of this Warrant to be performed and observed by Company and all obligations and liabilities hereunder (including but not limited to the provisions of Section 6 regarding the increase in the number of shares of Warrant Stock potentially issuable hereunder). Any such provision shall include provision for adjustments which shall be as nearly equivalent as possible to the adjustments provided for in this Warrant. The foregoing provisions of this Section 10 shall similarly apply to successive reclassifications, capital reorganizations and changes of shares of Common Stock and to successive consolidations, mergers, sales or conveyances. In the event that in connection with any such capital reorganization or reclassification, consolidation, merger, sale, conveyance or statutory exchange, additional shares of Common Stock shall be issued in exchange, conversion, substitution or payment, in whole in part, for a security of the Company other than Common Stock, any such issue shall be treated as an issuance of Common Stock covered by the provisions of Section 6 of this Warrant. Notice of any such event shall be mailed by certified mail to the Holders of the Warrants no less than thirty (30) days prior to such event. A sale of all or substantially all of the Company's assets for a consideration consisting primarily of securities shall be deemed a consolidation or merger for the foregoing purposes.

11. TRANSFER TO COMPLY WITH THE SECURITIES ACT OF 1933. This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold or otherwise disposed of except as follows:

(i) to a person who, in the opinion of counsel for the Company, or counsel for the Holder who is reasonably acceptable to the Company, is a person to whom this Warrant or Warrant Stock may legally be transferred without registration and without the delivery of a current prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section 11 with respect to any resale or other disposition of such securities which agreement shall be satisfactory in form and substance to the Company and its counsel; or

8

(ii) to any person upon delivery of a prospectus then meeting the requirements of the Act relating to such securities and the offering thereof for such sale or disposition.

12. GOVERNING LAW; JURISDICTION. The corporate laws of the State of Texas shall govern all issues concerning the relative rights of the Company and its stockholders. All issues concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to the principles of conflicts of law thereof. The parties hereto agree that venue in any and all actions and proceedings related to the subject matter of this Warrant shall be in the state and federal courts in and for New York, New York, which courts shall have exclusive jurisdiction for such purpose, and the parties hereto irrevocably submit to the exclusive jurisdiction of such courts and irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or proceeding. Service of process may be made in any manner recognized by such courts. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought.

13. NOTICES. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered VIA facsimile at the facsimile telephone number specified in this Section prior to 6:30 p.m. (New York City time) on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered VIA facsimile at the facsimile telephone number specified in this Agreement later than 6:30 p.m. (New York City time) on any date and earlier than 11:59 p.m. (New York City time) on such date,
(iii) the Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:

If to the Company: National Scientific Corporation Scottsdale Technology Center 14455 North Hayden Road, Suite 202 Scottsdale, AZ 85260-6497

If to the Holder: To the Address Set Forth on the cover page hereof.

14. MODIFICATION OF WARRANT. This Warrant shall not be modified, supplemented or altered in any respect, nor any provision waived, except with the consent in writing of the Holders representing not less than fifty percent (50%) of the Warrants then outstanding.

9

15. PAYMENT OF TAXES. The Company will pay all documentary stamp taxes attributable to the issuance of shares of Common Stock underlying this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificate for shares of Common Stock underlying this Warrant in a name other that of the Holder. The Holder is responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving shares of Common Stock underlying this Warrant upon exercise hereof.

IN WITNESS WHEREOF, this Warrant has been duly executed as of April 8, 2004.

NATIONAL SCIENTIFIC CORPORATION

By:

Michael A. Grollman Chairman and Chief Executive Officer

ATTEST:


Secretary

[CORPORATE SEAL]

10

SUBSCRIPTION (CASH)

The undersigned, ____________________________, pursuant to the provisions of the foregoing Warrant, hereby agrees to subscribe for and purchase ___________________ shares of the Common Stock, par value $_____ per share, of ______________________ covered by said Warrant, and makes payment therefor in full at the price per share provided by said Warrant.

Dated: ________________________ Signature: ___________________________

CASHLESS EXERCISE

The undersigned, ____________________________, pursuant to the provisions of the foregoing Warrant, hereby agrees to exchange its Warrant for ___________________ shares of the Common Stock, par value $_____ per share, of ______________________ pursuant to the Cashless Exercise provisions of the Warrant.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

11

ASSIGNMENT

FOR VALUE RECEIVED ___________________ hereby sells, assigns and transfers unto ________________________ the foregoing Warrant and all rights evidenced thereby, and does irrevocably constitute and appoint ___________________, attorney, to transfer said Warrant on the books of _________________________.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

PARTIAL ASSIGNMENT

FOR VALUE RECEIVED ___________________ hereby sells, assigns and transfers unto ________________________ the right to purchase ____________ shares of Common Stock, par value $_____ per share of _________________________ covered by the foregoing Warrant, and a proportionate part of said Warrant and the rights evidenced thereby, and does irrevocably constitute and appoint ___________________, attorney, to transfer such part of said Warrant on the books of _________________________.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

12

EXHIBIT 4.4

Form of Initiation Warrant to Purchase

W-___ Shares of Common Stock

NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND NEITHER THIS WARRANT NOR SUCH SHARES MAY BE SOLD, ENCUMBERED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT, AND, IF AN EXEMPTION SHALL BE APPLICABLE, THE HOLDER SHALL HAVE DELIVERED AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

VOID AFTER 5:00 P.M. NEW YORK CITY TIME ON THE LAST DAY OF THE EXERCISE PERIOD, AS DEFINED IN THE WARRANT

COMMON STOCK PURCHASE WARRANT
OF
NATIONAL SCIENTIFIC CORPORATION

This is to certify that, FOR VALUE RECEIVED, ________________ with an address at ______________________________ (and or its assign(s) and/or transferee(s)) (hereinafter, each a "Holder" and collectively the "Holders"), is entitled to purchase, subject to the provisions of this Warrant, from National Scientific Corporation, a Texas corporation (the "Company"), at an initial exercise price equal to $.10 per share__________________(________) fully paid and non-assessable shares of Common Stock, par value $.01 per share ("Common Stock"). The shares of Common Stock deliverable upon such exercise, and as adjusted from time-to-time as provided in this Warrant, are hereinafter sometimes referred to as "Warrant Stock," and the exercise price for the purchase of a share of Common Stock pursuant to this Warrant in effect at any time and as adjusted from time-to-time is hereinafter sometimes referred to as the "Exercise Price." The aggregate purchase price payable for the Warrant Stock purchasable hereunder is referred to as the "Aggregate Purchase Price." The Aggregate Purchase Price is not subject to adjustment. In the event of an adjustment to the Exercise Price, as provided in Section 6 herein, the number of shares of Warrant Stock deliverable upon exercise of this Warrant shall be adjusted by dividing the Aggregate Purchase Price by the Exercise Price in effect immediately after such adjustment.

This warrant and additional warrants of like tenor, including warrants issued in exchange and/or substitution thereof (collectively, the "Warrants") were originally issued in connection with a the execution of a Letter of Intent between the Company and Casimir Capital L.P., dated February 9, 2004, ("Letter") with respect to a proposed offering of securities by the Company ("Offering").


1. DEFINITIONS. The following terms have the meanings set forth below:

"Current Market Value" of a share of Warrant Stock as of a particular date (the "Determination Date") shall mean:

a. If the Common Stock is listed on a national securities exchange or admitted to unlisted trading privileges on such exchange or listed for trading on the NASDAQ National Market, the current market value shall be the last reported sale price of the Common Stock on such exchange or market on the last business day prior to the date of exercise of this Warrant or if no such sale is made on such day, the average closing bid and asked prices for such day on such exchange or market; or

b. If the Common Stock is not so listed or admitted to unlisted trading privileges, but is traded on the NASDAQ SmallCap Market, the current market value shall be the average of the closing bid and asked prices for such day on such market and if the Common Stock is not so traded, the current market value shall be the mean of the last reported bid-and asked prices reported by the National Quotation Bureau, Inc. on the last business day prior to the date of the exercise of this Warrant; or

c. If the Common Stock is not so listed or admitted to unlisted trading privileges and bid and asked prices are not so reported, the current market value shall be an amount, not less than book value thereof as at the end of the most recent fiscal year of the Company ending prior to the date of the exercise of the Warrant, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company.

"Convertible Securities" shall mean evidences of indebtedness, shares of stock or other securities, including but not limited to options, warrants or purchase, subscription or other rights, which are convertible into, exchangeable or exercisable for, or represent the right to receive, with or without payment of additional consideration in cash or property, shares of Common Stock (or other Convertible Securities), either immediately or upon the occurrence of a specified date or a specified event.

"Exercise Period" shall mean the period commencing on the date hereof and ending at 5 p.m., eastern time on the day preceding the seventh anniversary of the date hereof.

"Permitted Issuances" shall mean (i) Common Stock issuable or issued to employees, consultants or directors of the Company pursuant to a stock plan or other compensation arrangement approved by the Board of Directors of the Company, but in no event, more than Eight Million shares in the aggregate, and
(ii) Common Stock issued or issuable upon conversion of the Warrants or any other securities exercisable or exchangeable for, or convertible into shares of Common Stock outstanding as of February 9, 2004.

2. EXERCISE OF WARRANT.

(a) This Warrant may be exercised in whole or in part at any time or from time to time commencing on the date hereof and until February 9, 2011 (the "Exercise Period"), provided, however, that if either such day is a day on which banking institutions in the State of New York are authorized by law to close, then on the next succeeding day which shall not be such a day. This Warrant may be exercised by presentation and surrender hereof to

2

the Company at its principal office, or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of shares of Warrant Stock specified in such form. As soon as practicable after each such exercise of this Warrant, but not later than seven days from the date of such exercise, the Company shall issue and deliver to the Holder a certificate or certificates for the shares of Warrant Stock issuable upon such exercise, registered in the name of the Holder or its designee. If this Warrant should be exercised in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing the rights of the Holder thereof to purchase the balance of the shares of Warrant Stock purchasable thereunder. Upon receipt by the Company of this Warrant at its office, or by the stock transfer agent of the Company at its office, in proper form for exercise, the Holder shall be deemed to be the holder of record of the shares of Common Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such shares of Common Stock shall not then be physically delivered to the Holder.

(b) In lieu of the payment method set forth in Section (a) above, at any time during the Exercise Period, the Holder may, at its option, exchange this Warrant, in whole or in part (a "Warrant Exchange"), without the payment by the Holder of any additional consideration into the number of shares of Warrant Stock determined in accordance with this Section (b), by surrendering this Warrant at the principal office of the Company or at the office of its stock transfer agent, accompanied by a notice stating such Holder's intent to effect such exchange, the number of shares of Warrant Stock to be exchanged and the date on which the Holder requests that such Warrant Exchange occur (the "Notice of Exchange"). The Warrant Exchange shall take place on the date specified in the Notice of Exchange or, if later, the date the Notice of Exchange is received by the Company (the "Exchange Date"). Certificates for the shares issuable upon such Warrant Exchange and, if applicable, a new warrant of like tenor evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Exchange Date and delivered to the Holder within seven days following the Exchange Date. In connection with any Warrant Exchange, this Warrant shall represent the right to subscribe for and acquire the number of shares of Warrant Stock (rounded to the next highest integer) equal to (i) the number of shares of Warrant Stock specified by the Holder in its Notice of Exchange (the "Total Number") less (ii) the number of shares of Warrant Stock equal to the quotient obtained by dividing (A) the product of the Total Number and the existing Exercise Price by (B) the Current Market Value of a share of Common Stock. Current Market Value shall have the meaning set forth in Section (1) above, except that for purposes hereof, the date of exercise, as used in such Section (1), shall mean the Exchange Date.

3. RESERVATION OF SHARES/FRACTIONAL SHARES. The Company hereby agrees that at all times there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of Common Stock as shall be required for issuance and delivery upon exercise of this Warrant. If the Company hereafter lists its Common Stock on any national securities exchange, the Nasdaq National Market or the Nasdaq SmallCap Market, it shall use its best efforts to keep the Warrant Stock authorized for listing on such exchange upon notice of issuance. No fractional shares or script representing fractional shares shall be issued upon the exercise of this Warrant. With respect to any fraction of a

3

share, called for upon exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the Current Market Value of a share of Warrant Stock.

4. EXCHANGE, TRANSFER, ASSIGNMENT OR LOSS OF WARRANT. This Warrant (and all rights hereunder) is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the holder or any assignee and/or transferee thereof to purchase in the aggregate the same number of shares of Common Stock purchasable hereunder. Upon surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax, the Company shall, without charge, execute and deliver a new Warrant in the name of the assignee and/or transferee named in such instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided or combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and deliver a new Warrant of like tenor. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed, or mutilated shall be at any time enforceable by anyone.

5. RIGHTS OF THE HOLDER. The Holder shall not, by virtue of this Warrant, be entitled to any rights of a stockholder in the Company, either at law or equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein. In addition, no provision hereof, in the absence of affirmative action by Holder to purchase shares of Common Stock, and no enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of such Holder for the purchase price of any Common Stock or as a stockholder of Company, whether such liability is asserted by Company or by creditors of Company.

6. ANTI-DILUTION PROVISIONS. The Exercise Price in effect at any time and the number and kind of securities purchasable upon exercise of each Warrant shall be subject to adjustment as follows and the Company shall give each Holder notice of any event described below which requires an adjustment pursuant to this Section 6 at the time of such event:

(a) STOCK DIVIDENDS, SUBDIVISIONS AND COMBINATIONS. If, at any time or from time to time after the date of this Warrant, the Company shall (i) pay a dividend or make a distribution to any holder of its capital stock in shares of Common Stock, (ii) subdivide its outstanding shares of Common Stock into a greater number of shares, (iii) combine its outstanding shares of Common Stock into a smaller number of shares or (iv) issue by reclassification of its Common Stock any shares of capital stock of the Company, the Exercise Price shall be adjusted to be equal to a fraction, the numerator of which shall be the Aggregate Purchase Price and the

4

denominator of which shall be the number of shares of Common Stock or other capital stock of the Company that the Holder would have owned immediately following such action had such Warrant been exercised immediately prior thereto. An adjustment made pursuant to this Subsection (a) shall become effective immediately after the record date in the case of a dividend or distribution, and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification, and shall result in a corresponding adjustment to the number of shares of Warrant Stock issuable upon exercise of this Warrant.

(b) CERTAIN OTHER DISTRIBUTIONS AND ADJUSTMENTS. If, at any time or from time to time after the date of this Warrant, the Company shall issue or distribute to any holder of shares of Common Stock evidence of its indebtedness, any other securities of the Company or any cash, property or other assets (excluding a subdivision, combination or reclassification, or dividend or distribution payable in shares of Common Stock, referred to in Subsection (a), and also excluding cash dividends or cash distributions paid out of net profits legally available therefor in the full amount thereof (any such non-excluded event being herein called a "Special Dividend")), the Exercise Price shall be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which shall be the then Current Market Value in effect on the record date of such issuance or distribution less the fair market value (as determined in accordance with paragraph B. of this Section 6 (g)) of the evidence of indebtedness, cash, securities or property, or other assets issued or distributed in such Special Dividend applicable to one share of Common Stock and the denominator of which shall be the then Current Market Value in effect on the record date of such issuance or distribution. An adjustment made pursuant to this Subsection (b) shall become effective immediately after the record date of any such Special Dividend and shall result in a corresponding adjustment to the number of shares of Warrant Stock issuable upon exercise of this Warrant.

(c) ISSUANCE OF ADDITIONAL SHARES OF COMMON STOCK AND CONVERTIBLE SECURITIES.

(i) If at any time the Company shall issue or sell any shares of Common Stock or Convertible Securities (whether directly or by assumption in a merger in which Company is the surviving corporation), in exchange for consideration in an amount per share of Common Stock (determined by dividing (i) the total amount, if any, received or receivable by the Company in consideration of the issuance or sale of such securities plus the total consideration, if any, payable to the Company upon exercise, conversion or exchange thereof ("Total Consideration") by (ii) the number of additional shares of Common Stock issued, sold or issuable upon the exercise, conversion or exchange of such securities) that is less than the Exercise Price (excluding Permitted Issuances), then (A) the Exercise Price shall be adjusted so that it shall equal the price determined by multiplying such Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding on the date of issuance or sale (calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the number of shares of Common Stock which the aggregate offering price would purchase based upon the Exercise Price and the denominator of which shall be the number of

5

shares of Common Stock outstanding on the date of issuance or sale (calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the maximum number of additional shares of Common Stock issued, sold or issuable in connection with such offering or transaction, and (B) the number of shares of Common Stock for which this Warrant is exercisable shall be adjusted to equal the product obtained by multiplying the Exercise Price in effect immediately prior to such issue or sale by the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such issue or sale and dividing the product thereof by the Exercise Price resulting from the adjustment made pursuant to clause (A) above.

(ii) The provisions of paragraph (i) of this Section 6(c) shall not apply to any issuance of shares of Common Stock for which an adjustment is provided under Section 6(a) or 6(b). No adjustment of the number of shares of Common Stock for which this Warrant shall be exercisable shall be made under paragraph (i) of this Section 6(c) upon the issuance of any shares of Common Stock which are issued pursuant to the exercise of any warrants or other subscription or purchase rights or pursuant to the exercise of any conversion or exchange rights in any Convertible Securities, if any such adjustment shall previously have been made upon the issuance of such warrants or other rights or upon the issuance of such Convertible Securities.

(d) No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least one cent ($0.01) in such price; provided, however, that any adjustments which by reason of this Section 6(d) are not required to be made shall be carried forward and taken into account in any subsequent adjustment; provided, further, however that adjustments shall be required and made in accordance with the provisions of this Section 6 not later than such time as may be required in order to preserve the tax-free nature of a distribution to the Holder of this Warrant or Common Stock issuable upon the exercise hereof. All calculations under this Section 6(d) shall be made to the nearest cent or to the nearest one-hundredth of a share, as the case may be.

(e) The Company may retain a firm of independent public accountants of recognized standing selected by the Board (who may be the regular accountants employed by the Company) to make any computation required by this Section 6.

(f) In the event that at any time, as a result of an adjustment made pursuant to Section 6(a), (b) or (c) of this Warrant, the Holder of any Warrant thereafter shall become entitled to receive any shares of the Company, other than Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Common Stock contained in Sections 6(a) through (h), inclusive, of this Warrant.

(g) For purposes of any computation respecting consideration received pursuant to this Section 6, the following shall apply:

A. in the case of the issuance of shares of Common Stock for cash, the consideration shall be the amount of such cash, provided

6

that in no case shall any deduction be made for any commissions, discounts or other expenses incurred by the Company for any underwriting of the issue or otherwise in connection therewith;

B. in the case of the issuance of shares of Common Stock for a consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be the fair market value thereof as determined in good faith by the Board of Directors of the Company (irrespective of the accounting treatment thereof), whose determination shall be conclusive; and

C. in the case of the issuance of securities convertible, exchangeable or exercisable for shares of Common Stock, the aggregate consideration received therefor shall be deemed to be the consideration received by the Company for the issuance of such securities plus the additional minimum consideration, if any, to be received by the Company upon the conversion or exchange thereof (the consideration in each case to be determined in the same manner as provided in clauses (A) and (B) of this Subsection).

(h) Notwithstanding the foregoing, no adjustment shall be effected due to, or as a result of, any Permitted Issuances.

7. REGISTRATION RIGHTS. The Warrant Stock shall be entitled to the registration rights described in Section 8 of the Letter and subsequent to the first closing, in Section 5(b) the Placement Agent Agreement to be entered into by Casimir L.P. and the Company.

8. OFFICER'S CERTIFICATE. Whenever the Exercise Price(s) shall be adjusted as required by the provisions of Section 6 of this Warrant, the Company shall forthwith file in the custody of its Secretary or an Assistant Secretary at its principal office and with its stock transfer agent, if any, an officer's certificate showing the adjusted Exercise Price(s) and the adjusted number of shares of Common Stock issuable upon exercise of each Warrant, determined as herein provided, setting forth in reasonable detail the facts requiring such adjustment, including a statement of the number of additional shares of Common Stock, if any, and such other facts as shall be necessary to show the reason for and the manner of computing such adjustment. Each such officer's certificate shall be forwarded by certified mail to Holder as provided in Section 13

9. NOTICES TO WARRANT HOLDERS. So long as this Warrant shall be outstanding, (1) if the Company shall pay any dividend or make any distribution upon Common Stock, or (2) if the Company shall offer to the holders of Common Stock for subscription or purchase by them any share of any class or any other rights, or (3) if any capital reorganization of the Company, reclassification of the capital stock of the Company, consolidation or merger of the Company with or into another entity, tender offer transaction for the Company's Common Stock, sale, lease or transfer of all or substantially all of the property and assets of the Company, or voluntary or involuntary dissolution, liquidation or winding up of the Company shall be effected, or (4) if the Company shall file a registration statement under the Securities Act of 1933, as amended (the "Act"), on any form other than on Form S-4 or S-8 or any successor form, then in any such case, the Company shall cause to be mailed by certified mail to the Holder, at least fifteen days prior to the date specified in clauses (1), (2), (3) or
(4), as the case may be, of this Section 9 a notice containing a brief description of the proposed action and stating the date on which (i) a record is

7

to be taken for the purpose of such dividend, distribution or rights, or (ii) such reclassification, reorganization, consolidation, merger, tender offer transaction, conveyance, lease, dissolution, liquidation or winding up is to take place and the date, if any is to be fixed, as of which the holders of Common Stock or other securities shall receive cash or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation or winding up, or (iii) such registration statement is to be filed with the Securities and Exchange Commission.

10. RECLASSIFICATION, REORGANIZATION OR MERGER. In case of any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the Company, or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary in which merger the Company is the continuing or surviving corporation and which does not result in any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the class issuable upon exercise of this Warrant) or in case of any sale, lease or conveyance of all or substantially all of the assets of the Company, or in the case of any statutory exchange of securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company), the Company shall, as a condition precedent to such transaction, cause effective provisions to be made so that (i) the Holder shall have the right thereafter by exercising this Warrant, to purchase the kind and amount of shares of stock and other securities and property receivable upon such reclassification, capital reorganization and other change, consolidation, merger, sale, conveyance or statutory exchange by a holder of the number of shares of Common Stock which could have been purchased upon exercise of this Warrant immediately prior to such reclassification, change, consolidation, merger, sale, conveyance, or statutory exchange and (ii) the successor or acquiring entity shall expressly assume the due and punctual observance and performance of each covenant, agreement, obligation and condition of this Warrant to be performed and observed by Company and all obligations and liabilities hereunder (including but not limited to the provisions of Section 6 regarding the increase in the number of shares of Warrant Stock potentially issuable hereunder). Any such provision shall include provision for adjustments which shall be as nearly equivalent as possible to the adjustments provided for in this Warrant. The foregoing provisions of this Section 10 shall similarly apply to successive reclassifications, capital reorganizations and changes of shares of Common Stock and to successive consolidations, mergers, sales or conveyances. In the event that in connection with any such capital reorganization or reclassification, consolidation, merger, sale, conveyance or statutory exchange, additional shares of Common Stock shall be issued in exchange, conversion, substitution or payment, in whole in part, for a security of the Company other than Common Stock, any such issue shall be treated as an issuance of Common Stock covered by the provisions of Section 6 of this Warrant. Notice of any such event shall be mailed by certified mail to the Holders of the Warrants no less than thirty (30) days prior to such event. A sale of all or substantially all of the Company's assets for a consideration consisting primarily of securities shall be deemed a consolidation or merger for the foregoing purposes.

11. TRANSFER TO COMPLY WITH THE SECURITIES ACT OF 1933. This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold or otherwise disposed of except as follows:

(i) to a person who, in the opinion of counsel for the Company, or counsel for the Holder who is reasonably acceptable to the Company, is a

8

person to whom this Warrant or Warrant Stock may legally be transferred without registration and without the delivery of a current prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section 11 with respect to any resale or other disposition of such securities which agreement shall be satisfactory in form and substance to the Company and its counsel; or

(ii) To any person upon delivery of a prospectus then meeting the requirements of the Act relating to such securities and the offering thereof for such sale or disposition.

(iii) Notwithstanding (i) and (ii) above, The Company approves the transfer of this Warrant to affiliates of the Holders.

(iv) The registration rights contained in Section 7 of this Warrant may be assigned in full by a Holder in connection with the transfer of this Warrant or any other Warrant stock.

12. GOVERNING LAW; JURISDICTION. The corporate laws of the State of Texas shall govern all issues concerning the relative rights of the Company and its stockholders. All issues concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to the principles of conflicts of law thereof. The parties hereto agree that venue in any and all actions and proceedings related to the subject matter of this Warrant shall be in the state and federal courts in and for New York, New York, which courts shall have exclusive jurisdiction for such purpose, and the parties hereto irrevocably submit to the exclusive jurisdiction of such courts and irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or proceeding. Service of process may be made in any manner recognized by such courts. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought.

13. NOTICES. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered VIA facsimile at the facsimile telephone number specified in this Section prior to 6:30 p.m. (New York City time) on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered VIA facsimile at the facsimile telephone number specified in this Agreement later than 6:30 p.m. (New York City time) on any date and earlier than 11:59 p.m. (New York City time) on such date,
(iii) the Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:

If to the Company: National Scientific Corporation Scottsdale Technology Center 14455 North Hayden Road, Suite 202 Scottsdale, AZ 85260-6497

If to the Holder: To the Address Set Forth on the cover page hereof.

9

14. MODIFICATION OF WARRANT. This Warrant shall not be modified, supplemented or altered in any respect, nor any provision waived, except with the consent in writing of the Holders representing not less than fifty percent (50%) of the Warrants then outstanding.

15. PAYMENT OF TAXES. The Company will pay all documentary stamp taxes attributable to the issuance of shares of Common Stock underlying this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificate for shares of Common Stock underlying this Warrant in a name other that of the Holder. The Holder is responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving shares of Common Stock underlying this Warrant upon exercise hereof.

IN WITNESS WHEREOF, this Warrant has been duly executed as of February 9, 2004.

NATIONAL SCIENTIFIC CORPORATION

By:

Michael A. Grollman Chairman and Chief Executive Officer

ATTEST:


Secretary

[CORPORATE SEAL]

10

SUBSCRIPTION (CASH)

The undersigned, ____________________________, pursuant to the provisions of the foregoing Warrant, hereby agrees to subscribe for and purchase ___________________ shares of the Common Stock, par value $_____ per share, of ______________________ covered by said Warrant, and makes payment therefor in full at the price per share provided by said Warrant.

Dated: ________________________ Signature: ___________________________

CASHLESS EXERCISE

The undersigned, ____________________________, pursuant to the provisions of the foregoing Warrant, hereby agrees to exchange its Warrant for ___________________ shares of the Common Stock, par value $_____ per share, of ______________________ pursuant to the Cashless Exercise provisions of the Warrant.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

11

ASSIGNMENT

FOR VALUE RECEIVED ___________________ hereby sells, assigns and transfers unto ________________________ the foregoing Warrant and all rights evidenced thereby, and does irrevocably constitute and appoint ___________________, attorney, to transfer said Warrant on the books of _________________________.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

PARTIAL ASSIGNMENT

FOR VALUE RECEIVED ___________________ hereby sells, assigns and transfers unto ________________________ the right to purchase ____________ shares of Common Stock, par value $_____ per share of _________________________ covered by the foregoing Warrant, and a proportionate part of said Warrant and the rights evidenced thereby, and does irrevocably constitute and appoint ___________________, attorney, to transfer such part of said Warrant on the books of _________________________.

Dated: ________________________ Signature: ___________________________

Address: ___________________________

12

EXHIBIT 4.5

THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO NATIONAL SCIENTIFIC CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

Right to Purchase 640,000 shares of Common Stock of National Scientific Corporation (subject to adjustment as provided herein)

FORM OF COMMON STOCK PURCHASE WARRANT

No. 2004-JAN-001 Issue Date: January 6, 2004

NATIONAL SCIENTIFIC CORPORATION, a corporation organized under the laws of the State of Texas (the "Company"), hereby certifies that, for value received, STRATEGIC WORKING CAPITAL FUND, LP, 55 Harristown Road, Glen Rock, NJ 07452, telecopier: (201) 701-0260 (the "Holder"), or its assigns, is entitled, subject to the terms set forth below, to purchase from the Company from and after the Issue Date and at any time or from time to time before 5:00 p.m., New York time, through three (3) years after such date (the "Expiration Date"), up to 640,000 fully paid and nonassessable shares of Common Stock (as hereinafter defined), $.01 par value per share, of the Company at a per share purchase price of $.13 for years 1 and 2, and $.15 for year 3. The aforedescribed purchase price per share, as adjusted from time to time as herein provided, is referred to herein as the "Purchase Price". The number and character of such shares of Common Stock and the Purchase Price are subject to adjustment as provided herein. The Company may reduce the Purchase Price without the consent of the Holder. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain subscription agreement (the "Subscription Agreement"), dated at or about January ___, 2004, between the Company and the Holder.

As used herein the following terms, unless the context otherwise requires, have the following respective meanings:

(a) The term "Company" shall include National Scientific Corporation and any corporation which shall succeed or assume the obligations of National Scientific Corporation hereunder.

(b) The term "Common Stock" includes (a) the Company's Common Stock, $.01 par value per share, as authorized on the date of the Subscription Agreement,
(b) any other capital stock of any class or classes (however designated) of the Company, authorized on or after such date, the holders of which shall have the right, without limitation as to amount, either to all or to a share of the balance of current dividends and liquidating dividends after the payment of dividends and distributions on any shares entitled to preference, and the holders of which shall ordinarily, in the absence of contingencies, be entitled to vote for the election of a majority of directors of the Company (even if the right so to vote has been suspended by the happening of such a contingency) and
(c) any other securities into which or for which any of the securities described in (a) or (b) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

1

(c) The term "Other Securities" refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise.

1. EXERCISE OF WARRANT.

1.1. NUMBER OF SHARES ISSUABLE UPON EXERCISE. From and after the Issue Date through and including the Expiration Date, the Holder hereof shall be entitled to receive, upon exercise of this Warrant in whole in accordance with the terms of subsection 1.2 or upon exercise of this Warrant in part in accordance with subsection 1.3, shares of Common Stock of the Company, subject to adjustment pursuant to Section 4.

1.2. FULL EXERCISE. This Warrant may be exercised in full by the Holder hereof by delivery of an original or facsimile copy of the form of subscription attached as Exhibit A hereto (the "Subscription Form") duly executed by such Holder and surrender of the original Warrant within seven (7) days of exercise, to the Company at its principal office or at the office of its Warrant Agent (as provided hereinafter), accompanied by payment, in cash, wire transfer or by certified or official bank check payable to the order of the Company, in the amount obtained by multiplying the number of shares of Common Stock for which this Warrant is then exercisable by the Purchase Price then in effect.

1.3. PARTIAL EXERCISE. This Warrant may be exercised in part (but not for a fractional share) by surrender of this Warrant in the manner and at the place provided in subsection 1.2 except that the amount payable by the Holder on such partial exercise shall be the amount obtained by multiplying (a) the number of whole shares of Common Stock designated by the Holder in the Subscription Form by (b) the Purchase Price then in effect. On any such partial exercise, the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder hereof a new Warrant of like tenor, in the name of the Holder hereof or as such Holder (upon payment by such Holder of any applicable transfer taxes) may request, the whole number of shares of Common Stock for which such Warrant may still be exercised.

1.4. FAIR MARKET VALUE. Fair Market Value of a share of Common Stock as of a particular date (the "Determination Date") shall mean:

(a) If the Company's Common Stock is traded on an exchange or is quoted on the National Association of Securities Dealers, Inc. Automated Quotation ("NASDAQ") National Market System, the NASDAQ SmallCap Market or the American Stock Exchange, Inc., then the closing or last sale price, respectively, reported for the last business day immediately preceding the Determination Date;

(b) If the Company's Common Stock is not traded on an exchange or on the NASDAQ National Market System, the NASDAQ SmallCap Market or the American Stock Exchange, Inc., but is traded in the over-the-counter market, then the average of the closing bid and ask prices reported for the last business day immediately preceding the Determination Date;

(c) Except as provided in clause (d) below, if the Company's Common Stock is not publicly traded, then as the Holder and the Company agree, or in the absence of such an agreement, by arbitration in accordance with the

2

rules then standing of the American Arbitration Association, before a single arbitrator to be chosen from a panel of persons qualified by education and training to pass on the matter to be decided; or

(d) If the Determination Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation, dissolution or winding up pursuant to the Company's charter, then all amounts to be payable per share to holders of the Common Stock pursuant to the charter in the event of such liquidation, dissolution or winding up, plus all other amounts to be payable per share in respect of the Common Stock in liquidation under the charter, assuming for the purposes of this clause (d) that all of the shares of Common Stock then issuable upon exercise of all of the Warrants are outstanding at the Determination Date.

1.5. COMPANY ACKNOWLEDGMENT. The Company will, at the time of the exercise of the Warrant, upon the request of the Holder hereof acknowledge in writing its continuing obligation to afford to such Holder any rights to which such Holder shall continue to be entitled after such exercise in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to such Holder any such rights.

1.6. TRUSTEE FOR WARRANT HOLDERS. In the event that a bank or trust company shall have been appointed as trustee for the Holder of the Warrants pursuant to Subsection 3.2, such bank or trust company shall have all the powers and duties of a warrant agent (as hereinafter described) and shall accept, in its own name for the account of the Company or such successor person as may be entitled thereto, all amounts otherwise payable to the Company or such successor, as the case may be, on exercise of this Warrant pursuant to this
Section 1.

2. DELIVERY OF STOCK CERTIFICATES, ETC. ON EXERCISE. The Company agrees that the shares of Common Stock purchased upon exercise of this Warrant shall be deemed to be issued to the Holder hereof as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment made for such shares as aforesaid. As soon as practicable after the exercise of this Warrant in full or in part, and in any event within five (5) days thereafter ("Delivery Date"), the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and delivered to the Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and validly issued, fully paid and nonassessable shares of Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise, plus, in lieu of any fractional share to which such Holder would otherwise be entitled, cash equal to such fraction multiplied by the then Fair Market Value of one full share of Common Stock, together with any other stock or other securities and property (including cash, where applicable) to which such Holder is entitled upon such exercise pursuant to Section 1 or otherwise.

3. ADJUSTMENT FOR REORGANIZATION, CONSOLIDATION, MERGER, ETC.

3.1. REORGANIZATION, CONSOLIDATION, MERGER, ETC. In case at any time or from time to time, the Company shall (a) effect a reorganization, (b) consolidate with or merge into any other person or (c) transfer all or substantially all of its properties or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then, in each such case, as a condition to the consummation of such a transaction, proper and adequate provision shall be made by the Company whereby the Holder of this

3

Warrant, on the exercise hereof as provided in Section 1, at any time after the consummation of such reorganization, consolidation or merger or the effective date of such dissolution, as the case may be, shall receive, in lieu of the Common Stock (or Other Securities) issuable on such exercise prior to such consummation or such effective date, the stock and other securities and property (including cash) to which such Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder had so exercised this Warrant, immediately prior thereto, all subject to further adjustment thereafter as provided in Section 4.

3.2. DISSOLUTION. In the event of any dissolution of the Company following the transfer of all or substantially all of its properties or assets, the Company, prior to such dissolution, shall at its expense deliver or cause to be delivered the stock and other securities and property (including cash, where applicable) receivable by the Holder of the Warrants after the effective date of such dissolution pursuant to this Section 3 to a bank or trust company (a "Trustee") having its principal office in New York, NY, as trustee for the Holder of the Warrants.

3.3. CONTINUATION OF TERMS. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred to in this Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the Other Securities and property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be, and shall be binding upon the issuer of any Other Securities, including, in the case of any such transfer, the person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have expressly assumed the terms of this Warrant as provided in Section 4. In the event this Warrant does not continue in full force and effect after the consummation of the transaction described in this Section 3, then only in such event will the Company's securities and property (including cash, where applicable) receivable by the Holder of the Warrants be delivered to the Trustee as contemplated by Section 3.2.

3.4 SHARE ISSUANCE. If the Company, during the Outstanding Period (as defined in the Subscription Agreement), shall issue any shares of Common Stock except for the Excepted Issuances (as defined in the Subscription Agreement) prior to the complete exercise of this Warrant for a consideration less than the Purchase Price that would be in effect at the time of such issue, then, and thereafter successively upon each such issue, the Purchase Price shall be reduced as follows: (i) the number of shares of Common Stock outstanding immediately prior to such issue shall be multiplied by the Purchase Price in effect at the time of such issue and the product shall be added to the aggregate consideration, if any, received by the Company upon such issue of additional shares of Common Stock; and (ii) the sum so obtained shall be divided by the number of shares of Common Stock outstanding immediately after such issue. The resulting quotient shall be the adjusted Purchase Price. For purposes of this adjustment, the issuance of any security of the Company carrying the right to convert such security into shares of Common Stock or of any warrant, right or option to purchase Common Stock shall result in an adjustment to the Purchase Price upon the issuance of shares of Common Stock upon exercise of such conversion or purchase rights. The reduction of the Purchase Price described in this Section 3.4 is in addition to the other rights of the Holder described in the Subscription Agreement.

4. EXTRAORDINARY EVENTS REGARDING COMMON STOCK. In the event that the Company shall (a) issue additional shares of the Common Stock as a dividend or

4

other distribution on outstanding Common Stock, (b) subdivide its outstanding shares of Common Stock, or (c) combine its outstanding shares of the Common Stock into a smaller number of shares of the Common Stock, then, in each such event, the Purchase Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Purchase Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall thereafter be the Purchase Price then in effect. The Purchase Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described herein in this Section 4. The number of shares of Common Stock that the Holder of this Warrant shall thereafter, on the exercise hereof as provided in Section 1, be entitled to receive shall be adjusted to a number determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions of this
Section 4) be issuable on such exercise by a fraction of which (a) the numerator is the Purchase Price that would otherwise (but for the provisions of this
Section 4) be in effect, and (b) the denominator is the Purchase Price in effect on the date of such exercise.

5. CERTIFICATE AS TO ADJUSTMENTS. In each case of any adjustment or readjustment in the shares of Common Stock (or Other Securities) issuable on the exercise of the Warrants, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of the Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the consideration received or receivable by the Company for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or Other Securities) outstanding or deemed to be outstanding, and (c) the Purchase Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder of the Warrant and any Warrant Agent of the Company (appointed pursuant to Section 11 hereof).

6. RESERVATION OF STOCK, ETC. ISSUABLE ON EXERCISE OF WARRANT; FINANCIAL STATEMENTS. The Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of the Warrants, all shares of Common Stock (or Other Securities) from time to time issuable on the exercise of the Warrant. This Warrant entitles the Holder hereof to receive copies of all financial and other information distributed or required to be distributed to the holders of the Company's Common Stock.

7. ASSIGNMENT; EXCHANGE OF WARRANT. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred by any registered holder hereof (a "Transferor") with respect to any or all of the shares of Common Stock. On the surrender for exchange of this Warrant, with the Transferor's endorsement in the form of Exhibit B attached hereto (the "Transferor Endorsement Form") and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable securities laws, the Company at its expense, but with payment by the Transferor of any applicable transfer taxes, will issue and deliver to or on the order of the Transferor thereof a new Warrant or Warrants of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a "Transferee"), calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the Warrant so surrendered by the Transferor.

5

8. REPLACEMENT OF WARRANT. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

9. REGISTRATION RIGHTS. The Holder of this Warrant has been granted certain registration rights by the Company. These registration rights are set forth in the Subscription Agreement. The terms of the Subscription Agreement are incorporated herein by this reference. Upon the occurrence of a Non-Registration Event, or in the event the Company is unable to issue Common Stock upon exercise of this Warrant that has been registered in a Registration Statement described in Section 10 of the Subscription Agreement, within the time periods described in the Subscription Agreement, which Registration Statement must be effective for the periods set forth in the Subscription Agreement, then upon written demand made by the Holder, the Company will pay to the Holder of this Warrant, in lieu of delivering Common Stock, a sum equal to the closing price of the Company's Common Stock on the principal market or exchange upon which the Common Stock is listed for trading on the trading date immediately preceding the date notice is given by the Holder, less the Purchase Price, for each share of Common Stock designated in such notice from the Holder.

10. MAXIMUM EXERCISE. The Holder shall not be entitled to exercise this Warrant on an exercise date in connection with that number of shares of Common Stock which would be in excess of the sum of (i) the number of shares of Common Stock beneficially owned by the Holder and its affiliates on an exercise date, and (ii) the number of shares of Common Stock issuable upon the exercise of this Warrant with respect to which the determination of this limitation is being made on an exercise date, which would result in beneficial ownership by the Holder and its affiliates of more than 9.99% of the outstanding shares of Common Stock on such date. For the purposes of the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. Subject to the foregoing, the Holder shall not be limited to aggregate exercises which would result in the issuance of more than 9.99%. The restriction described in this paragraph may be revoked upon sixty-one (61) days prior notice from the Holder to the Company. The Holder may allocate which of the equity of the Company deemed beneficially owned by the Subscriber shall be included in the 9.99% amount described above and which shall be allocated to the excess above 9.99%.

11. WARRANT AGENT. The Company may, by written notice to the Holder of the Warrant, appoint an agent (a "Warrant Agent") for the purpose of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 1, exchanging this Warrant pursuant to Section 7, and replacing this Warrant pursuant to Section 8, or any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by such Warrant Agent.

12. TRANSFER ON THE COMPANY'S BOOKS. Until this Warrant is transferred on the books of the Company, the Company may treat the registered holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

13. NOTICES. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii)

6

deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be: (i) if to the Company to: National Scientific Corporation, 14455 N. Hayden, Suite 202, Scottsdale, AZ 85260-6947, telecopier number: (480) 483-8893 948-8324, with a copy by telecopier only to: Susan Regan, Esq., 14455 N. Hayden, Suite 202, Scottsdale, AZ 85260-6947, telecopier: (480) 483-8893, and (ii) if to the Holder, to the address and telecopier number listed on the first paragraph of this Warrant, with a copy by telecopier only to:
Grushko & Mittman, P.C., 551 Fifth Avenue, Suite 1601, New York, New York 10176, telecopier number: (212) 697-3575.

14. MISCELLANEOUS. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant shall be construed and enforced in accordance with and governed by the laws of New York. Any dispute relating to this Warrant shall be adjudicated in New York County in the State of New York. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

IN WITNESS WHEREOF, the Company has executed this Warrant as of the date first written above.

NATIONAL SCIENTIFIC CORPORATION

By:

Name:


Title:

Witness:


7

EXHIBIT A

FORM OF SUBSCRIPTION
(To be signed only on exercise of Warrant)

TO: NATIONAL SCIENTIFIC CORPORATION.

The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant for, and to purchase thereunder, __________ shares of Common Stock of National Scientific Corporation and herewith makes payment of $_______ therefor, and requests that the certificates for such shares be issued in the name of, and delivered to ________________________________ whose address is ____________________________________________________________________________.

The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the "Securities Act") or pursuant to an exemption from registration under the Securities Act.

Dated: ___________________


(Signature must conform to name of holder as specified on the face of the Warrant)


(Address)

8

EXHIBIT B

FORM OF TRANSFEROR ENDORSEMENT
(To be signed only on transfer of Warrant)

For value received, the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading "Transferees" the right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of NATIONAL SCIENTIFIC CORPORATION to which the within Warrant relates specified under the headings "Percentage Transferred" and "Number Transferred," respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on the books of NATIONAL SCIENTIFIC CORPORATION with full power of substitution in the premises.

------------------------- ---------------------------- -------------------------
TRANSFEREES                  PERCENTAGE TRANSFERRED        NUMBER TRANSFERRED
------------------------- ---------------------------- -------------------------

------------------------- ---------------------------- -------------------------

------------------------- ---------------------------- -------------------------

------------------------- ---------------------------- -------------------------

Dated: ______________, _____
(Signature must conform to name of holder as specified on the face of the warrant)

Signed in the presence of:


(Name)
(address)

ACCEPTED AND AGREED:
[TRANSFEREE]


(address)
(Name)

9

EXHIBIT 5.1

DAVID M. DOBBS P.C. ATTORNEY & COUNSELOR
8655 VIA DE VENTURA, SUITE G-200 DAVID M. DOBBS SCOTTSDALE, ARIZONA 85258
(480) 922-0077 Telephone
(928) 468-8118 Fax david.dobbs@azbar.org E-mail

June 23, 2004

National Scientific Corporation
14455 North Hayden Road
Suite 202
Scottsdale, Arizona 85260

Re: National Scientific Corporation Registration Statement on Form SB-2

Gentlemen:

We have acted as special counsel to National Scientific Corporation, Texas corporation (the "Company") in connection with the preparation and filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Act") on a registration statement on Form SB-2 (the "Registration Statement"). The Registration Statement relates to the registration of 10,334,266 shares of the Company's common stock (the "Shares") to be sold by the Selling Securityholders identified in the Registration Statement and the registration for resale of 10,669,197 shares (the "Warrant Shares") of common stock underlying warrants (the "Warrants") issued to the Selling Securityholders.

In our capacity as counsel to the Company and for purposes of providing the opinion specified in this letter, we have examined the Registration Statement, the Articles of Incorporation as amended and the Bylaws each as currently in effect, certain resolutions of the Board of Directors of the Company and such other documents and certificates of public officials and certificates of officers of the Company as we have deemed relevant and necessary as a basis for the opinions hereinafter expressed. For these purposes, we have relied upon information provided by (i) public officials, (ii) officers of the Company, and
(iii) other persons as to certain factual matters, and we have made no independent investigation thereof. We have assumed (i) the genuineness of all signatures, (ii) the authenticity of all documents submitted to us as originals,
(iii) the conformity to the original documents of all documents submitted to us as certified or photostatic copies, and (iv) the authenticity of the originals of the latter documents.

1. Based upon the foregoing it is our opinion that the Shares have been duly authorized and are validly issued, fully paid and nonassessable.

2. The Warrant Shares have been duly authorized and, when issued against payment of the requisite exercise price, will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement.

Sincerely,

David M. Dobbs, P.C.

/s/ David M. Dobbs
----------------------------
By: David M. Dobbs, President


EXHIBIT 10.2

EMPLOYMENT AGREEMENT

This Employment Agreement ("Agreement") is entered between National Scientific Corporation and Graham Clark, effective the date it has been fully executed by both parties. "NSC," "Employer," or "Company" as used in this Agreement means National Scientific Corporation and/or its subsidiaries or affiliate corporations located in the United States or elsewhere. "Employee" or "Clark" as used in this Agreement means Graham Clark.

For good and valuable consideration, including the covenants set forth herein, the parties agree as follows:

1. DISPLACEMENT OF EXISTING CONTRACTS: This Agreement supersedes and entirely revokes, abrogates, and displaces any and all existing independent contractor agreements and other agreements between the parties hereto, if any.

2. POSITION AND DUTIES OF EMPLOYEE: Effective January 1, 2003, Clark is retained by NSC in the position of Vice President of Technology Application and Sales, and Director and Board Secretary. Clark will perform such duties as are assigned by senior management consistent with that position and will devote his full knowledge, skills, attention, and efforts to the business of the Company.

3. PERIOD OF EMPLOYMENT: The term of this Agreement ("Period of Employment") will be one (1) year, commencing January 1, 2003, unless sooner terminated according to the provisions set forth herein. This Agreement will be self-renewing for subsequent one-year Periods of Employment unless one of the parties notifies the other in writing at least thirty days before the end of the then-current Period of Employment of his/its intent not to renew.

4. COMPENSATION: For his services under this Agreement, Clark will:

a. receive an annual gross salary of One Hundred Twenty Thousand Dollars ($120,000.00), payable monthly. Adjustments to annual

1

salary are to be determined by senior management and/or the Board of Directors. Adjustments to annual salary must be in writing. The cash portion of this salary may be deferred as described in Exhibit A to this Agreement, titled "Salary Deferral Agreement."

b. be entitled to participate in benefits programs offered employees of NSC in his benefits classification.

c. be entitled to four (4) weeks of paid vacation per year.

d. be eligible for future cash and stock incentives the Company may, in its sole discretion, decide to offer him, including the Stock Retainage Plan ("Stock Retainage Plan Agreement") as shown in Exhibit B.

e. be assisted with payment of legal fees and with other appropriate actions associated with securing "Green Card" US immigration status.

5. EXPENSES: NSC will reimburse Clark for all reasonable business expenses incurred and documented in compliance with Company policy and procedure.

6. EXTERNAL COVENANTS AND RESTRICTIONS: Clark certifies that he has notified NSC and provided NSC a copy of any and all restrictive covenants and similar obligations he may have undertaken by reason of a prior employment or other relationship. Clark agrees not to undertake, during his employment by NSC, any external obligation that could restrict his ability to perform his duties under this Agreement.

7. OWNERSHIP OF WORK PRODUCT: Clark acknowledges and agrees that the nature of his services to NSC and its clients/customers may have involved and continue to involve development and/or improvement of technology, systems, processes, procedures, computer-software programs, other programs, and related documentation.

2

a. Clark agrees that all new or improved technology, systems, processes, procedures, computer-software programs, other programs, related documentation and intellectual property that Clark has or has had any part in developing or improving THAT RELATE DIRECTLY TO ACTIVE AREAS OF NSC BUSINESS INTEREST will be and remain the sole and exclusive property of NSC and that Clark will acquire no right, title, or interest therein. Clark further agrees to execute any and all documents necessary for NSC to secure and protect its interest in any such technology, systems, processes, procedures, computer-software programs, other programs, related documentation and intellectual property, including but not limited to documents related to non-disclosure, patents, licenses, or copyrights, whether of any state, federal, or foreign government. . Clark agrees that, upon termination of his employment for any reason whatsoever, he will surrender and deliver to NSC all such information and materials

b. Clark further acknowledges and expressly agrees that all files, records, lists, books, literature, correspondence, documents, services, products and data of any type whatsoever related to or used in the conduct of the business of NSC, its customers/clients, or prospective customers/clients will remain the property of NSC. Clark agrees that, upon termination of his employment for any reason whatsoever, he will surrender and deliver to NSC all such information and materials.

c. The parties agree that this section survives the termination of this Agreement for a period of two (2) years from the date of such termination.

8. CONFIDENTIAL INFORMATION: Clark acknowledges that, in the course of his existing contract with NSC and this employment, he will generate work products, has acquired and will be acquiring, using, and adding to confidential information of a special and unique nature and value. Clark acknowledges and understands that NSC is in a highly competitive business and that its success depends in significant part on maintaining a competitive advantage. Clark acknowledges and understands that NSC maintains and uses work product and confidential information to gain and maintain such a competitive advantage.

3

a. For the purposes of this Agreement, "confidential Information" is that which is not routinely disclosed by the management or Board of Directors of NSC in response to inquiries and is not readily obtainable elsewhere without expenditure of significant time, effort, or expense. "Confidential information" includes but is not limited to information related to the business, operations, assets, systems, plans, work products, contracts, procedures, processes, intellectual property, documentation, computer programs, or software products of NSC and/or its customers or clients and any information about the development or improvement of any technology by NSC and/or its customers or clients. Information obtained by Clark in the course of his previous work with NSC or his employment under this Agreement is confidential information unless it can reasonably be presumed to be in the public domain.

b. Clark agrees that he will not, during or after his employment, disclose any confidential information to any person(s) without the express written permission of NSC.

c. Clark acknowledges and agrees that any disclosure of confidential information by him will constitute a material breach of this Agreement and cause for termination of this Agreement and will give rise to such other legal remedies as NSC may elect to pursue.

d. The parties agree that this section survives the termination of this Agreement.

9. AGREEMENT NOT TO COMPETE: Clark acknowledges that, in addition to confidential information which he generates or to which he has or had access and will have access during the course of his employment, he will be given the opportunity to develop and maintain close personal rapport and good relations on behalf of NSC with other employees of NSC and with existing and future customers

4

and prospective customers of NSC. Clark agrees that during the Period of Employment and any extension thereof and for a period of one (1) year after termination of this Agreement, he will not, directly or indirectly, as owner, partner, principal, shareholder, director, officer, agent, or in any other capacity:

a. solicit, divert, or accept business from any current or prospective customer or client of NSC with whom Clark had contact in his capacity as an employee or contractor of NSC during the one-year period before termination of this Agreement or

b. employ or solicit for employment any employee of NSC with whom Clark worked during the one-year period before termination of this Agreement.

c. For purposes of this Agreement, a "prospective" customer or client is one that, during the one-year period before termination of this Agreement, received a proposal from NSC or whose business was demonstrably solicited by NSC.

d. The parties agree that this section survives the termination of this Agreement by one (1) year from such termination, unless such termination is via section 10.c below, in which case this section will survive thirty (30) days from such termination via section 10.c below.

10. TERMINATION OF EMPLOYMENT: This Agreement will terminate as provided in Section 3 unless sooner terminated pursuant to any of the following events.

a. This Agreement will terminate upon mutual written agreement of NSC and Clark, in accordance with the terms of that mutual agreement.

b. This Agreement will terminate upon the sale of all or substantially all of the assets or outstanding capital stock of NSC or any other material change in control of the Company. In the event of such termination, NSC will pay Clark an amount equivalent to fifty percent (50%) of his then-current annual gross salary.

5

c. This Agreement will terminate upon the liquidation, dissolution or bankruptcy of NSC. In the event of such termination, however, NSC will pay Clark an amount equivalent to twenty-five percent (25%) of his then-current annual gross salary.

d. This Agreement will terminate on the date of Clark's death.

e. Clark may terminate this Agreement without cause upon thirty (30) days written notice to NSC. In the event of such termination, Clark will be entitled only to compensation earned on or before the final date of employment.

f. NSC may terminate this Agreement without cause upon written notice to Clark. In the event of such termination, however, NSC will pay Clark a lump sum payment equivalent twenty-five percent (25%) of his then-current annual gross salary.

g. Notwithstanding any other provision hereof, NSC may terminate this Agreement and Clark's employment for cause upon written notice to Clark, specifying the cause for termination. "Cause for termination" is defined as any of the following: neglect of duties, insubordination, failure to comply with lawful instructions, fraud, theft, habitual drunkenness or substance abuse, unethical business conduct, conviction of a felony, any act or failure to act that would constitute a felony if prosecuted pursuant to applicable criminal statutes, any material breach of this Agreement, any willful or repeated violation of material company policy; failure to comply with applicable federal or state statute or regulations in trading Company stock. In the event of termination for cause, Clark will be entitled only to compensation earned on or before the final date of employment.

11. SCOPE AND MODIFICATION OF AGREEMENT: The parties agree that this Agreement contains the entire agreement between the parties concerning Clark's employment by NSC, except for any existing Stock Option Agreements between NSC

6

and Clark, which remain in force. All previous and contemporaneous statements and representations by either party are of no effect and are expressly superseded and replaced by this Agreement. Neither party has relied on any statement or representation by the other party or any representative of the other party that is not expressly stated in this Agreement. Changes or amendments to this Agreement are of no effect unless in writing signed by both parties.

12. SEVERABILITY: The provisions herein entitled Position and Duties of Employee, Compensation, Expenses, Termination of Employment, and Prohibition of Assignment are not severable. The ruling of any court or arbitrator of competent jurisdiction that any severable provision is void, voidable, or otherwise unenforceable shall have no effect on the validity and enforceability of any other provision.

13. PROHIBITION OF ASSIGNMENT: This Agreement is personal to Clark and neither party can assign his/its performance obligations hereunder to any third party. Notwithstanding that, the rights of the parties under this Agreement inure to the benefit of their respective successors, heirs, and assigns.

14. CHOICE OF LAW: This Agreement is to be construed and interpreted in accordance with the laws of Arizona, except as those laws may be preempted by federal law. No action involving this Agreement may be brought except as provided in Sections 17 and 18 below, and no court action challenging the enforceability of Section 17 may be brought except in the United States District Court for the District of Arizona.

15. WAIVER: Waiver by either party of any breach under this Agreement shall not operate as a waiver of any subsequent breach of the same or any other provision of this Agreement.

16. NOTICES: Any notice required under this Agreement shall be sufficient if given in writing and sent by registered mail to the below address of the party to be noticed.

7

National Scientific Corporation         Graham Clark
14455 N. Hayden Rd Road                 15449 N. Cabrillo Drive
Suite 202                               Fountain Hills, AZ. 85268
Scottsdale, Arizona 85260

17. ARBITRATION OF CLAIMS AND DISPUTES: Except as otherwise expressly provided in this Agreement, any civil claim (except workers' compensation and unemployment compensation claims) which arises out of or relates in any way to this Agreement, to the parties' existing contract, or to the employment relationship between the parties shall be settled by exclusive, binding, and final arbitration in Phoenix, Arizona, in accordance with the following terms and procedures. This includes but is not limited to claims arising under the common law of contract, tort, or crimes and claims arising under any federal, state, county, or municipal constitution, charter, statute, rule, or regulation.
THE PARTIES EXPRESSLY AGREE TO FOREGO ANY RIGHT TO TRIAL BY A JUDGE AND/OR JURY IN FAVOR OF FINAL, BINDING, AND EXCLUSIVE ARBITRATION.

a. The party with a civil claim must notify the other party in writing by registered mail within the times set forth by statute for filing a civil claim of the type asserted of its desire to have the claim resolved by arbitration.

b. Upon notice of a timely civil claim, the parties will agree upon an arbitrator or, if unable to agree, will request a list from the American Arbitration Association or some other mutually-agreed-upon provider of arbitrators from which list the parties will alternate strikes until only one name remains. That last remaining name will be the arbitrator. If that person is unavailable, the name last struck will be the arbitrator, and so forth until an arbitrator is secured.

c. The arbitrator shall have no authority to add to, subtract from, or otherwise modify the terms of this Agreement or to make awards beyond those provided for by the statute or other theory of action under which the claim arises. Both parties must submit for arbitration at this time or permanently forego any and all existing claims against the other party arising from this Agreement, the existing contract between the parties, or the employment relationship between them.

8

d Any party to the arbitration may be represented by counsel. Each party shall bear his/its own attorney's fees. The party producing a witness is responsible for paying that witness' fees and expenses. The arbitrator's fees and expenses, including required travel and per diem costs, and the cost of any evidence or proof produced at the arbitrator's direction are apportionable and shall be borne as determined by the arbitrator. All decisions of the arbitrator made in accordance with this policy shall be final and conclusively binding upon the parties. The parties agree that the arbitrator's award may be entered as a judgment by any court of competent jurisdiction.

e. Issues of procedure, arbitrability, appeal, or confirmation of award shall be governed by the Federal Arbitration Act, 9 U.S.C. sections 1-16.

f. The parties agree that this section survives the termination of this Agreement.

18. RIGHT TO INJUNCTIVE RELIEF: Notwithstanding the parties' agreement to arbitrate any and all civil claims that may arise from this Agreement, their existing contract, or the employment relationship between them, Clark acknowledges and agrees that any breach or threatened breach of Section 8 or
Section 9 will cause NSC irreparable harm and entitle NSC to such injunctive relief as may be necessary to prevent such a breach by Clark and/or any person acting for or with him. This right to injunctive relief is in addition to and without limitation of any other rights, remedies, or damages available to NSC under this Agreement or at law or in equity. Clark shall reimburse NSC its costs and reasonable attorney's fees incurred in obtaining such injunctive relief.

19. DAMAGES FOR BREACH: NSC's liability to Clark for wrongful termination of this Agreement or any other breach thereof shall not exceed the amount of actual damages proven and, in any case, shall not exceed the amount of compensation and expenses Clark did not receive and would have received had he completed the then-current Period of Employment.

20. INDEPENDENT LEGAL COUNSEL: Each of the parties agrees that he/it has read and understands the terms of this Agreement and that he/it has had ample

9

opportunity to seek the counsel of his/its own attorney before executing this Agreement.

21. EXECUTION IN COUNTERPARTS: This Agreement may be executed in counterparts with the same effect as if the parties had signed the same document. The counterparts shall be construed together and shall constitute one Agreement.

10

      National Scientific Corporation            Graham Clark

By:   /s/ Michael A. Grollman              By:   /s/ Graham L. Clark
      -------------------------------            -------------------------------

Its:  CEO                                  Date: 1/1/2003
      -------------------------------            -------------------------------


Date: 1/1/2003
      -------------------------------

11

EXHIBIT A: SALARY DEFERAL AGREEMENT

THIS SALARY DEFFERAL AGREEMENT (hereinafter referred to as this "Deferral Agreement") made effective as of the 1st day of September 2002, is entered into by and between NATIONAL SCIENTIFIC CORPORATION, a Texas corporation ("NSC" or "Company") based in Scottsdale, AZ, and Graham Clark, whose principal residence is Fountain Hills, AZ ("Employee"). The aforementioned persons and entities are sometimes collectively referred to herein as the "parties" or "Parties" and individually as a "party."

RECITALS

WHEREAS, NSC is the current employer of the Employee; and

WHEREAS, NSC has paid the employee a gross salary each month for the last 12 months of approximately $10,000 in cash and other liquid forms, including stock option agreements; and

WHEREAS, NSC and the Employee have agreed that the Employee is willing to defer on a temporary basis a future portion of salary to assist the Company during a period of Company financial hardship;

NOW, THEREFORE, in consideration of the agreement by the parties and other good and valuable consideration, the receipt, adequacy and sufficiency of which is hereby acknowledged and confessed, the parties hereby agree as follows:

1. Each of the foregoing recitals is incorporated in this Deferral Agreement as a material term and condition.

2. The Employee agrees that for the one monthly payroll cycles during the month of September 2002 that the Company can defer the gross salary payment made to the Employee of $10,000, resulting in a total deferred amount ("Deferred Amount") for the month of $10,000.

3. The Company agrees and acknowledges that the Deferred Amount remains due and payable, with an annual interest rate of the Wells Fargo published prime rate plus 2% calculated from the date of the scheduled monthly payroll to the Employee by the Company, and that the Employee has the right to demand payment of the Differed Amount plus accrued interest at any time, and that the Company, if commercially reasonable and able, will make such a payment to the Employee immediately at the point of such demand.

4. The parties agree that NSC must seek the on-going written affirmation of the Employee to the terms of this Deferral Agreement each month by the 1st calendar day of that month, or this Agreement will terminate automatically. The Deferral Agreement will also terminate upon 30 days written notice by either party.

5. The Deferred Amount may change on a month by month basis, as documented in this Agreement.

1

6. The Employee has agreed to exchange $10,000 of this total deferred amount in Exchange for one "B Unit" under the Company's November 2002 Private Placement Offering Memorandum, when and if that Private Placement Offering is available.

7. The term of this Salary Deferral Agreement is from September 30, 2002 to December 31, 2003.

IN WITNESS WHEREOF, the Parties have executed this Deferral Agreement in Scottsdale, Arizona, on the date set forth beside their respective names.

NATIONAL SCIENTIFIC CORPORATION

By:   /s/ Michael A. Grollman
      -------------------------

Its:  CEO
      -------------------------

Date: September 1, 2002
      -------------------------

EMPLOYEE

By:   /s/ Graham L. Clark
      -------------------------

Its:  President
      -------------------------

Date: September 1, 2002
      -------------------------

2

EMPLOYEE AFFIRMATION OF SALARY DEFERRAL

By signing below each month, Employee affirms agrees to continue the salary deferral as described on the attached SALARY DEFFERAL AGREEMENT:

       Month             Deferred Amount           Approval
--------------------     ---------------      -------------------

       Sept-02                10,000

       Oct-02                 10,000

       Nov-02                 10,000

       Dec-02                  3,000

       Jan-03                  3,000

       Feb-03

       Mar-03

       Apr-03

       May-03

       Jun-03

       Jul-03

       Aug-03

       Sep-03

       Oct-03

       Nov-03

Dec-03

3

EXHBIT B: STOCK RETAINAGE PLAN AGREEMENT

THIS STOCK RETAINAGE PLAN AGREEMENT (hereinafter referred to as this "Stock Plan Agreement") made effective as of the 30th day of September 2002, is entered into by and between NATIONAL SCIENTIFIC CORPORATION, a Texas corporation ("NSC" or "Company") based in Scottsdale, AZ, and Graham Clark, whose principal residence is Fountain Hills, AZ ("Employee"). The aforementioned persons and entities are sometimes collectively referred to herein as the "parties" or "Parties" and individually as a "party."

RECITALS

WHEREAS, NSC is the current employer of the Employee; and

WHEREAS, NSC and the Employee have agreed that the Employee is willing to defer on a temporary basis a future portion of salary to assist the Company during a period of Company financial hardship as shown in Exhibit A, Salary Deferral Agreement;

WHEREAS, NSC's common stock ("Common Stock") has a market value at this month of September 2002 of approximately 7 cents per share, and this same Common Stock, restricted under SEC rule 144, would be expected to have a lower market value, were it salable on an open market;

WHEREAS, NSC's total revenues in calendar year 2002 through September 30, 2002 were less than $3,000;

WHEREAS, NSC and the Employee have agreed that the Employee is willing to provide best efforts to ensure the Company succeeds in growing its sales over the next fiscal year and beyond;

NOW, THEREFORE, in consideration of the agreement by the parties and other good and valuable consideration, the receipt, adequacy and sufficiency of which is hereby acknowledged and confessed, the parties hereby agree as follows:

1. Each of the foregoing recitals is incorporated in this Stock Plan Agreement as a material term and condition.

2. The Company agrees today to grant the Employee 500,000 shares of its Common Stock, restricted under SEC rule 144, provided that the Company revenues in calendar year 2003 surpass $200,000, a large increase over calendar year 2002, and also provided that the Employee remain continuously in the employment of NSC throughout this 2003 period. Should this not occur, this stock grant will be forfeited by the Employee, and such stock promptly returned to NSC.

3. The Company agrees to grant the Employee an additional 500,000 shares of its Common Stock, restricted under SEC rule 144, provided that the Company revenues in calendar year 2003 surpass $1,000,000, a large increase over calendar year 2002, and also provided that the Employee remain continuously in the employment of NSC throughout this 2003 period. Should this not occur, this stock grant will be forfeited by the Employee, and such stock promptly returned to NSC.

1

4. Such stock grants will be issued by NSC at the earliest reasonable date.

5. If Common Stock granted under this Agreement should be promptly returned to the Company, and is not promptly returned, the Company may take steps to cancel or otherwise nullify the grant of such shares of Common Stock as should be promptly returned, with the Employee bearing all costs incurred through this process.

6. The term of this Stock Plan Retainage Agreement is from September 30, 2002 to December 31, 2003.

IN WITNESS WHEREOF, the Parties have executed this Stock Plan Retainage Agreement in Scottsdale, Arizona, on the date set forth beside their respective names.

NATIONAL SCIENTIFIC CORPORATION

By:   /s/ Michael A. Grollman
      -------------------------

Its:  CEO
      -------------------------

Date: September 30, 2002
      -------------------------

EMPLOYEE

By:   /s/ Graham L. Clark
      -------------------------

Its:  President
      -------------------------

Date: September 30, 2002
      -------------------------

2

2003-4 STOCK RETAINAGE PLAN AGREEMENT
AMENDMENT

THIS STOCK RETAINAGE PLAN AGREEMENT (hereinafter referred to as this "Stock Plan Agreement") made effective as of the 30th day of September 2003, is entered into by and between NATIONAL SCIENTIFIC CORPORATION, a Texas corporation ("NSC" or "Company") based in Scottsdale, AZ, and Graham Clark, whose principal residence is Fountain Hills, AZ ("Employee"). The aforementioned persons and entities are sometimes collectively referred to herein as the "parties" or "Parties" and individually as a "party."

RECITALS

WHEREAS, NSC is the current employer of the Employee; and

WHEREAS, NSC and the Employee have agreed that the Employee is willing to defer on a temporary basis a future portion of salary to assist the Company during a period of Company financial hardship as shown in Exhibit A, Salary Deferral Agreement;

WHEREAS, NSC's common stock ("Common Stock") has a market value at this month of September 2003 of approximately .13 cents per share, and this same Common Stock, restricted under SEC rule 144, would be expected to have a lower market value, were it salable on an open market;

WHEREAS, NSC's total revenues in calendar year 2003 through September 30, 2003 were less than $100,000;

WHEREAS, NSC and the Employee have agreed that the Employee is willing to provide best efforts to ensure the Company succeeds in growing its sales over the next fiscal year and beyond;

NOW, THEREFORE, in consideration of the agreement by the parties and other good and valuable consideration, the receipt, adequacy and sufficiency of which is hereby acknowledged and confessed, the parties hereby agree as follows:

1. Each of the foregoing recitals is incorporated in this Stock Plan Agreement as a material term and condition.

2. The Company agrees today to grant the Employee 500,000 shares of its Common Stock, restricted under SEC rule 144, provided that the Company revenues in calendar year 2004 surpass $500,000, a large increase over calendar year 2003, and also provided that the Employee remain continuously in the employment of NSC throughout this 2004 period. Should this not occur, this stock grant will be forfeited by the Employee, and such stock promptly returned to NSC.

3. The Company agrees to grant the Employee an additional 500,000 shares of its Common Stock, restricted under SEC rule 144, provided that the Company revenues in calendar year 2003 surpass $1,500,000, a large increase over calendar year 2003, and also provided that the Employee remain continuously in the employment of NSC throughout this 2004 period. Should this not occur, this stock grant will be forfeited by the Employee, and such stock promptly returned to NSC.

1

4. Such stock grants will be issued by NSC at the earliest reasonable date.

5. If Common Stock granted under this Agreement should be promptly returned to the Company, and is not promptly returned, the Company may take steps to cancel or otherwise nullify the grant of such shares of Common Stock as should be promptly returned, with the Employee bearing all costs incurred through this process.

6. The term of this Stock Plan Retainage Agreement is from September 30, 2003 to December 31, 2004.

IN WITNESS WHEREOF, the Parties have executed this Stock Plan Retainage Agreement in Scottsdale, Arizona, on the date set forth beside their respective names.

NATIONAL SCIENTIFIC CORPORATION

By:   /s/ Michael A. Grollman
      -------------------------

Its:  CEO
      -------------------------

Date: September 30, 2003
      -------------------------

EMPLOYEE

By:   /s/ Graham L. Clark
      -------------------------

Its:  President
      -------------------------

Date: September 30, 2003
      -------------------------

2

EXHIBIT 10.3

NSC CONSULTING AGREEMENT

This Consulting Agreement (this "Agreement") is entered into as of August 1, 2001, by and between National Scientific Corporation, a Texas Corporation (the "Company"), and Dr. El-Badawy El-Sharawy (the "Consultant").

RECITALS

1. Consultant has expertise in the area of the Company's business and is willing to provide consulting services to the Company.

2. The Company is willing to engage Consultant as an independent contractor, and not as an employee, on the terms and conditions set forth herein.

AGREEMENT

In consideration of the foregoing and of the mutual promises set forth herein, and intending to be legally bound, the parties hereto agree as follows:

1. ENGAGEMENT.

a. The Company hereby engages Consultant to render, as an independent contractor, the consulting services described in Exhibit A hereto and such other services as may be agreed to in writing by the Company and Consultant from time to time.

b. Consultant hereby accepts the engagement to provide consulting services to the Company on the terms and conditions set forth herein.

2. TERM. This Agreement will commence on the date first written above, and unless modified by the mutual written agreement of the parties, shall continue until the satisfactory completion of the services set forth in Exhibit A, or for a period of two (2) years from the date of this Agreement, whichever is shorter. Company may terminate this Agreement upon 30 days written notice to Consultant.

3. COMPENSATION.

a. In consideration of the services to be performed by Consultant, the Company agrees to pay Consultant in the manner and at the rates set forth in Exhibit A.

b. Out of pocket expenses incurred by Consultant that are authorized in advance by the Company's Project Manager as describe din Exhibit A, and incurred and documented in accordance with the Company's published polices regarding out-of-pocket expenses, shall be reimbursed by Company to Consultant, as further defined in Exhibit A.

4. CONSULTANT'S BUSINESS ACTIVITIES.

a. Consultant shall devote such time, attention and energy to the business and affairs of the Company as requested by the Company, and in any event no less than the average amount of contact time specified in Exhibit A hereto.

NSC CONSULTING AGREEMENT: Page 1


b. Consultant shall keep and periodically provide to the Company a log describing the contract hours by Consultant, as defined in Exhibit A.

c. Consultant shall provide first right of refusal to the Company for any Invention or proposal to create an Invention that relates directly to the work defined in Exhibit A.

d. Consultant will be free to take any written proposal which the Consultant has presented to the Company that the Company has rejected or otherwise not acted upon for a period of 6 months after date of receipt, so long as this proposal does not contain information that would be defined as Confidential to the Company prior to the delivery of the proposal. "Acted" in this section only shall mean, "requested service related to the proposal, and paid for such service."

5. CONFIDENTIAL INFORMATION AND ASSIGNMENTS. Consultant is simultaneously executing a Confidential Information and Invention Assignment Agreement for Consultants in the form of Exhibit B (the "Confidential Information and Invention Assignment Agreement"). The obligations under the Confidential Information and Invention Assignment Agreement shall survive termination of this Agreement for any reason for a period of 5 years.

6. INTERFERENCE WITH THE COMPANY'S BUSINESS.

a. Notwithstanding any other provision of this Agreement, for a period of one year after termination of this Agreement, Consultant shall not employ, solicit for employment, or advise or recommend to any other person that such other person employ or solicit for employment, any person employed or under contract (whether as a consultant, employee or otherwise) by or to the Company during the period of such person's association with the Company and one year thereafter.

b. Notwithstanding any other provision of this Agreement, and to the fullest extent permitted by law, for a period of one year after termination of this Agreement, Consultant shall not directly solicit any clients or customers of the Company without first notifying the Company in writing. The Company has the right to request that the Consultant not pursue a given project with a given client or customers of the Company is such an action would he directly harmful or damaging to current active Company interests with that client or customer. The Consultant may not unreasonably refuse this request, and the Company shall not make such a request unless the potential for damage to the Company is clear and significant.

7. REPRESENTATIONS AND WARRANTIES. Consultant represents and warrants (i) that Consultant has no known obligations, legal or otherwise, inconsistent with the terms of this Agreement or with Consultant's undertaking this relationship with the Company, (ii) that the performance of the services called for by this Agreement do not and will not knowingly violate any applicable law, rule or regulation or any proprietary or other right of any third party, (iii) that Consultant will not use in the performance of his responsibilities under this Agreement any confidential information or trade secrets of any other person or entity and (iv) that Consultant has not entered into or will enter into any agreement in conflict with this Agreement.

8. ATTORNEY'S FEES. Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to litigation to enforce this Agreement, the party or parties prevailing in such litigation shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys' fees and costs in such litigation from the party or parties against whom enforcement was sought.

9. ENTIRE AGREEMENT. This Agreement, contains the entire understanding and agreement between the parties hereto with respect to its subject

NSC CONSULTING AGREEMENT: Page 2


matter and supersedes any prior or contemporaneous written or oral agreements, representations or warranties between them respecting the subject matter hereof.

10. AMENDMENT. This Agreement may be amended only by a writing signed by Consultant and by a representative of the Company duly authorized.

11. SEVERABILITY. If any term, provision, covenant or condition of this Agreement, or the application thereof to any person, place or circumstance, shall be held by a court of competent jurisdiction to be invalid, unenforceable or void, the remainder of this Agreement and such term, provision, covenant or condition as applied to other persons, places and circumstances shall remain in full force and effect.

12. NONWAIVER. No failure or neglect of either party hereto in any instance to exercise any right, power or privilege hereunder or under law shall constitute a waiver of any other right, power or privilege or of the same right, power or privilege in any other instance. All waivers by either party hereto must be contained in a written instrument signed by the party to be charged and, in the case of the Company, by an executive officer of the Company or other person duly authorized by the Company.

13. AGREEMENT TO PERFORM NECESSARY ACTS. Consultant agrees to perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Agreement.

14. ASSIGNMENT. This Agreement may not be assigned by Consultant without the Company's prior written consent. This Agreement may be assigned by the Company in connection with a merger or sale of all or substantially all of its assets, and in other instances with the Consultant's consent which consent shall not be unreasonably withheld or delayed.

15. COMPLIANCE WITH LAW. In connection with his services rendered hereunder, Consultant agrees to abide by all federal, state, and local laws, ordinances and regulations.

16. INDEPENDENT CONTRACTOR. The relationship between Consultant and the Company is that of independent contractor under a "work for hire" arrangement. All work product developed by Consultant shall be deemed owned and assigned to Company. This Agreement is not authority for Consultant to act for the Company as its agent or make commitments for the Company unless authorized explicitly in writing by the Company to make such a specific commitment. Consultant will not be eligible for any employee benefits, nor will the company make deductions from fees to the consultant for taxes, insurance, bonds or the like. Consultant retains the discretion in performing the tasks assigned, within the scope of work specified.

17. TAXES. Consultant agrees to pay all appropriate local, state and federal taxes.

18. GOVERNING LAW. This Agreement shall be construed in accordance with, and all actions arising hereunder shall be governed by, the laws of the State of Arizona.

NSC CONSULTING AGREEMENT: Page 3


Agreed to this date, 8/1/2001, in Phoenix, Arizona.

National Scientific Corporation Dr. El-Badawy El-Sharawy

By:    /s/ Michael A. Grollman             By:    /s/ Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Name:  Michael A. Grollman                 Name:  Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Title: CEO                                 Title: Consultant
       ------------------------------             ------------------------------

NSC CONSULTING AGREEMENT: Page 4


Exhibit A

1. DESCRIPTION OF SERVICES TO BE RENDERED

FIRST AREA: The Consultant shall provide consulting expertise in the area of electronic device and system design, manufacture, and testing, including resonators, inductors, transformers, HBT's, Distributed Amplifiers, memory designs including TMOS SRAM cell design. The deliverables for this area of work will vary on a month-to-month basis, and will be assigned by a designated project manager from the Company. This project manager will initially be Graham Clark, although the Company may change this assignment at any time by giving 7 days notice. Deliverables requested will be produced in a timely way with good quality, and include but are not limited to new designs, patent support materials, diagrams, test results, device prototypes, studies, and direct telephone or contact consulting hours. In addition to other deliverables, the Consultant will provide a monthly time report showing his activities, which upon approval by the project manager will form the basis calculation of compensation.

SECOND AREA: The Company specifically requests support in securing a patent on a mask device to be used in optimizing projection equipment. This device is the same device the parties have had under discussion for a number of years. The deliverables for this effort are a completed patent application, and those other documents as may be required to support the licensing of this patent to third parties.

2. MONTHLY COMPENSATION

For the First Area listed above, the Company will pay a $125 per contact hour of approved and documented work. The Company will pay each month of minimum retainer of $2000 per month in cash and $1000 per month in Stock Options (as defined below under "Stock Compensation"). The Consultant will receive this no less than this minimum retainer payment per month, even if the Consultant has not reported sufficient hours to generate that retainer when calculated on a hourly basis. However, the Consultant will only be paid the retainer upon submission and approval of his time report each month for contact hours.

Although the actual hours worked by the Consultant are expected to vary from month to month, the Company expects the Consultant on the average to deliver the Minimum Time To Be Expended as defined in (3) below. This amount may be increased or decreased by the Company based on as the Consultant's ability to deliver work or hours to the Company, or based on the current financial or business requirement of the Company.

For the Second Area listed above, the Company will pay the an additional 10% of net-of-company's-cost license fees generated and collected by this patent for the Company, up to a maximum payment of $2,000,000.

For purposes of this Agreement, "net-of-company's-cost license fees" shall mean the revenue derived by the Company from the sale of the technology product using the IP, less the cost of goods sold to have the product manufactured (if the Company manufactures it), and less the cost paid to other licensed holders whose products are used in the manufacture of the product, and less direct costs associated with achieving, supporting and maintaining the patent or intellectual property, including associated legal costs and any testing or development expenses associated with developing and proving the specific invention in question. Specifically excluded from "net-of-company's-cost license fees" calculation are such items as Company overhead, staff salaries, rent, utilities, and other general costs of operating the business that are not directly tied to the commercial exploitation of a specific license.

NSC CONSULTING AGREEMENT: Page 5


3. MINIMUM TIME TO BE EXPENDED

The Company expects an average 3 contact hours per week of time from the Consultant during the academic year, 5 contact average hours per week from the Consultant during the summer. The Consultant with also provide an unspecified number of non-contact Consulting hours on an as-needed basis.

4. PAYMENT TERMS

Payment to the Consultant will be net 7 business days or sooner from receipt by the accounting department of an approved time report.

NSC CONSULTING AGREEMENT: Page 6


5. SPECIAL BONUS COMPENSATION

After the filing and upon the award and issue of any new patents for which the Consultant has been the primary inventor and which have been filed according to the Company's standard approved procedures for filing, other than for the Mask Patent whose compensation is described separately under Compensation, the Company will pay the Consultant a bonus based on the mutually agreed value of the patent to the Company. This value agreement will fall into the following categories:

------------------------ ---------------------- --------------------- ---------------------- ----------------------
                         Class A                Class B               Class C                Class D
------------------------ ---------------------- --------------------- ---------------------- ----------------------
Description              This patent is         This patent is        This patent is         This patent is
                         expected to have       expected to have      expected to have       expected to have
                         major and dramatic     significant effects   significant effects    some effects on the
                         effects on the         on the technology     on the technology      technology
                         technology             marketplace, and to   marketplace, and to    marketplace, and to
                         marketplace, and to    generate revenues     generate revenues to   generate revenues to
                         generate revenues to   to the Company in     the Company in its     the Company in its
                         the Company in its     its first 5 years     first 5 years from     first 5 years from
                         first 5 years from     from date of issue    date of issue of       date of issue of
                         date of issue of       of more than          more than $10,000,000  more than $2,000,000
                         more than              $25,000,000
                         $100,000,000
------------------------ ---------------------- --------------------- ---------------------- ----------------------

Cash Portion of Bonus    $50,000                $25,000               $5,000                 $1000
------------------------ ---------------------- --------------------- ---------------------- ----------------------

Stock Option             $200,000               $100,000              $50,000                $10,000
Portion of Bonus
------------------------ ---------------------- --------------------- ---------------------- ----------------------

% of company's           8%                     4%                    1%                     0%
net-of-cost license
fees generated and
collected by this
patent for the Company
------------------------ ---------------------- --------------------- ---------------------- ----------------------

In no case will be total special bonus paid for any one patent exceed $5,000,000. In the event that the Company and the Consultant cannot reasonably agree on the Class of a given patent, the Company's estimate will be used until the actual market impact and revenues can be measured over an extended period of time, at which point the Consultant may request a change in bonus Class, which the Company shall not unreasonably withhold. If a patent is awarded which is less in impact and revenue than the Class D above, no bonus will be paid.

6. STOCK COMPENSATION

For purposes of this agreement, for Compensation to be provided in Stock Options, the Company will take the average closing price of NSCT common stock for the last 5 trading days before the end of a period, and this will be called the current share price of NSC stock. The Company will issue stock options at 75% of the value of this figure, with a one-year vesting period, which starts on the date of issue. In order to compute the number of options to be granted at this discount, the "Stock Option Dollars" shown in the table will be multiplied by 4. By way of example of not of limitation, to pay $1000 in stock option compensation if the NSCT share price is $1.00, the Company will issue 4000 options at $0.75 each.

Although stock option compensation will be earned monthly, all options contracts will be issued calculated quarterly for value accumulated during the previous 3 months, and will begin their vesting period on that date.

NSC CONSULTING AGREEMENT: Page 7


7. TRAVEL EXPENSES

When Consultant is requested in writing to travel exclusively on Company business, the Consultant will be reimbursed for his reasonable travel expenses as per the then-current Standard Company Expense Reimbursement Policy, a copy of which is maintained on the Company's primary internal web server for easy reference. Any hours spent traveling shall be billed to the Company at 1/2 of the normal hourly rate. When the Consultant is traveling for any purpose other than on exclusive Company business, no reimbursement will normally be provided for any travel expenses or travel time. Exceptions to this require a written approval by the project manager, and approved in writing by the CFO of National Scientific.

NSC CONSULTING AGREEMENT: Page 8


Exhibit B

CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT FOR CONSULTANT

This CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT (the "Agreement") is made between National Scientific Corporation, a Texas Corporation (the "Company") and the undersigned consultant.

In consideration of my relationship with the Company (which for purposes of this Agreement shall be deemed to include any subsidiaries or Affiliates of the Company), the receipt of confidential information while associated with the Company, and other good and valuable consideration, I, the undersigned individual, agree that:

1. TERM OF AGREEMENT. This Agreement shall continue in full force and effect for the duration of my relationship with the Company and shall continue thereafter until terminated through a written instrument signed by both parties.

2. CONFIDENTIALITY.

(a) DEFINITIONS. "Proprietary Information" is all information and any idea whatever form, tangible or intangible, pertaining in any manner to the business of the Company, or any of its Affiliates, or its employees, clients, consultants, or business associates, which was produced by any employee or consultant of the Company in the course of his or her employment or consulting relationship or otherwise produced or acquired by or on behalf of the Company. All Proprietary Information not generally known outside of the Company's organization, shall be deemed "Confidential Information." By example and without limiting the foregoing definition, Proprietary and Confidential Information shall include, but not be limited to:

(1) formulas, research and development techniques, processes, trade secrets, computer programs, software, electronic codes, mask works, inventions, innovations, patents, patent applications, discoveries, improvements, data, know-how, formats, test results, and research projects;

(2) information about costs, profits, markets, sales, contracts and lists of customers, and distributors;

(3) business, marketing, and strategic plans;

(4) forecasts, unpublished financial information, budgets, projections, and customer identities, characteristics and agreements; and

(5) employee personnel files and compensation information.

Confidential Information is to be broadly defined, and includes all information that has or could have commercial value or other utility in the business in which the Company is engaged or contemplates engaging, and all information of which the unauthorized disclosure could be detrimental to the interests of the Company, whether or not such information is identified as Confidential Information by the Company.

(b) EXISTENCE OF CONFIDENTIAL INFORMATION. The Company owns and has developed and compiled, and will develop and compile, certain trade secrets, proprietary techniques and other Confidential Information which have great value to its

NSC CONSULTING AGREEMENT: Page 9


business. This Confidential Information includes not only information disclosed by the Company to me, but also information developed or learned by me during the course of my relationship with the Company.

(c) PROTECTION OF CONFIDENTIAL INFORMATION. I will not use, make available, sell, disclose or otherwise communicate to any third party, other than in my assigned duties and for the benefit of the Company, any of the Company's Confidential Information, either during or after my relationship with the Company. In the event I desire to publish the results of my work for the Company through literature or speeches, I will submit such literature or speeches to the President of the Company at least 10 days before dissemination of such information for a determination of whether such disclosure may alter trade secret status, may be prejudicial to the interests of the Company, or may constitute an invasion of its privacy. I agree not to publish, disclose or otherwise disseminate such information without prior written approval of the President of the Company. I acknowledge that I am aware that the unauthorized disclosure of Confidential Information of the Company may be highly prejudicial to its interests, an invasion of privacy, and an improper disclosure of trade secrets.

(d) DELIVERY OF CONFIDENTIAL INFORMATION. Upon request or when my relationship with the Company terminates, I will immediately deliver to the Company all copies of any and all materials and writings received from, created for, or belonging to the Company including, but not limited to, those which relate to or contain Confidential Information.

(e) LOCATION AND REPRODUCTION. I shall maintain at my workplace only such Confidential Information as I have a current "need to know." I shall return to the appropriate person or location or otherwise properly dispose of Confidential Information once that need to know no longer exists. I shall not make copies of or otherwise reproduce Confidential Information unless there is a legitimate business need of the Company for reproduction.

(f) PRIOR ACTIONS AND KNOWLEDGE. I represent and warrant that from the time of my first contact with the Company I held in strict confidence all Confidential Information and have not disclosed any Confidential Information, directly or indirectly, to anyone outside the Company, or used, copied, published, or summarized any Confidential information, except to the extent otherwise permitted in this Agreement.

(g) THIRD-PARTY INFORMATION. I acknowledge that the Company has received and in the future will receive from third parties their confidential information subject to a duty on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree that I will at all times hold all such confidential information in the strictest confidence and not to disclose or use it, except as necessary to perform my obligations hereunder and as is consistent with the Company's agreement with such third parties.

(h) THIRD PARTIES. I represent that my relationship with the Company does not and will not breach any agreements with or duties to a former employer or any other third party. I will not disclose to the Company or use on its behalf any confidential information belonging to others and I will not bring onto the premises of the Company any confidential information belonging to any such party unless consented to in writing by such party.

(i) Consultant will be free to take any written proposal which the Consultant has presented to the Company that the Company has rejected or otherwise not acted upon for a period of 6 months after date of receipt, so long as this proposal does not contain information that would be defined as Confidential to the Company prior to the delivery of the proposal. "Acted" in this section only shall mean, "requested service related to the proposal, and paid for such service."

3. PROPRIETARY RIGHTS, INVENTIONS AND NEW IDEAS.

(a) DEFINITION. The term "Subject Ideas or Inventions" includes any and all ideas, processes, trademarks, service marks, inventions, designs, technologies, computer hardware or software, original works of authorship, formulas, discoveries, patents, copyrights, copyrightable works products, marketing and business ideas, and all improvements, know-how, data, rights, and claims related

NSC CONSULTING AGREEMENT: Page 10


to the foregoing that, whether or not patentable, which are conceived, developed or created which; (1) relate directly to the Company's program of research or development as defined in Exhibit A; (2) result from any work performed by me for the Company; (3) involve the use of the Company's equipment, supplies, facilities or trade secrets; (4) result from or are suggested by any work done by the Company or at the Company's request, or any projects specifically assigned to me; or (5) result from my access to any of the Company's memoranda, notes, records, drawings, sketches, models, maps, customer lists, research results, data, formulae, specifications, inventions, processes, equipment or other materials (collectively, "Company Materials").

(b) COMPANY OWNERSHIP. All right, title and interest in and to all Subject Ideas and Inventions, including but not limited to all registrable and patent rights which may subsist therein, shall be held and owned solely by the Company, and where applicable, all Subject Ideas and Inventions shall be considered works made for hire. I shall mark all Subject Ideas and Inventions with the Company's copyright or other proprietary notice as directed by the Company and shall take all actions deemed necessary by the Company to protect the Company's rights therein. In the event that the Subject Ideas and Inventions shall be deemed not to constitute works made for hire, or in the event that I should otherwise, by operation of law, be deemed to retain any rights (whether moral rights or otherwise) to any Subject Ideas and Inventions, I agree to assign to the Company, without further consideration, my entire right, title and interest in and to each and every such Subject Idea and Invention.

(c) DISCLOSURE. I agree to disclose promptly to the Company full details of any and all Subject Ideas and Inventions.

(d) MAINTENANCE OF RECORDS. I agree to keep and maintain adequate and current written records of all Subject Ideas and Inventions and their development made by me (solely or jointly with others) during the term of my relationship with the Company. These records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. These records will be available to and remain the sole property of the Company at all times.

(e) DETERMINATION OF SUBJECT IDEAS AND INVENTIONS. I further agree that all information and records pertaining to any idea, process, trademark, service mark, invention, technology, computer hardware or software, original work of authorship, design, formula, discovery, patent, copyright, product, and all improvements, know-how, rights, and claims related to the foregoing ("Intellectual Property"), that I do not believe to be a Subject Idea or Invention, but that is conceived, developed, or reduced to practice by the Company (alone by me or with others) during my relationship with the Company and for one (1) year thereafter, shall be disclosed promptly by me to the Company. The Company shall examine such information to determine if in fact the Intellectual Property is a Subject Idea or Invention subject to this Agreement.

(f) ACCESS. Because of the difficulty of establishing when any Subject Ideas or Inventions are first conceived by me, or whether it results from my access to Confidential Information or Company Materials, I agree that any Subject Idea and Invention shall, among other circumstances, be deemed to have resulted from my access to Company Materials if: (1) it grew out of or resulted from my work with the Company or is related to the business of the Company as defined in Exhibit A, and (2) it is made, used, sold, exploited or reduced to practice, or an application for patent, trademark, copyright or other proprietary protection is filed thereon, by me or with my significant aid, within one year after termination of my relationship with the Company.

(g) ASSISTANCE. I further agree to assist the Company in every proper way (but at the Company's expense) to obtain and from time to time enforce patents, copyrights or other rights or registrations on said Subject Ideas and Inventions in any and all countries, and to that end will execute all documents necessary:

(1) to apply for, obtain and vest in the name of the Company alone (unless the Company otherwise directs) letters patent, copyrights or other analogous protection in any country throughout the world and when so obtained or vested to renew and restore the same; and

(2) to defend any opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for revocation of such letters patent, copyright or other analogous protection; and

NSC CONSULTING AGREEMENT: Page 11


(3) to cooperate with the Company (but at the Company's expense) in any enforcement or infringement proceeding on such letters patent, copyright or other analogous protection.

(h) AUTHORIZATION TO COMPANY. In the event the Company is unable, after reasonable effort, to secure my signature on any patent, copyright or other analogous protection relating to a Subject Idea and Invention, whether because of my physical or mental incapacity or for any other reason whatsoever, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney-in-fact, to act for and on my behalf and stead to execute and file any such application, applications or other documents and to do all other lawfully permitted acts to further the prosecution, issuance, and enforcement of letters patent, copyright or other analogous rights or protections thereon with the same legal force and effect as if executed by me. My obligation to assist the Company in obtaining and enforcing patents and copyrights for Subject Ideas and Inventions in any and all countries shall continue beyond the termination of my relationship with the Company, but the Company shall compensate me at a reasonable rate after such termination for time actually spent by me at the Company's request on such assistance.

(i) ACKNOWLEDGEMENT. I acknowledge that there are no currently existing ideas, processes, inventions, discoveries, marketing or business ideas or improvements for the subject area of this Agreement as defined in Exhibit A which I desire to exclude from the operation of this Agreement. To the best of my knowledge, there is no other contract to assign inventions, trademarks, copyrights, ideas, processes, discoveries or other intellectual property that is now in existence between me and any other person (including any business or governmental entity).

(j) NO USE OF NAME. I shall not at any time use the Company's name or any the Company trademark(s) or trade name(s) in any advertising or publicity without the prior written consent of the Company.

4. COMPETITIVE ACTIVITY.

(a) ACKNOWLEDGMENT. I acknowledge that the pursuit of the activities forbidden by Section 4(b) below would necessarily involve the use, disclosure or misappropriation of Confidential Information.

(b) PROHIBITED ACTIVITY. To prevent the above-described disclosure, misappropriation and breach, I agree that during my relationship and for a period of one (1) year thereafter, without the Company's express written consent, I shall not, directly or indirectly, (i) employ, solicit for employment, or recommend for employment any person employed by the Company (or any Affiliate); and (ii) engage in any present or contemplated business activity that is or may be competitive with the Company (or any Affiliate) in any state where the Company conducts its business, unless I can prove that any action taken in contravention of this subsection (ii) was done without the use in any way of Confidential Information.

5. REPRESENTATIONS AND WARRANTIES. I represent and warrant (i) that I have no obligations, legal or otherwise, inconsistent with the terms of this Agreement or with my undertaking a relationship with the Company; (ii) that the performance of the services called for by this Agreement do not and will not violate any applicable law, rule or regulation or any proprietary or other right of any third party; (iii) that I will not use in the performance of my responsibilities for the Company any confidential information or trade secrets of any other person or entity; and (iv) that I have not entered into or will enter into any agreement (whether oral or written) in conflict with this Agreement.

6. TERMINATION OBLIGATIONS.

(a) Upon the termination of my relationship with the Company or promptly upon the Company's request, I shall surrender to the Company all equipment, tangible Proprietary Information, documents, books, notebooks, records, reports, notes, memoranda, drawings, sketches, models, maps, contracts, lists, computer disks (and other computer-generated files and data), any other data and records of any kind, and copies thereof (collectively, "Company Records"), created on any medium and furnished to, obtained by, or prepared by myself in the course of or incident to my relationship with the Company, that are in my possession or under my control.

NSC CONSULTING AGREEMENT: Page 12


(b) My representations, warranties, and obligations contained in this Agreement shall survive the termination of my relationship with the Company.

(c) Following any termination of my relationship with the Company, I will fully cooperate with the Company in all matters relating to my continuing obligations under this Agreement.

(d) I hereby grant consent to notification by the Company to any of my future employers or companies I consult with about my rights and obligations under this Agreement.

(e) Upon termination of my relationship with the Company, I will execute a Certificate acknowledging compliance with this Agreement in the form reasonably requested by the Company.

8. MODIFICATION. No modification of this Agreement shall be valid unless made in writing and signed by both parties.

9. BINDING EFFECT. This Agreement shall be binding upon me, my heirs, executors, assigns and administrators and is for the benefit of the Company and its successors and assigns.

10. GOVERNING LAW. This Agreement shall be construed in accordance with, and all actions arising under or in connection therewith shall be governed by, the internal laws of the State of Arizona (without reference to conflict of law principles).

11. INTEGRATION. This Agreement sets forth the parties' mutual rights and obligations with respect to proprietary information, prohibited competition, and intellectual property. It is intended to be the final, complete, and exclusive statement of the terms of the parties' agreements regarding these subjects. This Agreement supersedes all other prior and contemporaneous agreements and statements on these subjects, and it may not be contradicted by evidence of any prior or contemporaneous statements or agreements. To the extent that the practices, policies, or procedures of the Company, now or in the future, apply to myself and are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control unless changed in writing by the Company.

12. ENTIRE AGREEMENT. This Agreement contains the entire understanding and agreement between the parties hereto with respect to its subject matter and supersedes any prior or contemporaneous written or oral agreements, representations or warranties between them respecting the subject matter hereof.

13. CONSTRUCTION. This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. By way of example and not limitation, this Agreement shall not be construed against the party responsible for any language in this Agreement. The headings of the paragraphs hereof are inserted for convenience only, and do not constitute part of and shall not be used to interpret this Agreement.

14. SEVERABILITY. If any term, provision, covenant or condition of this Agreement, or the application thereof to any person, place or circumstance, shall be held to be invalid, unenforceable or void, the remainder of this Agreement and such term, provision, covenant or condition as applied to other persons, places and circumstances shall remain in full force and effect.

15. NONWAIVER. The failure of either the Company or me, whether purposeful or otherwise, to exercise in any instance any right, power or privilege under this Agreement or under law shall not constitute a waiver of any other right, power or privilege, nor of the same right, power or privilege in any other instance. Any waiver by the Company or by me must be in writing and signed by either myself, if I am seeking to waive any of my rights under this Agreement, or by an officer of the Company (other than me) or some other person duly authorized by the Company.

16. NOTICES. Any notice, request, consent or approval required or permitted to be given under this Agreement or pursuant to law shall be sufficient if it is in

NSC CONSULTING AGREEMENT: Page 13


writing, and if and when it is hand delivered or sent by regular mail, with postage prepaid, to my residence (as noted in the Company's records), or to the Company's principal office, as the case may be.

17. AGREEMENT TO PERFORM NECESSARY ACTS. I agree to perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Agreement.

18. ASSIGNMENT. This Agreement may not be assigned without the Company's prior written consent.

19. COMPLIANCE WITH LAW. In connection with his services rendered hereunder, Consultant agrees to abide by all federal, state, and local laws, ordinances and regulations.

Agreed to this date, August 1, 2001, in Phoenix, Arizona,

National Scientific Corporation Dr. El-Badawy El-Sharawy

By:    /s/ Michael A. Grollman             By:    /s/ Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Name:  Michael A. Grollman                 Name:  Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Title: CEO                                 Title: Consultant
       ------------------------------             ------------------------------

NSC CONSULTING AGREEMENT: Page 14


Exhibit C

LIST OF COMPANIES THAT THE CONSULTANT HAS NOTIFIED THE COMPANY IN WRITING THAT
HE PLANS TO PURSUE FOR BUSINESS DISTINCT AND SEPARATE FROM THE COMPANY'S
BUSINESS

Motorola - modeling

Transtec - materials

Protek - measurements & filters

Northup Grumman - ferrite work

AIM Atomic Technologies - nuclear waste management

AIM Aerospace - engines

AIM Super Lattice - materials

Intel - packaging

Conexant - packaging

NSC CONSULTING AGREEMENT: Page 15


NSC CONSULTING AGREEMENT CHANGE ORDER

This Consulting Agreement Change Order ("Change Order") is entered into as of August 1, 2002, by and between National Scientific Corporation, a Texas Corporation (the "Company"), and Dr. El-Badawy El-Sharawy (the "Consultant"). This Change Order modifies the Agreement between these same parties entitled "NSC Consulting Agreement" dated August 1, 2001.

The parties intend to leave all elements of the previous contract in force, except as follows:

CHANGE AREA #1: MINIMUM HOURS / MONTH REMOVED FROM AGREEMENT

Replace the first two paragraphs under "Compensation" entitled "Monthly Compensation with 1 paragraph shown below, and to strike the section entitled "Minimum Time to be Expended" from that same section "Compensation."

MONTHLY COMPENSATION

FOR THE FIRST AREA LISTED ABOVE, THE COMPANY WILL PAY A $125 PER CONTACT HOUR OF APPROVED AND DOCUMENTED WORK. THE COMPANY WILL BE FOR THESE SERVICES USING 50% CASH AND 50% STOCK OPTIONS (AS DEFINED BELOW UNDER "STOCK COMPENSATION"). THE CONSULTANT WILL NOT RECEIVE A MINIMUM RETAINER PER MONTH, AND MUST BE PRE-APPROVED IN WRITING TO WORK HOURS PRIOR TO WORKING ANY HOURS. THE CONSULTANT WILL ONLY BE PAID FOR DOCUMENTED HOURS WORKED, AND ONLY THEN UPON SUBMISSION AND APPROVAL OF HIS TIME REPORT EACH MONTH.

CHANGE AREA #2: BACKPAY COMPENSATION FOR 2002

The parties are that the Consultant was paid in full as per this Agreement for services rendered through December 2001. The parties also agree that payments from January 20002 to July 2002 were not made in accordance with the original Agreement. In exchange for a full release of obligation from the Consultant for any missing payments under this Agreement from it origin up to and including July 2002, NSC will pay the Consultant 150,000 options in NSC common stock at a strike price of 7 cents each.

Agreed to this date, 8/1/2002, in Scottsdale, Arizona,

National Scientific Corporation Dr. El-Badawy El-Sharawy

By:    /s/ Michael A. Grollman             By:    /s/ Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Name:  Michael A. Grollman                 Name:  Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Title: President                           Title: Consultant
       ------------------------------             ------------------------------

NSC CONSULTING AGREEMENT: Page 16


NSC CONSULTING AGREEMENT

AMENDMENT: July 31, 2003

This is an amendment ("Amendment") to the Consulting Agreement (the "Agreement") entered into as of August 1, 2001, by and between National Scientific Corporation, a Texas Corporation (the "Company") with offices at 14455 N. Hayden Rd Ste 202, Scottsdale, AZ, 85260, and Dr. El-Badawy El-Sharawy (the "Consultant") located at 15832 S. 22nd St., Phoenix, AZ. 85048. The terms of the Agreement, including the change order dated 8/1/2002 previously accepted by the parties, are incorporated into the Amendment by reference.

TERMS

By mutual agreement of the parties today, Section 2 of the original Agreement, Term, is herby modified so that the Agreement will continue in force for an additional period of time. The revised termination date of the Agreement shall now be December 31, 2005.

Agreed to this date, 7/31/2003, in Scottsdale, Arizona,

National Scientific Corporation Dr. El-Badawy El-Sharawy

By:    /s/ Michael A. Grollman             By:    /s/ Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Name:  Michael A. Grollman                 Name:  Dr. El-Badawy El-Sharawy
       ------------------------------             ------------------------------

Title: CEO
       ------------------------------

NSC CONSULTING AGREEMENT: Page 17


EXHIBIT 10.5

FORM OF STOCK RETAINAGE PLAN AGREEMENT

THIS STOCK RETAINAGE PLAN AGREEMENT (hereinafter referred to as this "Stock Plan Agreement") made this ________ day of _______________, 2004, is entered into by and between NATIONAL SCIENTIFIC CORPORATION, a Texas Corporation ("NSC") based is Scottsdale, Az., and _______________________, whose principal residence is ______________________. The aforementioned persons and entities are sometimes collectively referred to herein as the "parties" or "Parties" and individually as a "party".

RECITALS

WHEREAS, ____________________ is an employee of NSC; and

WHEREAS, NSC compensates employees for services to the Company; and

WHEREAS, NSC's common stock ("Common Stock") has a market value at this month of _______________, 2004 of approximately ______cents per share, and this same Common Stock restricted under SEC rule 144 would be expected to have a lower market value were it saleable on an open market; and

WHEREAS, NSC's total revenues in calendar year 2003 through ______(month) were less than $__________; and

WHEREAS NSC and the employee have agreed that the employee is willing to provide best efforts to guide the company towards growth and success over the next fiscal year and beyond;

NOW THEREFORE, in consideration of the agreement by the parties and other good and valuable consideration, the receipt, adequacy and sufficiency of which is hereby acknowledged and confessed, the parties hereby agree as follows:

1. Each of the foregoing recitals is incorporated in this Stock Plan Agreement as a material term and condition.
2. The company agrees today to grant the employee __________ shares of its Common Stock restricted under SEC rule 144, provided that the Company revenues in Calendar Year 2004 surpass $200,000, a large increase over Calendar Year 2003, and also provided that the employee remain continuously employed with NSC throughout ____________. Should this not occur, this stock grant will be forfeited by the employee, and such stock promptly returned to NSC.
3. The Company agrees to grant the employee an additional _____ shares of its common stock, restricted under SEC rule 144, provided that the Company revenues in Calendar Year 2004 surpass $1,000,000, a large


increase over Calendar Year 2003, and also provided that the employee remain continuously employed with NSC throughout the 2004 period. Should this not occur, this stock grant will be forfeited by the employee, and such stock promptly returned to NSC.
4. Such stock grants will be issued by NSC at the earliest reasonable date.
5. If Common Stock granted under this Agreement should be promptly returned to the Company, and is not promptly returned, the Company may take steps to cancel or otherwise nullify the grant of such shares of Common Stock as should be promptly returned, with the employee bearing all the costs incurred through this process.
6. The term of this Stock Retainage Plan Agreement is from ___________, 2004 to ______________________.

IN WITNESS WHEREOF, THE Parties have executed this Stock Plan Agreement in Scottsdale, Arizona, on the date set forth beside their respective names.

NATIONAL SCIENTIFIC CORPORATION EMPLOYEE

By:     _________________________________           ____________________________

Title:  _________________________________           ____________________________

Date:   _________________________________           ____________________________

2

EXHIBIT 10.7

DISTRIBUTION AND MARKETING AGREEMENT

THIS AGREEMENT made this 16th day of December, 2002.

BETWEEN:

FUTURECOM GLOBAL, INC.,
a Nevada corporation having an office at 15690 N. 83rd Way,
Suite B, Scottsdale, AZ 85260
(hereinafter referred to as "FCG")

OF THE FIRST PART

AND:

NATIONAL SCIENTIFIC CORPORATION

a Texas corporation having offices at 1455 North Hayden Road Suite 202, Scottsdale, AZ 85260-6947


(hereinafter referred to as "NSC")

OF THE SECOND PART

WHEREAS NSC is a developer of tracking and location equipment, and related products, based upon locator technology that is a merger of cell phone and global positioning systems technology; and

WHEREAS FCG is, among others, engaged in the distribution and marketing of communication equipment and other technology-based products; and

WHEREAS FCG is desirous of entering into a formal agreement with NSC for the distribution and marketing of NSC tracking and location equipment in certain international and regional markets; and

WHEREAS NSC is agreeable to appointing FCG as its Distributor and Marketing Agent in accordance with the terms and conditions herein; and

Page 1 of 13

WHEREAS the Parties of the First and Second Part hereto wish to enter into this Agreement to set forth the terms and conditions of the distribution and marketing appointment.

NOW THEREFORE THE PARTIES HERETO AGREE AS FOLLOWS:

1. DISTRIBUTION AND MARKETING RIGHTS

(i) NSC hereby grants to FCG for One (1) year from the date hereof the renewable rights to sell within the Territory the products and equipment manufactured by NCS described in Schedule "A" attached hereto and forming a part hereof (hereinafter collectively referred to as the "Products"), which Schedule shall stipulate whether or not the distribution rights granted hereunder are on an exclusive basis.

(ii) FCG may describe itself as an authorized distributor of the Products but shall not characterize itself or enter into any transaction as an agent of, except as permitted herein, or in the name of, NSC.

2. THE TERRITORY

(i) FCG is hereby appointed as the distributor for the territory (herein referred to as the "Territory") described in Schedule "B", which is attached hereto and forms a part hereof.

(ii) In the event the Products and/or Territory are expanded, reduced, or revised in any manner, Schedule "B" shall be modified accordingly without the requirement for a new Distribution and Marketing Agreement unless the Parties hereto determine otherwise.

3. LABELING RIGHTS

FCG or its customers shall not be entitled to market any Products covered herein under any private label brand name utilized by FCG or its customers from time to time without prior written consent from NSC. However, FCG is authorized to add labeling with "Distributed by FCG" type identification.

4. TERMS AND PRICES FOR THE PRODUCTS

(i) NSC shall supply FCG with the Products on the terms and at the prices set forth in Schedule "C" which is attached hereto and forms a part hereof. For greater certainty, the prices set forth in Schedule "B" are current prices quoted as of the date of the Agreement, and may be revised by NSC from time to time with 45-day advance written notice of

Page 2 of 13

change provided to FCG. Any and all written, issued, and acknowledged Purchase Orders for Products from customers of FCG received by FCG prior to, or before the end of, the 45-day change notification period will be honored at the existing price(s) before the intended change.

(ii) FCG shall be entitled to re-sell the Products at whatever price(s) it deems fit into any sales channels available.

5. TRAINING AND PRODUCT SUPPORT

(i) At the request of FCG from time to time, NSC shall provide, without charge, adequate training of FCG's employees or agents, in the proper use of the Products.

(ii) NSC shall furnish and provide to FCG during the term of this Agreement, without charge, periodic follow-up assistance and instruction that FCG deems necessary or appropriate.

(iii) The Parties hereto agree that the Products may be marketed at trade shows to be agreed upon. Actual trade show costs shall be shared by the Parties hereto, according to a formula to be determined at a later date, but prior to each applicable show. Any and all customer and/or sales prospects generated at, or as a result of participation in, a trade show, will be immediately turned over to FCG for all follow-up effort, as long as the lead is for application within the Territory, and will not be acted upon by NSC or any NSC third party.

(iv) For those Products sold under the NSC, or NSC created, name, NSC shall provide and furnish to FCG without significant cost, reasonable quantities of advertising and user information, primarily in electronic form, as required to assist FCG in selling the Products. In addition, a reasonable quantity of marketing sample products to support testing or new product evaluation will be provided to FCG as soon as final production products are available to NSC.

6. DELIVERY

(i) NSC shall deliver the Products F.O.B. in Scottsdale, AZ to FCG, or to a place designated by FCG, in accordance with the ongoing delivery schedules to be set forth in specific FCG Purchase Orders issued to NSC from time-to-time.

(ii) FCG shall have the right of pre-delivery inspection of the Products to be shipped, which right shall extend to any duly authorized agent of FCG.

Page 3 of 13

7. PRODUCT IMAGE

Otherthan in the matter of pricing, neither Party shall do, or permit anything to be done, to prejudice the market image of the Products.

8. COMMERCIALLY REASONABLE EFFORTS

(i) NSC agrees to utilize Commercially Reasonable efforts to supply FCG with the Products as provided in this contract. Furthermore, NSC agrees to coordinate its production and manufacturing to facilitate the orderly manufacture and shipping of the Products as hereinafter-set forth in greater detail.

(ii) FCG shall use its Commercially Reasonable efforts to promote the sale of the Products within the Territory and to provide timely quantity forecasts to NSC on a regular basis for the duration of this Agreement.

9. FCC AND OTHER APPROVALS

NSC shall be responsible for securing, on a timely basis, and for payment of any and all costs pertaining to, FCC, UL, and all other necessary regulatory approvals within the Territory.

10. RESTRAINT OF COMPETITION

NSC agrees that it will not sell, or assist any third party in sales, any competing Products within the Territory to any of FCG's pre-existing customers or actively solicited potential customers during the term of this agreement.

11. ORDERS

In order to ensure the prompt delivery of the Products to customers, and to facilitate the orderly scheduling of production and shipments, NCS agrees to submit to FCG its production capabilities on a quarterly basis. FCG agrees to submit to NSC its orders for product as far as possible in advance of desired delivery. NSC will then provide FCG a specific schedule of production to meet FCG's commitment. FCG agrees to accept all of NSC's products ordered by FCG. NSC will not ship the Products to FCG except upon FCG's orders. All orders are subject to approval and acceptance by FCG at its corporate head office in Scottsdale, Arizona.

FCG also agrees to provide NSC with quarterly estimates and forecasts of FCG's prospective requirements of the Products in order to facilitate NSC's production planning, but such estimates are not to be treated by NSC in any way as firm purchase orders from FCG.

Page 4 of 13

12. WARRANTIES AND DEFECTIVE PRODUCTS

NSC warrants that the products it provides to FCG will perform in accordance with the published specifications in the documentation provided by NSC and will achieve the functionality described therein. NSC's obligation under this warranty will be to promptly bring any non-complying products into compliance with NSC's published specifications, or to promptly replace the products, or grant a full refund of the actual net price paid for any such defective products, all of which will be performed at no cost or obligation to FCG. This warranty will commence on the date of receipt of each product by the end-user and shall continue for a period of one (1) year thereafter. The warranty provided in this provision is in lieu of all other warranties, express or implied, including, but not limited to, the warranties of merchantability and fitness for a particular purpose, warranties through course of dealing or usage of trade or any other implied warranties.

NSC also warrants and represents that it has the right to sell the Products, and that the Products sold hereunder shall be free of all liens, encumbrances and charges of whatsoever nature or cause. Furthermore, the Products will not infringe upon any intellectual property or design/development rights.

13. CUSTOMER COMPLAINTS

FCG will receive, investigate, and handle all complaints received from customers with a view toward protecting the good will of the Parties hereto in the sales of the Products. Recognizing the importance of customer good will, FCG will make every reasonable effort to satisfy owners of the Products as provided for herein, and in pursuance thereof, establish regular contact either by correspondence or personal interview with such owners or purchasers. All warranty complaints received by FCG, which cannot be readily remedied by FCG when FCG applies commercially reasonable efforts to do so, shall be promptly reported to NSC who will then undertake to remedy such complaints, and FCG will be relieved of primary responsibility in that regard.

14. NON-AGENCY

It is expressly agreed to by the Parties hereto that the relationship created in this Agreement between FCG and NSC is not that of a principal and agent and under no circumstances shall this Agreement be intended to constitute a partnership between any of the Parties.

15. USE OF TRADE NAMES

NSC agrees that in marketing the Products, FCG may use NSC's current trade names and may add FCG's distribution authorization data to existing Product packages and/or labeling.

Page 5 of 13

16. ASSIGNMENT OF CONTRACT

This Agreement may be assigned by one party without the prior written consent of the other party to any entity legally controlled by the first party. Any assignment to other entities shall be subject to the prior written consent of the second party, which consent shall not be unreasonably withheld.

17. TERMINATION

(i) The Parties hereto may terminate this Agreement by mutual consent at any time, but with the provision that all open orders will be satisfied by the Parties, as required.

(ii) Subject to clause 18 herein, either Party may terminate any renewal hereof prior to the applicable termination date upon three (3) months written notice to the other.

(iii) Each of the Parties hereto shall have the right to terminate this Agreement upon the occurrence of any of the following events, such termination to be effective immediately upon the receipt or deemed receipt by the other Party of notice to that effect and the expiry of any applicable period for remedy of the default:

(a) if a Party is in default of any of the materials terms or condition of this Agreement and fails to remedy such default within 60 days of written notice thereof from the other Party;

(b) if the other Party becomes bankrupt or insolvent, makes an assignment for the benefit of its creditors or attempts to avail itself of any applicable statute relating to insolvent debtors;

(c) if the other Party winds-up, dissolves, liquidates or takes steps to do so or otherwise ceases to function as a going concern or is prevented from reasonably performing its duties hereunder; or

(d) if a receiver or other custodian (interim or permanent) of any of the assets of the other Party is appointed by private instrument or by court order or if any execution or other similar process of any court becomes enforceable against the other Party or its assets or if distress is made against the other Party's assets or any part thereof.

Page 6 of 13

18. TERM

(i) This Agreement shall be effective for one (1) year from the date hereof. FCG shall have the first right of renewal for two (2) additional one (1) year terms. FCG shall notify NSC of FCG's intention to renew two (2) months prior to the expiration date of this agreement, or any renewal thereof, as the case may be.

(ii) In the event no notice to terminate has been given by any Party prior to the termination date of any renewals referred to in clause 18(i) above in accordance with this Agreement, then in such event this Agreement or renewal thereof shall automatically be renewed, mutates mutandi, for a further one (1) year term.

19. RIGHT OF FIRST REFUSAL

The Parties agree that FCG shall have the right of first refusal on the distribution within the Territory of any Products that are essentially upgrades, major modifications, or replacements to the Products covered by this distribution agreement. All other new product offerings from NSC will be discussed with FCG regarding the possibilities of FCG distribution prior to distribution decisions with other parties.

20. CONFIDENTIAL INFORMATION

The Parties hereto ratify and confirm the terms and conditions of any and all agreements entered into between them pertaining to the maintaining and disclosure of confidential information.

21. SEPARABILITY

If any provision of this Agreement is invalid, unenforceable, or not enforced, this Agreement shall be considered divisible as to such provisions without affecting the validity of the balance of this Agreement.

22. FORCE MAJURE

Neither Party hereto shall be liable for failure to perform its respective part of this Agreement if such failure is due to fire, flood, strikes, or other industrial disturbances, inevitable accident, war, riot, insurrections, or other causes beyond the control of the Parties.

Page 7 of 13

23. ENTIRE AGREEMENT

(i) This Agreement constitutes the entire Agreement between the Parties pertaining to the subject matter contained in it and supercedes all prior and contemporaneous agreements, representations, and understandings of the Parties. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by all the parties to this Agreement. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the party making the waiver.

(ii) There are no representations, constitutions, terms or collateral contracts affecting the transaction contemplated in the Agreement except as expressly set forth herein.

24. NOTICES

All notices, requests, demands, and other communications under this Agreement shall be in writing and shall be deemed to have been duly given on the date of service if served personally on the party to whom notice is to be given, or on the second (2nd) day after pickup by a courier service, if delivered to the Party to whom notice is to be given, by such courier service.

25. HEADINGS

The capitalized headings in this Agreement are only for convenience of reference and do not form part of or affect the interpretation of this Agreement.

26. TIME OF ESSENCE

Time is of the essence of this Agreement.

27. GOVERNING LAW AND ARBITRATION

This contract and the Agreement of the Parties shall be governed and construed according to the laws of the State of Arizona.

All disputes, controversies or claims arising out of or in connection with this Agreement which cannot be settled by mutual agreement shall be finally settled by arbitration. Arbitration shall be held in Scottsdale, AZ and shall be conducted in accordance with the rules of the International

Page 8 of 13

Chamber of Commerce then in force and effect. Arbitration shall be by three
(3) arbitrators, one chosen by FCG, one chosen by NSC, and the third chosen by both parties; or, if the selection of a third arbitrator cannot be made within thirty (30) days after the appointment of the first two arbitrators, then such third arbitrator shall be chosen by the International Chamber of Commerce Court of Arbitration. Demand for arbitration shall be served upon the Party to whom the demand is made. Judgment upon the award rendered may be entered in any court having jurisdiction, or application may be made to such court for enforcement as the case may be.

28. FURTHER ASSURANCES

The Parties hereto covenant and agree each with the other that they shall and will, from time to time and at all times hereinafter, execute such further assurances and do all such further acts as may be reasonably required to give effect to the intent of the Parties hereto.

29. ENUREMENT

The Agreement shall enure to the benefit of and be binding upon the Parties hereto and their respective successors and assigns.

30. LIMITATION OF LIABILITY

Neither Party will be liable for any indirect, incidental, special, or consequential damages, including, but not limited to, loss of profits, data, time, or use incurred by either Party, or any third party, even if informed of their possibility, except for liability relating to a breach of the confidentiality and intellectual property provisions of this Agreement, and for claims of bodily injury for which the other Party is legally liable, in no event will cumulative liability exceed the total amount that has been paid under this Agreement for the Products and any services provided. This provision represents each Party's entire liability and exclusive remedy.

Page 9 of 13

IN WITNESS WHEREOF the Parties hereto have executed this Agreement as of the date above written.

FUTURECOM GLOBAL, INC.

Per:   /s/ Ronald R. Kelly
       -------------------------------------

Name:  Ronald R. Kelly
       -------------------------------------

Title: CEO and President
       -------------------------------------

NATIONAL SCIENTIFIC CORPORATION

Per:   /s/ Michael A. Grollman
       -------------------------------------

Name:  Michael A. Grollman
       -------------------------------------

Title: CEO and President
       -------------------------------------

Page 10 of 13

SCHEDULE A: PRODUCTS

1. NSC Followit Transponders and related accessories
2. NSC StarPilot Location Servers and related accessories
3. NSC KidCall Children's Security System and related accessories

NOTE: NO PRODUCTS COVERED BY THIS AGREEMENT ARE TO BE DISTRIBUTED BY FCG FOR NSC ON AN EXCLUSIVE BASIS.

AS AMENDED AND APPROVED:

DATE:  DEC 16, 2002

FUTURECOM GLOBAL, INC.                     NATIONAL SCIENTIFIC CORPORATION

By: /s/ Ron Kelly                          By: /s/ Michael Grollman
    ---------------------------------          ---------------------------------

Page 11 of 13

SCHEDULE B: TERRITORY

The General Non-Exclusive Territory shall be comprised of customers within North and South America and Europe for all products other than Followit, which is initially limited to North America only.

For Accounts listed below as assigned accounts ("Assigned Accounts") NSC will not compete with FCG, nor will it knowingly support or assist in any third party potential competition, to FCG.

FCG agrees to assign active representation and appropriate sales representation and appropriate sales representation to all accounts and to endeavor to sell the products covered in this Agreement, with face-to-face account contact on at least, a quarterly basis, and to produce orders from active accounts within 3 quarters of initial contact.

Target markets and major accounts within that geography will include, but are not limited to, retail and other vertical market applications as defined within this Schedule B. Customer identification to be defined within this Schedule B as update from time to time by FCG (and accepted by NSC) as circumstances warrant.

AS AMENDED AND APPROVED:

DATE:  DEC 16, 2002

FUTURECOM GLOBAL, INC.                     NATIONAL SCIENTIFIC CORPORATION

By: /s/ Ron Kelly                          By: /s/ Michael Grollman
    ---------------------------------          ---------------------------------

Page 12 of 13

SCHEDULE C: PRICING & PAYMENT TERMS

The specific unit pricing, any other applicable pricing data, in addition to the payment terms for Product purchased by FCG under this Distribution Agreement will be defined, as appropriate, at a later date, within this Schedule C.

AS AMENDED AND APPROVED:

DATE:  DEC 16, 2002

FUTURECOM GLOBAL, INC.                     NATIONAL SCIENTIFIC CORPORATION

By: /s/ Ron Kelly                          By: /s/ Michael Grollman
    ---------------------------------          ---------------------------------

Page 13 of 13

Exhibit 10.8

March 10, 2003

Mr. Michael Grollman
President
National Scientific Corporation
14455 North Hayden Rd
Suite 202
Scottsdale, AZ
85260

Dear Michael:

Verify Systems is pleased to work with National Scientific Corporation on iVerified for schools hardware products. The proposed solutions you have presented are a direct reflection on the expertise and professionalism National Scientific Corporation brings to Verify Systems. We are extremely fortunate to partner with an organization such as yours. We look forward to many successful transactions in the years ahead.

As we have discussed, the secondary data transmission is still a formidable piece missing. While we continue to work towards a common goal it is important to begin manufacture of units. The following is the general terms and conditions we have discussed and I hope meets your satisfaction.

Proposed General Terms and Conditions:

For product delivery between March 15, 2003 and June 30, 2004

o Terms are net 30 date of shipment for shipments under $10,000 in a given month
o For larger shipments, terms are 50% at point of shipment, 50% net 30, unless otherwise agreed to on an order-by-order basis
o Firm confirmed requirement for April and May are expected to be approximately 20 total units for pilot purposes, with technical details and unit breakdown of these 20 units to be agreed on or around March 30.
o Basic preliminary specifications as defined in NSC Proposal of February 2003, but specifications and associated unit pricing are expected to evolve during project.
o Pricing below is per the 150 unit order level, even though most of the categories or shipments do not equal that amount, NSC will extend that volume discount based on the Blanket PO. If volume quickly ramps beyond the 150 level, future orders will be at the more aggressive discounts shown in the proposal.
o All orders are shipped F.O.B Scottsdale in 8 weeks upon receipt of release from blanket PO. Blanket PO includes only estimated quantities and specifications - amounts of each type can be changed (re-balanced) as end customer needs become more clear, keeping overall total number of dollars in the PO reasonably stable over the long term of the order.

54 Hazard Avenue, Suite 329 Enfield, CT 06082 TEL 866.VERIFYU


Unit Part no.       Unit Function      Est. Units        Price         Total
================================================================================

NSC-VER-001         Bus                   100            $941        $ 94,100
--------------------------------------------------------------------------------
NSC-VER-002         Depot                  75            $637        $ 47,775
--------------------------------------------------------------------------------
NSC-VER-003         Classroom             150            $467        $ 70,050
--------------------------------------------------------------------------------
NSC-VER-004         Perimeter              40            $457        $ 18,280
--------------------------------------------------------------------------------
NSC-VER-005         Mobile Reader           5            $550        $  2,750
--------------------------------------------------------------------------------
NSC-VER-006         Mobile Dock             5            $550        $  2,750
--------------------------------------------------------------------------------
NSC-VER-007         Concentrator           30            $520        $ 15,600
--------------------------------------------------------------------------------
                                              Total                  $251,305
================================================================================

An overview of the iVerified for school system:

iVerified for Schools is a student locating system that allows school administrators and parents to instantly locate their student(s) while on a bus or within the school. For parents, it gives them peace of mind and a degree of control to know that their child is safe and where they should be. For schools, it provides for the security and automation of attendance that is forefront in their minds. Schools can instantly determine the location of any bus in their fleet and which students are onboard. The system logs where and when a student embarked and disembarked the bus. Schools can instantly learn who is in school and who is absent, as well as precisely where any given student is located within the school. Our system can even tie into a school's access control system giving only authorized students access the school's property.

We had five goals while designing the iVerified for Schools system:

o Allow parents and school administrators to track the location of their students
o Make the system as non-invasive and as passive as possible
o Improve school security
o Automate time and attendance
o Operate system at a low cost

On behalf of everyone at Verify Systems I want to thank you and your staff at National Scientific Corporation for being an integral partner in bringing iVerified to market.

Respectfully,

/s/ Mark A. O'Neill
Mark A. O'Neill
President
Verify Systems
March 10, 2003

cc: Graham Clark
Anthony Grosso
Steven Mercadante

54 Hazard Avenue, Suite 329 Enfield, CT 06082 TEL 866.VERIFYU


EXHIBIT 10.9

NATIONAL SCIENTIFIC CORPORATION
14455 NORTH HAYDEN RD. SUITE 202
SCOTTSDALE, ARIZONA 85260-6947

April 23, 2004

Mr. Anthony Grosso
President, CIS Services, LLC
251 Quail Run Road
Suffield, CT. 06078

Re: Letter of Understanding

Dear Anthony;

This letter of understanding is a follow-up to our e-mails and telephone conversations in which we mapped out a near term plan between yourself, CIS Services LLC dba Verify Systems and NSC. The conversations and e-mails have indicated that our mutual intent was NSC would undertake certain actions for the purpose of advancing our sales in the school bus and student tracking market; and you and Verify Systems would undertake complimentary actions serving the same intended purpose. This letter is intended to confirm this relationship in the form of a binding agreement ("Agreement") between Anthony Grosso (Grosso) as an individual and as owner of CIS Services, LLC (CIS) dba Verify Systems, and National Scientific Corporation (NSC) as a Texas Corporation. This letter replaces all previous negotiations and discussions, and contains the complete understanding for the current and future relationship between CIS, Grosso and NSC. Together these individuals and entities are known the parties ("Parties") to this Agreement, and the effective date of this Agreement is the date of this letter.

National Scientific Corporation agrees to use commercially reasonable efforts to: 1) spend at least four months from the date of this letter attempting to convert (where all Parties deem it practical) PCG, Nextel, and other Verify Systems School Bus leads into pilot programs for NSC and Verify to work on in the future; and 2) further develop NSC IBUS hardware platform to better fit customer requirements; and 3) develop IBUS to PCG software interface, if PCG is ready to use it for Medicaid reimbursement and related markets; and 4) develop IBUS to Nextel software interface, if Nextel is ready to use it in any areas, for general school and related markets; and 5) fund the NSC qualified execution pilots that may come up during the four month period with "blue boxes," and other materials and staff; and 6) pay a $6,000 one-time consulting fee to Anthony Grosso.


Additionally, NSC agrees to pay Grosso a finder's fee ("Finder's Fee") equal to 10% of any net revenues related to school bus or student tracking Verify System software sales derived directly during the first year of this Agreement. . The Finder's Fee is limited to application software sales (or application software licensing revenues) NSC receives from its direct use of its license for Verify Systems application software (see below). This fee does not apply to other hardware or software products NSC may develop related to school bus or child tracking, only to Verify Systems application software as it exists today. The Finder's Fee will be payable within 30 days of the receipt by NSC of the customer funds.

Mr. Grosso's and the associated Verify Systems Corporation, assets, and subsidiaries part of the plan includes the following: Grosso will: 1) keep full legal control of Verify Systems legal entity or entities, including all assets, title to the Intellectual Property, title to the Software, methods and practices and customer records, which are currently held free and clear in an entity called CIS Services, LLC, other than for any modifications to Verify Systems application software that may be made in the future by NSC, which NSC would own; and 2) keep Verify Systems entity in physical existence in the marketplace including maintaining the website, name and image, timely returning phone calls and emails from customers and partners for at least 6 months from the date of this letter; and 3) give NSC full and unrestricted legal access and support for all existing Verify Systems accounts and leads to pursue in any way NSC sees fit, including PCG and Nextel and any other accounts NSC or Mr. Grosso deem worthy of pursuing at the time; and 4) execute a three year exclusive supplier agreement between NSC and Verify Systems ("Exclusive Supplier Agreement") and any successor firms (where Verify Systems key people and assets are involved in the same school market space) to purchase all its bus and related tracking hardware systems from NSC; and 5) grant to NSC an unlimited perpetual source code level license including unlimited distribution rights to all existing Verify Systems software, brands, logos, and marketing materials; which shall be exclusive rights in any accounts NSC invests in direct sales call activity with, where NSC's only payment obligation for this application software shall bee the Finder's Fee; and 6) NSC has the right at any time during the next three years to purchase full and exclusive title to the Verify application software for $50,000; and 7) full and unlimited access to former Verify Systems personnel to help implement it as needed for customers and pilots and projects (NSC to pay these people directly as needed, including Dan Raboin and Anthony Grosso); and
8) deliver electronics copies of all such materials in a useable form to NSC; and 9) direct all relevant new bus system leads to NSC, whereby Grosso would earn a Finders Fee for Verify Systems application software sales (see above).

The following other elements are important to this Agreement, and accepted by all parties to the Agreement:

1. The parties agree to keep all confidential information as confidential for two years from the date of this letter, and will execute a standard NSC NDA agreement to fully commemorate this matter ("Confidentiality Agreement").
2. The term of this Agreement is three years from the date of this letter
3. This Agreement is governed by the laws of and the courts in the State of Arizona.

2

If you find the foregoing represents our understanding, kindly sign and return this to us, whereupon this letter along with all its counterparts will become a binding agreement between us.

Very Truly Yours,

/s/  Michael Grollman

Michael Grollman



NSC Accepted by:                 Anthony Grosso for himself and CIS Services LLC

/s/ Michael Grollman             /s/ Anthony Grosso
----------------------------     ----------------------------
Title:                           Title:

CEO                              CEO
----------------------------     ----------------------------


DATE: 5/11/2004                  DATE: 5/14/04
      ----------------------           ----------------------

3

EXHIBIT 10.10

LETTER OF INTENT

Date: February 20, 2003

John O. Williams, CEO
Bike & Cycle Trak USA, Inc.
2116 2nd Avenue South
Minneapolis Minnesota, USA

Dear Mr. Williams:

This letter is intended to set forth a letter of intent by NSC Corporation ("NSC"), an Arizona corporation, and Bike & Cycle Trak USA, Inc ("BCT"), a Delaware corporation.

1. OVERALL STRUCTURE. Our mutual goal is to design, manufacture, and sell a product to enhance the safety of users of power sports equipment. Our initial belief as to the overall structure and purpose of the project is set forth in the attached Term Sheet, which would need to be properly documented in definitive agreements before having effect.

2. NEGOTIATIONS. We agree to negotiate to determine if the joint venture will be appropriate for the parties, provided, however, that either party may terminate negotiations at any time for any reason. Both parties agree to not negotiate or enter into or continue discussions with any other person or company or solicit or encourage, directly or indirectly, or furnish information to any other person or company, with respect to a similar business arrangement for the power sports industry sector, during the ninety (90) days following the date this letter is accepted by you.

3. CONFIDENTIALITY OF NEGOTIATIONS. The parties shall use best efforts to maintain at all times as confidential information the fact that you or we have executed this letter, the terms of this letter and the existence and content of any negotiations between us except that both parties may (i) inform advisors, counsel, and employees with a need to know as each party deems necessary, and
(ii) make appropriate disclosures if required by applicable securities laws, and
(iii) issue press releases regarding substance of the negotiations if they have been pre-approved by both parties.

4. GOVERNING LAW. This letter shall be governed by the substantive laws of the State of Arizona.

5. ENTIRETY. This letter constitutes the entire understanding and agreement between the parties hereto and their affiliates with respect to its subject matter and supersedes all prior or contemporaneous agreements, representations, warranties and understandings of such parties (whether oral or written). No promise, inducement, representation or agreement, other than as expressly set forth herein, has been made to or by the parties hereto. This letter and its exhibit hereto may be amended only by written agreement, signed by the parties

Letter of Intent, Page 1 of 4


to be bound by the amendment. Parol evidence and extrinsic evidence shall be inadmissible to show agreement by and between such parties to any term or condition contrary to or in addition to the terms and conditions contained in this letter and its exhibit.

6. CONSTRUCTION. This letter shall be construed according to its fair meaning and not strictly for or against either party. This letter does not, and is not intended to, impose any binding obligations on the parties, except as provided in Section 2 and 3 above.

If the terms and conditions of this letter are acceptable, please sign and return to us a copy of this letter so that we can move forward with our discussions.

Very truly yours,

/s/ Michael A. Grollman
-------------------------------
National Scientific Corporation
By: Michael A. Grollman
Title: President and CEO

Accepted and Agreed:

/s/ John O. Williams
-------------------------------
Bike & Cycle Trak USA, Inc.
By: John O. Williams
Title: CEO

Letter of Intent, Page 2 of 4


TERM SHEET

This term sheet summarizes the principal terms with respect to the project, whose stakeholders will be NSC Corporation ("NSC") and Bike & Cycle Trak, Inc ("BCT"). This term sheet is intended solely as a basis for further discussion and is not intended to be and does not constitute a legally binding obligation of the parties. No legally binding obligations on the parties will be created, implied, or inferred until appropriate documents in final form are executed regarding the subject matter of this term sheet and containing all other essential terms of an agreed upon transaction and delivered by all parties. Without limiting the generality of the foregoing, it is the parties' intent that, until that event, no agreement binding on the parties shall exist and there shall be no obligations whatsoever based on such things as parol evidence, extended negotiations, "handshakes," oral understandings, or courses of conduct (including reliance and changes of position). Efforts by either party to complete due diligence, negotiate, obtain financing or prepare a contract shall not be considered as evidence of intent by either party to be bound by this term sheet or otherwise. The performance by either party prior to execution of a formal contract of any of the obligations which may be included in a contract between the parties when negotiations are completed shall not be considered as evidence of intent by either party to be bound by this term sheet.

The parties are discussing a transaction on the following terms:

GENERAL: This is a joint effort to co-develop an electronic product, but is not a partnership or a joint venture.

PURPOSES: The product to be developed is planned to be a GPS enabled tracking device to enhance safety for riders of motorcycles, snow machines, and other power sports equipment.

BUSINESS PLAN: The parties would agree prior to the start of the project on a Business Plan for the first two (2) years of operation of the project.

OWNERSHIP OF INTELLECTUAL PROPERTY: The parties would plan to agree prior to the start of the project on an ownership plan for any intellectual property that may result from the project. It is expected that some intellectual property will be owned separately both the parties, and some may be owned jointly.

ELECTRONICS BUDGET: The cost project budget is estimated to be $150,000 to produce the electronics and internal software systems for the first prototype, which the parties would like to share in approximately equal basis. NSC intends to perform the majority of this work and incur the majority of this cost directly, although BCT plans to assist directly with some of the sensor design. BCT will plan to make cash contribution of roughly $75,000 towards its share of these costs directly to NSC, in phased payments including an initial payment to be determined at a later time.

CASING: BCT plans to design and prototype the enclosure and mounting for this product.

MARKETING, SALES, AND DISTRIBUTION: BCT plans to take a leadership role in sale and distribution of the product, especially in the Midwest, as well as in establishing call center support for the product.

Letter of Intent, Page 3 of 4


MANUFACTURING: NSC plans to take a leadership role in manufacture of the product.

PRODUCT COST AND REVENUE SHARING: The parties intend to sell the product for a profit, and share the resulting revenues and margin from this effort, based roughly on their respective contributions of cost and effort to the development, manufacture, marketing, and sales effort associated with the project, which are today uncertain.

STOCK SWAP: Sometime shortly after the completion of the prototype, NSC plans to exchange approximately $30,000 of its SEC 144 Restricted Common Stock for approximately 3% of the outstanding shares of BCT. NSC stock shall be valued at the average closing price of its stock during the 30 calendar day period before this transaciton is consummated.

FOLLOW-ON AGREEMENT STRUCTURE: The parties plan to draft a master project agreement ("Master Project Agreement") that will broadly define the binding elements of this project. The parties then plan to draft separate agreements in the areas of joint development ("Joint Development Agreement"), intellectual property ("Intellectual Property Agreement"), product manufacturing ("Product Manufacturing Agreement") and product distribution and marketing ("Distribution and Marketing Agreement"). These agreements are likely not to be executed all at once, but rather executed in approximately the sequence listed in this paragraph, as the project advances through development and into its production and sales phases.

NEGOTIATIONS SCHEDULE: The parties hope to complete the Master Project Agreement before the end of February, and the other agreements within 2-3 months of the Master Project Agreement, if not sooner.

PROJECT SCHEDULE: This development phase of this project is expected to last approximately six months. The overall development and sales processes is expected to last approximately 2 years, with extensions likely after that point.

DUE DILIGENCE: Both parties will promptly begin and diligently pursue an investigation of the legal, business, environmental and financial condition of the proposed project. Each party will extend its full cooperation to the other party and its lawyers, accountants and other representatives in connection with such investigation. Each party, its lawyers, accountants and other representatives shall have full access to the other party's books and records, facilities, accountants and key employees for the purpose of conducting such investigation. The consummation of the transactions contemplated by this letter shall be conditional upon both parties complete satisfaction with such purchase investigation.

Letter of Intent, Page 4 of 4


EXHIBIT 10.11


BIKE & CYCLE TRAK USA, INC. Purchase Order #

2116 SECOND AVENUE SOUTH 030310-01
MINNEAPOLIS, MINNESOTA 55404 ----------------------------

Date: March 7, 2003
TELEPHONE: 651-646-6886 ----------------------------

                 FAX: 612-874-9793                      Authorized by: JOW
--------------------------------------------------- ----------------------------
Issued to: National Scientific Corporation                Ship via: n/a
                                                    ----------------------------
                                                        Ship to attn.: n/a
--------------------------------------------------- ----------------------------
Telephone Number: (480) 948-8324                       Ship by (date): n/a

--------------------------------------------------- ----------------------------
                  Description                                  Price
--------------------------------------------------- ----------------------------
Design & Engineering Services                              $ 75,000.00
trakFORCE product, agreements pending
--------------------------------------------------- ----------------------------


Purchase order number must appear on all invoices and correspondence.

Signed:  /s/ John O. Williams
        ---------------------
        President                                       Date: March 7, 2003
--------------------------------------------------------------------------------


Exhibit 23.1

CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference of our report dated December 4, 2003, which is included in this Form SB-2 Registration statement.

/s/ Michael Hurley

Hurley & Company
Granada Hills, California
June 23, 2004